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ABSTRACT 
The clinical background to this work confirms the very poor outcome of patients with 
recurrent diffuse large B-cell lymphoma (DLBCL) and highlights the need for better 
therapies. One such potential option would be to add selenium (Se) to conventional 
chemotherapy. Previous work has demonstrated the ability of non-toxic concentrations of 
Se to sensitise DLBCL cell lines to chemotherapy and to protect normal cells from 
chemotherapy-induced toxicity. The aims of this study were therefore to identify 
mechanisms of Se action and potential biomarkers of Se activity. The form of Se used 
was methylseleninic acid (MSA), a precursor of methylselenol, which is the metabolite 
thought to be responsible for the anti-tumour effects of organic Se compounds.  
 
DLBCL cell lines differed in their sensitivity to MSA, which may relate to differences in 
intracellular glutathione depletion by MSA. MSA sensitivity, however, was not related to 
the induction of DNA damage or to the p53 status of lymphoma cell lines. Although 
cytotoxic concentrations of MSA induced apoptosis, chemo-sensitising concentrations 
did not enhance apoptosis or alter pro-apoptotic pathways. MSA induced endoplasmic 
reticulum (ER) stress in a concentration-dependent manner, however, in an MSA-
resistant cell line, this led to autophagy and cell survival. Thus, ER stress induction is not 
a mechanism of chemo-sensitisation. MSA inhibited HDAC activity in DLBCL cell lines 
but only in a cell-based assay, suggesting that a metabolite of MSA is responsible for this 
effect. In addition, MSA inhibited the hypoxia-induced induction of HIF-1α in DLBCL 
cell lines. 
 
Peripheral blood mononuclear cells (PBMCs) were relatively resistant to MSA and this 
was associated with increased expression of two pro-survival proteins, GRP78 and NF-
κB. In addition, the metabolism of MSA differed between PBMCs and DLBCL cell lines, 
suggesting that methylselenol is formed more efficiently in the latter. In contrast, 
keratinocytes and fibroblasts were relatively sensitive to MSA, but MSA was unable to 
protect keratinocytes from the toxicity of chemotherapeutic agents. These results differ 
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from those obtained in DLBCL cell lines in which MSA enhances the activity of 
chemotherapeutic agents. 
 
Combining MSA and bortezomib in mantle cell lymphoma cell lines unexpectedly 
resulted in an antagonistic interaction. This was associated with the induction of ER 
stress and autophagy and increased expression of two pro-survival proteins, Bcl-2 and 
Mcl-1. 
 
A proteomics approach identified novel protein changes induced by chemo-sensitising 
concentrations of MSA in two DLBCL cell lines. 
 
Several potential biomarkers of Se activity were identified; GRP78, NF-κB, vascular 
endothelial growth factor and acetylated histone H3. 
 
In conclusion, Se in the form of MSA affects many intracellular pathways in DLBCL cell 
lines, such that it has not been possible to identify a single unifying mechanism of Se 
action. However, differences have been observed between PBMCs and DLBCL cell lines 
and this work has identified novel protein changes and mechanisms of Se action.  
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ANOVA    analysis of variance 
AO     acridine orange 
ASCT     autologous stem cell transplant 
ATF     activating transcription factor 
Bak     Bcl2-associated killer protein 
Bax     Bcl2-associated X protein 
Bcl-2     B-cell lymphoma-2 
BCA     bicinchoninic acid 
CDK cyclin-dependent kinase  
cDNA complementary DNA 
CHOP cyclophosphamide, doxorubicin, vincristine,    
prednisolone 
CHOEP cyclophosphamide, doxorubicin, vincristine, 
etoposide, prednisolone  
CI     confidence interval 
CNS     central nervous system 
COC     cryogenic oven cooling 
cps     counts per second 
CR     complete remission 
CRu     complete remission unconfirmed  
CRP     C-reactive protein 
CT     computed tomography 
CTCL     cutaneous T-cell lymphoma 
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CVA     cerebrovascular accident 
DAPI     4’,-diamidino-2-phenylindole 
DEPC     Diethylpyrocarbonate 
DDB     DNA damage-binding protein 
DLBCL    diffuse large B-cell lymphoma 
DMBA    dimethylbenz(a)anthracene 
DMSO     dimethyl sulfoxide 
DNA     deoxyribonucleic acid 
dNTPs     deoxynucleoside triphosphate 
DSHNHL German High-Grade Non-Hodgkin Lymphoma 
Study Group 
DTNB     5,5’-dithiobis(2-nitrobenzoic acid) 
DTT     dithiothreitol 
ECL     enhanced chemiluminescence 
ECOG     Eastern Cooperative Oncology Group 
EDTA     ethylene diamine tetraacetic acid 
ELISA     enzyme-linked immunosorbent assay                                                                                                                         
eIF2α     eukaryotic initiating factor 2α 
ER     endoplasmic reticulum 
Erk     extracellular signal-regulated kinase 
ESI     electron spray ionisation 
FA     formic acid 
FC     fold change 
FDA Federal Drug Administration 
FDG-PET [
18
F]fluorodeoxyglucose-positron emission 
tomography  
FL follicular lymphoma   
GADD growth arrest and DNA damage inducible gene 
GAPDH    glyceraldehyde-3-phosphate dehydrogenase 
GC     gas chromatography 
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GCB     germinal centre B-cell 
GELA     Groupe d’Etude des Lymphoma de l’Adulte 
GIT     gastrointestinal tract 
GPx     glutathione peroxidase 
GR     glutathione reductase 
GRP     glucose regulated protein 
GSH     glutathione 
GSK     glutamine transaminase K 
GSSH     glutathione disulphide 
HAT histone acetyltransferase 
HBSS Hanks’ Buffered Salt solution 
4-HC 4-hydroperoxycyclophosphamide  
HDAC histone deacetylase 
HDACi histone deacetylase inhibitor 
HDT high dose therapy 
HEPES 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid 
HIF hypoxia inducible factor 
H2O2 hydrogen peroxide 
HPLC high performance liquid chromatography 
HRP horseradish peroxidase 
HSP heat shock protein 
HUVEC human umbilical vein endothelial cell 
ICE ifosphamide, carboplatin, etoposide  
ICP inductively coupled plasma 
IGEPAL
®
    Octylphenyl-polyethylene glycol 
IHC Immunohistochemical  
IKK IκB kinase 
IMAC immobilised metal ion affinity chromatography  
IPA Ingenuity Pathway Analysis 
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IPI international prognostic index 
IRE1 inositol requiring protein 1 
IS internal standard 
JC-1 5,5
’
,6,6
’
-tetrachloro-1,1
’
,3,3 -
tetraethylbenzimidazolylcarbocyanine iodide  
Jnk Jun N-terminal kinase 
Keap Kelch-like ECH-associated protein  
KMSB -keto- -methylselenobutyrate 
LDH lactate dehydrogenase   
LPL lymphoplasmacytic lymphoma 
MAPK mitogen activated protein kinase 
MCL mantle cell lymphoma 
Mcl-1 myeloid cell leukaemia-1  
MCM mini-chromosome maintenance 
MDC mediator of DNA damage checkpoint protein   
MFI mean fluorescence intensity  
MInT Mabthera international Trial 
M-MLV moloney-mouse leukaemia virus 
MMP mitochondrial membrane potential 
mmu millimass units 
MS mass spectrometry 
MSA  methylseleninic acid  
MSC methylselenocysteine  
MSP methylselenopruvate 
MTD  maximum tolerated dose 
mTOR mammalian target of rapamycin 
m/z mass to charge ratio  
NADPH nicotinomide adenine dinucleotide phosphate 
(reduced form) 
NaF     sodium fluoride 
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Na3VO4    sodium orthovanadate 
NF-κB     nuclear factor-kappa B 
NHL     non-Hodgkin lymphoma 
NPC     National Prevention of Cancer 
NR no response 
Nrf2 nuclear factor (erythroid-derived 2) related factor 2 
OS     overall survival 
PARP     poly(ADP-ribose)polymerase 
PBMCs    peripheral blood mononuclear cells 
PBS     phosphate buffered saline 
PBS-T     phosphate buffered saline with Tween-20  
PC     principal component 
PCA     principal component analysis 
PCR     polymerase chain reaction 
PD     progressive disease 
PDI     protein disulfide isomerase 
PERK     protein kinase RNA(PKR)-like ER kinase  
PHD     prolyhydroxylases 
PI     propidium iodide 
PI3K     phosphoinositide 3-kinase 
PKC     protein kinase C 
PLP     pyridoxal 5’-phosphate 
PMSF     phenylmethanesulfonyl fluoride 
PR     partial remission 
Prx     peroxiredoxin 
PVDF     polyvinylidene fluoride 
R     rituximab 
RD     remission duration 
R-IPI     revised international prognostic index 
RNA     ribonucleic acid 
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ROS     reactive oxygen species 
RLU     relative light units 
RR     response rate 
SAHA     suberoylanilide hydroxamic acid 
SBH     St Bartholomew’s Hospital 
SCX     strong cation exchange 
SD     standard deviation 
Se      selenium 
Sec     selenocysteine 
SECIS     selenocysteine insertion sequence 
SELECT    selenium and vitamin E cancer prevention trial 
shRNA    short hairpin ribonucleic acid 
SLM     selenomethionine 
SNP     single nucleotide polymorphism 
SOD superoxide dismutase 
SPME solid phase microextraction 
ST staurosporine 
TBI total body irradiation 
TBS Tris buffered saline 
TCP T-complex protein 
TFA trifluoroacetic acid 
TG thapsigargin 
TLCK tosyl-L-lysine chloromethyl ketone 
TNB 5′-thio-2-nitrobenzoic acid 
TNFα tumour necrosis factor alpha 
TOFMS time of flight mass spectrometry 
TRAIL tumour necrosis-related apoptosis-inducing ligand 
tRNA transfer ribonucleic acid  
TRB3 Tribbles-related protein 3 
Tris     tris(hydroxymethyl)aminomethane 
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Trx     thioredoxin 
TrxR     thioredoxin reductase 
TSA     trichostatin 
UK     United Kingdom 
UPLC     ultra high-performance liquid chromatography 
UPP     ubiquitin-proteasome pathway 
UPR     unfolded protein response 
USA     United States of America 
UV     ultraviolet 
VEGF     vascular endothelial growth factor 
VHL     von Hipple-Lindau 
WHO     World Health Organisation  
XBP1     X-box binding protein 1 
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CHAPTER 1: Introduction 
1.1 Background 
The first description of lymphoma came from Thomas Hodgkin in 1832 (Hodgkin, 1832). 
He described the post-mortem, gross anatomical appearance of seven patients who had 
presented with lymphadenopathy and splenomegaly. Later, it became apparent that some 
of these patients had the disease that now bears his name, Hodgkin lymphoma (Wilks, 
1865). Rudolf Virchow, in 1863, was the first to use the term lymphosarcoma to 
encompass the diseases we now know as Hodgkin and non-Hodgkin lymphomas (Jaffe et 
al, 2008). Since that time the classification of lymphoma has developed and changed 
extensively as different clinical, histological and immunophenotypic subtypes have been 
recognised and advances in the understanding of the underlying molecular pathogenesis 
have been made.  The most widely used classification is that of the World Health 
Organisation (WHO) (Swerdlow SH, 2008) which aims at defining specific entities 
according to their clinical, morphological, immunophenotypic and genetic characteristics.  
 
Non-Hodgkin lymphomas (NHL) account for around 4% of all new cancer diagnoses in 
the United Kingdom (UK) (http://info.cancerresearchuk.org/cancerstats) and the United 
States of America (USA) (Jemal et al, 2009). However, the incidence varies worldwide 
with the highest found in North America, Australia and New Zealand and the lowest in 
Eastern and South Central Asia (IARC). Variations also exist in the types of lymphoma 
seen in different parts of the world, such that T-cell and NK-cell lymphomas are more 
common in Asian countries (Swerdlow SH, 2008).  The incidence of NHL in Western 
countries has been increasing over the last 20 years, the reason for which is unclear. In 
2007, 10,917 people in the UK were diagnosed with NHL and in 2008 4,438 people died 
from NHL in the UK (http://info.cancerresearchuk.org). The incidence in men and 
women is roughly the same but because there are more women than men in the 
population, the male age-standardised incidence rate of 16.8/100,000 population is higher 
than the female rate of 11.9/100,000 population.  The incidence of NHL increases with 
age and 70% of all cases are diagnosed in people over the age of 60 
(http://info.cancerresearchuk.org).  
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1.2 Diffuse Large B-cell lymphoma  
1.2.1 Classification 
Diffuse large B-cell lymphoma (DLBCL) is the commonest subtype of NHL accounting 
for around 30% of all lymphomas worldwide (Anon, 1997). The disease we now call 
DLBCL has had many different names in the past. When the cell of origin of NHLs was 
not known, the classification of lymphoma was based on morphological appearance and 
growth pattern and terms included reticulum cell sarcoma (Gall & Mallory, 1942) and 
diffuse histiocytic lymphoma (Hicks et al, 1956). In the 1970s it was recognised that 
NHLs were tumours of the immune system derived from B- or T-cells and this led to an 
immunologically based classification. During the 1980s and 1990s, the Kiel classification 
dominated in Europe and what we know as DLBCL was sub-classified into 
immunoblastic, centroblastic and large cell anaplastic (B-cell) lymphomas (Gerard-
Marchant et al, 1974). In North America, however, the Working Formulation became the 
main classification and diffuse mixed, diffuse large cell and immunoblastic lymphomas 
were the terms used (Anon, 1982). In the late 1990s a new classification by the 
International Lymphoma Study Group, the ‘REAL’ classification, incorporated aspects of 
both the Kiel classification and Working Formulation and the term DLBCL came into use 
(Harris et al, 1994) .   
 
Since 2001, the WHO classification has been most widely used. In the 2001 3
rd
 edition, 
the term DLBCL was used to encompass all clinical and histological subtypes of the 
disease. However, in the most recent 2008 4
th
 edition, variants, sub-groups and subtypes 
of DLBCL are defined on the basis of site of disease, clinical factors and pathological 
features (Table 1.1) (Swerdlow SH, 2008). After separating these less common, new 
subtypes of DLBCL, there remains the group that represents the most common type of 
DLBCL that cannot be further sub-classified based on clinical or pathological features 
and this is classified as DLBCL, not otherwise specified (NOS).  In the rest of this thesis, 
the term DLBCL refers to DLBCL-NOS as defined in the 2008 WHO classification.   
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Table 1.1 The 2008 WHO classification of DLBCL.  
DLBCL, not otherwise specified 
      Common morphological variants       
         Centroblastic 
         Immunoblastic 
         Anaplastic    
      Rare morphological variants 
    
      Molecular Subgroups  
         Germinal centre B-cell-like 
         Activated B-cell-like 
     
      Immunohistochemical subgroups 
        CD5-positive DLBCL    
T-cell/histiocyte-rich large B-cell lymphoma 
 
Primary DLBCL of the central nervous system 
 
Primary cutaneous DLBCL, leg type 
 
EBV* positive DLBCL of the elderly 
 
DLBCL associated with chronic inflammation 
 
Other lymphomas of large B-cells 
Borderline cases 
      Features intermediate between DLBCL and 
      Burkitt or classical Hodgkin lymphoma 
 
*EBV, Ebstein-Barr virus 
 
1.2.2 Clinical features and staging 
DLBCL is an aggressive malignancy of large, mature B-cells which if left untreated has a 
median overall survival of less than a year. It usually arises de novo, but can also arise as 
a consequence of histological transformation of a less aggressive lymphoma, most 
commonly follicular lymphoma (FL). DLBCL is slightly more common in males than 
females and the median age at diagnosis is in the 7
th
 decade (Anon, 1997). The aetiology 
of the disease remains unknown although underlying immunodeficiency is a significant 
risk factor. Patients usually present with a rapidly enlarging, symptomatic mass which 
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may be nodal or extranodal and in up to 40% of patients the disease is initially confined 
to extranodal sites (Harris et al, 1994). The commonest extranodal site is the 
gastrointestinal tract with the stomach and ileocaecal region most frequently involved 
(Koch et al, 2001). B symptoms consisting of fever, drenching night sweats and 
significant weight loss are present in around 30-40% of patients at diagnosis (Coiffier et 
al, 2002; Pfreundschuh et al, 2008b). 
 
The extent of disease at diagnosis is determined by clinical examination, computed 
tomography (CT) scanning of the chest, abdomen and pelvis and a bone marrow biopsy. 
Increasingly, [
18
F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) is 
being used to better delineate the extent of disease (Cheson et al, 2007). Around half of 
patients have disseminated disease at diagnosis (stage III/IV) (Anon, 1997).  
 
1.2.3 Prognostic factors 
Clinical prognostic factors 
At diagnosis, patients can be stratified into prognostic groups based on the International 
Prognostic Index (IPI) (Anon, 1993) which considers five unfavourable clinical 
parameters; age >60 years, Eastern Cooperative Oncology Group (ECOG) performance 
status ≥2, advanced stage (III/IV),  ≥2 extranodal sites involved and elevated serum 
lactate dehydrogenase (LDH). Patients can thus be grouped into four risk groups which 
predict treatment response, progression-free survival and overall survival (OS; Table 1.2). 
For patients ≤60 years, the age-adjusted IPI (aaIPI) score can be used which considers 
three unfavourable variables; poor performance status, elevated LDH and advanced stage, 
and divides patients into four risk groups (Table 1.2). Since the IPI score was validated in 
patients who had not received rituximab (R) as part of their treatment (see below in 
Treatment; section 1.2.4), its prognostic value in the rituximab era needed to be re-
assessed. A retrospective analysis of patients treated with combination chemotherapy and 
rituximab addressed this issue and found that the IPI score remained predictive but was 
only able to identify two risk groups. However, when the same factors were redistributed 
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into a revised IPI score (R-IPI), it was possible to identify three distinct prognostic 
groups (Table 1.3) (Sehn et al, 2007).  
 
Table 1.2 Outcome of patients with DLBCL according to the IPI score, prior to the use of 
rituximab.  
IPI score Risk category No. of risk 
factors 
% Patients % Complete 
remission 
% 5-year 
OS 
Full score Low 0,1 35 87 73 
 Low-
intermediate 
2 27 67 51 
 High-
intermediate 
3 22 55 43 
 High 4,5 16 44 26 
Age-
adjusted 
≤60 years 
Low 0 22 92 83 
 Low-
intermediate 
1 32 78 69 
 High-
intermediate 
2 32 57 46 
 High 3 14 46 32 
Adapted from Anon, N Engl J Med, 1993. 
 
 
Table 1.3 Outcome of DLBCL according to the IPI score in patients treated with 
rituximab.  
IPI score Risk category No. of risk 
factors 
% Patients % 4-year 
OS 
Full score Low 0,1 28 82 
 Low-
intermediate 
2 27 81 
 High-
intermediate 
3 21 49 
 High  4,5 24 59 
Revised Very good 0 10 94 
 Good 1,2 45 79 
 Poor 3,4,5 45 55 
Adapted from Sehn, LH, et al., Blood, 2007. 
 
In addition to the IPI score, bulky disease was found to be an independent adverse 
prognostic marker in the Mabthera international Trial (MInT) (Pfreundschuh et al, 2008a). 
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This was a study evaluating the use of ‘CHOP’ (cyclophosphamide, doxorubicin, 
vincristine, prednisolone) or ‘CHOP-like’ chemotherapy, with or without rituximab, in 
patients aged between 18 and 60 years with good-prognosis disease; defined as an aaIPI 
score of 0 or 1, stages II-IV and stage 1 with bulky disease (i.e. a tumour mass >5cm in 
diameter).  A linear prognostic effect on outcome was found in patients with a maximum 
tumour diameter between 5 and 10cms. In contrast, the Groupe d’Etude des Lymphoma 
de l’Adulte (GELA) study comparing ‘CHOP’ with and without rituximab in patients 
aged >60 years did not find that tumour bulk was a prognostic factor (Coiffier et al, 
2002). Therefore, whether tumour bulk in the rituximab era is prognostic in all patient 
groups still needs to be clarified. 
 
Molecular prognostic factors 
In addition to the clinical prognostic factors discussed above, molecular characteristics of 
the disease have also been found to influence patient outcome. Studies using 
deoxyribonucleic acid (DNA) microarrays to investigate gene expression in tumour 
samples from patients with DLBCL have identified two distinct molecular subgroups 
with gene expression patterns reflecting different stages of B-cell development. One 
subgroup has the gene expression profile of germinal centre B-cells and is termed GCB-
like. The other expresses genes normally induced during in vitro activation of peripheral 
blood B-cells and is termed activated B-cell-like (ABC-like). A third subgroup, termed 
type 3 has also been described but this group is heterogenous and not well defined 
(Alizadeh et al, 2000; Rosenwald et al, 2002).  The outcome in patients with GCB-like 
gene expression signature is far superior with a 5-year survival of 60% compared with 
35% in the ABC-like and 38% in the type 3 subgroup (Rosenwald et al, 2002). Although 
prognosis has improved in both the GCB-like and ABC-like subgroups with the use of 
rituximab, there remains a significant difference in outcome between the two groups 
(Lenz et al, 2008a).  
 
The GCB- and ABC-like subgroups have characteristic chromosomal aberrations and 
alterations in different oncogenic pathways (Lenz et al, 2008b). For example, the t(14;18) 
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translocation, amplification of the REL locus on chromosome 2 and deletion of the 
tumour suppressor PTEN on chromosome 10 occurs exclusively in the GCB-like 
subgroup. In the ABC-like subgroup there is over-expression of Bcl-2 protein in the 
absence of the t(14;18) translocation and the transcription factor interferon regulatory 
factor 4 (IRF4). Other frequent aberrations include trisomy 3, deletion of chromosome 
arm 6q, and deletion of the INK4a/ARF (inhibitor of kinase 4A-alternative reading frame) 
tumour suppressor locus on chromosome 9.  In addition, the ABC-like subgroup is 
characterised by constitutive activation of the nuclear factor-kappa B (NF-κB) pathway 
which promotes cell survival through activation of a large number of target genes. 
Activation of the NF-κB pathway is thought to be a mechanism of chemo-resistance in 
different tumour types and therefore may partly explain the poor prognosis of the ABC-
like subgroup (Guo et al, 2004).  
 
Since gene expression profiling is not routinely available in clinical practice, 
immunohistochemical (IHC) staining of tumours has been used as a surrogate to classify 
patients into GBC and non-GCB subgroups. The most widely used algorithm is that 
developed by Hans et al. (2004), which makes used of three IHC markers; CD10, Bcl-6 
and IRF4. This was able to divide patients into two prognostic groups with a 76% and 
34% 5-year OS for the GCB and non-GCB groups respectively (Hans et al, 2004). 
However, these results have not been confirmed by all studies and correlation with the 
gene-expression defined molecular subgroups remains imperfect (De Paepe et al, 2005). 
In addition, the value of IHC-based classification in patients treated with rituximab has 
not been confirmed (Nyman et al, 2007) and the reproducibility and interpretation of 
some IHC stains remains a problem (de Jong et al, 2007).  
 
The GCB and ABC subgroups of DLBCL have not been formally incorporated into the 
WHO classification for three main reasons. Firstly, gene expression profiling is currently 
not available in routine clinical practice. Secondly, as mentioned above, the 
reproducibility and value of IHC-defined subgroups is not clear. Thirdly, the molecular 
subgroup does not currently influence patient management. With regards to the latter 
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point, clinical trials have begun to incorporate the molecular subgroup into their 
treatment protocols. An example of this is the current National Cancer Institute (USA) 
trial in which patients with non-GCB DLBCL are randomised to receive rituximab plus 
‘CHOP’ chemotherapy with or without bortezomib, a drug that inhibits the NF-κB 
pathway (www.cancer.gov). A similar study is due to start shortly in the UK.   
 
The gene-expression signature of the non-malignant cells present in the tumour 
microenvironment has also been shown to influence survival (Lenz et al, 2008a).  Two 
gene-signatures termed stromal-1 and stromal-2 have been identified. The stromal-1 
signature, associated with a favourable outcome, reflected extracellular matrix deposition 
and macrophage infiltration of the tumour. In contrast, the stromal-2 signature, associated 
with an inferior outcome, identified tumours expressing genes related to angiogenesis and 
this was also associated with increased tumour blood-vessel density. 
 
1.2.4 Treatment 
Vincent DeVita and his colleagues from the National Cancer Institute (USA) were the 
first to report, in 1975, that combination chemotherapy was potentially curative for 
‘diffuse histiocytic lymphoma’, the majority of cases of which were probably DLBCL 
(DeVita et al, 1975). Since that time, DLBCL has been treated with a combination of 
non-cross resistant chemotherapy agents, the most widely used regimen has being 
‘CHOP’. This regimen combines cyclophosphamide, doxorubicin, vincristine and 
prednisolone given every 21 days (McKelvey et al, 1976). Subsequently, more intensive 
regimens were tested and were initially thought to be more effective but when a 
randomised comparison was made with ‘CHOP’, no difference was demonstrated in the 
response rate (RR) or OS and long-term OS was around 40% (Fisher et al, 1993). 
Additional strategies to improve the efficacy of ‘CHOP’ have consisted of intensifying 
the regimen by adding drugs such as etoposide (‘CHOEP’) and by giving ‘CHOP’ every 
14 days instead of every 21 days (Pfreundschuh et al, 2004a; Pfreundschuh et al, 2004b; 
Tilly et al, 2003). Both these strategies have improved RRs, however, most centres have 
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continued using ‘CHOP’ every 21 days because of the increased toxicity of the newer 
regimens. 
 
Localised disease 
Localised DLBCL usually refers to patients with stage I disease. However, some patients 
with stage II disease, where the disease can be incorporated into a single radiotherapy 
field, are also sometimes referred to as having localised disease. Until recently, an 
abbreviated course of chemotherapy followed by involved field radiotherapy has been 
standard treatment in patients with localised DLBCL. This approach was based on a 
randomised trial by the Southwest Oncology Group in the USA that showed superiority 
of 3 cycles of ‘CHOP’ chemotherapy plus radiotherapy over 8 cycles of ‘CHOP’ 
chemotherapy alone, in patients with localised ‘aggressive’ lymphoma (Miller et al, 
1998).  However, updated results from this trial no longer show a survival difference 
between the two treatment groups, mainly due to late relapses and deaths from lymphoma 
in patients who received abbreviated ‘CHOP’ plus radiotherapy (Miller et al, 2001). 
Furthermore, a randomised trial conducted by the GELA group in patients older than 60 
years with localised, ‘aggressive’ lymphoma, compared 4 cycles of ‘CHOP’ alone or the 
latter followed by radiotherapy. At a median follow-up of 7 years, there was no 
significant difference between the two arms in 5-year event-free or OS. Whilst the 
addition of radiotherapy did reduce recurrence at the initial site of disease it failed to 
prevent distant recurrence (Bonnet et al, 2007). In addition to this study, the GELA trial 
in younger patients (<60 years) comparing a dose-intensified ‘CHOP’ regimen with 3 
cycles of ‘CHOP’ plus involved field radiotherapy in patients with localised ‘aggressive’ 
lymphoma found that the chemotherapy alone arm had a superior outcome (Reyes et al, 
2005). In contrast, a study conducted by the ECOG, in which patients were randomised to 
receive or not to receive radiotherapy following 8 cycles of ‘CHOP’ chemotherapy, did 
report a significant disease-free survival benefit in the radiotherapy group (Horning et al, 
2004). It should be noted, however, that this study included patients with less favourable 
characteristics such as bulky or extranodal disease.   
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Although the studies discussed above differ in design, patient characteristics, the type of 
chemotherapy and the number of cycles administered, overall it can be concluded that a 
‘full course’ of combination chemotherapy alone is the optimal treatment for patients 
with localised DLBCL. Radiotherapy may result in better local disease control but to 
prevent recurrence at distant sites, adequate systemic chemotherapy is required. It has 
been extrapolated that the addition of rituximab (see below) to chemotherapy is likely to 
benefit patients with localised disease and thus ‘CHOP’ plus rituximab is the standard 
treatment in most centres.     
 
Disseminated disease 
The most significant advance in the treatment of DLBCL in recent years has been the 
addition of rituximab to ‘CHOP’ chemotherapy. Rituximab is a chimeric antibody, which 
targets the CD20 antigen on B-cells. The study that changed practice was conducted by 
the GELA study group and it was demonstrated that the addition of rituximab to ‘CHOP’ 
(‘CHOP-R’) chemotherapy in 399 previously untreated patients, aged between 60 and 80 
years, significantly improved RR and OS. The complete remission (CR)/CR unconfirmed 
(CRu) rate and 2-year OS in the ‘CHOP-R’ group was 75% and 70% respectively 
compared with 63% and 57% in the ‘CHOP’ group (Coiffier et al, 2002). The long-term 
results of this study have been published and confirm the superiority of the ‘CHOP-R’ 
regimen. The 5-year OS survival in the ‘CHOP-R’ group was 58% compared with 45% 
in the ‘CHOP’ group. (Feugier et al, 2005). The MInT study subsequently confirmed the 
superiority of 6 cycles of ‘CHOP’ (or ‘CHOP’-like) plus rituximab given every 21 days 
over ‘CHOP’ (or ‘CHOP’-like) in 824 patients aged between 18-60 years with good 
prognosis DLBCL. The addition of rituximab increased the 3-year OS from 84% to 93%. 
However, significantly different results were obtained according to the aaIPI score. 
Patients with an aaIPI score of 0 and no bulk had a 3-year event-free survival of 97% 
compared with 78% in patients with an aaIPI score of 1 +/- bulky disease (Pfreundschuh 
et al, 2006).  
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Hence, in both young and elderly patients with good or poor prognosis disease, the 
addition of rituximab to ‘CHOP’ given every 21 days has become the standard of care in 
the ‘western world’. However, unanswered questions remain regarding the scheduling of 
the CHOP-R regimen and whether intensification of the regimen yields better results in 
poor prognostic groups. In addition, patients with a very good prognosis may require less 
treatment, which could reduce toxicity.  
 
These questions are being addressed in current clinical trials. For younger patients (<60 
years) with an aaIPI score of 0 and no bulk the prognosis is very favourable and therefore 
the FLYER trial being conducted by the German High-Grade Non-Hodgkin Lymphoma 
Study Group (DSHNHL) is comparing 6 cycles of  ‘CHOP-R’ given every 21 days with 
4 cycles. In younger patients with an intermediate prognosis (aaIPI score 1 or 0 with 
bulky disease), the DSHNHL UNFOLDER trial is addressing whether ‘CHOP-R’ given 
every 14 days yields better results than ‘CHOP-R’ given every 21 days. 
 
In younger patients with an unfavourable prognosis (aaIPI score 2, 3) there is no 
established standard of care. Randomised trials addressing the role of rituximab in this 
group of patients are lacking but the benefit of rituximab has been assumed from 
retrospective analyses and extrapolation from rituximab trials in other patient cohorts. 
Phase II trials of ‘CHOP-R’ have yielded disappointing results with one study reporting a 
CR rate of 74% and a 2-year OS of 68% (Brusamolino et al, 2006). Novel high-dose 
chemotherapy regimens are currently being investigated using cytotoxic agents to their 
maximum tolerated doses. One such is the DSHNHL ‘Mega-CHOEP’ trial which 
compared 8 cycles of conventional dose ‘CHOEP-R’, given every 14 days, with dose-
escalated ‘CHOEP-R’ (‘Mega-CHOEP’) requiring haematopoietic stem cell support. 
Results published in abstract form reported that the ‘CHOEP-R’ group had a 3-year 
event-free survival of 71% and an estimated 3-year OS of 84%. These are the best results 
reported in young, high-risk patients with DLBCL. The ‘Mega-CHOEP’ arm was 
discontinued prematurely due to its higher toxicity and inferior survival (Schmitz et al, 
2009).  
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The prognosis for elderly patients (>60 years) is worse than in younger patients and thus 
attempts are being made to improve upon the results of the landmark study by the GELA 
group which compared 8 cycles of ‘CHOP’ with ‘CHOP-R’ every 21 days (Feugier et al, 
2005). The DSHNHL study group have previously demonstrated that ‘CHOP’ given 
every 14 days results in better RR and OS than ‘CHOP’ given every 21 days 
(Pfreundschuh et al, 2004a). Hence, the same study group conducted the RICOVER-60 
trial comparing 6 and 8 cycles of ‘CHOP’ given every 14 days with and without 
rituximab. This demonstrated that 6 cycles of ‘CHOP’ given every 14 days plus 8 doses 
of rituximab was the best regimen, with significantly improved event-free, progression-
free and OS (Pfreundschuh et al, 2008b). However, the results of trials formally 
comparing ‘CHOP-R’ every 14 days with every 21 days in all age groups are still awaited 
(Cunningham et al, 2009). 
 
Other unanswered questions include the role of radiotherapy in patients with 
disseminated disease and high-dose therapy (HDT) followed by autologous 
haematopoietic stem support in the first-line treatment of high-risk patients. Regarding 
radiotherapy, there have been no randomised trials showing its benefit, in addition to 
chemotherapy, to areas of bulky or extranodal disease. This question is being addressed 
in the above mentioned UNFOLDER study. The superiority of HDT followed by 
autologous haematopoietic stem cell support over conventional chemotherapy in the first-
line treatment of high-risk patients has not been established due to conflicting results 
obtained in clinical trials attempting to address this question (Haioun et al, 2000; Linch et 
al, 2010). A meta-analysis of all randomised trials of HDT as first-line treatment of 
‘aggressive’ lymphoma was not able to show an overall survival benefit of HDT (Strehl 
et al, 2003). However, this meta-analysis was performed prior to the routine use of 
rituximab and thus the role of HDT as first-line treatment with the incorporation of 
rituximab is currently being investigated. Of note, the ‘Mega-CHOEP’ trial discussed 
above concluded that HDT with autologous haematopoietic stem cell support has no role 
to play in first-line treatment if rituximab is combined with conventional chemotherapy 
(Schmitz et al, 2009).  
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Central nervous system prophylaxis 
The issue of central nervous system (CNS) prophylaxis in the treatment of DLBCL 
remains unresolved. It is routine practice in most treatment centres to administer CNS 
prophylaxis to those patients considered at high risk of CNS relapse as this carries an 
extremely poor prognosis. However, there is considerable variation in practice regarding 
indications for and methods of prophylaxis. Factors most commonly used to identify 
patients at high risk include site of disease involvement such as paranasal sinus, testis, 
epidural, bone marrow. In addition, factors such as stage IV disease, raised LDH, high-
risk IPI score and >1 extranodal site involved have been identified as important in 
predicting CNS relapse (Cheung et al, 2005).  
 
The most widely used method of prophylaxis is the administration of intra-thecal 
methotrexate. However, the results of the RICOVER-60 trial have added more confusion 
to this area as it reported that the addition of rituximab to ‘CHOP’ reduced the risk of 
CNS recurrence but that the addition of intra-thecal methotrexate did not further reduce 
this risk in patients treated with ‘CHOP-R’ (Boehme et al, 2009). The problem with these 
results is that this was a post-hoc analysis and the study was not powered to determine 
reduction in risk of CNS recurrence. It may be that the risk of CNS recurrence is reduced 
by rituximab purely because it reduces the overall risk of recurrence. Therefore, this issue 
requires further investigation and clarification. 
 
It can be concluded that the addition of rituximab to ‘CHOP’ chemotherapy has resulted 
in significant improvement in the first-line treatment of all patients with DLBCL. 
However, it is clear that there are sub-groups of patients for which this regimen is not 
optimal. Therefore, future clinical trials need to concentrate on a more personalised 
approach to treatment, taking into account clinical and molecular prognostic factors and 
tailoring treatment accordingly. 
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Treatment of DLBCL at St Bartholomew’s Hospital  
At St Bartholomew’s Hospital (SBH), NHL of ‘unfavourable histology’, (which would 
have included what we now call DLBCL), has been treated with an anthracycline-
containing combination since the early 1970’s. Initially, the regimen known as ‘OPAL’ 
(originally developed as treatment for adults with acute leukaemia) was used (Lister et al, 
1978b). Consisting of what would now be considered relatively low doses of 
myelosuppressive drugs given every two weeks, the regimen comprised doxorubicin and 
vincristine given every 14 days for up to 6 doses, L-asparaginase given daily for 14 days 
and prednisolone given daily for the duration of treatment (Lister et al, 1978a).  
Subsequently, asparaginase was removed from the regimen to give a three drug 
combination known as ‘VAP’. With the latter, the CR rate was 61% and the 3-year OS, 
48% (Blackledge et al, 1980).  
 
In the mid-1980’s, the results of a regimen known as ‘MACOP-B’, used to treat patients 
with DLBCL, were published from Vancouver (Klimo & Connors, 1985). The regimen 
was derived from the Goldie-Colman hypothesis and was based on the precept that pairs 
of non-cross-resistant drugs given on alternate weeks would be more effective than 
conventional dosing schedules (Goldie & Coldman, 1986).  Treatment was short, only 12 
weeks. The results were indeed impressive, with a CR rate of 84% and, with a median 
follow-up of 4 years, the OS was 65%. Thus, the regimen was adopted at SBH and at the 
Christie Hospital, Manchester but with a modification: etoposide was substituted for 
methotrexate and the regimen was known as ‘VAPEC-B’ (Radford et al, 1994). This was 
an 11-week schedule of intravenous doxorubicin, cyclophosphamide, vincristine and 
bleomycin combined with oral etoposide and prednisolone. The CR rate was 62%, with a 
4-year OS of 45%. 
 
Between 1980 and 1986, an open-label study was conducted at SBH in which patients 
with newly diagnosed ‘intermediate’ and ‘high-grade’ NHL were treated with ‘MACOP’ 
(also known as ‘CHOP-M’) (Dhaliwal et al, 1993). Similar to the ‘CHOP’ regimen as 
currently used, it included, in addition, mid-cycle, intermediate dose, intravenous 
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methotrexate with leucovorin rescue and intra-thecal methotrexate. The regimen was 
essentially a hybrid between ‘M-BACOD’ (as originally used at the Dana-Farber Cancer 
Institute) that included bleomycin and high-dose methotrexate, and conventional-dose 
‘CHOP’. (Skarin et al, 1983) The aim was to try and give the non-myelosuppressive 
methotrexate mid-cycle, to prevent progression between cycles. In the SBH regimen 
however, the dose of methotrexate was lower and bleomycin was omitted. The results 
achieved were similar to those expected had ‘CHOP’ been used but not as good as those 
for ‘M-BACOD’. However, the patient populations at SBH and the Dana-Farber Cancer 
Institute are different and this was not a planned, randomised comparison, thus such a 
comparison is not valid. 
 
In most recent times, the standard ‘CHOP’ regimen has been used to treat newly 
diagnosed patients with DLBCL and since 2003, rituximab has been added. Prior to 2001, 
the policy at SBH was to give all patients prophylactic intra-thecal methotrexate with 
each cycle of chemotherapy. Subsequently, only those deemed at high risk for CNS 
relapse received this. These included patients with high LDH, a high-risk IPI score and 
involvement by DLBCL at specific anatomical sites; bone marrow, testes, the post-nasal 
space and Waldeyer’s ring. Those with a paraspinal mass were also given CNS 
prophylaxis. 
 
1.2.5 Response assessment 
Prior to 1999, assessment of response to therapy varied widely. Therefore, the 
International Working Group published guidelines on the subject, which were readily 
adopted. This recommended the following categories based on clinical examination, CT 
scanning and bone marrow biopsy (if the bone marrow was involved at diagnosis); 
complete remission (CR), complete remission unconfirmed (CRu), partial remission (PR), 
stable disease (SD) and relapsed or progressive disease (PD) (Cheson et al, 1999). In 
2007, these guidelines were revised to incorporate the results of FDG-PET scanning and 
thus the category of CRu was eliminated (Table 1.4) (Cheson et al, 2007).  
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Table 1.4 Response assessment in patients with DLBCL  
 1999 2007 
Response Definition Definition 
CR Complete clinical and radiological 
disappearance of disease. 
Complete clinical and radiological 
disappearance of disease. PET 
negative. 
CRu A residual lymph node mass 
greater than 1.5 cm in 
greatest transverse diameter that 
has regressed by more than 75% 
in diameter. Indeterminate bone 
marrow biopsy. 
N/A 
PR ≥50% decrease in diameter of up 
to 6 of the largest dominant 
masses.  
≥50% decrease in diameter of up to 6 
of the largest dominant masses. PET 
positivity in a previously involved 
site. 
SD Failure to attain CR/PR or PD Failure to attain CR/PR or PD 
Relapsed or PD Any new lesion or increase by 
≥50% of a previously involved 
site.  
Any new lesion or increase by ≥50% 
of a previously involved site. 
Adapted from Cheson, BD et al., J Clin Oncol, 1999 and 2007. 
 
 
1.2.6 Recurrence 
Despite improvements in the treatment of newly diagnosed patients with DLBCL, the 
outcome of recurrent disease remains very poor.  A significant proportion of patients, due 
to advanced age and co-morbidities, are deemed unsuitable for further intensive 
chemotherapy. For those considered suitable, HDT followed by autologous 
haematopoietic stem cell support remains the standard treatment for patients with 
recurrent disease (Philip et al, 1995) but it is only of value to patients who remain 
sensitive to second-line ‘conventional dose’ chemotherapy (Prince et al, 1996). A 
standard second-line chemotherapy regimen does not exist but such regimens usually 
contain a platinum agent or cytosine arabinoside. Overall RR to commonly used second-
line regimens are around 60% with CR rates of only 25-35% (Moskowitz et al, 1999; 
Velasquez et al, 1988; Velasquez et al, 1994). Although the IPI score is predictive for 
overall and progression-free survival in patients with recurrent disease (Guglielmi et al, 
2001; Hamlin et al, 2003), patients (i.e. those being treated with curative intent) are 
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treated without attention being paid to the IPI score. The importance of re-biopsy at 
recurrence should also be emphasised as a small proportion of patients have a different 
histology at recurrence, most commonly FL, and therefore would be treated differently 
(Larouche et al, 2010). 
 
Cure is only possible in around 30-40% of patients with recurrent DLBCL who get to the 
point of HDT (Vose et al, 2004). Several reasons prevent a significant proportion of 
patients from receiving HDT such as chemoresistance, advanced age and co-morbidities 
and therapeutic options for those patients are limited. The addition of rituximab to 
second-line therapy has improved response rates. CR rates in a study evaluating the 
efficacy of ‘R-ICE’ (rituximab, ifosphamide, carboplatin, etoposide) as second-line 
therapy were 53% compared with 27% in historical controls not treated with rituximab 
(Kewalramani et al, 2004). However studies to date have been conducted in rituximab-
naive patients and the efficacy of rituximab in patients failing first-line 
immunochemotherapy is currently being investigated. Interestingly, rituximab 
monotherapy in patients with recurrent/refractory DLBCL, not previously exposed to 
rituximab, was shown to result in a RR of 37% (Coiffier et al, 1998).  
 
Evidence is now emerging to suggest that the outcome of patients with recurrent DLBCL, 
who have already been exposed to rituximab, may be even worse. A retrospective study 
evaluating the influence of prior exposure to rituximab on RR and survival in patients 
with relapsed/refractory DLBCL found prior exposure to be an independent adverse 
prognostic factor. Patients previously treated with rituximab had a 3-year progression-
free survival of 17% compared with 57% in those not previously receiving rituximab and 
a 3-year OS of 38% compared with 67% (Martin et al, 2008). An interim analysis of the 
prospective, phase III CORAL study comparing ‘R-ICE’ with ‘R-DHAP’ 
(dexamethasome, cytarabine, cisplatin) has also reported an inferior event-free survival in 
patients previously exposed to rituximab (Giesselbrecht C, 2007). Thus, rituximab 
resistance appears to be a significant problem and better second-line therapies are needed. 
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In contrast to the situation at diagnosis, the molecular subgroup at recurrence does not 
appear to correlate with outcome in the small number of studies that have been performed, 
both the GCB and ABC-like subgroups having an equally poor prognosis (Costa et al, 
2008; Moskowitz et al, 2005). There also appears to be concordance between the 
molecular subgroup at diagnosis and recurrence although this has by no means been 
widely studied (Moskowitz et al, 2005). A recently reported clinical trial studied the role 
of bortezomib in patients with relapsed/refractory DLBCL. Although bortezomib had no 
clinical activity as a single agent, when combined with conventional chemotherapy it 
resulted in a significantly higher RR and OS in patients with the ABC subgroup 
compared with the GCB subgroup. The overall RR and CR rate were 83% and 42% 
respectively in the ABC subgroup, compared to only 13% and 6.5% respectively in the 
GCB subgroup. The median OS was 10.8 months in the ABC subgroup compared to only 
3.4 months on the GCB subgroup (Dunleavy et al, 2009). This is a potentially important 
finding, suggesting that the role of bortezomib in both first- and second-line treatment of 
DLBCL needs to be investigated further. In addition, the study highlights the importance 
of the molecular subgroup when considering different therapeutic options, thus enabling 
better tailoring of targeted agents. As mentioned above, a clinical trial is currently open in 
the USA and another will be opening in the UK to investigate the role of bortezomib in 
the first-line treatment of patients with non-GCB DLBCL.  
 
1.2.7 Treatment of recurrent DLBCL at St Bartholomew’s Hospital 
Over a long period of time, the ‘second-line’ regimen at SBH for patients with 
recurrent/refractory DLBCL was intermediate dose cytosine arabinoside and etoposide 
(Whelan et al, 1992). Although other centres had reported good results with the platinum-
containing ‘ESHAP’ regimen, at SBH, this was found to have very limited efficacy and 
was therefore abandoned (Johnson et al, 1993). With the advent of HDT, since 1985, 
patients less than 65 years of age achieving either a CR/CRu or a PR to ‘second-line’ 
therapy have been considered for HDT with autologous haematopoietic stem cell support. 
Prior to 1997, the myeloablative regimen used was cyclophosphamide and total body 
irradiation. However, this regimen was found to be associated with a significant risk of 
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secondary myelodysplasia and acute myelogenous leukaemia (AML) (Rohatiner et al, 
2007). Therefore, in 1997 the ‘drug-only’ myeloablative regimen ‘BEAM’ (carmustine, 
etoposide, cytarabine and melphalan) was introduced. 
 
Clearly there is a need for better therapies for relapsed/refractory DLBCL and a number 
of new promising targeted agents are currently being investigated. These include the 
radio-immunoconjugate 
90
Y-ibritumomab-tiuxetan, the anti-angiogenic agents 
bevacizumab and lenalidomide and the humanised anti-CD20 monoclonal antibody, 
ofatumumab. This thesis has investigated the potential therapeutic role of selenium (Se) 
in DLBCL. The basis for this comes mainly from work performed in solid tumours, in 
which the addition of Se has been shown to enhance the efficacy of standard 
chemotherapeutic agents whilst protecting normal tissue from chemotherapy-induced 
toxicity (Cao et al, 2004). The background to the use of Se in cancer therapy will now be 
discussed in more detail.  
 
 
1.3 Selenium 
1.3.1 Background 
Se is a trace element occurring in inorganic and organic forms that is fundamental to 
human health. It is unique amongst trace elements in that the main form of Se, 
selenocysteine (Sec) is encoded in DNA by the TGA codon. Sec is the 21
st
 amino acid 
that is incorporated into selenoproteins, of which there are 25 in man (Kryukov et al, 
2003). Se was first discovered in 1817 by the Swedish chemist Jon Jakob Berzelius who 
named it after the Greek goddess of the moon, Selene (Papp et al, 2007). The discovery 
initially came about because of its toxic effects when Berzelius was investigating the 
cause of illness amongst workers at a sulphuric acid manufacturing plant (Franke, 1934). 
In fact, it is likely that even before Se was discovered, reports of conditions occurring in 
animals were in fact due to excessive Se. The explorer, Marco Polo, described the 
splitting and falling off of hooves in horses and other animals grazing in a particular 
mountainous region of China (Marco, 1967). On the basis of current knowledge, it is 
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likely that these animals were grazing in areas where soil Se was at toxic levels. 
Therefore, research initially focussed on avoiding or ameliorating the toxic effects of Se. 
In fact, in 1943 Se was reported to be a carcinogen (Nelson et al, 1943). However, it soon 
became apparent that Se was an essential element and that diseases in animals and man 
could be caused by Se deficiency (Anon, 1979; Muth et al, 1958). This changed the 
emphasis of research and since, much has been learnt about the biological role of Se and 
the beneficial effects on human health.   
 
Two diseases in man are associated with overt Se deficiency. These were first recognised 
in an area of China where soil Se is extremely low. Keshan disease is a cardiomyopathy 
affecting mainly children and women of child-bearing age and is frequently fatal. It is 
named after the north-east region of China where it was endemic (Cheng & Qian, 1990). 
Large scale Se supplementation has now reduced the disease incidence. Subsequently, it 
was discovered that the aetiology of Keshan disease is in part due to infection with an 
endemic Coxsackie virus which is more virulent in the presence of Se deficiency (Beck et 
al, 1994). Keshin-Beck disease is an osteoarthropathy that occurs in rural areas of China, 
Tibet and Siberia that is associated with severe Se deficiency but other factors are also 
important such as iodine status (Moreno-Reyes et al, 1998). In addition, it has been 
demonstrated that a low serum/plasma Se is associated with increased all cause mortality 
in the elderly (Akbaraly et al, 2005), a decline in cognitive function (Akbaraly et al, 
2007), reduced fertility in men (Scott et al, 1998), pregnancy complications such as 
preeclampsia and miscarriage in women (Barrington et al, 1997; Rayman et al, 2003) and 
possibly an increased risk of cardiovascular disease (Flores-Mateo et al, 2006). 
Supplementation with Se above the recommended daily intake has beneficial effects on 
the immune system, mainly by enhancing cell-mediated immunity (Kiremidjian-
Schumacher et al, 1994). It may have a role in delaying the progression of HIV infection 
(Hurwitz et al, 2007) and protects against disorders of the thyroid gland (Turker et al, 
2006).  
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Se deficiency, therefore, results in a number of disparate effects, which are ameliorated 
by Se supplementation. However, the mechanism of these effects is not entirely clear. 
The anti-oxidant function of many selenoproteins is likely to be important although this 
does not provide a full explanation as some beneficial effects of Se supplementation are 
observed at levels above that required for full selenoprotein activity.      
 
In addition to the effects of Se mentioned above, there has been much interest and 
research into the role of Se supplementation in cancer prevention and more recently as an 
adjuvant treatment in established cancer, mainly in solid malignancies. Pre-clinical work 
at the Institute of Cancer (Barts Cancer Centre, London, UK) has focused on the potential 
therapeutic role of Se supplementation in haematological malignancies. The role of Se in 
cancer will be the focus of the remainder of this chapter.     
 
1.3.2 Selenocysteine Synthesis and Selenoproteins 
Sec is unique amongst amino acids in that it is synthesised on its own transfer ribonucleic 
acid (tRNA) (Figure 1.1). The tRNA is initially aminoacylated with serine, which serves 
as the backbone for Sec synthesis. The tRNA is therefore known as tRNA
[Ser]Sec 
(Lee et al, 
1989). Biosynthesis of Sec requires the enzyme selenophosphate synthetase 2, itself a 
selenoprotein, that is involved in generating the active Se donor, monoselenophosphate 
(Glass et al, 1993). Sec is coded for by the UGA codon in mRNA, which is also a stop 
codon. In order to distinguish between these two functions, a Sec insertion sequence 
(SECIS) element, which is a secondary RNA stem-loop structure, is required for the 
incorporation of Sec into proteins. The SECIS element is located in the 3΄-untranslated 
region of selenoprotein mRNA and recruits additional factors such as the SECIS-specific 
elongation factor and the SECIS-binding protein that are required for the correct insertion 
of Sec into polypeptide chains (Berry et al, 1993). 
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Figure 1.1 Selenocysteine biosynthesis pathway.  
Adapted from Papp, LV et al., Antioxidants & Redox Signaling, 2007. Sec biosynthesis 
begins with the attachment of serine to the Sec tRNA
[Ser]Sec 
by seryl tRNA synthetase to 
produce Seryl-tRNA
[Ser]Sec
. The phosphoseryl tRNA kinase phosphorylates the complex. 
The phosphate is then replaced by the Se donor selenide, which is activated by 
selenophosphate synthetase. The resulting molecule, selenocysteyl-tRNA
[Ser]Sec
, delivers 
the Sec into the growing polypeptide chain. 
 
 
The function of many of the 25 human selenoproteins is still unknown. The best 
characterised are the glutathione peroxidases (GPx), thioredoxin reductases (TrxR) and 
iodothyronine deiodinases. The latter are involved in thyroid hormone metabolism and 
will not be discussed further. Most selenoproteins have been shown to have a redox 
regulatory function through the action of Sec within the catalytic sites. Selenoproteins 
relevant to cancer will be discussed below. 
 
Glutathione Peroxidases  
GPx was the first mammalian selenoprotein to be discovered (Rotruck et al, 1973). They 
are a family of antioxidant enzymes which catalyse the reduction of hydrogen peroxide 
(H2O2) and organic hydroperoxides and therefore protect cells from oxidative damage. 
Glutathione (GSH) is an essential cofactor for the GPx enzymes and reactions involve the 
oxidation of GSH to glutathione disulphide (GSSG). The GSSG is then reduced back to 
GSH by glutathione reductase (GR) and nicotinamide adenine dinucleotide phosphate 
(NAPDH). Sec, located in the N-terminal region of GPx is oxidised to selenenic acid 
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during the catalytic reaction and GSH is required for reduction back to Sec. In humans 
there are seven known GPxs but two contain cysteine instead of Sec. The Se containing 
proteins are GPx1, an enzyme found in the cytosol of all cells; GPx2, mainly a 
gastrointestinal epithelium enzyme; GPx3, an extracellular enzyme found in plasma; 
GPx4, a phospholipid hydroperoxide enzyme including a sperm nuclei-specific enzyme; 
GPx6, located in olfactory epithelium and embryonic tissue (Papp et al, 2007). The 
reaction catalysed by GPx is shown in Figure 1.2. 
 
 
Figure 1.2 Reaction catalysed by glutathione peroxidase.  
Glutathione is oxidised to glutathione disulphide. Glutathione disulphide is then reduced 
back to glutathione by glutathione reductase and nicotinamide adenine dinucleotide 
phosphate (NAPDH). 
 
 
Thioredoxin reductases 
The thioredoxin system within cells consists of TrxR, thioredoxin (Trx) and NADPH and 
plays an essential redox regulatory role. Three mammalian TrxR enzymes, containing 
Sec at the active site, have been identified; TrxR1 which is cytosolic, TrxR2 which is 
mitochondrial and TrxR3 which is testes-specific. Trx is the major cellular protein 
disulfide reductase and TrxR is the only enzyme known to catalyse the NADPH-
dependent reduction of oxidised Trx (Figure 1.3). Trx has a number of important target 
proteins that require disulfide reduction for their function. These include ribonucleotide 
reductase, essential for DNA synthesis, and peroxiredoxins and methionine sulfoxide 
reductases, important antioxidant proteins. The thioredoxin system is also involved in the 
control of redox sensitive transcription factors such as NF-κB, p53, Ref1, and apoptosis-
regulating kinase. In addition, TrxR has a number of other substrates including protein 
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disulfide isomerase (PDI) required for protein folding within the endoplasmic reticulum 
(ER) and glutaredoxin-2 which promotes cell survival. Interestingly, several Se 
compounds are also substrates of TrxR including selenite, selenodiglutathione and 
selenocysteine thus the thioredoxin system participates in selenoprotein synthesis and Se 
metabolism (Arner, 2009; Papp et al, 2007). 
 
Given that the Trx system has a wide range of cellular functions, its role in cancer is 
complex. The effect of the Trx system is dependent on the cell type and various external 
stimuli such as growth factors.  A number of studies describe over-expression of Trx and 
TrxR in tumours resulting in tumour growth, progression and chemo-resistance, 
suggesting that Trx would be a good target for cancer therapy (Grogan et al, 2000; 
Wakasugi et al, 1990; Yoo et al, 2006). In fact, many widely used chemotherapy agents 
have been shown to inhibit TrxR including, cisplatin, melphalan and arsenic trioxide 
(Arner, 2009).  On the other hand, it has been demonstrated that over-expression of Trx 
and TrxR may induce apoptosis and reduce tumour proliferation through a p53-dependent 
mechanism, thus preventing cancer progression (Ueno et al, 1999).   
 
 
Figure 1.3 Reaction catalysed by thioredoxin reducatase. 
Oxidised thioredoxin is reduced by the action of thioredoxin reductase and nicotinamide 
adenine dinucleotide phosphate (NAPDH). 
 
 
Selenoprotein P  
Selenoprotein P is the most abundant selenoprotein in plasma containing approximately 
50% of the plasma Se. It is synthesised in the liver and secreted into the plasma but its 
expression is detected in all tissues (Hill et al, 2003). Selenoprotein P is the only 
selenoprotein with multiple Sec residues (Kryukov et al, 2003). Its main function is the 
transport and delivery of Se to tissues (discussed further below) (Hill et al, 2003). 
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Selenoprotein P may also have an antioxidant role as it has been shown in vitro to reduce 
phospholipid hydroperoxides (Saito et al, 1999). In addition, it may serve as a heavy 
metal chelator protecting against toxicity (Sasakura & Suzuki, 1998). 
 
Sep15 
Sep15 is a selenoprotein so named because of its 15kDa molecular mass. The protein is 
widely expressed with highest levels in the liver, kidney, testes, brain and prostate 
(Kumaraswamy et al, 2000). Although its precise function is unknown, its localisation to 
the ER and its interaction with the UDP-glucose:glycoprotein glycosyltransferase 
suggests it may play a role in protein folding within the ER (Korotkov et al, 2001). 
Studies have reported that Sep15 is required for apoptosis and loss of Sep15 is associated 
with a malignant phenotype (Papp et al, 2007). 
 
1.3.3 Dietary sources of selenium, intake and requirements 
Se enters the food chain through the consumption of plants and the amount in food is 
mainly dependent on the Se content of soil, which varies markedly with geographical 
location. In addition, plants vary in their ability to accumulate Se and factors relating to 
the quality of the soil can affect uptake. Thus, the Se content of food is highly variable 
and the same food produced in different countries may have different Se content (Keck & 
Finley, 2006). The result is that the Se status of individuals varies from country to 
country and therefore there is no accepted ‘normal’ reference range for plasma/serum Se. 
Brazil nuts are the richest source of Se. Other foods with a high Se content include offal, 
eggs, fish and cereals and grains (Rayman et al, 2008).  
 
In the UK, Se intake and status has fallen over the past two decades. This parallels the 
change in the sourcing of wheat from Canada, where soil Se is high, to that grown in the 
UK where soil Se is low (Rayman, 2008). The current recommended daily intake of Se in 
the UK is 75µg in men and 60µg for women (COMA, 1991). This has been determined 
based on the intake required for optimal activity of plasma GPx which correlates with a 
plasma Se concentration of around 1.2μmol/l (Thomson et al, 1993).  The minimum 
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intake of Se required to prevent deficiency diseases such as Keshan disease is 17µg/day 
(Anon, 1979). A higher than currently recommended intake is required for full expression 
of selenoprotein P (Xia et al, 2005) and a supra-nutritional intake is likely to be required 
for its anti-cancer effects (Rayman & Rayman, 2002).  It is therefore probable that the 
current recommended intake is inadequate to exploit all the benefits of Se.  
 
1.3.4 Chemical forms of selenium, bioavailability and metabolism  
Chemical forms of selenium (Figure 1.4) 
The biological effects of Se are dependent on the chemical form and dose. The main 
inorganic species in plants is selenate which is taken up directly from the soil.  From this 
plants can synthesise organic species including selenomethionine (SLM), Sec, Se-
methylselenocysteine (MSC) and γ-glutamyl-Se-methylselenocysteine (Rayman et al, 
2008). Therefore, the majority of dietary Se is available in organic forms. Only a small 
amount of the inorganic species, selenite, is found in food. However, selenite has been 
extensively used as a supplement both in vitro and in vivo. The disadvantage of using 
selenite and other inorganic forms of Se as a supplement is that they have been shown to 
be genotoxic, resulting in single strand DNA breaks (Kaeck et al, 1997).  
 
To exploit the health benefits of Se, various compounds are available as tablet 
formulations to buy ‘over the counter’. The most commonly available forms are sodium 
selenite, SLM and MSC. Clinical trials that have investigated the role of Se 
supplementation in various diseases have mainly used sodium selenite and SLM. SLM is 
the form that has been most widely used in cancer prevention and cancer therapy trials as 
it is not genotoxic. In addition, Se-enriched yeast, containing SLM as the main form of Se, 
has also been used in cancer prevention trials.  
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Figure 1.4 Chemical forms of selenium.  
Adapted from Abdulah, R et al., J Trace Elem Med Biol, 2005. Selenite (A), selenate (B), 
methylselenol (C), methylseleninic acid (D), trimethylselenonium ion (E), 
selenomethionine (F), selenocysteine (G), methylselenocysteine (H). 
 
Bioavailability 
In humans, SLM has greater bioavailability than selenite. A study in Se-deficient 
individuals found that almost double the dose of selenite was required compared with 
SLM to optimise GPx3 activity (Xia et al, 2005). In a study in Se-replete individuals, a 
greater proportion of administered Se was excreted in urine in those given SLM 
compared with selenite, suggesting absorption of selenite is two-thirds that of SLM (Burk 
et al, 2006). MSC has not been used in clinical trials in humans although it is available as 
an ‘over the counter’ supplement. Animal data suggest that it is well absorbed when 
given orally (Dong et al, 2001; Ip et al, 1999).  
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Metabolism (Figure 1.5) 
It has become clear that the metabolism of Se compounds is necessary for its anti-cancer 
activity and that monomethylated metabolites, especially methylselenol are crucial (Ip et 
al, 2000). Once absorbed, both inorganic and organic selenium species can be used with 
similar efficacy to form selenoproteins. However, Se species differ in their ability to form 
methylselenol.  Conversion to hydrogen selenide is the central reaction in the formation 
of selenoproteins. Hydrogen selenide is then converted to selenophosphate and 
incorporated as Sec into selenoproteins. If surplus Se is available, then hydrogen selenide 
undergoes methylation reactions, firstly to methylselenol which is then converted to 
dimethylselenide, exhaled in breath, and trimethylselenonium, excreted in urine.  
Hydrogen selenide can also be directly converted to selenosugars which are excreted in 
urine. Hydrogen selenide can produce superoxide anion and H2O2 through oxidative 
metabolism and this is responsible for the induction of DNA single strand breaks, 
particularly a problem with inorganic compounds such as selenite (Rayman et al, 2008).  
 
As mentioned above, if excess Se is present, such that selenoprotein synthesis is saturated, 
hydrogen selenide undergoes methylation to form methylselenol. However, SLM can be 
non-specifically incorporated into body proteins in place of methionine especially if 
methionine is in reduced supply. This results in tissue accumulation of Se and SLM is 
less available for conversion to monomethylated metabolites. Conversion of SLM to 
methylselenol can occur directly through the action of the enzyme γ-lyase, but the extent 
of this in humans is not clear (Okuno et al, 2006). In contrast, MSC can be directly 
converted to methylselenol by the enzyme β-lyase and does not have the problem of 
excessive tissue accumulation as non-specific incorporation into proteins does not occur. 
Therefore, MSC is a superior source of monomethylated Se species (Ohta et al, 2009; 
Suzuki et al, 2006a; Suzuki et al, 2007) and it has been demonstrated to have better anti-
carcinogenic properties than SLM and selenite (Ip & Hayes, 1989; Ip et al, 1991). Studies 
in rats using enriched stable isotopes of Se suggest that orally administered MSC and 
SLM can both be delivered in their intact forms to organs and tissues but MSC is a more 
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efficient source of methylselenol as SLM is preferentially converted to hydrogen selenide 
(Suzuki et al, 2006a; Suzuki et al, 2008). 
 
Methylselenol is highly reactive and volatile and therefore cannot be used directly for in 
vitro studies. Therefore, the compound methylseleninic acid (MSA) has been developed. 
It is a water soluble, stable metabolite that is easily taken up into cells and upon reaction 
with cellular thiols, such as GSH, is reduced to methylselenol (Ip et al, 2000).  
 
A recent in vivo study compared the efficacy of MSA, SLM, MSC and selenite in 
xenograft models of prostate cancer. MSA and MSC were found to be equally effective 
and more potent than SLM and selenite at inhibiting tumour growth in the DU145 
xenograft model but MSA was superior to the other three compounds in the PC-3 
xenograft model. The study also examined DNA strand breaks in peripheral lymphocytes 
and found that MSA, MSC and SLM did not increase DNA strand breaks as assessed by 
the COMET assay whereas selenite did (Li et al, 2008a). This study adds further 
evidence to the superiority of Se compounds that are directly converted to 
monomethylated species. 
 
For the reasons discussed above, studies at the Institute of Cancer (Barts Cancer Centre) 
have focussed on MSA for in vitro studies with a view to using MSC in a clinical trial. 
The remainder of this chapter will focus mainly on organic Se compounds that are 
precursors of methylselenol.  
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Figure 1.5 Metabolic pathway of dietary selenium in humans.  
Adapted from Rayman, MP et al., Br J Nutr, 2008. SLM, selenomethionine; SeCys, 
selenocysteine; GSSeSG, selenodiglutathione; γ-glutamyl-CH3SeCys, γ-glutamyl-
methylselenocysteine; H2Se, hydrogen selenide; HSePO3
2-
 selenophosphate;  MSC, 
methylselenocysteine; CH3SeH, methylselenol; (CH3)2Se, dimethylselenide; SeO2, 
selenium dioxide; (CH3)3Se
+
, trimethylselenonium ion.  
 
 
1.3.5 Selenium transport and uptake into cells 
The uptake of Se into individual cells is poorly understood. From studies in mice with 
deletion of the selenoprotein P gene (Sepp
-/-
) it is apparent that selenoprotein P is 
important in transporting Se from the liver to other tissues. Deletion of the gene in mice 
results in a marked decrease in the Se concentration of brain and testes tissue, a modest 
decrease in kidney tissue, no change in heart tissue and no change or an increase in liver 
tissue (Hill et al, 2003; Schomburg et al, 2003). Sepp
-/-
 mice develop neurological 
dysfunction but when fed a high-Se diet, these changes can be prevented. This suggests 
that Selenoprotein P is required for delivery of Se to the brain but that other mechanisms 
are involved when selenoprotein P is not present (Hill et al, 2004). Male Sepp
-/- 
mice are 
infertile and feeding a high-Se diet does not reverse this (Olson et al, 2005). Further 
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research has identified that the apolipoprotein E receptor-2 is essential for uptake of Se 
from selenoprotein P into the brain and testes tissue (Burk et al, 2007; Olson et al, 2007). 
However, uptake in the brain is likely to be more complex as there is no evidence that 
apolipoprotein E receptor-2 is present at the blood-brain barrier and hence the full 
mechanism is not yet elucidated. Selenoprotein P is also required for delivery of Se to the 
kidney which is the main site of production of GPx3 but the apolipoprotein E receptor-2 
is not involved in Se uptake into kidney tissue (Burk et al, 2007). It has recently been 
demonstrated that the lipoprotein receptor, megalin, mediates selenoprotein P uptake in 
the proximal tubule of the kidney (Olson et al, 2008). 
 
The uptake of Se into other cell types, including neoplastic cells, is less clear. Since 
selenoprotein P deficient mice are capable of distributing Se to most tissues when it is 
supplemented in the diet, this suggests a small molecule form can be taken up by cells 
(Hill et al, 2003). In vitro, it has been demonstrated that selenoamino acids, such as SLM 
and MSC, are transported into epithelial cells by various amino acid transporters (Nickel 
et al, 2009). Selenite uptake into red blood cells is via an anion transporter (Suzuki et al, 
1998). A study which investigated the uptake of selenite after reduction to selenide, 
found that selenide was actively transported into HaCat cells (keratinocyte cell line) 
through an anion transporter and that this was ATP-dependent (Ganyc & Self, 2008). 
Another in vitro study found that uptake of selenite required it to be reduced and that 
reduction was dependent on the secretion of cysteine by cells through the multidrug 
resistance protein efflux pumps. This cysteine secretion was in turn dependent on cystine 
uptake through the xc
-
cystine/glutamate antiporter in exchange for glutamate, and 
intracellular NAPDH-dependent reduction to cysteine. The xc
-
cystine/glutamate 
antiporter is over-expressed in a number of tumours and is associated with resistance to 
chemotherapy whereas high expression of the transporter is associated with increased 
sensitivity to selenite (Olm et al, 2009). Selenocysteine uptake into red blood cells has 
been shown to be ATP-dependent and incubation with cysteine inhibited this, suggesting 
uptake through the cysteine transporter (Imai et al, 2009). 
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Further work is required to identify mechanisms by which clinically relevant Se species 
are taken up into cells and to compare uptake in normal and tumour cells.  
 
1.3.6 Selenium toxicity 
There is both acute and chronic toxicity associated with Se ingestion. There have been 
reports in the literature of acute Se poisoning (Kise et al, 2004; See et al, 2006). The 
ingested dose in these cases was extremely high (2g and 10g).  Symptoms included 
vomiting, garlic-odour breath, mucosal irritation (gastritis, gastric ulcer), abdominal pain, 
hypersalivation, liver necrosis, cerebral and pulmonary oedema, seizures, cardiovascular 
collapse and death. Chronic toxicity, known as selenosis, has been more widely 
documented based on studies in subjects living in seleniferous areas of the USA and 
China. These studies indicate that selenosis is associated with intakes of greater than 
910μg/day over a period of months to years (Yang et al, 1983). Most common symptoms 
are brittle nails and hair (progressing to nail and hair loss), and garlic-odour breath and 
urine. Other side effects reported include gastrointestinal symptoms (diarrhoea, nausea), 
skin rashes, fatigue, mottled teeth and a decrease in haemoglobin concentration. Dental 
caries, irritability, muscle tenderness, tremor, hyperflexia and metallic taste have been 
reported but a direct causal relationship has not been confirmed (Barceloux, 1999).  
 
Recently, a case series has been reported of 201 individuals who unknowingly ingested 
toxic concentrations of Se in the form of a liquid dietary supplement, due to a 
manufacturing error (MacFarquhar et al, 2010). The dose of Se, in the form of sodium 
selenite, was stated as 200μg/fluid ounce but when tested the actual concentration was 
40,800μg/fluid ounce. The individuals identified had taken the supplement for a median 
of 29 days (range 1-109 days) and ingested a median of 41,585μg/day (range 3400-
244,800μg/day). Serum Se concentrations were obtained for 8 individuals at a median of 
1 day after stopping the supplement and the mean serum concentration was 9.6μmol/l 
(range 4-19μmol/l) The most frequently reported side-effects were diarrhoea, fatigue, hair 
loss, joint pain, nail discolouration or brittleness, nausea, headache, foul breath and skin 
complaints.     
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Most cancer prevention studies have supplemented Se at a dose of 200μg/day which does 
not appear to result in overt toxicity when taken over several years (Clark et al, 1996). 
Studies from Roswell Park Cancer Institute (Buffalo, NY, USA) have used high doses of 
SLM in patients with cancer and doses up to 7,200μg twice daily for a week followed by 
daily maintenance appear to be safe with the only definite Se-related side effect being 
garlic-odour breath and urine. Patients received supplementation with SLM for up to 49 
weeks (Fakih et al, 2008). However, concern has been raised recently that prolonged 
elevation of serum Se levels, in individuals who, prior to supplementation, had Se 
concentrations at the high end of the population range, may result in more subtle adverse 
health effects (discussed below). These finding require further research and remain to be 
confirmed.  
 
1.3.7 Selenium and cancer prevention 
The main body of evidence with regards to cancer is in cancer prevention. This link was 
first made in the 1960’s when it was reported that overall cancer mortality, in both males 
and females, was lower in states in the USA with high Se containing soils, and therefore a 
high dietary Se intake (Shamberger & Frost, 1969). This finding is supported by the 
results of subsequent observational, animal and human interventional studies relating to a 
wide range of cancers. The strongest evidence for the role of Se in cancer prevention 
relates to prostate cancer, but there is also good evidence to support its role in the 
prevention of lung, oesophageal and gastric cancers. Some of these studies are discussed 
below. 
 
Epidemiological and pre-clinical studies 
An epidemiological study investigated the relationship between the Se content of food 
crops and cancer mortality over a 19-year period in counties of the USA. A significant 
inverse association was found for the incidence of lung, rectal, bladder, oesophageal, and 
cervical cancers in rural counties and lung, breast, bladder, rectal, oesophageal, and 
uterine cancers in all counties (Clark et al, 1991). A prospective study of 39,268 Finnish 
residents found that in men with the lowest serum Se level there was an increased risk of 
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cancer, with the strongest association for gastric and lung cancers (Knekt et al, 1990). 
Toenail Se levels and the incidence of advanced prostate cancer was investigated in an 
epidemiological case-control study of 33,737 men in the USA who were followed for 6 
years. Those with higher Se levels had a reduced risk of advanced prostate cancer 
(Yoshizawa et al, 1998). A meta-analysis of sixteen epidemiological studies has shown a 
significantly increased risk of lung cancer associated with low Se exposure, the effect 
being most marked in populations where daily intake of Se is <55µg/day (Zhuo et al, 
2004). It would be wrong to suggest, however, that all observational studies had found an 
inverse correlation between serum/plasma Se and cancer risk. Nonetheless, the data are 
compelling.  
 
The mammary gland is the most widely studied organ in animals with regards to the 
inhibitory effects of Se on tumour development. Se has been shown to inhibit tumour 
development in many rodent models of mammary cancer including virus-induced, 
chemical carcinogen-induced and spontaneous mammary tumours (El-Bayoumy & Sinha, 
2004).  An example is a study in which rats injected with the carcinogen methylurea were 
fed a normal diet or one that contained Se-enriched broccoli. This latter group developed 
fewer mammary tumours (Finley et al, 2001). The predominant species in Se-enriched 
broccoli has previously been shown to be MSC (Cai et al, 1995), which is more effective 
than SLM in suppressing mammary tumours in rodents (Ip et al, 1991). 
 
Interventional studies 
On the strength of the observational and animal chemoprevention studies, many 
interventional studies have been conducted with Se supplementation but the results are 
far from clear-cut. The Linxian province in China is a region where the mean serum Se 
concentration in the population is low and which has some of the highest incidences of 
oesophageal squamous cell cancer and gastric-cardia adenocarcinoma in the world. A 
significant inverse relationship has been demonstrated between baseline Se and the risk 
of developing and also dying from these two cancers (Mark et al, 2000; Wei et al, 2004).  
The General Population Intervention Trial was a randomised, placebo-controlled, primary 
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oesophageal and gastric cancer prevention trial conducted in the Linxian province from 
1985 to 1991. 29,584 adults participated and were given different combinations of 
vitamin and mineral supplements to take daily. Results published in 1993 reported that 
the combination of Se (50µg as Se-enriched yeast), vitamin E and beta-carotene 
significantly reduced total mortality, total cancer mortality and mortality from gastric 
cancer (Blot et al, 1993). Recently reported, updated results of this trial found that even 
10 years after completing active intervention, the group receiving the above 
supplementation still showed a 5% reduction in total mortality and an 11% reduction in 
gastric cancer mortality. This protective effect was, however, only apparent in individuals 
younger than 55 years (Qiao et al, 2009). 
 
The strongest evidence for Se in cancer prevention comes from the Nutritional Prevention 
of Cancer (NPC) trial (Clark et al, 1996), the aim of which was to investigate the role of 
Se supplementation in preventing the recurrence of non-melanomatous skin cancer. This 
double-blind, placebo-controlled trial of Se-enriched yeast (200μg/day) randomised 1312 
patients with a diagnosis of non-melanomatous skin cancer, with the primary end point 
being recurrence of skin cancer. An interim analysis, however, demonstrated a reduction 
in the incidence and mortality of other cancers, thus the trial was modified to include 
various secondary endpoints; incidence and mortality of lung, prostate, colon and total 
cancer. Results for the first 10 years of the trial were not able to show a reduction in the 
primary endpoint, but did show a significant reduction in all the secondary endpoints. 
After longer follow-up, a reduction in total cancer and prostate cancer incidence and 
mortality was still apparent, but there was no longer an effect on lung or colon cancer 
incidence and mortality (Duffield-Lillico et al, 2003; Duffield-Lillico et al, 2002).  
 
For several reasons, the results of the NPC trial required clarification. Firstly, the primary 
endpoint of incidence of recurrent skin cancer was higher in the Se-supplemented group. 
However, when cases occurring in the first two years after randomisation were excluded, 
the risk of developing recurrent skin cancer was non-significant. Secondly, the benefits of 
Se supplementation were only seen in men, although three quarters of the study 
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population were male. Thirdly, the benefits of Se supplementation were only seen in 
those with a low plasma/serum Se level at the start of the trial (Duffield-Lillico et al, 
2002).   
 
In order to address some of these unanswered questions, the Se and vitamin E cancer 
prevention trial (SELECT), sponsored by the National Cancer Institute (USA) was 
initiated. This was a Phase III, randomised, double-blind, placebo-controlled trial 
designed to test the efficacy of Se (200μg SLM) and vitamin E both alone and in 
combination, in the prevention of prostate cancer (Lippman et al, 2009). Vitamin E, in 
addition to Se, was investigated because a previous randomised trial studying the effects 
of vitamin E and beta carotene on the incidence of lung cancer reported, as a secondary 
end-point, a protective effect of vitamin E against prostate cancer (Anon, 1994). The 
SELECT trial, the largest cancer prevention trial to date, recruited 35,533 between 2001 
and 2004 and planned for a minimum follow-up of 7 years and a maximum of 12 years. 
However, the study was discontinued in 2008 after a median follow-up of 5.5 years after 
a planned interim analysis showed no significant difference in the incidence of prostate 
cancer between the study groups or in the secondary cancer end-points and that the pre-
specified 25% risk reduction was unlikely to be achieved with additional study time.  In 
fact there was a statistically non-significant increase in the risk of prostate cancer in the 
vitamin E alone group and of type 2 diabetes in the Se alone group.  
 
There are a few reasons that may potentially explain the negative results of the SELECT 
trial and the apparent discrepancy with the results of the NPC trial. Prospective studies 
suggest that a mean plasma Se concentration between 1 and 1.8μmol/l are required for a 
reduction in cancer risk (Nomura et al, 2000; Wei et al, 2004). These plasma 
concentrations can be achieved with a dietary intake of around 140μg/day (Rayman et al, 
2006). Recently, however, there has been concern that maintaining too high a plasma Se 
concentration may have a detrimental effect.  In the NPC trial the benefit of Se treatment 
was restricted to those with a baseline plasma Se ≤1.35µmol/L. In addition, data collected 
by the NPC trial revealed an increased risk of self-reported type II diabetes in those 
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supplemented with Se, the effect being greatest in those with a baseline plasma Se 
concentration >1.54µmol/L (Stranges et al, 2007). However, results from studies 
investigating the relationship between plasma Se and diabetes are conflicting with some 
reporting a protective effect of high plasma Se (Akbaraly et al, 2010).  A sub-study of the 
NPC trial randomised 424 patients to receive 400µg/day of Se or placebo. This dose of 
Se appeared to have no effect on total cancer incidence, which is clearly in contrast to the 
finding of the main NPC trial that supplemented 200µg/day. However, due to the small 
sample size, this study is likely to have lacked sufficient power to detect differences in 
the primary end-points (Reid et al, 2008). Another study which evaluated the association 
between serum Se levels and all-cause, cancer and cardiovascular mortality found that Se 
concentrations >1.9µmol/L were associated with a small increase in all-cause and cancer 
mortality (Bleys et al, 2008).  
 
The SELECT trial was conducted in a group of men who were Se-replete at baseline with 
a mean plasma Se concentration of 1.7µmol/L and after SLM supplementation of 
3.2µmol/L. Subgroup analysis of the SELECT trial is still awaited. It appears, therefore, 
that a balance needs to be struck between exploiting the benefits of Se supplementation 
and reducing the potential risks associated with prolonged maintenance of high plasma Se 
concentrations. This is going to be dependent on an individual’s baseline Se level which 
will vary on the basis of country and region of residence. Of note, soil Se, and thus intake, 
is considerably lower in the UK and other European countries than in the USA (Rayman 
& Rayman, 2002). Therefore, had the SELECT study been conducted in Europe, the 
results may have been different. 
 
As alluded to above, it is the monomethylated metabolites, particularly methylselenol, 
that are thought to be crucial for the anti-cancer effects of Se (Ip et al, 2000). These 
methylation reactions mainly occur when selenoprotein synthesis has been saturated and 
Se is present in excess. The SELECT trial used SLM whereas the NCP trial used Se-
enriched yeast. Although SLM is the major component of Se-yeast, others forms, such as 
MSC are also present. As discussed above, MSC is thought to be a more effective 
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chemopreventive agent as it is more efficiently converted to methylselenol and therefore 
it may be that the best form of Se was not used in the SELECT trial.  
 
An individual’s response to Se is also influenced by genetic factors, for example the 
genotype of antioxidant enzymes. A recent study reported a relationship between plasma 
Se at diagnosis, the prognosis of prostate cancer and the genotype of the manganese 
superoxide dismutase (SOD2) gene (Chan et al, 2009). A SOD2 variant has a substitution 
of alanine for valine at amino acid 6. In men with the AA genotype, higher Se levels were
 
associated with a reduced risk of presenting with aggressive
 
disease whereas in men
 
with 
a V allele, higher Se levels were associated with
 
an increased risk of aggressive disease. 
The genotype of a number of selenoproteins also appears to be important in determining 
cancer risk (discussed further below; section 1.3.9.2). This gives further support to the 
fact that Se requirements vary between individuals and are modified by a number of 
factors.  
 
Unfortunately, the negative results of the SELECT trial mean that funding for future 
cancer prevention trials of Se will be difficult to secure. However, should further trials 
take place they need to be better designed and conducted in subsets of the population 
taking into account an individual’s baseline Se level and antioxidant 
enzyme/selenoprotein genotype. In addition, trials using MSC need to be performed. 
 
1.3.8 Selenium in established cancer 
In addition to its role in cancer prevention, there is evidence to support the role of Se in 
cancer therapy. Supra-nutritional concentrations have been shown to enhance the efficacy 
of standard chemotherapeutic agents whilst protecting normal tissue from chemotherapy-
induced toxicity. The best evidence for this comes from mice bearing human squamous 
cell carcinoma of the head and neck and colon carcinoma xenografts (Cao et al, 2004). 
When SLM or MSC was administered orally with standard cytotoxic agents, the result 
was an increase in the maximum tolerated dose (MTD) of the cytotoxic agents, for some 
by more than two-fold (Figure 1.6). This effect was apparent across different classes of 
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drugs. The anti-tumour activity of irinotecan was further investigated and it was found 
that when combined with MSC, cure rates increased from 0% to 20%, 20% to 100%, 
30% to 100% and 10% to 60% in four different tumour models (Figure 1.7). The cure 
rates in irinotecan-resistant tumours were improved further when irinotecan was given at 
the increased MTD which was made possible by the co-administration of MSC. The 
optimal schedule was administration of SLM or MSC for 7 days before and concurrently 
with chemotherapy. Se was thus shown to be an effective modulator of the therapeutic 
efficacy of irinotecan and to provide protection against chemotherapy-induced toxicity. It 
was determined from these studies that plasma concentrations of Se >14µmol/L were 
needed to achieve maximum protection against chemotherapy-induced toxicity and 
concentrations >23µmol/L to achieve potentiation of anti-tumour activity. These levels 
were determined following administration of SLM (Azrak, 2004).  
 
 
 
 
Figure 1.6 Toxicity of six chemotherapeutic agents with and without 
methylselenocysteine (MSC) pre-treatment in nude mice. All chemotherapy drugs were 
given at doses above the normal maximum tolerated dose. Methylselenocysteine was able 
to protect the mice from the toxicity of all the drugs. FU is 5-fluorouracil, CDDP is 
cisplatin. (Cao S et al., Clin Cancer Res, 2004) 
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Figure 1.7 Methylselenocysteine (MSC) increased the cure rate of human tumour 
xenografts treated with irinotecan. HCT-8 and HT-29 are colorectal carcinoma xenografts, 
FaDu and A253 are head and neck squamous cell carcinoma xenografts. (Cao S et al., 
Clin Cancer Res 2004). 
 
 
Based on these xenograft studies, investigators from Roswell Park Cancer Institute 
conducted a phase I trial to determine the MTD of irinotecan with a fixed dose of SLM in 
patients with advanced solid tumours. SLM at 2,200µg/day was started one week before 
the first dose of irinotecan and continued throughout the chemotherapy period. However, 
SLM did not allow escalation of the irinotecan dose beyond the previously documented 
MTD but SLM at this high dose was well tolerated and the only reported side-effects 
were garlic-odour breath and urine. Pharmacokinetic studies revealed a slow 
accumulation of Se, which did not reach a steady state concentration for at least 4-6 
weeks. Therefore, the desired plasma concentration of >14µmol/L before the start of 
irinotecan was not achieved (Fakih et al, 2006). The same group, therefore, conducted a 
phase I dose-escalation study of SLM in combination with fixed dose irinotecan in 
patients with advanced solid tumours to determine the dose of SLM that achieves a 
plasma Se concentration >15µmol/L (Fakih et al, 2008). Thirty-one patients with 
advanced solid-tumours were treated at 7 dose levels, with SLM given twice daily for one 
week prior to commencing irinotecan, followed by once daily maintenance for the 
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duration of chemotherapy. Dose levels ≥4,800µg resulted in a day 8 plasma Se 
concentration of >15µmol/L whilst the highest dose level reached of 7,200µg resulted in 
a day 8 plasma Se concentration of >20µmol/L. SLM was well tolerated and the only 
toxicity attributable to SLM was mild garlic-odour breath and urine which improved with 
prolonged treatment. Two patients had dose-limiting toxicities as defined by the study 
protocol but in the context of advanced cancer these may not have been attributable to the 
SLM. The study was not designed to evaluate the protective effects of SLM on 
irinotecan-induced toxicity, however, a major protective effect was not observed. A few 
patients achieved a better response to treatment than might have been expected 
considering the advanced nature of their disease. Although conclusions cannot be drawn 
from these anecdotal cases it perhaps suggests that the clinical use of SLM is worth 
pursuing. A phase II study has now been initiated by the same group (personal 
communication from Professor Y.M. Rustum). 
 
The role of Se in reducing chemotherapy- and radiotherapy-induced toxicity has been 
investigated in human trials but evidence to support its use is not conclusive and is not 
recommended outside the context of a clinical trial despite some provocative results 
(Dennert & Horneber, 2006). In a cross-over design study in patients with solid tumours 
receiving cisplatin chemotherapy, 4000µg of Se (seleno-kappacarrageenan) was 
administered from 4 days before to 4 days after chemotherapy. Compared with the 
control group, the supplemented group had higher white cell counts after chemotherapy, a 
lower requirement for granulocyte-colony stimulating factor and blood transfusions and 
less nephrotoxicity as determined by the excretion of urinary enzymes. There were no 
side-effects associated with Se supplementation (Hu et al, 1997).   
 
In another study, patients with ovarian cancer receiving various combinations of 
cytotoxic agents, including cisplatin, were supplemented with 200µg of Se over a 3-
month period. Se supplementation resulted in significantly higher neutrophil counts and 
less nausea, vomiting, stomatitis, and abdominal pain compared with the control group. 
However, patients in this study received Se in a capsule that also contained vitamin C, 
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vitamin E, riboflavin, niacin and β-carotene and therefore it is difficult to exclude the 
possibility that the benefits were derived from the combination rather than Se alone (Sieja 
& Talerczyk, 2004). 
  
The results of a multi-centre, phase III trial comparing Se supplementation with 
observation in 81 patients receiving radiotherapy following surgery for cervical and 
uterine cancer have recently been reported (Muecke et al, 2010). The aim of the study 
was to assess whether Se, in the form of selenite, could improve the post-operative Se 
status and reduce radiotherapy side-effects. Selenite, 500µg, was given orally on the days 
of radiotherapy and 300µg on the days without treatment. Most patients had a low plasma 
Se concentration prior to entry into the study and supplementation increased plasma Se 
into the lower end of the recommended normal range. In addition, Se reduced the number 
of episodes and severity of radiotherapy-induced diarrhoea and improved quality of life.  
 
1.3.9 Anti-cancer mechanisms of selenium in cancer prevention and established 
cancer 
The exact mechanism by which Se compounds exert their anti-cancer effects is still not 
fully understood. However, it is apparent that the effects are dependent on the chemical 
form and concentration or dose. Thus, high concentrations are cytotoxic (Last et al, 2006), 
intermediate concentrations can modulate the therapeutic efficacy of chemotherapeutic 
agents (Juliger et al, 2007) and low but supra-nutritional concentrations are 
chemopreventive (Finley et al, 2001). Mechanisms differ between these different actions 
of Se and also between different cancer cell types. Most of the in vitro work has been 
performed in prostate cancer and breast cancer cell lines. As discussed above, the 
metabolism of Se compounds to monomethylated forms is crucial for the anti-cancer 
properties and MSC, which can be directly converted to methylselenol, is the most 
efficacious naturally occurring Se compound available (Abdulah et al, 2005).  
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1.3.9.1 Selenoproteins 
Although it is generally accepted that at the supra-nutritional doses of Se, selenoprotein 
activity will be saturated, there is evidence to suggest that selenoproteins do have a 
mechanistic role predominantly through the reduction of oxidative stress and hence DNA 
damage which is important in carcinogenesis (Federico et al, 2007). A study conducted in 
New Zealand men who had a raised prostate specific antigen level and therefore an 
increased risk of prostate cancer found an inverse relationship between serum Se and 
DNA stability/damage in blood lymphocytes. This was most apparent in the group of 
subjects that had a baseline serum Se level <1.2μmol/l and therefore below the level 
required to saturate GPx activity (Karunasinghe et al, 2004). The protective role of GPx 
is also apparent from genetically modified animals. GPx2 knockout mice were more 
susceptible to the development of squamous cell cancer of the skin after γ-irradiation 
(Walshe et al, 2007). GPx1/GPx2 double knockout mice had an increased rate of 
inflammation-induced intestinal cancer (Chu et al, 2004). 
 
Baseline Se concentration has been shown to be important in determining the effect of Se 
supplementation in cancer prevention trials, such that those individuals with low Se 
concentrations benefit the most (Duffield-Lillico et al, 2003). It would therefore appear 
that, at least in the context of cancer prevention, the activity of selenoproteins is 
mechanistically important in the action of Se. 
  
1.3.9.2 Selenoprotein polymorphisms 
Further evidence for the anti-cancer role of selenoproteins comes from genotype data. It 
has become clear that individuals differ in their ability to increase the activity of 
selenoproteins in response to dietary Se and that this may be due to polymorphisms in 
selenoprotein genes. A recent study described two single nucleotide polymorphisms 
(SNPs) in the selenoprotein P gene that have functional effects and are associated with 
differences in plasma Se, GPx and TrxR activity at baseline and in response to Se 
supplementation. The effects of these two SNPs were influenced by gender and body 
mass index (Meplan et al, 2007). A large study of 2,915 cases of prostate cancer in 
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Sweden (a low Se area) examined the effect of SNPs in the selenoprotein P and 
mitochondrial SOD2 genes on prostate cancer risk. SOD2 is the major detoxifying 
enzyme in the mitochondria and converts superoxide to H2O2 which is then detoxified to 
water by GPx. Se status has previously been shown to modify the risk associated with a 
SOD2 SNPs and prostate cancer (Li et al, 2005). In the Swedish study, there was no 
effect of selenoprotein P genotype alone but an interaction was found between Se status, 
a combination of a SOD2 and selenoprotein P SNP and prostate cancer 
risk/aggressiveness. The SNP in the SOD2 gene results in an overactive enzyme and a 
higher generation of H2O2. Therefore higher Se and GPx levels are required to remove 
H2O2. It is thought that in the absence of adequate Se and GPx levels, H2O2 would 
promote tumourigenesis. This further supports the notion that Se supplementation may 
benefit certain individuals more that than others (Cooper et al, 2008). 
 
A link between the risk of cancer and polymorphisms in the GPx1 gene at codon 198 has 
been reported. In a case-control study, the presence of an allele encoding leucine rather 
than proline at this position was associated with an increased risk of developing lung 
cancer in Caucasians (Ratnasinghe et al, 2000). Another study which examined tumour 
tissue from patients with breast cancer found that the leucine-containing allele was more 
frequently found than the proline-containing allele when compared with a control group 
that were free of cancer. In addition, it was shown in a human breast cancer cell line that, 
in the presence of the leucine allele, GPx1 enzyme activity was less responsive to 
supplementation by Se (Hu & Diamond, 2003).  This finding is supported by a study in 
humans which found that this polymorphism influences GPx1 activity in response to Se, 
such that in individuals with the leucine allele, GPx1 activity increases to a lesser degree 
with increasing plasma Se concentration than in individuals with the proline allele 
(Jablonska et al, 2009). However, one study contradicts these results and reported that 
individuals with the GPx1 leucine allele had a significantly lower risk of developing 
prostate cancer although no significant difference was found in erythrocyte GPx activity 
by genotype (Arsova-Sarafinovska et al, 2009). Clearly other, yet undefined factors must 
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be important in influencing the risk of cancer in individuals with polymorphisms of 
selenoprotein genes.  
 
A SNP in the GPX4 gene has been reported to have functional consequences influencing 
GPx4 activity and concentration in lymphocytes and also the activity and concentration 
of GPx1, GPx3 and TrxR1 (Meplan et al, 2008).  Another study examined the influence 
of genetic variations in selenoprotein genes in 832 cases of colorectal cancer and 705 
controls and reported an association between SNPs in selenoprotein P, SelS and GPx4 
and the risk of developing the cancer (Meplan et al, 2010).  
 
Sep15 has been implicated in the effect of Se in cancer prevention. Two SNPs have been 
identified located at positions 811 (C/T) and 1125 (G/A). The C811 allele only associates 
with G1125 allele and the T811 allele with A1125. Therefore, there are only 2 possible 
haplotypes within the human Sep15 gene (Hu et al, 2001). In vitro, gene expression of the 
T811/A1125 variant was found to increase to a lesser degree in response to the addition 
of Se when compared with the C811/G1125 variant and therefore these SNPs may 
influence expression of Sep15 and response to Se supplementation in vivo (Hu et al, 
2001; Kumaraswamy et al, 2000). Of relevance is that normal prostate tissue has high 
expression of Sep15 but tissue from prostate cancer expresses a reduced level 
(Kumaraswamy et al, 2000). Amongst African-Americans, allele frequencies were found 
to be different in DNA obtained from head and neck and breast tumours compared with 
DNA obtained from lymphocytes of cancer-free individuals suggesting a loss in 
heterozygosity at the Sep15 locus in these tumours (Hu et al, 2001).  
 
A recent case-control study investigated whether the 1125 G/A polymorphism in the 
Sep15 gene combined with Se status was associated with the risk of lung cancer in 
smokers of Polish origin (Jablonska et al, 2008). 325 cases of lung cancer and 287 age-
matched controls were analysed. Plasma Se concentration was significantly lower in 
individuals with lung cancer. At a Se concentration near the population average 
(0.6μmol/l) the risk of lung cancer was similar for all genotypes. However, at Se levels 
76 
 
below this, individuals with the AA genotype had a much greater increase in lung cancer 
risk compared with those with the GA and GG genotypes, suggesting that individuals 
with the AA genotype may benefit most from increasing dietary Se. Of concern, in 
individuals carrying the GG and GA genotypes, plasma Se concentrations above 1μmol/l 
were associated with an increasing risk of lung cancer whereas individuals with the AA 
genotype continued to have a decreasing risk. This supports the suggestion that the 
potential benefits of Se supplementation will differ between individuals, with some not 
benefiting at all. The finding of an increased risk of lung cancer with high Se levels needs 
further research.  
 
In addition to its role in cancer prevention, Sep15 has also been implicated in cancer 
progression. Knockdown of Sep15 was able to inhibit colon cancer growth and metastasis 
in an animal model (Irons et al, 2010). A large, prospective, case-controlled study of 
Sep15 genetic variation in prostate cancer did not find an association between Sep15 
polymorphisms and prostate cancer risk but did find a significant association with 
prostate cancer mortality (Penney et al, 2010).  
 
Thus, the role of selenoproteins in cancer is complex. It is perhaps becoming apparent 
that selenoproteins do play a role in cancer prevention but once the malignancy is 
initiated they may also play a role in tumour promotion.  
 
1.3.9.3 Redox modification of proteins 
Methylselenol and other Se metabolites have the ability to affect a large number of 
cellular proteins and pathways due to redox modification of protein thiol groups; sulphur-
hydrogen bonds (S-H). Se can modify proteins by the formation of selenotrisulfide bonds 
(S-Se-S), selenenylsulfide bonds (S-Se), diselenide bonds (Se-Se) and the formation or 
disruption of disulfide bonds (S-S) (Ganther, 1999). The amino acid cysteine, often found 
in the catalytic region of proteins, has a thiol as the function group and is therefore 
susceptible to modification by Se metabolites. Thus, the function of redox-regulated 
proteins, including transcription factors, can be altered by Se. An example of this is the 
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inactivation of protein kinase C (PKC) by Se. PKC is a family of intracellular 
serine/threonine kinases that are involved in signal transduction following the activation 
of receptor tyrosine kinases. The different family members have distinct but opposing 
roles in cell proliferation, differentiation, apoptosis and angiogenesis (Griner & Kazanietz, 
2007). The effect of Se on PKC activity has mainly been investigated in prostate and 
breast cancer cells (Gundimeda et al, 2008; Sinha et al, 1999). MSA and MSC have both 
been found to inhibit the activity of PKC but the PKC isoenzymes have differing 
sensitivities. This inhibition of enzyme activity by Se is due to redox modification of 
cysteine residues in the catalytic domain and in prostate cancer cells, MSA-induced 
inactivation of PKCε appears to be particularly important in its growth-inhibitory and 
apoptotic effects (Gundimeda et al, 2009).  
 
A more global approach has been taken to characterise protein redox modification by 
MSA in the prostate cancer cell line, PC-3 (Park et al, 2005). This study (discussed 
further in section 1.3.9.11) labelled proteins containing reactive thiols with a thiol-
specific reagent, N-(biotinyl)-N’-(iodoacetyl) ethylenediamine (BIAM), and identified 
proteins in which the BIAM labelling increased or decreased in response to MSA by 2D-
gel electrophoresis and mass spectrometry. 94 proteins were found to be sensitive to 
redox modification by MSA of which 85 were identified. This study high-lights the 
potential for Se to affect the function of a large number of cellular proteins. The proteins 
affected are likely to differ depending on the cell type and the form of Se used and thus 
may explain, in part, how Se supplementation can result in such differing effects in 
normal and tumour cells.  
  
1.3.9.4 Cell cycle arrest and induction of apoptosis 
Se can induce cell cycle arrest in some cancer cell lines but the effect is dependent on the 
chemical form and the cell type (Figure 1.8). In prostate and breast cancer cell lines, 
MSA arrests cells in the G1 phase of the cell cycle, this being associated with a decrease 
in expression of cell-cycle regulated genes and an increase in cyclin-dependent kinase 
inhibitors (Dong et al, 2002; Zhao et al, 2004). In contrast, studies in DLBCL cell lines 
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performed in our laboratory showed that apoptosis was associated with an increase in the 
sub-G1 (apoptotic) fraction but was not preceded by cell cycle arrest (Last et al, 2006). 
MSC was found to induce S phase arrest in a mouse mammary cancer cell line and this 
was associated with inhibition of cyclin-dependent kinase (CDK)-2 activity (Sinha & 
Medina, 1997). SLM was reported to induce p53-mediated G2/M cell cycle arrest in 
colon cancer cell lines (Goel et al, 2006), however, in lung cancer cell lines SLM did not 
induce cell cycle arrest (Seo et al, 2002a).  
 
 
Figure 1.8 Cell cycle regulation.  
Red symbols indicate proteins that can be inhibited by the action of Se. Cell cycle 
progression is a highly regulated process that controls cell growth and proliferation. 
There are 4 phases; G1 (gap 1) when the cell is preparing for DNA synthesis, S 
(synthesis) when DNA synthesis occurs, G2 (gap 2) when the cell is preparing for cell 
division and M (mitosis) when cell division occurs. Cyclins and cyclin-dependent kinases 
(CDKs) are the main proteins that control transition from one phase to another, CDKs 
being activated by forming complexes with cyclins. The Rb (retinoblastoma) family of 
proteins also plays a critical role, as proliferation occurs when Rb is phosphorylated (P) 
by CDKs and thus inactivated. Most cells remain quiescent in Go until mitogenic signals 
are received.  
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Both MSA and MSC have been shown to induce caspase-mediated apoptosis, mainly 
through activation of the intrinsic, mitochondrial apoptotic pathway, in various cancer 
cell lines (Figure 1.9) (Jiang et al, 2001; Jung et al, 2001). In some solid tumour cell lines 
and in vivo tumour models, non-toxic concentrations of MSA and MSC have been shown 
to interact synergistically with both conventional cytotoxic agents and targeted agents. 
This interaction was found to involve enhanced apoptosis (Azrak et al, 2006; Lee et al, 
2009b; Li et al, 2009). In contrast, in a human head and neck cancer xenograft model, 
MSC was found to potentiate the activity of irinotecan and hence dramatically increase 
cure rates but this was not associated with increased markers of apoptosis. The results, 
instead, suggested that the observed synergy correlated with inhibition of angiogenesis. 
This is discussed further below (section 1.3.9.13) (Yin et al, 2006).  
 
The intrinsic apoptotic pathway is regulated by members of the Bcl-2 family of proteins 
and organic Se compounds have been shown to alter the expression of various family 
members. A study combining MSC with the pro-apoptotic cytokine TRAIL found that 
sensitisation of renal cancer cell lines to TRAIL-mediated apoptosis by MSC was due to 
the down-regulation of the anti-apoptotic protein, Bcl-2 (Lee et al, 2009b). In prostate 
cancer cell lines, MSA was shown to sensitise cells to the apoptotic effects of taxanes 
through the down-regulation of the anti-apoptotic protein Bcl-xL and also survivin (Hu et 
al, 2008). MSA-mediated apoptosis in the PCa prostate cancer cell line was found to be 
associated with down-regulation of Bcl-2 and up-regulation of the pro-apoptotic proteins, 
Bax, Bak and Bid (Reagan-Shaw et al, 2008)     
 
Se may also activate the extrinsic, death receptor-mediated, apoptosis pathway but 
studies reporting this are few. In the MCF-7 breast cancer cell line, MSA enhanced 
doxorubicin-induced apoptosis by up-regulating FADD protein (Fas-associated death 
domain) which is involved in transmitting the apoptotic signal after activation of the 
death receptor signalling (Li et al, 2007a).  
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Figure 1.9 Cellular apoptosis pathway.  
Adapted from Hotchkiss, RS et al., N Engl J Med, 2009. The death-receptor pathway is 
activated by the binding of death receptor ligands to their corresponding receptor. The 
adaptor protein Fas-associated death domain (FADD) is recruited to the death receptor 
which then activates caspase 8. This leads to activation of caspases 3 and 7, the main 
effectors of apoptosis. The mitochondrial apoptosis pathway requires release of 
cytochrome c from the mitochondria and, in association with Apaf-1 (apoptotic protease-
activating factor 1), activates caspase 9 which then activates caspases 3 and 7. Members 
of the Bcl-2 family of proteins act to either inhibit or promote the release of cytochrome c. 
Activation of caspases 3 and 7 result in cell death by cleaving proteins such as PARP, 
and activating DNases, which results in DNA fragmentation. (IAPs – inhibitors of 
apoptosis protein).  
 
There are conflicting in vitro data regarding whether apoptosis by methylselenol and its 
precursors is due to the generation of reactive oxygen species (ROS) such as superoxide 
(Jiang et al, 2002; Zhao et al, 2006). This is in contrast to inorganic Se compounds where 
studies are consistent in demonstrating the production of ROS through redox cycling 
leading to genotoxicity and apoptosis (Jiang et al, 2002; Shen et al, 1999). In DLBCL 
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cells line, studies from our laboratory showed an increase in ROS with the inorganic Se 
compound, selenodiglutathione, but not with  MSA (Last et al, 2006).  
 
These studies again emphasise how the effect of Se is very much dependent on the 
chemical form used and the cell type.  
 
1.3.9.5 Induction of phase II enzymes 
Phase II enzymes, such as glutathione-S-transferase and uridine diphosphate 
glucuronyltransferase, function in metabolising and inactivating xenobiotics and toxins 
through conjugation with GSH or glucuronic acid, and therefore protect cells against 
carcinogens. Studies have shown that different forms of Se including MSC and MSA are 
able to up-regulate phase II enzymes and hence this may be a mechanism of tumour 
suppression. An example is a study in a dimethylbenz(a)anthracene (DMBA)-induced 
mammary cancer model in rats. Supplementation with Se-enriched garlic, the main Se 
component of which is MSC, led to the inhibition of mammary carcinogenesis and a 
reduction in DMBA-induced DNA adducts. This was accompanied by a 40% increase in 
urinary excretion of DMBA metabolites and a 2-2.5 fold increase in glutathione-S-
transferase and uridine diphosphate glucuronyltransferase activity in liver and kidney. 
Phase I enzymes, including members of the cytochrome P450 family, were not affected 
(Ip & Lisk, 1997). Thus, one way in which Se may prevent the development of cancer is 
by enhancing cellular detoxification mechanisms.  
 
1.3.9.6 Activation of p53 protein 
p53 is a transcription factor that activates a number of genes in response to DNA damage. 
This results in the arrest of cells in the G1 phase of the cell cycle to allow DNA repair 
and the promotion of apoptosis hence preventing the proliferation of genetically-altered 
cells. p53 is thus a tumour suppressor and is mutated or non-functional in a high 
proportion of human cancers (Riley et al, 2008).  The effect of Se on p53 is dependent on 
the chemical form of Se. The organic compound SLM has been shown to differentially 
affect cells that are p53 wild-type or mutated. Cancer cells lines that are wild-type appear 
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to be more sensitive to the apoptotic effects of SLM than p53-mutated or -null cells and 
this is associated with activation of p53 (Goel et al, 2006; Zhao et al, 2006).  SLM has 
been shown to activate p53 in a human lung cancer cell line, in the absence of DNA 
damage, through reduction of its cysteine residues which requires the redox factor, Ref1 
(Seo et al, 2002a). Another study, using a prostate cancer cell line, reported that SLM 
increased intracellular superoxide resulting in p53 activation, again in the absence of 
DNA damage. This p53 activation resulted in apoptosis via the mitochondrial pathway 
(Zhao et al, 2006). MSA has also been shown to activate p53 through phosphorylation of 
threonine residues (Smith et al, 2004).  
 
Using mouse embryonic fibroblasts as a model for non-cancer cells, pre-treatment with 
SLM was able to protect p53 wild-type cells from DNA damage when exposed to 
ultraviolet (UV) radiation and DNA damaging cytotoxic agents whereas p53-null cells 
were not protected. In p53 wild-type cells, SLM led to induction of the nucleotide 
excision repair pathway which is responsible for DNA repair and regulated by p53. In 
this study however, MSA did not induce a protective response in mouse embryonic 
fibroblasts and p53 wild-type cells were more sensitive to its apoptotic effects compared 
to p53 null cells (Fischer et al, 2007).  
 
These studies again demonstrate that the effect of Se is dependent on the chemical form 
and the cell type, but in addition that genetic alterations within the cell influence the 
action of Se. The ability of Se to activate p53 suggests that this may be a mechanism by 
which Se prevents cancer development as cells that are in the early phase of neoplastic 
transformation are likely to still have wild-type p53. However, given that mutation or 
deletion of p53 occurs commonly in solid tumours, p53-dependent effects of Se are 
unlikely to be important in established cancer. Activation of p53 in normal cells may be 
one mechanism by which Se protects these cells from the toxic effects of 
chemotherapeutic agents and radiotherapy.  
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1.3.9.7 Nrf2-Prx1 pathway 
Peroxiredoxins (Prx) are a family of thiol-specific antioxidant proteins. There are 6 
isoforms expressed in mammalian cells that are classified according to the number and 
position of conserved cysteine residues that participate in the catalytic reactions (Rhee et 
al, 2005). Prx1 is the major cytoplasmic Prx, it has two conserved cysteine residues, is 
expressed in most cell types and it detoxifies peroxides. The full function of the protein 
still remains unclear because Prx1 is susceptible to inactivation by oxidative stress. It has 
been suggested that over-oxidation of the active site promotes a change in function from 
a peroxidase enzyme to a molecular chaperone under conditions of stress (Moon et al, 
2005). In addition, Prx1 appears to play a role in the growth and survival of cells and has 
been found to be elevated in a variety of cancer types including lung (Chang et al, 2001), 
thyroid (Yanagawa et al, 1999) and breast (Noh et al, 2001). Studies suggest that over-
expression of Prx1 plays a part in radio- and chemo-resistance of malignant cells (Chen et 
al, 2006). 
 
In the setting of cancer, Prx1 has been shown to be regulated by the transcription factor 
nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) which is activated by various 
stimuli, including hypoxic and unstable oxygen conditions commonly found within solid 
tumours (Kim et al, 2007d). Nrf2 is kept inactive in the cytoplasm through its association 
with Kelch-like ECH-associated protein 1 (Keap1), but the mechanism by which Nrf2 
dissociates from Keap1 allowing it to translocate to the nucleus remains unclear. Keap1 
may act as a redox sensor leading to the modification of cysteine residues and release of 
Nrf2 under conditions of chemical or oxidative stress (Dinkova-Kostova et al, 2002). 
Phosphorylation of Nrf2 by kinases has also been described as a mechanism for its 
activation (Huang et al, 2002). Once in the nucleus Nrf2 binds to the antioxidant response 
element in the promoter of target genes thus activating their transcription. Nrf2 regulates 
a number of genes in addition to Prx1, many of which are involved in the protection of 
cells against oxidative stress and xenobiotic insult and include the selenoproteins TrxR 
and GPx2 (Copple et al, 2008).  
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In the study discussed previously by Cao et al (Cao et al, 2004) where tumour-bearing 
mice were treated with Se, it was found that Se modulated Nrf2-Prx1 pathways 
differently in tumour and non-tumour tissue. Se suppressed Nrf2 activation and reduced 
expression of Prx1 in tumour tissue but increased the expression of Prx1 and other Nrf2 
target genes in normal tissue. The authors postulate that this differential response may be 
related to the different oxygen conditions found in tumour and non-tumour tissue (Kim et 
al, 2007e) (Figure 1.10). 
 
Therefore, the action of Se on the Nrf2-Prx1 pathway may be a mechanism by which it is 
able to inhibit tumour growth whilst protecting normal tissue from chemotherapy-induced 
toxicity.  
 
 
Figure 1.10 Proposed effect of selenium on the Nrf2-Prx1 pathway.  
Adapted From Kim, YJ et al., Journal of Cancer Molecules, 2007. 
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1.3.9.8 PI3-kinase/Akt and MAP kinase pathways 
The phosphoinositide 3-kinase (PI3K)/Akt pathway is a key pro-survival pathway within 
cells which is frequently up-regulated in human cancers (Cantley, 2002). Activation of 
down-stream effector molecules results in increased proliferation, reduced apoptosis and 
chemo-resistance (West et al, 2002). Akt is a serine/threonine kinase that requires PI3K 
for its phosphorylation and activation in response to growth factor and cytokine 
stimulation of surface receptors. Akt has a vast number of downstream targets which, in 
general, promote cell survival (Alessi et al, 1997; Sarbassov et al, 2005). In a study 
examining tumour samples from 100 patients with DLBCL, phosphorylated Akt (p-Akt) 
was detected in 52% of cases and high p-Akt expression was associated with a shorter 
survival (Uddin et al, 2006). A number of inhibitors of the PI3K pathway are currently 
being investigated for the treatment of several different tumour types.   
 
There have been a number of studies that have reported dephosphorylation of Akt by 
MSA and this may be a mechanism by which Se sensitises cancer cells to chemotherapy 
(Gonzalez-Moreno et al, 2007; Hu et al, 2005b).  In a study using the breast cancer cell 
line MCF-7 it was found that combining doxorubicin with MSA led to enhanced 
apoptosis compared with doxorubicin alone. Doxorubicin alone led to increased 
phosphorylation of Akt which was reversed by the addition of MSA. However, MSA was 
unable to sensitise cells to doxorubicin when Akt was over-expressed (Li et al, 2007b). In 
a prostate cancer cell line, it was shown that MSA dephosphorylated Akt by inhibiting 
PI3K activity which is required for Akt activation. In addition, Se-mediated calcium 
release from the ER may also be important since inhibiting calcium release prevented 
dephosphorylation of Akt by Se (Wu et al, 2006). In a mouse mammary cancer cell line, 
MSC has also been shown to dephosphorylate Akt by inhibiting PI3K activity (Unni et al, 
2005) 
 
The mitogen-activated protein kinase (MAPK) pathway is another key intracellular 
signalling pathway involved in the regulation of cell proliferation, survival and 
differentiation. Six distinct groups of MAPKs have been characterised in mammalian 
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cells; extracellular signal-regulated kinase (Erk)1/2, Erk3/4, Erk5, Erk7/8, Jun N-terminal 
kinase (Jnk)1/2/3 and the p38 kinases (p38α/β/γ/δ). Activation of these kinases requires 
phosphorylation by mitogen-activated protein kinase kinases and in general the Erk1/2 
pathway is activated by growth factor-stimulated cell surface receptors, whereas Jnk, p38 
and Erk5 are activated by stress and growth factors. Activation of Erk1/2 results in cell 
proliferation whereas activation of Jnk1/2 and p38MAPK has tumour suppressive effects. 
These pathways are commonly mutated and disrupted in cancer and attention is being 
focussed on modulating MAPKs for cancer treatment (Dhillon et al, 2007).  
 
In vitro experiments in prostate cancer cell lines have demonstrated that Se has an effect 
on the MAPK pathway but that different forms of Se have a differential effect. In the 
DU145 cell line, MSA at apoptotic concentrations led to dephosphorylation of Erk1/2, an 
effect that preceded the occurrence of caspase-mediated apoptosis suggesting its 
importance in MSA-induced apoptosis. MSA had no effect on Jnk1/2 or p38MAPK. In 
contrast, exposure to selenite resulted in increased phosphorylation of Jnk1/2 and 
p38MAPK but had no effect on Erk1/2 (Jiang et al, 2002).  
 
A study examining the effect of MSA on tumour stage-specific prostate cells used three 
mouse cell lines: Pr111, a slow-growing and non-tumourigenic cell line; Pr14, a 
tumourigenic cell line derived from a primary tumour; Pr14C1, a subclone of Pr14 
explanted from a lung metastasis. MSA decreased phosphorylation of Akt and Erk1/2 in 
the tumour cells which correlated with its cytotoxic and apoptotic effects. However, in 
Pr111 cells MSA increased phosphorylation of Akt and Erk1/2 suggesting a differential 
effect of MSA in tumour and non-tumour cells (Gonzalez-Moreno et al, 2007) 
 
These studies support the use of Se in established cancer and suggest that Se may affect 
pro-survival pathways differently in normal and tumour cells.  
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1.3.9.9 Inhibition of the NF-κB pathway 
NF-κB is a family of inducible transcription factors that consists of five proteins; RelA 
(p65), RelB, c-Rel, NF-κB1 (p105/p50) and NF-κB2 (p100/52). These proteins form 
various homodimers and heterodimers that are kept inactive in the cytoplasm by the IκB 
family of inhibitory proteins (Baldwin, 1996). In response to various stimuli, such as 
oxidative stress, lipopolysaccaride, viruses and cytokines such as TNFα, NF-κB 
translocates to the nucleus where it binds to specific DNA sequences in the promoter of 
target genes and stimulates their transcription (Figure 1.11). These various stimuli first 
activate the multi-protein IκB-kinase (IKK) that phosphorylates the inhibitory IκB 
proteins resulting in their polyubiquitinylation and proteolytic degradation by the 
proteasome. NF-κB dimers are thus released and are able to move to the nucleus (Karin, 
1999). The target genes are involved in cell survival and can be grouped into several 
functional classes such as positive cell-cycle regulators, anti-apoptotic factors (including 
inhibitor of apoptosis proteins), inflammatory and immunoregulatory genes (Jost & 
Ruland, 2007). NF-κB activity has been found to be elevated in many tumour types, 
including lymphoma, and is associated with drug-resistance (Bentires-Alj et al, 2003). In 
vitro data suggest that inhibition of the NF-κB pathway can sensitise cancer cells to 
chemotherapy and favourable clinical results have also been obtained with proteosome 
inhibitors, such as bortezomib, that indirectly inhibit NF-κB activation (Nakanishi & Toi, 
2005). 
 
There have been several studies demonstrating the ability of Se to inhibit NF-κB activity. 
Work from our own group in DLBCL cell lines found that low, non-cytotoxic 
concentrations of MSA inhibited NF-κB activity by 50-70% after a short exposure time 
of 4 hours and that this was a potential mechanism by which MSA enhanced the activity 
of cytotoxic agents (Juliger et al, 2007). In prostate cancer cell lines MSA, at apoptotic 
concentrations, inhibited NF-κB activation and this was through the inhibition of IKK 
activity, thus inhibiting IκBα phosphorylation and NF-κB nuclear translocation. In 
addition, inhibition of NF-κB activity by transfection of cells with an IκBα mutant 
resulted in increased sensitivity of the cell lines to MSA (Gasparian et al, 2002). In 
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contrast, a study using a different prostate cancer cell line was not able to demonstrate an 
effect of MSA on IκBα phosphorylation and NF-κB nuclear translocation but did show 
that MSA inhibited NF-κB binding to DNA (Christensen et al, 2007).  
 
 
Figure 1.11 The NF-κB pathway.  
In response to various stimuli, the multi-protein IκB-kinase (IKK) is activated. This 
phosphorylates the inhibitory IκB proteins resulting in their polyubiquitinylation and 
proteolytic degradation by the proteasome. NF-κB dimers are thus released and move to 
the nucleus where they bind to specific DNA sequences in the promoter of target genes 
and stimulate their transcription. 
 
 
In inflammatory conditions, an inverse relationship between serum Se and C-reactive 
protein (CRP) has been demonstrated. NF-κB is known to up-regulate CRP synthesis by 
the liver and hence the effect of Se on NF-κB was further investigated in the human 
hepatoma cell line, HuH-7 (Maehira et al, 2003). In this study cells were either deprived 
of Se in the culture medium or cultured with medium containing Se at physiological 
levels in the form of sodium selenite. It was found that NF-κB activity and CRP synthesis, 
induced by TNFα, was inhibited by Se, but when Se was present at a concentration that 
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was equivalent to the low levels found in subjects with inflammatory conditions, CRP 
synthesis was maximal.   
 
NF-κB activation has been linked with the development of vascular complications in 
patients with type II diabetes (Hofmann et al, 1999). Therefore the effect of Se 
supplementation, at a dose of 960μg/day for 3 months, on NF-κB activation, was studied 
in a group of patients with type II diabetes. When compared to the placebo group, the 
supplemented group had a significant reduction in NF-κB activation measured in 
peripheral blood mononuclear cells (PBMCs) reaching the same level as non-diabetic 
controls (Faure et al, 2004).  
 
Given the important role of the NF-κB pathway in tumour promotion and chemo-
resistance, these studies provide a sound rationale for the use of Se in established cancer. 
Of relevance to DLBCL is that this pathway is activated in the ABC-subgroup which has 
a poor outcome (Alizadeh et al, 2000). 
 
1.3.9.10 Suppression of survivin expression 
Survivin, which is a member of the inhibitor of apoptosis family of proteins, has been 
found to be a target of Se. In addition to inhibiting apoptosis, survivin plays an essential 
role in the control of cell division. It is often over-expressed in malignant tumours and 
this is associated with aggressive, drug-resistant disease. Survivin is not expressed in 
most terminally differentiated normal tissues and hence is being investigated as a 
therapeutic drug target (Altieri, 2003). The Sp1 family of transcription factors have been 
found to be important in controlling survivin gene expression (Li & Altieri, 1999). In 
addition, survivin is a downstream target of NF-κB (Tracey et al, 2005).   
 
MSA has been shown to down-regulate the expression of survivin both in vitro and in 
vivo (Chun et al, 2007; Hu et al, 2008). In a xenograft model of prostate cancer, orally 
administered MSA inhibited the expression of survivin in tumour samples. In addition, 
MSA enhanced the in vivo activity of paclitaxel in the xenografts and this was associated 
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with inhibition of paclitaxel-induced survivin expression (Hu et al, 2008). The 
mechanism by which MSA inhibited survivin in prostate cancer cell lines was reported to 
be its ability to prevent the binding of Sp1 or Sp1-like proteins to the promoter of the 
survivin gene (Chun et al, 2007). In the ovarian cell line SKOV3, silencing survivin with 
shRNA resulted in synergy between MSA and paclitaxel which was not apparent in wild-
type SKOV3 cells (Azrak et al, 2008). Synergy between MSC and docetaxel in prostate 
cancer cell lines was associated with decreased expression of survivin (Azrak et al, 2006). 
 
Inhibition of survivin is currently being investigated for cancer therapy. This action of Se 
may be important for its use in established cancer especially given that most normal 
tissue does not express survivin.   
 
1.3.9.11 Endoplamic reticulum stress and the unfolded protein response 
The ER is the site where secreted and membrane proteins undergo assembly and folding. 
This involves the formation of disulfide bonds and the addition of oligosaccharides 
allowing the tertiary structure of the protein to be formed. A number of insults, including 
disturbance of calcium homeostasis, changes in redox state and inhibition of protein 
glycosylation, can lead to protein misfolding in the ER. The accumulation of misfolded 
or unfolded proteins is known as ER stress and this triggers what is called the unfolded 
protein response (UPR). The UPR is a survival response which functions to reduce the 
accumulation of unfolded proteins and restore normal ER functioning. However, if the 
cellular stress cannot be resolved, the cell will undergo apoptosis (Szegezdi et al, 2006). 
 
The UPR is an intracellular signalling pathway mediated by the protein chaperone 
glucose regulated protein (GRP)-78, a member of the heat shock protein (HSP)-70 family, 
and three transmembrane ER stress transducers (Figure 1.12). The three transducers are 
protein kinase RNA (PKR)-like ER kinase (PERK), inositol requiring protein-1 (IRE1) 
and activating transcription factor-6 (ATF6). In the resting, unstressed state, GRP78 
binds to the ER luminal domains of the three transducers keeping them inactive. In 
response to disturbance of ER homeostasis and the accumulation of unfolded proteins, 
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GRP78 dissociates from the transducers and moves into the ER lumen where it binds to 
the misfolded proteins. Once released from GRP78, the three transducers are activated 
through different mechanisms and the result is the up-regulation of a number of 
transcription factors (Ron & Walter, 2007). ER chaperones, including GRP78, are also 
up-regulated by activation of the transducers and hence an increase in GRP78 expression 
is a good marker of ER stress (Kozutsumi et al, 1988; Lee et al, 2003).  
 
 
Figure 1.12 The unfolded protein response resulting from endoplasmic reticulum stress.  
From Szegezdi, E. et al., EMBO Rep, 2006. CHOP is also known as GADD153. 
 
 
When PERK is released from GRP78 it is activated through dimerisation and 
autophosphorylation. This leads to the phosphorylation of eukaryotic initiation factor 2α 
(eIF2α) which acts to reduce the rate of general protein translation (Harding et al, 2000). 
However, p-eIF2α also increases the translation of some genes, the best studied being the 
transcription factor ATF4 involved in promoting cell survival (Scheuner et al, 2001). 
After dissociation from GRP78, ATF6 moves to the Golgi, where it is activated through 
cleavage by proteases. It then moves to the nucleus where it binds to the ER stress 
response element of target genes resulting in their induction (Haze et al, 1999). IRE1 is 
92 
 
also activated through dimerisation and autophosphorylation when released from GRP78 
and it then splices a 26-nucleotide intron from X-box-binding protein-1 (XBP1) mRNA 
(Calfon et al, 2002) . The activated transcription factors, ATF4, XBP1 and ATF6, all 
function to increase the expression of genes encoding proteins that enhance the protein 
folding capacity of the ER. This includes GRP78 and proteins that catalyse folding such 
as PDI. In addition, there is induction of genes required for protein degradation and if the 
survival response is unsuccessful, there is induction of pro-apoptotic genes. Proteins for 
degradation are transported to the cytoplasm and degraded mainly by the proteasome 
(Ron & Walter, 2007; Scheuner et al, 2001).  
 
The precise mechanism by which the cell switches to apoptosis in response to ER stress 
has not been fully elucidated (Figure 1.13). There is evidence to support the role of 
growth-arrest and DNA damage inducible gene 153 (GADD153; also known as CHOP), 
Jnk and the Bcl-2 family of proteins in committing the cell to apoptosis, eventually 
leading to caspase activation and cell death (Szegezdi et al, 2006).   
 
Figure 1.13 Mediators of endoplasmic reticulum stress-induced apoptosis.  
From Szegezdi, E. et al., EMBO Rep, 2006. CHOP is also known as GADD153. 
UP=Uniporter. Blue molecules are inactive, red are active. Rounded shapes are pro-
apoptotic and rectangles are anti-apoptotic molecules. 
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The transcription factor GADD153 appears to be essential for ER stress-induced 
apoptosis and all three ER transducers can lead to increased transcription of GADD153 
(Zinszner et al, 1998). Target genes that are up-regulated by GADD153 include, 
GADD34 (Marciniak et al, 2004), which promotes apoptosis through a yet unknown 
mechanism and Tribbles-related protein (TRB)-3, which can inhibit Akt and hence 
promote apoptosis (Du et al, 2003; Ohoka et al, 2005). Bcl-2, an anti-apoptotic protein, is 
down-regulated by GADD153 (McCullough et al, 2001). Of note, GADD34 provides a 
negative feed-back mechanism whereby it promotes dephosphorylation of eIF2α thus 
releasing the block on protein translation (Brush et al, 2003)  
 
Jnk activation has been reported in response to ER stress and this can promote apoptosis 
through regulation of Bcl-2 family members. Jnk can phosphorylate Bcl-2, which inhibits 
its anti-apoptotic effects. It can also phosphorylate Bcl-2 homology domain-3-only 
members, such as Bim, and enhance their pro-apoptotic effect (Davis, 2000). These 
changes allow activation of the pro-apoptotic proteins Bax and Bak which promote the 
release of cytochrome c, resulting in the activation of caspases (Lei & Davis, 2003). The 
exact complement of caspases linked to ER stress-induced apoptosis has not been fully 
elucidated but may involve caspases 4, 7, 8 and 9 (Jimbo et al, 2003; Rao et al, 2001).  
 
In general, cancer cells are exposed to conditions within the tumour environment, such as 
hypoxia and glucose deprivation, that induce a basal level of ER stress. Therefore, as a 
cyto-protective response, levels of ER chaperones such as GRP78 are over-expressed 
compared with normal, non-malignant cells. Studies have shown that over-expression of 
GRP78 promotes tumour growth and chemoresistance and targeting GRP78 can restore 
chemo-sensitivity (Lee, 2007; Pyrko et al, 2007). In addition, therapeutic agents that 
further induce ER stress, thus over-loading the cell’s capacity to deal with misfolded 
proteins, can promote apoptosis (Davenport et al, 2008). For example, in multiple 
myeloma, the malignant plasma cells produce large quantities of immunoglobulin which 
increases the cellular protein load resulting in ER stress. Bortezomib, which has shown 
impressive activity in myeloma, inhibits the proteasome and thus the cells’ capacity to 
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degrade proteins. This leads to increased ER-stress, now shown to be one mechanism by 
which bortezomib induces cell death (Obeng et al, 2006).  
 
Selenium and endoplasmic reticulum stress 
Se has been shown to induce ER stress. A proteomics study examined the effect of MSA 
on reactive protein thiols in the PC-3 human prostate cancer cell line. MSA was found to 
cause global thiol redox modification of proteins and disruption of disulfide bonds which 
is a form of cellular stress that can lead to protein misfolding (Park et al, 2005). The 
effect of MSA on markers of ER stress was therefore further investigated. All three UPR 
transducer arms were found to be up-regulated within a few hours, in PC-3 cells treated 
with MSA. This was accompanied by increased expression of GRP78 and GADD153 and 
cleavage of caspase 7, 12 and PARP. A higher concentration of MSA was required to 
induce the apoptotic proteins compared to the pro-survival proteins. When GRP78 was 
over-expressed in PC-3 cells, the ability of MSA to up-regulate GADD153 and cleave 
caspases was reduced. Conversely, when GRP78 was knocked down in PC-3 cells, MSA 
exposure resulted in a more marked increase in GADD153 expression (Wu et al, 2005; 
Zu et al, 2006).  
 
ER stress induction has been reported to be the mechanism by which Se sensitises 
prostate cancer cell lines to taxanes (Wu et al, 2009). In this study a non-cytotoxic 
concentration of MSA was shown to induce GRP78, p-EIF2α and GADD153. Knock-
down of GRP78 enhanced cell death induced by the combination of MSA and paclitaxel, 
with the reverse being true when GRP78 was over-expressed. Knock-down of GADD153 
also inhibited cell death in the combination. Sensitisation was greatest when cells were 
pre-treated with MSA for 6 hours, suggesting that cells require priming and time to 
respond to ER stress induction by MSA.  
 
The effect of Se on the ER is not cell-type specific. GADD153 was induced when a 
mouse mammary cancer cell line was treated with sodium selenite or MSC (Sinha et al, 
1999). In addition, proteins within normal, non-malignant cells are also likely to undergo 
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redox modification when exposed to Se and this may also lead to ER stress. It has been 
demonstrated that Se has a differential effect on tumour and normal tissue and is able to 
protect normal cells from chemotherapy-induced toxicity (Cao et al, 2004). This suggests 
that different cells handle cellular stress in different ways and it may be that Se triggers a 
pro-survival response in normal cells. In fact, the induction of ER stress has been 
reported to protect normal cells from oxidative stress and toxicity from cytotoxic agents 
(Bedard et al, 2004; Hung et al, 2003) 
 
In addition to Se compounds that are precursors of monomethylated Se species, two 
selenoproteins have been implicated in the ER stress response. Both selenoprotein S and 
Sep15 are induced in response to ER stress and act as molecular chaperones, facilitating 
protein folding and helping to alleviate ER stress (Kelly et al, 2009; Labunskyy et al, 
2009)   
 
Despite the strong in vitro evidence for the mechanistic role of ER stress induction in the 
action of Se, there has been doubt cast by a recent in vivo study (Jiang et al, 2009). The 
action of MSA, MSC and selenite was investigated in a chemically-induced rat mammary 
carcinoma model and a human DU145 prostate cancer xenograft model. All three 
compounds were able to inhibit tumour growth, with evidence of increased apoptosis 
within the Se-treated tumours. However, the levels of GADD153 and GADD34 within 
the Se-treated tumours, measured by real-time polymerase chain reaction (PCR) and 
western blotting, were not higher than in untreated tumours. Se treatment did, however, 
result in decreased expression of the cell cycle protein cyclin D1, increased expression of 
the cyclin-dependent kinase inhibitor, p27, and activation of Jnk, which may explain the 
Se-induced tumour growth inhibition and apoptosis. Clearly further work is required to 
define the role of Se-induced ER stress induction in vivo. 
 
1.3.9.12 Autophagy 
Autophagy, used here to refer to macroautophagy, is a cellular degradation pathway 
involved in the clearance of long-lived proteins and organelles (Figure 1.14). It occurs at 
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low levels in all cells as a normal homeostatic process whereby defective proteins, 
damaged organelles and abnormal protein aggregates are removed. However, autophagy 
is activated in response to cellular stress such as starvation and hypoxia, resulting in 
protein degradation to provide cellular energy and amino acids, fatty acids and 
nucleotides for the synthesis of essential proteins. Therefore, autophagy is generally 
considered a cellular survival mechanism (He & Klionsky, 2009). In addition to 
macroautophagy, there are two other forms of autophagy – chaperone-mediated and 
microautophagy- but these will not be discussed further as their role in cell death and 
cancer is less well understood. 
 
The process of autophagy involves the formation of a double-membrane vesicle called an 
autophagosome, which contains the proteins/organelles to be degraded. The 
autophagosome fuses with a lysosome to form an autolysosome, which is followed by 
lysis of the autophagosome inner membrane and degradation of its contents by acid 
hydrolases. Autophagy is controlled mainly by mTOR kinase, which interacts with a 
number of signalling pathways such as the PI3K/Akt and MAPK pathways. Downstream 
of mTOR kinase, a large number of genes, known as Atg genes, encode proteins essential 
for the execution of autophagy (Levine & Kroemer, 2008).   
 
When cells are exposed to excessive stress, autophagy can result in cell death. 
Morphologically this is distinct from apoptotic cell death and is characterised by massive 
vacuolisation of the cytoplasm in the absence of chromatin condensation, little or no 
interaction with phagocytes, and does not involve caspase activation. However, there are 
difficulties distinguishing between cells that are dying by autophagy and those that are 
dying with autophagy. In the latter, autophagy may be activated in an attempt to rescue 
the cell from death but is not the mechanism of cell death (Kroemer et al, 2009). 
 
The induction of ER stress by various stimuli, including the accumulation of misfolded 
proteins, has recently been shown to activate autophagy. This is mainly thought to be a 
cyto-protective response preventing the accumulation of abnormal protein aggregates. 
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However, if the level of ER stress and hence autophagy is excessive, cell death may 
occur (Hoyer-Hansen & Jaattela, 2007). Both the PERK-eIF2α and the IRE1-Jnk 
pathways of the UPR have been shown to be important in the activation of autophagy 
(Kouroku et al, 2007; Ogata et al, 2006). 
 
 
 
Figure 1.14 The autophagy pathway.  
Adapted from Levine, B. Nature, 2007. In response to various signals, cytoplasmic 
material is sequestered by a membrane-bound vesicle, the autophagosome. This then 
fuses with a lysosome forming an autolysosome which degrades the cytoplasmic material. 
LC3 is microtubule-associated protein 1 light chain 3 and after post-translational 
modification is called LC3-I, which resides in the cytosol. When autophagy is induced, 
LC3-I is converted to LC3-II by conjugation to phosphatidylethanolamine and relocates 
specifically to associate with autophagosome membranes. LC3-II is degraded by the 
autolysosome. Autophagy can lead to cell survival or cell death. 
 
Autophagy and cancer 
The role of autophagy in cancer has been the subject of intensive investigation but the 
data are complicated and somewhat contradictory as evidence supports the role of 
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autophagy both in cancer development and suppression (Mathew et al, 2007). Many 
oncogenes and tumour suppressor genes have been implicated in the regulation of 
autophagy (Maiuri et al, 2009). Regarding cancer development, there is evidence to 
suggest that Atg genes are tumour suppressors, as many cancers have been shown to have 
deletions of these genes, for example, inactivation of the Atg gene beclin 1 has been 
shown to promote tumour growth in mice (Liang et al, 1999). However, in established 
cancer, autophagy can promote cancer cell survival, especially in cells with defective 
apoptosis (Degenhardt et al, 2006) and inhibition of autophagy can sensitise tumour cells 
to the effects of chemotherapy (Zhu et al, 2010). To further complicate the data, it has 
been reported that certain chemotherapeutic agents induce cancer cell death by autophagy 
in the absence of apoptosis (Kanzawa et al, 2004; Kanzawa et al, 2003) and induction of 
autophagy may explain the synergistic interaction between some cytotoxic agents 
(Lambert et al, 2008). Combining agents that induce ER stress with inhibitors of 
autophagy is also being explored for cancer therapy (Schonthal, 2009). Clearly targeting 
autophagy for therapeutic benefit may yield promising results but it is still not apparent in 
which tumour models autophagy should be inhibited and in which it should be promoted.  
 
Autophagy and selenium 
There are little published data describing the effect of Se on autophagy, but given that Se 
induces ER stress it would be expected to also induce autophagy. Two studies have 
investigated the effect of selenite on autophagy. In malignant glioma cells lines, selenite 
was shown to induce autophagic cell death in the absence of apoptosis. This was 
demonstrated to be a consequence of selenite-induced superoxide generation resulting in 
mitochondrial damage and mitochondrial autophagy. Pre-treatment of the cells with an 
inhibitor of autophagy reduced selenite-induced cell death (Kim et al, 2007b). In contrast 
to these results, a recent study using the acute promyelocytic leukaemia cell line, NB4, 
showed that selenite-induced apoptosis was associated with inhibition of autophagy, 
through the down-regulation of the PI3K/Akt pathway. Further inhibition of autophagy 
by specific inhibitors resulted in enhanced selenite-induced apoptosis (Ren et al, 2009).  
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Therefore, from the limited available data it appears that the role of autophagy in the 
action of Se differs between cell types. In addition, the effect of organic Se compounds 
on autophagy has not been investigated.  
 
1.3.9.13 Inhibition of angiogenesis 
New vessel formation is a crucial component of solid tumour growth, progression and 
metastasis. There is evidence to suggest that Se has anti-angiogenic properties. When rats 
with chemically-induced mammary cancers were supplemented with sodium selenite, 
MSC or Se-enriched garlic, there was a significant reduction in intra-tumoural 
microvessel density and vascular endothelial growth factor (VEGF) expression compared 
with the untreated controls. However, the microvessel density of the uninvolved 
mammary glands was not affected by Se treatment, suggesting a tumour specific effect 
(Jiang et al, 1999). In vitro, effects of MSA on HUVEC (human umbilical vein 
endothelial cell) cells have been studied and MSA induces G1 cell cycle arrest at low 
concentrations and caspase-mediated apoptosis at higher concentrations.  Sub-apoptotic 
concentrations of MSA led to a dose-dependent reduction in phosphorylation of Akt, 
Erk1/2 and Jnk1/2 but no change in p38MAPK, while apoptotic concentrations of MSA 
increased phosphorylation of p38MAPK (Wang et al, 2001). MSA-induced G1 cell cycle 
arrest in telomerase-immortalised microvascular endothelial cells was associated with 
increased expression of the cyclin-dependent kinase inhibitors p21, p27
 
and p16 which 
resulted in the inhibition of the kinase activity of CDK2, CDK4, and CDK6 (Wang et al, 
2008).  
 
Treatment of HUVEC cells with relatively low concentrations of MSA (2µmol/L) 
inhibited the gelatinolytic activity of metalloproteinase-2, a protein that is secreted by 
vascular endothelial cells when stimulated and is required to break down the adjacent 
tissue matrix. However, this inhibitory effect was dependent on the cellular metabolism 
of MSA as medium conditioned with MSA did not affect the gelatinase activity of 
metalloproteinase-2 in a test tube. In addition, selenite was not able to inhibit 
metalloproteinase-2 activity suggesting that an immediate precursor of methylselenol is 
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necessary for this effect (Jiang et al, 1999). The inhibitory effect of MSA on 
metalloproteinase-2 activity in HUVEC cells and VEGF expression in epithelial cancer 
cell lines occurs rapidly, within 30 minutes and 1-2 hours respectively and was apparent 
at non-apoptotic concentrations of MSA. However, inhibition of metalloproteinase-2 
activity appears to be sustained even after removal of MSA from the cell medium 
whereas inhibition of VEGF secretion required continuous exposure. In addition, 
inhibition of VEGF expression in the DU145 prostate cancer cell line required only low 
non-apoptotic concentration of MSA whereas selenite in the same concentration range 
was not able to decrease VEGF expression once again suggesting that the generation of 
methylselenol is required (Jiang et al, 2000). In a DU145 prostate cancer xenograft model, 
daily treatment of mice with MSA, 3mg/kg, resulted in significant inhibition of tumour 
growth, accompanied by a significant decrease in intra-tumoural microvessel density 
when assessed by IHC staining for CD34 expression (Wang et al, 2008).  
 
Inhibition of angiogenesis has been shown to be an important mechanism by which MSC 
sensitises tumours to the effects of chemotherapy in xenograft models, specifically 
through the down-regulation of hypoxia inducible factor (HIF)-1α. In a xenograft model 
of squamous cell head and neck carcinoma, MSC administered 7 days before and during 
chemotherapy, was able to significantly enhance the anti-tumour activity of irinotecan 
and increased the cure rate from 30% to 100%. This was not associated with increased 
levels of apoptosis in tumour samples but was associated with decreased expression of 
cyclo-oxygenase 2 enzymes and HIF-1α. Both these proteins are important in stimulating 
angiogenesis by up-regulating VEGF expression and secretion. The combination of MSC 
and irinotecan was found to decrease microvessel density in the xenografts but this 
reduction in microvessel density was not seen in normal mouse liver tissue, suggesting a 
tumour specific effect of MSC (Bhattacharya et al, 2008; Yin et al, 2006).  
 
In addition to increased vessel density, tumours have morphologically and functionally 
abnormal vasculature. MSC alone was found to reverse these abnormalities in vivo by 
inducing tumour vessel maturation, reducing tumour vessel leakiness and improving 
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tumour vascular function. This led to improved delivery of chemotherapy to the tumours 
in xenograft models of head and neck and colon cancer (Bhattacharya et al, 2008; 
Bhattacharya et al, 2009). However, it was found that histological features of the tumour 
influenced the response to MSC, such that well differentiated, morphologically 
heterogenous tumours with multiple avascular hypoxic regions responded less well to 
MSC than well-vascularised, poorly differentiated, homogenous tumours (Bhattacharya 
et al, 2009; Rustum et al, 2010).  
 
The effect of Se on HIF-1α specifically has been studied in vitro and in vivo. In the FaDu 
xenograft model of head and neck squamous cell carcinoma, HIF-1α knockdown by 
shRNA had a similar inhibitory effect on tumour growth and microvessel density as 
treatment with MSC alone, which was also shown to inhibit HIF-1α and VEGF 
expression in the tumours. In addition, when the FaDu xenografts were treated with 
irinotecan, the knock-down of HIF-1α had a similar synergistic effect to the 
administration of MSC resulting in almost 100% cure (Chintala et al, 2010). The 
mechanism by which Se inhibited HIF-1α was further investigated. Prolyhydroxylases 
(PHDs) are involved in the regulation of HIF-1α such that under normoxic condition they 
hydroxylate proline molecules of HIF-1α. This facilitates interaction with von Hipple-
Lindau (VHL) protein and subsequent ubiquitinylation and degradation of HIF-1α by the 
proteasome. Under hypoxic conditions, these PHDs are inhibited thus preventing the 
degradation of HIF-1α (Jaakkola et al, 2001). In vitro, FaDu cells grown under hypoxic 
conditions had very low levels of PHDs, however, when these cells were treated with 
MSA there was up-regulation of PHDs and inhibition of HIF-1α expression. mRNA 
levels of HIF-1α were unchanged in the MSA-treated cells, suggesting no effect on HIF-
1α synthesis  In addition, under hypoxic conditions, MSA was found to inhibit the 
generation of ROS, which are known to be important in inhibiting PHDs and thus 
activating HIF-1α (Chandel et al, 2000). FaDu cells grown under hypoxic conditions 
were resistant to irinotecan but when treatment was combined with low non-cytotoxic 
concentrations of MSA there was enhanced cytotoxicity. This sensitisation did not occur 
under normoxic conditions (Chintala et al, 2010).  
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Inhibition of angiogenesis is a promising target for cancer therapy. These studies suggest 
that precursors of methylselenol not only inhibit new vessel formation but improve 
tumour vascular function and reverse chemo-resistance induced by hypoxia. This 
provides strong evidence for the potential therapeutic use of Se in established cancer.   
 
1.3.9.14 Tumour specific effects of selenium 
In addition to the general, common effects of Se compounds that occur in a number of 
tumour types, there are some effects of Se that are specific to the tumour-type. This is 
particularly true of prostate and breast cancer. In prostate cancer, both in vitro and in vivo 
studies have demonstrated that MSA and MSC can decrease the expression of the 
androgen-receptor, disrupt androgen receptor signalling and suppress the expression and 
secretion of prostate-specific antigen. Prostate-specific antigen in known to be controlled 
through androgen-receptor signalling and is a prognostic marker in prostate cancer (Dong 
et al, 2004; Lee et al, 2006). Similarly, breast cancer studies have shown that Se can 
decrease the expression of the oestrogen receptor and disrupts oestrogen receptor 
signalling (Lee et al, 2005). A synergistic interaction between Se and tamoxifen has been 
demonstrated and Se appears to be able to reverse tamoxifen resistance (Li et al, 2008b). 
In a breast cancer xenograft model the synergy between MSC and tamoxifen involved 
enhanced inhibition of oestrogen receptor expression and signalling (Li et al, 2009). 
  
1.3.10 Selenium and its effect on normal tissue 
Evidence from xenograft models and clinical trials suggest that Se is able to protect 
normal tissue from chemotherapy-induced toxicity (Cao et al, 2004; Hu et al, 1997). 
Additional studies supporting these data include an in vitro study that investigated 
whether the addition of SLM could protect human peripheral lymphocytes from the 
genetic damage induced by doxorubicin (Santos & Takahashi, 2008). SLM was able to 
reduce the cytotoxicity, genotoxicity and clastogenicity of doxorubicin. It has been 
demonstrated, in vitro, that pre-treatment of primary human keratinocytes with Se, in the 
form of selenite or SLM, protects these cells from oxidative damage and apoptosis 
resulting from exposure to UV radiation (Rafferty et al, 2003a; Rafferty et al, 2003b). 
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Work from our group has shown that PBMCs harvested from healthy individuals are 
relatively resistant to the cytotoxic effects of MSA with a 72-hour EC50 of 84.2μM 
(Juliger et al, 2007).  
 
The mechanism by which Se compounds are able to protect normal tissue is not fully 
understood. As discussed above there are several proposed mechanisms. These include a 
possible pro-survival response in normal cells to the induction of ER stress (Bedard et al, 
2004; Hung et al, 2003), protection from DNA damage through induction of p53 (Fischer 
et al, 2007) and activation of pro-survival cell signalling pathways such as Akt and 
Erk1/2 (Gonzalez-Moreno et al, 2007). 
 
1.3.11 Functional markers of selenium status 
If Se supplementation, at supra-nutritional doses, is going to be used as a therapeutic 
agent in cancer therapy it would be useful to have a functional marker of its biological 
effect, a biomarker. Current markers are inadequate. Plasma or serum Se is widely used 
but this reflects short-term status and is affected by non-nutritional factors. For example, 
there is an inverse relationship between CRP, a marker of the acute phase response, and 
serum Se in a number of pathological conditions (Maehira et al, 2002). Toenail and hair 
Se better reflect long-term Se status.  
 
The measurement of selenoproteins may be a more accurate reflection of Se status. 
However, there are differences between selenoproteins in the response to Se deficiency 
with preferential incorporation of Se into some. In addition, polymorphisms in the genes 
coding for selenoproteins have been shown to account for inter-individual variation in the 
ability to increase the activity of these proteins (this has been discussed earlier in section 
1.3.9.2) (Hu & Diamond, 2003; Meplan et al, 2007). Within the GPx family, Se 
deficiency leads to a rapid decrease in activity of GPx-1 and 3 whereas GPx-2 and 4 are 
depleted more slowly (Weitzel et al, 1990; Wingler et al, 1999). In addition, plasma 
selenoproteins such as GPx3 and selenoprotein P plateau at certain Se concentrations. 
The recommended dietary intake of Se has been determined based on optimising GPx3 
104 
 
activity and hence in individuals who are Se replete, GPx3 does not respond to Se 
supplementation (Burk et al, 2006). This maximal activity is reached at a plasma Se 
concentration of around 1.2µmol/L (Duffield et al, 1999; Thomson et al, 1993). Platelet 
GPx activity however is saturated at higher plasma Se concentrations, 1.2-1.5μmol/L for 
inorganic forms and 1.4-1.7µmol/L for organic forms (Neve, 1995; Thomson et al, 1993). 
The reason for the difference between inorganic and organic forms of Se is not clear. 
Selenoprotein P also plateaus but at a higher plasma Se concentration than GPx3, in the 
range of 1.2-1.7µmol/L (Persson-Moschos et al, 1998; Xia et al, 2005). However, in a 
high dose Se supplementation study where individuals were Se replete with an average 
serum Se concentration of 1.58µmol/L, there was no further increase in selenoprotein P 
levels (Burk et al, 2006). This has been confirmed by a more recent Se supplementation 
study in which selenoprotein P levels reached a plateau at a plasma Se concentration of 
1.57µmol/L (Hurst et al, 2010)  
 
Haemolysate TrxR activity was correlated with serum Se levels in a supplementation 
study (Karunasinghe et al, 2006). Activity increased with increasing Se concentration and 
had not plateaued at concentrations of 1.62µmol/L. However, work in animals suggests 
that  supra-nutritional doses of MSC and MSA are unable to further increase TrxR 
activity in tissues (Ganther & Ip, 2001).  
 
As discussed above, Se metabolites are excreted in the urine. Until recently it was 
thought that selenosugars were the major metabolites when Se was ingested at normal 
dietary doses and that trimethylselenonium became the dominant metabolite when Se was 
ingested at supra-nutritional doses (Kobayashi et al, 2002). However, a recent study in 
patients with cancer who were supplemented with very high doses of SLM (up to 
8000µg/day) found that trimethylselenonium was only a minor metabolite in urine and 
selenosugars made up the greatest proportion (Kuehnelt et al, 2007). These results 
support those of an earlier study (Kuehnelt et al, 2005). Therefore, trimethylselenonium 
in urine is unlikely to be useful as a biomarker of high Se intake. 
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Se status will probably best be assessed by a combination of plasma protein markers and 
others need to be sought to assess the efficacy of supra-nutritional doses.   
 
1.3.12 Studies of selenium in lymphoma 
Work at SBH has focussed on the role of Se in lymphoma, particularly DLBCL. Serum 
Se concentration at diagnosis was found to be independently predictive of treatment 
response and long-term survival in patients with ‘aggressive’ B-cell NHL, the majority 
having DLBCL (Last et al, 2003). This retrospective analysis of stored sera in a group of 
100 patients found that 73% had a serum Se level below the UK reference range. When 
the patient group was split into quartiles based on their serum Se level, response to first 
treatment was 54% in the lowest quartile and 88% in the highest (p=0.011) with a lower 
OS in patients with lower Se (p=0.03). Presentation Se was also predictive of delivered 
dose intensity, reflecting whether cytotoxic chemotherapy could be administered on time 
and at full dose. Serum Se concentration correlated closely with performance status but 
with no other clinical variables, including albumin. Figure 1.15 shows the OS, from 
diagnosis, of the 100 patients split into serum Se quartiles. 
 
Other studies have reported a lower serum Se concentration in patients with NHL. A 
study in patients with cutaneous T-cell lymphoma found that serum Se was associated 
with advanced stage and a poorer response to treatment (Deffuant et al, 1994). Another 
study in patients with lymphoid malignancy reported similar findings. Compared with a 
control group, patients with advanced stage, but not localised disease, had a significantly 
lower Se level (Avanzini et al, 1995). However, serum Se positively correlated with 
albumin to which a proportion of Se is bound. A smaller study in paediatric patients 
investigated the hair Se status of newly diagnosed patients with lymphoid malignancies 
(Ozgen et al, 2007). Hair Se, which is a reflection of more long-term status, was lower 
than that of a control group but this was only statistically significant in malnourished 
patients.  
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Figure 1.15 Overall survival of patients with ‘aggressive’ B-cell NHL split into serum 
selenium quartiles. From Last, KW et al., J Clin Oncol, 2003. 
 
 
There is some debate in the literature about the interpretation of low Se levels in patients 
with malignancy. It may merely be a reflection of tumour burden, disease progression, an 
acute phase response and a marker of general nutritional deficiency. With regards to this 
point it is interesting to note that patients in the intensive care unit with systemic 
inflammatory response syndrome and multi-organ failure have been found to have low 
serum Se concentration and GPx activity, and this is associated with increased mortality 
(Sakr et al, 2007). This has led to several clinical trials of Se supplementation, mainly in 
the form of sodium selenite, in critically ill patients; the rationale being that Se will 
increase the activity of anti-oxidant selenoproteins. However, the results of these studies 
have largely been inconclusive (Manzanares et al, 2010).  
 
Alternatively, the presence of low serum Se at diagnosis may predict for chemo-
resistance and hence a poorer outcome, thus Se supplementation may represent a 
potential therapeutic intervention. This hypothesis forms part of the rationale for the 
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proposed clinical trial of Se supplementation in patients with recurrent/refractory DLBCL 
(discussed further below). Interestingly, studies in solid malignancy have found that a 
low serum Se level is associated with a significantly increased tumour Se concentration 
when compared to adjacent non-neoplastic tissue (Charalabopoulos et al, 2006a; 
Charalabopoulos et al, 2006b). Whether the increased Se concentration in the neoplastic 
tissue is responsible for the low serum Se is not clear. Another explanation may be that 
Se forms part of the defence mechanism in tumour tissue in line with the anti-oxidant 
properties of some selenoproteins. These findings, however, require further study.  
 
In addition to Se levels, the activity and gene expression of GPx and other antioxidants 
have been studied in patients with lymphoma. One study measured red cell GPx activity 
in 50 patients with untreated lymphoma and 47 controls and found that patients with 
lymphoma had significantly lower levels. Patients also had significantly lower levels of 
superoxide dismutase, suggesting a general deficiency in the cellular anti-oxidant system. 
Plasma Se levels were not measured in this study (Bewick et al, 1987).  
 
Contradictory results regarding alterations in gene expression of antioxidant enzymes 
have been reported. One study analysed the expression of a number of antioxidant genes 
in tumour samples from patients with de novo DLBCL and found that decreased 
expression of GPx (GPx1, 3 and 4) and other antioxidant enzymes was associated with a 
poor prognosis (Tome et al, 2005). However, a similar study found that high expression 
of GPx1 was significantly associated with early treatment failure and a poor outcome and 
this remained significant after adjusting for the IPI score and molecular subgroup 
(Andreadis et al, 2007). The Pro197Leu polymorphism in the GPx1 gene has been 
analysed in patients with lymphoma and a moderate association was found between 
having the leucine allele and the risk of different NHLs (OR 1.24-1.34) (Lightfoot et al, 
2006).  
 
It is difficult to pull all these results together as there is evidence in the literature to 
suggest that oxidative stress may play a role in tumour initiation and progression but also 
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may be involved in inducing tumour cell death. Suffice to say that the intracellular redox 
environment is crucial to cellular function and that the selenoprotein GPx plays an 
important part.  
 
Our laboratory has conducted a number of pre-clinical studies investigating the activity of 
Se alone and in combination with cytotoxic agents in DLBCL cell lines and primary 
patient samples. MSA induced apoptosis in DLBCL cell lines, but these cell lines 
differed markedly in their sensitivity to MSA. Cell death was not associated with cell 
cycle arrest or with the generation of ROS. In addition, primary lymphoma cultures from 
4 patients with B-cell NHL  (2 mantle cell lymphoma, 1 FL and 1 chronic lymphocytic 
lymphoma) showed a concentration-dependent decrease in cell viability in response to 
MSA (Last et al, 2006).  
 
A synergistic interaction was demonstrated between low, non-cytotoxic concentrations of 
MSA and three cytotoxic agents, etoposide, doxorubicin and 4-             
hydroperoxycyclophosphamide (4-HC), in DLBCL cell lines. Best results were obtained 
when MSA was administered simultaneously with the cytotoxic drugs.  A potential 
mechanism for this synergistic interaction with cytotoxic drugs was found to be a Se-
induced decrease in NF-κB activity in DLBCL cell lines. To confirm that inhibiting NF-
κB activity increased sensitivity to chemotherapeutic agents, the same experiments were 
conducted with the known NF-κB inhibitor, BAY 11-7082. BAY 11-7082 significantly 
increased the cytotoxic activity of etoposide and doxorubicin in the DLBCL cell lines. 
Figure 1.16 shows inhibition of NF-κB activity by MSA and BAY 11-7082. In addition, 
it was demonstrated that the synergistic interaction between MSA and chemotherapeutic 
agents was not due to enhanced DNA damage (Juliger et al, 2007).  
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Figure 1.16 Inhibition of NF-κB activity by MSA and BAY 11-7082 in a DLBCL cell 
line (DHL4). From Juliger, S. et al., Cancer Res, 2007.  
 
 
In a collaboration between our laboratory and LGC (Teddington, London, UK), novel 
mass-spectrometry methods were developed for quantification of total intracellular Se 
and the identification of intracellular and volatile Se species. These experiments are 
important for determining the Se species responsible for the observed effects (Goenaga-
Infante et al, 2007b). DLBCL cell lines differed in their basal Se concentration. The 
MSA-sensitive cell line, RL, had a much higher concentration than two resistant cell lines, 
DHL4 and DoHH2. After 4-hour exposure to MSA, the DHL4 cell line had a much larger 
increase in Se concentration than the RL cell line.  
 
Intracellular Se metabolites generated after exposure to MSA in DHL4 cells (a resistant 
DLBCL cell line) were investigated. MSC was detected as the main metabolite with a 
maximal concentration after 30-minute exposure. SLM and γ-glutamyl-MSC were also 
detected, but at a much lower level, and were formed at a slower rate than MSC. MSA 
itself was not detected. Investigation of the volatile Se species generated after exposure to 
MSA revealed that dimethyldiselenide was formed after 10-minute exposure. There was a 
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massive increase in dimethyldiselenide generation after 20-minute exposure and the 
appearance of a second metabolite, dimethylselenide (Juliger et al, 2007).  
 
Based on these clinical and in vitro studies in lymphoma, a phase I/II multi-centre study 
of MSC in combination with ‘R-ICE’ chemotherapy in patients with relapsed/refractory 
DLBCL will commence shortly. This trial will supplement patients with supra-nutritional 
doses of MSC aiming to achieve a plasma Se concentration of 20µmol/L prior to 
commencing chemotherapy. This trial is funded by Leukaemia and Lymphoma Research 
and will be run from SBH. 
 
There has been a randomised study of high-dose sodium selenite in patients with NHL 
treated with CHOP chemotherapy (Asfour et al, 2009). This was in a group of patients 
with ‘intermediate’ and ‘high-grade’ lymphomas, all of whom had bone marrow 
involvement. Selenite was given on days 3-7 for the first cycle of chemotherapy only. 
The main endpoint was the number of apoptotic bone marrow lymphoma cells on day 8 
compared with day 0, as assessed by flow cytometric analysis of propidium iodide 
stained cells. The study reported a significant increase in the percentage of apoptotic 
lymphoma cells in the selenite-treated group. In addition, a significantly greater reduction 
in cervical and axillary lymphadenopathy, spleen size and percent bone marrow 
infiltration was reported in the selenite-treated group. In the control group there was a 
significant decrease in cardiac ejection fraction after chemotherapy. This was not 
observed in the selenite group, suggesting a possible cardio-protective effect of selenite.  
 
This study, however, has a number of limitations. Although it is reported that selenite 
increased the percentage of apoptotic lymphoma cells in the bone marrow, the lymphoma 
cells were not selected for in the separation process so all mononuclear cells were 
analysed. It is known that marrow infiltration by lymphoma is patchy and therefore it is 
unclear what proportion of cells analysed were indeed lymphoma cells and what were 
normal bone marrow cells. It is not obvious how the reduction in lymphadenopathy was 
assessed. Given that spleen size was reported ‘in fingers’ it suggests that the 
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lymphadenopathy may also have been assessed clinically, rather than by CT scanning. 
This is clearly a subjective method of assessment and is a source of bias given that the 
study was not blinded. This study was performed in a heterogenous group of patients and 
unusually they all had splenomegaly, with over three-quarters of patients also having 
hepatomegaly. This is unusual given that DLBCL should be the most common subtype. 
 
In summary, there is robust evidence for the therapeutic use of organic Se compounds in 
solid tumours and evidence is emerging to suggest it may also be of value in treating 
patients with lymphoma. Clearly, Se has a number of potential mechanisms of action 
which differ based on the chemical form, concentration and tumour type. Thus, further 
investigation is required into mechanisms which are important in its action in lymphoma, 
particularly DLBCL. In addition, the effects of Se differ between normal and tumour 
cells and the mechanism for this differential activity have not been well defined. For the 
purposes of the planned phase I/II clinical trial in patients with relapsed/refractory 
DLBCL, better biomarkers of Se activity are required. Therefore, these areas of 
investigation form the basis of this thesis. 
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1.4 HYPOTHESIS AND AIMS  
Better therapies are needed for the treatment of DLBCL, particularly at recurrence. One 
such treatment could be the addition of Se to standard chemotherapy regimens. The 
hypothesis being tested here is that chemo-sensitisation of DLBCL cell lines by MSA is 
due to enhanced apoptosis through the induction of cellular stress, and that the response 
to cellular stress differs between normal, non-malignant cells and lymphoma cells. This 
was investigated through the following aims: 
 
1. To analyse the patterns of survival in newly diagnosed patients with DLBCL 
presenting to St Bartholomew’s Hospital between 1985 and 2003. 
2. To investigate mechanisms by which Se, in the form of MSA, sensitises DLBCL 
cell lines to chemotherapy.  
3. To investigate the effects of MSA in normal cells and identify mechanisms by 
which Se protects these cells from chemotherapy-induced toxicity. 
4. To investigate the uptake of MSA by PBMCs and DLBCL cell lines. 
5. To investigate the Se metabolites generated after exposure of PBMCs and 
DLBCL cell lines to MSA. 
6. To identify potential biomarkers for the clinical evaluation of Se. 
7. To investigate the combination of Se and bortezomib in mantle cell lymphoma 
cell lines. 
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CHAPTER 2: Materials and Methods 
This chapter contains methods used throughout the thesis. Methods that are specific to a 
particular chapter are described in those chapters. 
 
2.1 Cell Culture  
A panel of B-NHL cell lines were used in experiments. The DHL4 cell line was obtained 
from the Dana-Farber Cancer Institute (kind gift from Dr Margaret Shipp). The DoHH2, 
SUD4, RL and JVM2 cell lines were all obtained from Cancer Research UK cell services. 
These suspension cell lines were all maintained in RPMI-1640 culture medium (Sigma-
Aldrich, Poole, UK) supplemented with 10% foetal calf serum (Sigma Aldrich) and 1% 
penicillin (100units/ml) and streptomycin (100µg/ml) (both from Invitrogen™, 
California, USA) at 37°C in a humidified atmosphere with 5% CO2. Cells were passaged 
twice weekly and reset at 2x10
5
/ml. For experiments, cells were used in their exponential 
growth phase. Therefore, cells were reset in fresh culture medium the day before 
exposure to the various drugs of interest. 
 
2.1.1 Cell line characteristics 
The RL cell line is established from the ascites of a patient with DLBCL (Beckwith et al, 
1991). The SUD4 cell line, also known in the literature as SU-DHL4, is derived from the 
pleural effusion of a patient with DLBCL (Epstein et al, 1978). The DoHH2 cell line is 
established from the pleural effusion of a patient with FL, which had transformed to 
DLBCL (Kluin-Nelemans et al, 1991). The DHL4 cell line is a drug-resistant variant of 
the SUD4 cell line, established in the laboratory of Dr Margaret Shipp (Dana Farber 
Cancer Institute). JVM2 is now accepted as a mantle cell lymphoma (MCL) cell line 
(Tucker et al, 2006), however, it was first reported as being derived from a patient with 
pro-lymphocytic lymphoma, before the diagnosis of MCL was widely recognised (Melo 
et al, 1988). The RL, SUD4 and DoHH2 cell lines all have the t(14;18) translocation and 
the JVM2 cell line has a t(11;14) translocation. All the cell lines, except JVM2, have 
mutated p53. The RL, DHL4 and SUD4 cell lines have homozygous mutations whilst the 
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DoHH2 cell line has a heterozygous mutation (Strauss et al, 2007). In this thesis the RL, 
SUD4, DoHH2 and DHL4 cell lines are collectively termed DLBCL cell lines.  
 
2.1.2 Culture of cell lines under hypoxic conditions 
To investigate the effect of MSA on HIF-1α and Prx1 expression and VEGF production, 
RL and DHL4 cell lines were cultured in a hypoxic incubator (1% O2, 5% CO2, 94% N2) 
at 37°C in a humidified atmosphere. 5x10
6 
cells, resuspended in 10mls culture medium, 
were placed in the hypoxic incubator overnight prior to exposure to different 
concentrations of MSA for a further 24 hours. As a control, cells were also cultured under 
normoxic conditions. After 24 hours, cells were pelleted by centrifugation at 210g for 6 
minutes at room temperature and the supernatant collected and stored at -80°C for 
subsequent determination of VEGF levels. The cells were used for whole cell, nuclear 
and cytoplasmic protein separation and western blotting was performed. 
 
2.1.3 Harvesting peripheral blood mononuclear cells  
Collection of PBMCs from healthy volunteers received a favourable ethical opinion from 
the East London and City HA Local Research Ethics Committee. PBMCs were obtained 
through venesection and 20-40mls of blood was collected into blood tubes containing 
ethylene diamine tetraacetic acid (EDTA; BD Vacutainer
®
, Plymouth, UK). The blood 
was then layered over an equal volume of Histopaque
® 
(Sigma-Aldrich), and density-
gradient centrifugation (600g for 20 minutes at room temperature) was used to isolate the 
mononuclear cell fraction. The isolated PBMCs were washed once in RPMI-1640 culture 
medium and then resuspended in RPMI-1640 culture medium supplemented with 10% 
foetal calf serum, and 1% penicillin (100units/ml) and streptomycin (100µg/ml).   
 
2.2 Drug preparation 
2.2.1 Methylseleninic acid 
MSA (PharmaSe
®
 Inc., Texas, USA) was dissolved in deionised water as stock solutions 
of 10mmol/L and 20mmol/L and stored at -80°C. These stocks were further diluted prior 
to use in cell culture medium to obtain a range of experimental working concentrations. 
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2.2.2 Methylselenocysteine  
MSC (PharmaSe
®
 Inc., Texas, USA) was dissolved in deionised water as a stock solution 
of 10mmol/L and stored at -80°C. These stocks were further diluted prior to use in cell 
culture medium to obtain a range of experimental working concentrations. 
 
2.2.3 Doxorubicin  
Doxorubicin hydrochloride solution (Sigma-Aldrich), 3.45mmol/L, was made up to the 
desired concentration in cell culture medium prior to use.  
 
2.2.4 4-hydroperoxycyclophosphamide  
4-HC is the active metabolite of cyclophosphamide. It is formed in vivo in the liver by the 
action of p450 oxidases. Thus, for in vitro experiments 4-HC (Squarix Biotechnology, 
Marl, Germany) was used. It forms aldophosphamide, which is in turn converted to 
phosphoramide mustard, the cytotoxic molecule. A 5mmol/L stock solution of 4-HC was 
prepared in deionised water and stored at -80°C.  These stocks were further diluted prior 
to use in cell culture medium to obtain a range of experimental working concentrations.  
 
2.2.5 Bortezomib 
A 5mmol/L stock solution of bortezomib (LC laboratories, MA, USA) was prepared in 
dimethyl sulfoxide (DMSO, Sigma Aldrich) and stored at -80°C. These stocks were 
further diluted prior to use in cell culture medium to obtain a range of experimental 
working concentrations.  
 
2.2.6 Suberoylanilide hydroxamic acid  
A 10mmol/L stock solution of suberoylanilide hydroxamic acid (SAHA; synthesised in 
the Chemistry department, University College London) was prepared in DMSO and 
stored at -80°C. These stocks were further diluted prior to use in cell culture medium to 
obtain a range of experimental working concentrations.  
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2.2.7 Staurosporine 
1mmol/L staurosporine solution in DMSO (Sigma-Aldrich) was made up to the desired 
concentration in cell culture medium prior to use. 
 
2.2.8 Bafilomycin A1 
Bafilomycin A1 (Sigma-Aldrich) was dissolved in DMSO to a concentration of 0.1mg/ml 
and stored -80°C. This stock solution was further diluted prior to use in cell culture 
medium to obtain a final working concentration of 10nmol/L.  
 
2.2.9 Thapsigargin  
Thapsigargin (Sigma-Aldrich) was dissolved in DMSO as a stock solution of 15mmol/L 
and stored at -80°C. This stock solution was further diluted prior to use in cell culture 
medium to obtain a final working concentration of 3μmol/L.  
 
2.3 Cell proliferation and cytotoxicity assays 
2.3.1 Trypan blue exclusion 
Cell count and viability of PBMCs was established by trypan blue exclusion. After 
mixing, 10μl of cells was mixed with 10μl 0.4% trypan blue (Sigma-Aldrich) and placed 
onto a haemocytometer for counting under a light microscope. Live cells are colourless 
and dead cells stain blue since they are unable to exclude the dye due to impaired 
membrane integrity. 
 
2.3.2 ViaLight
®
 HS assay (ATP assay) 
The activity of various drugs in a number of different cell lines was determined using the 
ViaLight HS bioluminescence kit (Lonza, Basel, Switzerland). Cells were plated in 96-
well microtitre plates at a concentration of 2x10
5
/ml for suspension cells and 5x10
4
/ml 
for adherent cells. After 24 hours, the drug of interest was added to the experimental 
wells and cells were incubated for a further 48 or 72 hours. The Vialight HS assay is 
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based on the measurement of ATP and uses the enzyme luciferase to catalyse the reaction 
between ATP and luciferin, resulting in the generation of light. The reaction is as follows: 
 
ATP + luciferin + O2                                 Oxyluciferin + AMP + PPi + CO2  + Light 
 
 
There is a linear relationship between the light emitted and the ATP concentration, this 
being measured by a luminometer. This assay is based on the observation that as cells 
lose viability they lose the ability to regenerate ATP, such that intracellular ATP 
concentration provides a measure of the viability of a population of cells.  
 
After incubating the cells with the drug(s) of interest, 100µl of the nucleotide releasing 
agent was added to each well and the 96-well plate was incubated at room temperature 
for 5 minutes. Following this, 180µl from each well was transferred to a white 96-well 
microtitre plate. The plate was then placed in the POLARstar OPTIMA plate reader 
(BMG Labtech, Offenburg, Germany), 20µl of ATP monitoring reagent was 
automatically dispensed into each well and luminescence measured immediately. The 
results were expressed relative to the control value and data analysis is described in 
section 2.14.  
 
2.3.3 Gauva
®
 Viacount
®
 Assay 
The ViaCount
®
 assay (Millipore, MA, USA) uses a reagent which is a mixture of two 
DNA binding dyes to obtain absolute cell counts and assess cell viability. One dye is 
membrane permeable and stains all nucleated cells, the other is membrane impermeable 
and only enters cells when the membrane has been breached thus identifying 
apoptotic/dead cells. Cells stained with this reagent were analysed on the Guava
®
 PCA-
96 system (Millipore) which has a green laser for excitation, two fluorescence detectors, 
and a detector of forward scatter that assesses relative size. Data were analysed using the 
Guava
®
 ViaCount
® 
software (Millipore) and cell viability and cell number data obtained. 
Luciferase 
Mg
2+ 
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Cells were added to 96-well microtitre plates at a concentration of 1x10
5
/ml. After 24 
hours, different drugs were added to the experimental wells and plates were incubated for 
a further 48 hours. Following this, 100µl of the Guava
®
 ViaCount
®
 reagent, diluted 1:400 
in cell culture medium, was added to each well. Plates were analysed immediately on the 
Guava
®
 PCA-96 system. Examples of the results obtained are shown below (Figure 2.1). 
The results were expressed relative to the control value and data analysis is described in 
section 2.14.  
 
 
 
Figure 2.1 Gauva
®
 Viacount
®
 Assay. Live cells shown in red and dead cells shown in 
black (a) An example of control cells (b) An example of cells treated with bortezomib. 
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2.4 Sample preparation for western blot analysis 
2.4.1 Treatment of cell lines 
Cells lines were reset in fresh medium at 5x10
5
/ml in volumes of 6mls. After 24 hours, 
the drug(s) of interest was added and cells were incubated for various lengths of time. 
 
2.4.2 Methylseleninic acid treatment of peripheral blood mononuclear cells 
PBMCs were set in fresh medium at 2x10
6
/ml in volumes of 4mls. MSA was added at a 
concentration range of 1-20µmol/L and cells incubated for various time-points.  
 
2.4.3 Whole cell protein extraction 
Cells were pelleted by centrifugation at 210g for 6 minutes at room temperature. The 
medium was discarded and the cells washed twice in Hanks’ Buffered Salt solution 
(HBSS; Sigma-Aldrich) by centrifugation at 210g for 6 minutes at 4°C. The cells were 
resuspended in lysis buffer [1x phosphate buffered saline (PBS), 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% sodium dodecylsulphate, 1mM EDTA, made up to 500ml 
with deionised water, pH set to 7.4, stored at 4°C; all chemical were obtained from 
Sigma-Aldrich].  Protease inhibitor cocktail (Roche, Basel, Switzerland) was added to the 
lysis buffer at a 1:25 dilution just prior to use. Samples were left on ice for 20 minutes 
and then centrifuged at 20,800g for 10 minutes to remove insoluble cellular debris. The 
supernatant was removed, placed into fresh eppendorf tubes (Eppendorf UK Limited, 
Cambridge, UK) and stored at -80°C prior to western blot analysis 
  
2.4.4 Nuclear and cytoplasmic protein separation 
All chemicals were obtained from Sigma-Aldrich. Cells were pelleted by centrifugation 
at 210g for 6 minutes at room temperature. The medium was discarded and the cells were 
washed twice in HBSS by centrifugation at 210g for 6 minutes at 4°C. Each cellular 
sample was then resuspended in 200µl of buffer A [10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM 
phenylmethanesulfonyl fluoride (PMSF), 1mM dithiothreitol (DTT), protease inhibitor 
cocktail, made up to 10mls with deionised water] and incubated for 20 minutes on ice. 
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0.4% Octylphenyl-polyethylene glycol (IGEPAL
® 
CA-630) was then added and the 
samples centrifuged at 750g for 5 minutes at 4°C. The supernatant containing the 
cytoplasmic protein fraction was removed and placed into fresh eppendorf tubes. The 
remaining pellet was washed once in buffer A and then resuspended in 50µl of buffer B 
[20mM HEPES pH 7.9, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM PMSF, 
1mM DTT, protease inhibitor cocktail, made up to 2mls with deionised water]. The 
samples were incubated on ice for 45 minutes and vortexed every 5 minutes. The samples 
were then centrifuged at 20,800g for 12 minutes and the supernatant containing the 
nuclear protein fraction removed and placed into fresh eppendorf tubes. Both cytoplasmic 
and nuclear fractions were stored at -80°C prior to use.   
 
2.4.5 Whole cell, nuclear and cytoplasmic protein quantification 
The protein content of each lysate was determined using the BCA™ (bicinchoninic acid) 
protein assay kit (Pierce, Illinois, USA). This assay makes use of the fact that protein can 
reduce Cu
+2 
to Cu
+1 
in an alkaline medium. The reagent containing BCA is used for 
colorimetric detection of Cu
+1
 (purple coloured reaction product is formed when two 
molecules of BCA are chelated with one Cu
+1
 ion). The absorbance, read at 562nm, has a 
linear relationship to the protein concentration. 10µl of lysate was pipetted into a 96-well 
plate with 10µl of lysis buffer. BCA™ reagent A (sodium carbonate, sodium bicarbonate, 
BCA and sodium tartrate in 0.1M sodium hydroxide) was mixed with BCA™ reagent B 
(4% cupric sulphate) in a 50:1 ratio and 160 µl added to each well. The plate was 
incubated at 37°C for 20 minutes and absorbance read at 562nm. The protein content was 
determined by comparison with a standard concentration curve created by dilutions of 
bovine serum albumin (2mg/ml) from 0 to 20µg in lysis buffer. The protein 
concentrations of the samples were calculated by linear regression analysis. An example 
of the standard curve generated is given below (Figure 2.2; r=0.998). 
 
121 
 
 
Figure 2.2 An example of a standard curve of bovine serum albumin quantified using the 
BCA
TM
 assay kit. 
 
2.5 Western blot analysis 
2.5.1 Electrophoresis of proteins 
20μg to 40µg of cellular protein was added to 1x NuPAGE® LDS sample buffer 
(Invitrogen™). The samples were heated at 95°C for 5 minutes. Pre-cast gels (NuPAGE® 
Novex
® 
Bis-Tris midi or mini gel system; Invitrogen™), were placed in a gel tank and 
running buffer (1x NuPAGE
® running buffer, Invitrogen™) added to the tank to a level 
that covered the gels. The samples were then loaded into the wells of the gels. In the first 
well of each gel the Novex
® sharp standard (Invitrogen™) was loaded. This is a pre-
stained standard protein molecular weight marker of between 3.5kDa and 260kDa. For 
blots that were to be developed using the Fujifilm image analyser (see below in section 
2.5.5), a luminescent marker was loaded; MagicMark™ XP Western Protein Standard 
(Invitrogen™) with bands between 20-220kDa. Electrophoresis of the gel was performed 
at a constant voltage of 200V.  
 
2.5.2 Transfer of proteins from the gel to the polyvinylidene fluoride membrane 
Protein transfer was performed using the iBlot™ gel transfer device (Invitrogen™) for 
dry blotting of proteins according to the manufacturers’ instructions. It is a self-contained 
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blotting unit with an integrated power supply. The device requires iBlot™ gel transfer 
stacks which are disposable stacks with an integrated polyvinylidene fluoride (PVDF) 
transfer membrane. Each transfer stack contains a copper electrode and appropriate 
cathode and anode buffers in a gel matrix. After completion of protein electrophoresis the 
gels were removed from the gel tank and placed on the anode stack that had the PVDF 
membrane as its upper most layer. Filter paper, pre-soaked in distilled water, was placed 
on the pre-run gel and air bubbles removed using a roller device. The cathode stack was 
then placed on top of the filter paper and the transfer device closed and programmed to 
perform the protein transfer. 
 
2.5.3 Antibody staining of western blots 
Protein expression was determined by antibody staining. After removing the PVDF 
membrane from the protein transfer device, it was blocked in 1x 
tris(hydroxymethyl)aminomethane (Tris) buffered saline (TBS) [1L of 10x TBS; 24.2g 
Trizma
® 
base (Sigma-Aldrich) and 80g NaCl made up with distilled water, pH adjusted to 
7.6] with 0.1% (v/v) Tween-20
®
 (Sigma-Aldrich) and 5% (w/v) non-fat dry milk for 1 
hour. For phospho-proteins, the membrane was blocked in 5% (w/v) albumin from 
bovine serum (Sigma-Aldrich). Following 3 washing steps with TBS-tween-20
®
 solution, 
the primary antibody was added either overnight at 4°C or for 1 hour at room temperature 
depending on the antibody used. The membrane was again washed three times with TBS-
tween-20
®
 solution and then incubated with a horseradish peroxidase (HRP)-conjugated 
secondary antibody. An HRP-conjugated anti-mouse IgG1 (1:2000 dilution) was used as 
secondary antibody for mouse primary antibodies, and an anti-rabbit IgG was used 
(1:2000 dilution) for rabbit primary antibodies, both from Dako Ltd, (Cambridge, UK). 
 
2.5.4 Antibodies used for protein detection 
The following primary antibodies were used in western blot analysis (Table 2.1). All 
antibodies were diluted in TBS-tween-20
®
.   
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Table 2.1 Primary antibodies used in western blotting experiments 
Protein MW* Company Dilution 
Acetylated histone H3 17 Millipore
1
 1:3000 
Acetylated α-tubulin 52 Sigma-Aldrich 1:3000 
β-actin 40 Dako4 1:3000 
Akt 60 Cell Signaling
2
 1:1000 
Bak 23 Santa Cruz
3
 1:1000 
Bax 30 Santa Cruz 1:1000 
Bcl-2 26 Dako 1:1000 
Bcl-xL 30 Santa Cruz 1:1000 
Cleaved PARP 89 Abcam
5
 1:1000 
eIF2α 38 Cell Signaling 1:1000 
Erk1/2 42, 44 Cell Signaling 1:1000 
GAPDH 36 Abcam 1:1000 
GRP78 78 Santa Cruz  1:1000 
HIF-1α 120 Abcam 1:500 
Histone H3  17 Cell Signaling 1:1000 
HSP70 70 Cell Signaling  1:3000 
HSP90 90 Santa Cruz  1:3000 
IκB-α 35-41 Santa Cruz  1:1000 
Jnk 46, 54 Cell Signaling 1:1000 
LC3B 14, 16 Cell Signaling 1:1000 
Mcl-1 40 Santa Cruz  1:1000 
NF-κB p65 65 Santa Cruz  1:1000 
Nrf2 57 Santa Cruz  1:1000 
p53 53 Dako 1:1000 
p21 21 Santa Cruz  1:200 
PARP 116, 89 Cell Signaling 1:1000 
Peroxiredoxin-1 24 Abcam 1:3000 
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Phospho-Akt (Ser473) 60 Cell Signaling 1:1000 
Phospho-eIF2α (Ser51) 38 Cell Signaling 1:1000 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
42, 44 Cell Signaling 1:200 
Phospho-SAPK/Jnk 
(Thr183/Tyr185) 
46, 54 Cell Signaling 1:1000 
Phospho-Histone H2AX 
(Ser139) 
15 Cell Signaling 1:1000 
Protein disulfide isomerise 
(PDI) 
55 Santa Cruz  1:1000 
Survivin 16.5 Santa Cruz  1:500 
α-tubulin 52 Cell Signaling 1:1000 
Ubiquitin - Santa Cruz  1:500 
*MW, molecular weight; 
1Millipore™, Billerica, MA, USA; 2Cell Signaling 
Technology
®
, Inc., Danvers, MA, USA; 
3
Santa Cruz Biotechnology
®
, Inc., Santa Cruz, 
CA, USA; 
4 
Dako Ltd, Cambridge, UK; 
5
Abcam
®
, Cambridge, UK. 
 
2.5.5 Visualisation of protein bands 
The protein bands were visualised using an enhanced chemiluminescence method (ECL 
reagent, GE Healthcare UK Limited, Little Chalfont, UK). In this method, hydrogen 
peroxide catalyses the oxidation of luminol in alkaline conditions. This results in 
excitation of luminol, which subsequently decays whilst emitting light. PVDF 
membranes were incubated with ECL reagent for 30 seconds then blotted to remove 
excess reagent. Following this the membrane was placed between two transparent acetate 
films and exposed to high performance chemiluminescence film (GE healthcare) for up to 
20 minutes depending on the strength of the bands. The films were then developed 
manually using Kodak developer and fixer obtained from Sigma-Aldrich. For the last 7 
months of this work, a Fujifilm luminescent image analyser (Fujifilm LAS-4000, Tokyo, 
Japan) was used for visualisation of protein bands. Densitometric analysis was performed 
using Gelscan version 5.1 software (BioSciTech, Frankfurt, Germany). Values were 
normalised to the loading control. 
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2.5.6 Validation of loading control 
For all western blots, equal protein loading was assessed by determining the expression 
of a ‘housekeeping’ protein. Commonly used proteins are β-actin, α/β tubulin and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Proteins of interest were 
normalised to the ‘housekeeping’ protein in densitometric analysis of western blots. 
Therefore, housekeeping proteins were validated by loading increasing concentrations of 
protein from whole cell lysates of the DHL4 cell line. Figure 2.3 shows western blots 
obtained for β-actin, α/β tubulin and GAPDH (Figure 2.3). For β-actin, the antibody is 
saturated at protein concentrations of ≥10µg and beyond this there is no longer a linear 
increase in band density. For α/β tubulin and GAPDH, the antibody is saturated at 
concentrations of ≥25µg. GAPDH shows a larger increase in band density between 
different protein concentrations than α/β tubulin and thus was selected as the loading 
control for the majority of experiments. For most western blot experiments a maximum 
of 20µg protein was loaded with the exception of western blots required to assess the 
expression of phospho-proteins, when 40µg protein was loaded. However, phospho-
protein expression was compared to the relevant total protein expression rather than the 
loading control. 
 
Figure 2.3 Western blotting of different protein loading. Protein concentration is shown 
above and densitometry values below each blot. 
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2.6 Intracellular glutathione measurement 
The effect of MSA on total intracellular GSH was determined using a 96-well plate-based 
GSH assay kit (Sigma-Aldrich). Both reduced glutathione (GSH) and the oxidized form, 
glutathione disulfide (GSSG), are measured by the kit. In the assay, GSH results in the 
reduction of 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) to 5′-thio-2-nitrobenzoic acid 
(TNB). During this reaction, GSH is oxidised to GSSG, which is then converted back to 
GSH by the action of glutathione reductase and NAPDH. The reaction is as follows: 
 
2 GSH + DNTB → GSSG + 2 TNB 
 
GSSG + NAPDH + H
+         glutathione reductase          
2 GSH + NADP
+ 
 
The reaction rate is proportional to the concentration of GSH.  The yellow product, TNB, 
can be measured spectrophotometrically at 412nm 
 
DHL4, RL and SUD4 cell lines were exposed to a range of MSA concentrations (1-
20µmol/L) for 2 and 24 hours. 10 million
 
cells were used for each experimental 
condition. After exposure to MSA, cells were pelleted by centrifugation at 210g for 6 
minutes at room temperature. The medium was discarded and cells were washed twice by 
centrifugation at 210g for 6 minutes with 20mls of PBS.  The cells were then resuspended 
in 1ml PBS and transferred to 1.5ml eppendorf tubes. The cells were centrifuged again at 
600g to obtain a packed cell pellet and the supernatant removed. 200µl of 5% 5-
sulfosalicylic acid was added to each sample to deproteinise the cells. The samples were 
vortexed well and then exposed to 3 freeze/thaw cycles (dry-ice to freeze and a 37°C 
heated block to thaw). The cell suspension was left on ice for 5 minutes and then 
centrifuged at 10,000g for 10 minutes at 4°C. The supernatant was recovered into fresh 
eppendorf tubes and used in the assay. 
 
The assay was performed using a 96-well plate. GSH standards (supplied in the kit) were 
prepared using a concentration range of 250-4000nmol/L and 10µl of each concentration 
127 
 
was added to a 96-well plate in duplicate. 10µl of the cell extracts were also transferred to 
the 96-well plate, in duplicate. Two wells contained 10µl of 5% 5-sulfosalicylic acid as a 
reagent blank. 150µl of the freshly prepared working mixture (containing glutathione 
reductase enzyme 6units/ml and DNTB, 1.5mg/ml) was added to each well and the plate 
was incubated for 5 minutes at room temperature. 50µl of NADPH solution (0.16mg/ml) 
was then added to each well and the plate immediately analysed using the POLARstar 
OPTIMA plate reader (BMG Labtech) to measure absorbance at 412nm. Using the GSH 
standards, a standard curve was generated and used to determine the GSH concentration 
in the unknown samples. An example of a GSH standard curve is shown below (Figure 
2.4; r=0.986) 
 
 
 
 
Figure 2.4 An example of the standard curve of glutathione quantified using the 
glutathione assay kit with a concentration range of 250-4000nmol/L. 
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2.7 Analysis of cell cycle distribution using flow cytometry  
2.7.1 Sample preparation 
Cells (1x10
6
) for analysis were pelleted by centrifugation at 210g for 6 minutes at room 
temperature. The medium was discarded and the cells washed twice in ice-cold HBSS. 
Cells were fixed in 5mls of 70% ice-cold ethanol (Fisher Scientific, Leicestershire, UK) 
and incubated at 4°C for 30 minutes or stored at -20°C until further use (maximum 2 
weeks). 
 
2.7.2 Staining with propidium iodide and cell cycle analysis 
Cells, previously fixed in 70% ethanol, were pelleted by centrifugation at 210g for 6 
minutes at room temperature. The supernatant was discarded and cells washed once in 
ice-cold HBSS. 500μl of propidium iodide (PI; Sigma-Aldrich; 50μg/ml PI and 50μg/ml 
RNAse A in HBSS) was added to each sample and mixed thoroughly. Ten thousand cells 
per sample were then analysed immediately using a FACSCaliber
TM 
flow cytometer 
(Becton Dickenson, NJ, USA) with CellQuest 
TM 
software (Becton Dickenson). The 
percentage of cells in the sub-G1 (apoptotic fraction), G1, S and G2/M phases were 
determined using the cell cycle analysis program WinMDI (version 2.8). 
 
2.8 Intracellular doxorubicin measurement by flow cytometry 
Doxorubicin is fluorescent and therefore the cellular fluorescence intensity measured by 
flow cytometry can be used to indicate intracellular drug accumulation (Luk & Tannock, 
1989). DLBCL cell lines were treated with different concentrations of doxorubicin with 
and without MSA for 24 hours. Cells (1x10
6
) were pelleted by centrifugation at 210g for 
6 minutes at room temperature and then washed twice in PBS. The cell pellet was then 
resuspended in 500μl of PBS and samples analysed immediately using a FACSCaliberTM 
flow cytometer (Becton Dickenson) with CellQuest 
TM 
software (Becton Dickenson). Red 
(560-590nm) fluorescence
 
emission when excited by the 488nm laser was measured for 
ten thousand cells.  
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2.9 Measurement of mitochondrial membrane potential 
Mitochondrial membrane potential (MMP) was measured using JC-1 (5,5
’
,6,6
’
-
tetrachloro-1,1
’
,3,3-tetraethylbenzimidazolylcarbocyanine iodide), a fluorescent cationic 
dye. In healthy, non-apoptotic cells the mitochondrial membrane has a negative charge, 
allowing the JC-1 dye to accumulate in the mitochondria and form aggregates, which 
fluoresce red. During apoptosis (intrinsic pathway) the mitochondrial potential collapses, 
therefore the dye is unable to accumulate in the mitochondria and remains in a 
monomeric form in the cytoplasm, which fluoresces green.  
 
The MMP detection kit (Stratagene, Agilent Technologies, Texas, USA) was used 
according to the manufacturers’ instructions. After exposure to MSA, 5x105 cells were 
pelleted by centrifugation at 400g for 5 minutes at room temperature and the supernatant 
discarded. The cells were re-suspended in 250μl of 1x JC-1 reagent solution and 
incubated for 15 minutes in the dark at 37°C. The cells were then pelleted by 
centrifugation at 400g for 5 minutes at room temperature and the supernatant discarded. 
Cells were washed in 1ml of 1x assay buffer, re-suspended in 500μl of 1x assay buffer 
and analysed immediately using a FACSCaliber
TM 
flow cytometer (Becton Dickenson) 
with CellQuest 
TM 
software (Becton Dickenson). Red (590nm) and green (530nm) 
fluorescence
 
emission when excited by the 488nm laser was measured for fifteen 
thousand cells.  
 
2.10 Real-time polymerase chain reaction  
2.10.1 Sample preparation 
RL and DHL4 cells were set in fresh cell culture medium at a concentration of 5x10
5
/ml 
in 6mls. Harvested PBMCs were set in medium at a concentration of 1x10
6
/ml in 10mls. 
After 24 hours, RL cells were exposed to 1, 3, and 5µmol/L MSA and DHL4 cells to 5, 
10, 30 and 60µmol/L MSA for 4, 6, 24 and 48 hours. PBMCs were exposed to 20µmol/L 
MSA for 4, 6, and 24 hours. Cells were then pelleted by centrifugation at 210g for 6 
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minutes at room temperature and resuspended in 1ml of TRIzol
®
 reagent (Invitrogen™), 
incubated at room temperature for 5 minutes and then stored at -80°C till required. 
 
2.10.2 RNA extraction and quantification 
Samples were thawed on ice and then 0.2ml chloroform (American Chemical Society, 
ACS, grade; Thermo Fisher Scientific, Delaware, USA) added per 1ml of TRIzol
®
. 
Samples were shaken vigorously for 15 seconds then incubated at room temperature for 
2-3 minutes. This was followed by centrifugation at 12,000g for 15 minutes at 4°C. 
Following centrifugation, the colourless, upper aqueous phase containing the RNA was 
recovered and precipitated with 0.5ml isopropanol (ACS grade, Thermo Fisher Scientific) 
per 1ml TRIzol
®
.
 
Samples were incubated at room temperature for 10 minutes followed 
by centrifugation at 12,000g for 10 minutes at 4°C. The supernatant was carefully 
removed and the precipitated RNA washed once by adding 1ml of 75% ethanol (ACS 
grade, Thermo Fisher Scientific) per 1ml TRIzol
® 
 followed by centrifugation at 7500g 
for 5 minutes. The supernatant was removed and samples allowed to air dry. The RNA 
was then dissolved in 12µl diethylpyrocarbonate (DEPC)-treated water (Sigma-Aldrich) 
and samples were vortexed thoroughly. The RNA in each sample was quantified using 
the NanoDrop
TM
 1000 spectrophotometer (Thermo Fisher Scientific) using a 260/280nm 
ratio according to the manufacturers’ instructions.  
 
2.10.3 Synthesis of complementary DNA from RNA 
1µg of RNA was used to synthesise complementary DNA (cDNA) in 0.5ml micro-
centrifuge tubes. All materials were kept on ice following removal from storage. DEPC-
treated water was added to the RNA to make up to a volume of 11.5μl. 1.5µl of 
50µmol/L random hexamer (Cancer Research UK, Oligonucleotide Synthesis Service, 
London, UK) was then added to each sample. The samples were incubated at 70°C for 5 
minutes, to melt the secondary structure within the template, followed by incubation on 
ice for 5 minutes to prevent reformation. The following components were then added to 
each sample to make a final volume of 30µl: Moloney-Murine Leukaemia Virus (M-
MLV) reverse transcriptase, RNase H Minus, Point Mutant (Promega Corporation, 
131 
 
Madison, USA), 1µl; M-MLV 5x buffer (Promega Corporation), 6µl; deoxynucleoside 
triphosphate (dNTPs) (Amersham Biosciences, Amersham UK), 10µl (comprising equal 
volumes of 2.5mM dATP, dCTP, dGTP, dTTP). The samples were incubated at 42°C for 
1 hour followed by 95°C for 5 minutes (to inactivate the remaining enzyme). cDNA was 
stored at -20°C until use. 
 
2.10.4 Real-time quantitative polymerase chain reaction for GADD153 
TaqMan
®
 gene expression assays (Applied Biosystems, Warrington, UK) were used for 
the detection and quantitation of GADD153 relative to GAPDH, a housekeeping gene. 
Normalisation to an endogenous reference provides a method for correcting for differing 
amounts of starting cDNA. The pre-developed TaqMan
®
 gene expression assays contain 
the primers and probe in a ready to use mix which has already been optimised. The probe 
for GADD153 is labelled with a FAM™ reporter dye at the 5΄ end and a non-fluorescent 
quencher at the 3΄ end. The probe for GAPDH is labelled with VIC® reporter dye and a 
non-fluorescent quencher at the 3΄ end.  
 
For each sample, a 20µl reaction was set up in duplicate in an optical 96-well fast 
reaction plate (Applied Biosystems), consisting of the following components: TaqMan
® 
universal PCR master mix 2x (Applied Biosystems), 10µl; TaqMan
®
 gene expression 
assay mix 20x, 1µl; undiluted cDNA, 2µl; water (Sigma-Aldrich), 7µl. Negative controls 
for both GADD153 and GAPDH were included where water (Sigma-Aldrich) was added 
rather than cDNA. Real-time PCR amplification was performed using the 7900HT fast 
real-time PCR sequence detection system (Applied Biosystems). The PCR conditions 
were 2 minutes at 50°C, 10 minutes at 95°C followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute.  
 
The comparative ΔΔCT   method was used to determine relative quantification using the 
SDS software v2.3 (Applied Biosystems). The CT or cycle threshold is the number of 
cycles at which the fluorescent signal of the reporter becomes detectable above 
background. The ΔCT is calculated using the mean target gene CT minus the mean CT for 
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the endogenous control. The ΔΔCT is then calculated by subtracting the ΔCT of the 
untreated control sample from the ΔCT of the treated sample and this is then expressed as 
a fold difference. 
 
ΔΔCT = (CT GADD153 - CT GAPDH)treated – (CTGADD153 - CTGAPDH)untreated 
 
2.11 LC3 immunofluorescence 
The DHL4 cell line was exposed to 10μM and 30μM MSA for 24 hours. 1x106 cells were 
then pelleted by centrifugation at 210g for 6 minutes at room temperature and the 
supernatant discarded. The cells were washed once in PBS and then resuspended in cell 
culture medium containing 10% fetal calf serum. 10μl of the cell suspension was drawn 
up in a pipette tip and spread onto a microscope slide. Once the slides had been air-dried, 
cells were fixed in 4% formaldehyde (diluted in PBS; Sigma-Aldrich) for 20 minutes at 
room temperature. Slides were then washed in PBS containing 0.1% Tween-20
® 
(PBS-T). 
Blocking buffer [3% goat serum (Sigma-Aldrich) and 0.1% saponin (Sigma-Aldrich) 
diluted in PBS] was added to the cells for 30 minutes at room temperature. Without 
washing the slides, LC3B antibody (rabbit; Cell Signaling) diluted 1:100 in blocking 
buffer was added to the cells for 1 hour at room temperature.  Slides were washed twice 
in PBS-T followed by the addition of a fluorescent goat anti-rabbit secondary antibody 
(Alexa Fluor
® 488 F(ab’)2 fragment, Invitrogen™), diluted 1:100 in blocking buffer, for 1 
hour at room temperature in the dark. Slides were washed three times in PBS-T after 
which DAPI (4’,-diamidino-2-phenylindole; Invitrogen™) at a final concentration of 
100nmol/L was added as a counter-stain. Once the slides were dry they were mounted 
with ProLong
® Gold antifade reagent (Invitrogen™). Slides were viewed using a Zeiss 
Axioskop fluorescence microscope (Zeiss, Germany) attached to a CCD camera 
(Photometric LtD, Tuscon, AZ) which uses IPLLabs Spectrum and SmartCapture 
(Cambridge, UK) software. The filter wheel was set at green (excitation 450 to 
490nm/emission 515 to 565nm) and DAPI (excitation 310 to 380nm/emission 435 to 485 
nm). 
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2.12 Acridine orange staining using flow cytometry 
Acridine orange (AO), an acidotropic dye, was used to quantify the formation of acidic 
vesicular organelles in the cytoplasm of cells. When cells are stained with AO, the 
cytoplasm and nucleolus fluoresce bright green and dimly red respectively, and acidic 
vesicles fluoresce bright red (Paglin et al, 2001). After exposure of the DHL4 cell line to 
10µmol/L and 20µmol/L MSA or 3µmol/L TG for 24 hours, cells (1x10
6
) for analysis 
were pelleted by centrifugation at 210g for 6 minutes at room temperature. The medium 
was discarded and the cells washed twice in PBS. AO (Sigma-Aldrich) at a final 
concentration of 1μg/ml (diluted in PBS) was added and cells incubated for 15 minutes in 
the dark at 37°C. Cells were then pelleted by centrifugation and the supernatant 
discarded. Cells were washed once in PBS and then resuspended in 500μl of PBS and 
analysed immediately using a FACSCaliber
TM 
flow cytometer (Becton Dickenson) with 
CellQuest
TM 
software (Becton Dickenson). Green (510–530nm) and red (650nm) 
fluorescence
 
emission when excited by the 488nm laser was measured for ten thousand 
cells.  
 
2.13 Quantification of the phosphinositide 3-kinase/Akt signal 
transduction pathway - ‘Aktide assay’ 
2.13.1 Principle of the assay 
This assay uses a synthetic Akt substrate peptide, RPRAAFT (‘Aktide’), to quantify 
PI3K/Akt activity in whole cell extracts.  The reaction is as follows: 
 
RPRAATF + ATP
 
   
                                                
RPRAApTF (phospho-Aktide) + ADP 
 
The cell lysate was incubated with Aktide, ATP and Mg
2+
. When the reaction was 
stopped, a known amount of phospho-Aktide (p-Aktide) labelled with a stable isotope 
was added and used as an internal standard (IS) to quantify the amounts of p-Aktide 
produced.  The IS used was RP*PAApTF (Cambridge BioScience, Cambridge, UK), 
where P*P is L-proline-
13
C5,
15
N, a 6-Da heavier version of L-proline. p-Aktide 
  Akt kinase 
     
      Mg
2+ 
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(Cambridge BioScience) was used to construct a standard curve. In the assay, an excess 
of Aktide peptide was used but this causes overloading of the HPLC column when the 
reaction is directly analysed by LC-MS. To avoid this problem, p-Aktide is separated 
from Aktide in the sample based on their different basicity. The different isoelectric 
points of p-Aktide (approximately 6.8) and Aktide (approximately 12) makes it possible 
to separate them by strong cation exchange (SCX).  Quantification of p-Aktide produced 
in the reaction was by mass spectrometry.  
  
2.13.2 Sample preparation 
The JVM2 cell line was used for this assay. 1x10
6 
cells were used per reaction and all 
samples were prepared in duplicate. Cells were stimulated with 100µmol/L pervanadate 
for 30 minutes at 37°C. 30mM pervanadate solution was prepared in PBS by combining 
30mM sodium orthovanadate (Na3VO4; Sigma-Aldrich) with 0.18% H2O2 (Sigma-
Aldrich). This mixture was incubated in the dark at room temperature for 15 minutes 
prior to adding to the cells. Following stimulation with pervanadate, cells were treated 
with a range of MSA concentrations for 30 minutes and 2 hours at 37°C. Wortmannin 
(Calbiochem, San Diego, CA), a known inhibitor of PI3K, was used as a positive control. 
A stock solution of wortmannin 10mM was prepared in DMSO and aliquots were stored 
at -20°C. Prior to use, wortmannin was diluted further in cell culture medium to a final 
concentration of 1μM. 
 
Following treatment with pervanadate and MSA, cells were pelleted by centrifugation at 
210g for 6 minutes at room temperature. From this stage onwards samples were kept in 
protein LoBind
®
 eppendorf tubes (Eppendorf UK Limited). Cells were then lysed using 
50µl of cold lysis buffer and incubated on ice for 30 minutes. Stocks of lysis buffer 
consisting of 50mM Tris-hydrochloric acid (Tris-HCl) ph7.4, 150mM NaCl, 1mM 
EDTA, 1% (v/v) Triton X-100 were prepared and stored at -20°C. Prior to use, 1ml of 
stock lysis buffer was supplemented with 1µl 0.5N sodium fluoride (NaF; Sigma-
Aldrich), 10µl 100mM Na3VO4, 20µl of 50x protease inhibitor cocktail (Roche), 1µl 1M 
DTT, 10ul 100mM PMSF, 2µl 0.5mM okadaic acid (Sigma-Aldrich), 1µl 10mg/ml tosyl-
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L-lysine chloromethyl ketone (TLCK; Sigma-Aldrich) and 25µl of 40x phosphatase 
inhibitor cocktail (Roche). Following incubation in lysis buffer, samples were centrifuged 
at 20,800g for 10 minutes at 5°C and the supernatant transferred to fresh tubes and kept 
on ice. 
 
2.13.3 Aktide assay 
The reaction mix was prepared. This consisted of 20% reaction buffer (20mM Tris-HCl 
ph-7.4, 1mM Na3VO4, 25mM  β-glycerol-phosphate, 75mM MgCl2, 0.75mM ATP), 15%  
Aktide  (1mM stock, Millipore) and 65% deionised H2O.  In new tubes, 10µl of the 
reaction mix and 5µL of cell lysate were mixed and samples were incubated for 30 
minutes at 37°C, shaking gently. The reaction was stopped by adding 100µl of stop 
solution [20% acetonitrile (ACN), 0.1% trifluoroacetic acid (TFA); LGC standards, 
Teddington, UK] containing 0.05µmol/L IS peptide. 
 
2.13.4 Product extraction by strong cation exchange 
2.5µl of Dynabeads
®
 SCX (Invitrogen™) were used per reaction. The total volume of 
beads required was transferred to an eppendorf tube. The magnetic beads were separated 
from the solvent using a magnetic rack (MagnaRack™, Invitrogen™). 800µl of 
conditioning solution (1M NaCl, 50mM ammonium bicarbonate) was added to the beads. 
The beads were resuspended by vortexing and incubated for 10 minutes at room 
temperature. The beads were then washed 3 times in 800µl loading solution (25% ACN, 
0.1% TFA, 0.01% Tween-20) using the magnetic rack. The beads were resuspended in 
loading solution (10µl/reaction) ready for use. 
 
10µl of the conditioned Dynabeads
®
 SCX were added to each sample. Samples were 
vortexed well and then incubated for 45 minutes at room temperature shaking gently.  
Following this, the samples were placed in the magnetic rack and the solvent discarded. 
The beads were then washed twice with 200µl of loading solution and once with 200µl 
washing solution (25% ACN, 0.1% TFA).  To elute the reaction products and IS from the 
beads, 20µl of eluting solution (150mM ammonium bicarbonate, 5% ACN, 0.1% TFA) 
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was added, samples vortexed and then incubated for 10 minutes at room temperature 
shaking at 1000rpm. Using the magnetic rack, the eluents were transferred to fresh tubes 
and samples dried in a speed vac. Dried samples were reconstituted in 25µl of 0.1% TFA 
in ultrapure H2O prior to analysis 
 
2.13.5 Quantification of the enzymatic reaction by ultra-high performance liquid 
chromatography and mass spectrometry 
5µl of each sample was injected into a Thermo Scientific Accela™ ultra high-
performance liquid chromatography (UPLC) system (Thermo Fisher Scientific) for 
separation of p-Aktide and the IS. The chromatogram was run over 12 minutes. This was 
combined with detection of p-Aktide and the IS using a TSQ Vantage triple stage 
quadrupole mass spectrometer (MS; Thermo Fisher Scientific) by monitoring the parent-
daughter ion transition of m/z 449.7→400.6 for p-Aktide and m/z 452.7→403.6 for the IS 
(of note, the IS has a double charge, therefore, although it is 6Da heavier than p-Aktide, 
the m/z only differs by 3). The UPLC and MS conditions are shown in Table 2.2. A series 
of standards were run in parallel with the unknown samples in order to construct a 
standard curve for absolute quantification of the product. Standards were prepared by 
serial dilutions of p-Aktide in 0.1% formic acid (FA, Thermo Fisher Scientific)/ultrapure 
H2O (concentration range 50-5000nmol/L) containing 0.1µmol/L IS peptide. p-Aktide in 
the standards and the unknown samples was quantified by measuring the area under the 
curve of the extracted ion chromatogram for the fragment ion at m/z 400.6 and the 
obtained areas were normalised by the area of the p-Aktide IS fragment at m/z 403.6. A 
standard curve was generated by plotting the ratio of the p-Aktide:IS signal on the y axis 
and p-Aktide concentration on the x axis and p-Aktide in the unknown samples was 
calculated by fitting the area values to the linear regression equation. An example of a 
standard curve for p-Aktide is shown in Figure 2.5 (r=1) and an example of the 
chromatograms obtained for p-Aktide and the IS are shown in Figure 2.6. 
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Table 2.2 Ultra high-performance liquid chromatography and mass spectrometry 
conditions for the ‘Aktide assay’. 
UPLC conditions 
Column 
Injection loop 
Flow rate  
Mobile phase 
 
Gradient 
 
Vydoc C18 (150mm x 800µm id x 5µm)* 
5µl 
200µl/min 
Solution A 0.1% FA in ultrapure H2O 
Solution B 0.1% FA in ACN 
1) 98% A to 20% A over 4 minutes 
2) 20% A for 2 minutes 
3) 98% A to 20% A over 6 minutes 
MS conditions 
Ionisation 
Spray voltage 
Sheath gas pressure 
Auxiliary gas pressure 
Capillary temperature 
Collision gas 
Collision gas pressure 
 
Positive mode 
4501 v 
35  psi 
10 arbitrary units 
270°C 
Argon 
1.5mTorr 
* LC Packings, Dionex Ltd, Surrey, UK 
 
 
 
 
Figure 2.5 An example of the standard curve obtained for p-Aktide generated by plotting 
the ratio of the p-Aktide:IS signal on the y-axis and p-Aktide concentration on the x-axis. 
Concentration range 50-5000nmol/L. 
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Figure 2.6 An example of the chromatograms obtained from the ‘Aktide assay’. (a) p-
Aktide, by monitoring parent-daughter ion transition of m/z 449.7→400.6 (b) Internal 
standard, by monitoring the parent-daughter ion transition of m/z 452.7→403.6. 
 
 
2.14 Statistical analysis 
Standard statistical methods such as mean and standard deviation (SD) have been used to 
summarise data. Data have been represented in graphical and tabular form.  For most 
experiments, 3 independent sets of data were obtained. The data were assumed to be 
normally distributed and parametric statistical tests were used. The paired t-test was used 
to compare the means of two groups and one-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test was used to compare the means of more than 2 
samples. A p value <0.05 was considered statistically significant. 
 
The activity of various drugs, obtained using the ATP and Gauva
®
 viacount
®
 assays, was 
summarised to an EC50 value (the concentration required to cause 50% of the maximum 
effect) using the GraphPad PRISM
®
 software (version 5.03). This software fits the data to 
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a sigmoidal concentration-effect model with variable slope using a modification of the 
equation shown in Figure 2.7 (Holford & Sheiner, 1982). 
 
                    
                           
 
Figure 2.7 The equation used to obtain an EC50 value for drug activity.  
Epred is the predicted effect, Econt is the effect without the drug, Emax is the maximum 
effect that can be obtained, C is the drug concentration and n is the sigmoid factor. 
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CHAPTER 3: Patterns of survival in patients with diffuse large B-cell 
lymphoma. Long follow-up from St Bartholomew’s Hospital. 
 
3.1 INTRODUCTION 
The outcome of patients with newly diagnosed DLBCL has improved significantly with 
the addition of rituximab to first-line chemotherapy regimens (Coiffier et al, 2002; 
Feugier et al, 2005; Pfreundschuh et al, 2006). However, recurrent disease remains 
difficult to treat. HDT with autologous hematopoietic stem cell support is generally 
considered to be the ‘standard of care’ for younger patients with recurrent disease (Philip 
et al, 1995) but is only of value to those who remain ‘sensitive’ to second-line, 
‘conventional-dose’ chemotherapy (Prince et al, 1996).  
 
Overall response rates to commonly used, second-line regimens are around 60%, with CR 
rates of only 25-35% (Moskowitz et al, 1999; Velasquez et al, 1988; Velasquez et al, 
1994). Although the IPI score is predictive for overall and progression-free survival in 
patients with recurrent disease (Guglielmi et al, 2001; Hamlin et al, 2003), in general, all 
patients are treated in a similar way. Therefore, cure is theoretically only possible for the 
30-40% of patients who reach the point of HDT (Vose et al, 2004). Several reasons 
prevent a significant proportion of patients with recurrent disease from receiving HDT 
and therapeutic options for the latter group are limited. Evidence is also now emerging 
that recurrent disease in those who have already been exposed to rituximab may be even 
more difficult to treat (Giesselbrecht C, 2007; Martin et al, 2008). 
 
This retrospective analysis reports the outcome of a large series of patients with DLBCL 
with a median follow-up of 12 years. The focus is on patterns of outcome and survival in 
an unselected group, diagnosed at a single centre.  
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3.2 PATIENTS AND METHODS 
3.2.1 Patients 
Between January 1985 and May 2003, 461 patients were diagnosed with DLBCL at SBH. 
Three hundred and eighty-four (83%) were treated with curative intent and form the basis 
of this analysis. Clinical characteristics are shown in Table 3.1. Patients with primary 
CNS lymphoma, primary mediastinal B-cell lymphoma and HIV infection were excluded. 
Staging investigations comprised clinical examination, bone marrow biopsy and CT 
scanning (Lister et al, 1989). Histological subtype at diagnosis is shown in Table 3.2. 
Prior to 2001, the Kiel classification (Gerard-Marchant et al, 1974) was used and after 
2001, the WHO classification (Jaffe et al, 2001). The IPI score (Anon, 1993) was 
assigned retrospectively for patients diagnosed before  2001. Prior to 1989, 
hydroxybutyrate dehydrogenase was measured instead of lactate dehydrogenase (LDH) 
and they are assumed to be equivalent (Foo et al, 1981; Leung & Henderson, 1981).  
 
3.2.2 Treatment at diagnosis and recurrence 
Three hundred and fifty-four of those treated with curative intent (92%) received an 
anthracycline-containing regimen according to protocols in use at the time (Table 3.3) 
(Dhaliwal et al, 1993; Radford et al, 1994). Thirty patients (8%) with localised disease 
(Stage I, 27 patients; Stage II, 3 patients) received radiotherapy alone. Prior to 2001, the 
local policy was to give all patients with DLBCL prophylactic intra-thecal methotrexate 
with each cycle of chemotherapy; 78% of patients actually received this. Subsequently, 
only those deemed at high risk for CNS relapse did so; 51% received this. Patients 
considered to be at high risk for CNS relapse were those with a high LDH, a high-risk IPI 
score and involvement by DLBCL at specific anatomical sites; namely bone marrow, 
testes, the post-nasal space and Waldeyer’s ring.  Those with a paraspinal mass were also 
given CNS prophylaxis. 
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Table 3.1 Clinical Characteristics at diagnosis and recurrence of DLBCL 
 Diagnosis Recurrence 
Characteristic Number (%) Number (%) 
Number of patients 384 80 
Age, years 
     Median 
     Range 
 
60 
17-95 
 
59 
17-93 
Male gender 208 (54) 39 (49) 
B symptoms 146 (38) 23 (29) 
Bulky disease
1 
161 (42) 20 (25) 
Stage 
   I/IE
2 
   II/IIE 
   III 
   IV 
   Not known 
 
99 (26) 
88 (23) 
55 (14) 
142 (37) 
 
22 (28) 
11 (14) 
18 (23) 
26 (33) 
3 (4) 
IPI score 
   Low-risk 
   Low-intermediate 
   High-intermediate 
   High-risk 
   Not known 
 
189 (49) 
110 (29) 
64 (17) 
21 (5) 
 
42 (53) 
24 (30) 
7 (9) 
4 (5) 
3 (4) 
1
defined as a mediastinal mass >1/3 of the intra-thoracic diameter at the level of T5 vertebra or a 
mass >10cm in its maximum dimension. 
2
 Suffix added if a single extranodal site involved, or if contiguous or proximal to known nodal 
sites of disease.  
 
 
At recurrence, patients for whom this was deemed appropriate received further intensive 
chemotherapy (Table 3.3). In patients less than 65 years of age, the intention was to 
induce a second remission (CR/CRu or PR) and consolidate this with HDT and 
autologous hematopoietic stem cell support. Prior to 1997, the myeloablative regimen 
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used was cyclophosphamide and total body irradiation (TBI). However, this was found to 
be associated with a significant risk of secondary myelodysplasia and AML, albeit 
particularly in patients with FL (Rohatiner et al, 2007). Therefore, the myeloablative 
regimen was changed to the ‘drug-only’ regimen, ‘BEAM’ (carmustine, etoposide, 
cytarabine and melphalan) (Mills et al, 1995) 
 
3.2.3 Definitions and statistical analysis 
Response to treatment was determined at least 4 weeks after completing chemotherapy 
and was defined according to local criteria used at the time (Dhaliwal et al, 1993; 
Johnson et al, 1995). CR is equivalent to CR as defined in the consensus statement by the 
International Working Group (Cheson et al, 1999). ‘Good partial remission (GPR)’ was 
defined as the presence of minimal, residual, but equivocal abnormalities on CT scanning 
or bone marrow examination and is considered to be equivalent to CRu according to the 
consensus statement. ‘Poor PR’ is comparable to PR in the consensus statement. For the 
purposes of this analysis, CR and GPR have been grouped together and are henceforth 
referred to as CR/CRu. Patients with stable or progressive disease after treatment have 
been defined as having had ‘no response’ (NR). 
 
The terms ‘composite’ and ‘discordant’ are used to describe the simultaneous occurrence 
of two different histological subtypes of lymphoma in the same biopsy specimen, or in 
biopsies from different anatomical sites respectively.  
  
OS was measured from the date of diagnosis to the date of last follow-up or death. Cause-
specific survival was measured from the date of diagnosis to the date of death from 
DLBCL or from complications resulting from its treatment. Survival from recurrence was 
measured from the date of recurrence to the date of last follow-up or death. Remission 
duration (RD) was measured from the date of CR/CRu being achieved to the date of 
recurrence.  
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Death from treatment-related infection was recorded as the cause of death if death from 
infection occurred during or within 3 months of completing a cycle of treatment.  
 
The Kaplan-Meier method was used to construct survival and RD curves. Univariate 
analysis, to test for the prognostic significance of variables, was performed using the log-
rank test. Categorical data were compared using the chi-squared test. The Stata
®
 data 
analysis and statistical software was used. A p value less than 0.05 was considered 
statistically significant. 
 
 
Table 3.2 Histological subtype at diagnosis and recurrence of DLBCL 
Histology Diagnosis Recurrence 
 Number Number 
DLBCL 343 673
 
Composite  i.e. DLBCL 
with, in addition: 
     Follicular lymphoma 
     LPL1 
     Gastric ‘MALT’ 
24 
 
22 
1 
1 
1 
 
0 
1 
0 
Discordant 172
 
24 
Follicular Lymphoma -           11 
Gastric ‘MALT’ -           1 
1
lymphoplasmacytic lymphoma 
2
all with follicular lymphoma in the bone marrow 
3
10 patients did not have a biopsy but were treated as DLBCL 
4
1 patient with lymphoplasmacytic lymphoma, 1 patient with marginal zone lymphoma 
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Table 3.3 Treatment at diagnosis and recurrence of DLBCL 
Treatment Diagnosis Recurrence 
 Number (%) 
N=384 
Number (%) 
N=68 
   Radiotherapy alone 
   CHOP
1 
   MACOP
2 
   VAPEC-B
3 
   PMitCEBO
4 
   Etoposide/cytarabine   
   CHOP+rituximab 
   ICE
5
+rituximab 
   Other  
30 (8) 
117 (30) 
 69 (18) 
154 (40) 
  7 (2) 
- 
- 
- 
  7 (2) 
5 (7) 
4 (6) 
10 (15) 
12 (18) 
- 
29 (43) 
3 (4) 
1 (1) 
4 (6) 
1
Cyclophosphamide, doxorubicin, vincristine and prednisolone 
2
Methotrexate with leucovorin rescue, cyclophosphamide, doxorubicin, vincristine and 
prednisolone 
3
Doxorubicin, cyclophosphamide, etoposide, vincristine, bleomycin, prednisolone 
4
Prednisolone, mitoxantrone, cyclophosphamide, etoposide, bleomycin, vincristine 
5
Ifosphamide, carboplatin and etoposide 
 
 
 
3.3 RESULTS 
3.3.1 Clinical characteristics at diagnosis 
Patient characteristics at diagnosis are shown in Table 3.1. Eight-five patients (22%) had 
primary extra-nodal disease, either Stage IE or IIE. The commonest sites of primary 
extranodal disease were the gastrointestinal tract (GIT) in 24 patients (6%) and the 
tonsillar/nasopharyngeal region in 34 patients (9%). In patients with stage IV disease 
(n=142), the commonest extra-nodal sites were the bone marrow (61%), liver (40%), lung 
(32%) and GIT (24%). At diagnosis, the CNS was involved in 14 patients (4%). 
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3.3.2 Response to initial treatment and remission duration  
(Figure 3.1, Table 3.4) 
3.3.2.1 Patients in whom CR/CRu was achieved following initial therapy 
CR/CRu was achieved in 241/384 patients (63%). On univariate analysis, response to 
initial therapy was significantly associated with age (≤45 years vs > 45 years; p=0.001; 
Table 3.5), stage (p<0.001; Table 3.6), and the IPI score (p<0.001; Table 3.7) at diagnosis. 
With a median follow-up for living patients of 12 years (range 2-24 years), the median 
RD has not been reached (Figure 3.2a) and was not significantly different between 
patients in whom CR or CRu was achieved (p=0.7; Figure 3.2b) On univariate analysis, 
the following prognostic factors were significantly associated with RD: age (≤45 years vs 
>45 years p=0.02; Figure 3.3a), stage (I/II vs III/IV p=0.007; Figure 3.3b) and the IPI 
score (0-II vs III-V p=0.007; Figure 3.3c) at diagnosis.  
 
3.3.2.2 Patients in whom PR was achieved following initial therapy 
PR was achieved in 66/384 patients (17%) after initial therapy. Forty-seven of the latter 
(71%) went on to receive further treatment, in an attempt to improve upon the initial 
response. CR/CRu was subsequently achieved in 21/47 patients (45%) and a further PR 
in 9/47. Fifteen had no further response and two died of treatment-related infection. In 
patients who achieved CR/CRu, the majority (16/21) did so after only one additional 
regimen, Subsequently 6 patients (5 in CR and 1 in PR) received HDT to consolidate 
second remission. The patient receiving HDT in PR had no further response and 
ultimately died of progressive disease. For the 21/66 patients in whom a first CR/CRu 
was eventually achieved, the median RD was 3.6 years (Figure 3.3d). However, almost 
half of the 21 patients (48%) developed recurrent disease with a median time to 
recurrence of 8 months.  
 
Nineteen patients did not receive further treatment with curative intent after initial PR 
was achieved. Disease progression occurred in 10, with a median time to progression of 
only 2 months. Six patients died in PR without evidence of disease progression (4 of 
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infection, 1 of liver disease, 1 of a cerebrovascular accident (CVA) and 3 patients are still 
alive after a median follow-up of 9 years. 
 
3.3.2.3 Patients in whom initial treatment failed 
Twenty-four patients (6%) died of treatment-related infection. Fifty-three of 384 patients 
(14%) did not respond to initial therapy. Twenty-one received further treatment but in 
only two was CRu achieved with a second-line regimen (etoposide and intermediate-dose 
cytarabine (Whelan et al, 1992). One who presented with stage IE disease in the tonsil, 
with a ‘low- risk’ IPI score, is alive and free of disease at 9 years. The other had stage IV 
disease with a ‘high-intermediate’ IPI score and died of heart failure 3 months after CRu 
had been documented.  PR was observed in four patients, two of whom subsequently 
received HDT; 1 had a further PR and the other progressed. Fifteen patients had no 
response to further treatment.  
 
Thirty-two patients did not receive further intensive treatment because it was deemed 
inappropriate to do so; all died of progressive disease, with a median time to death of 3 
weeks (range 0 days-3 months). Therefore, of the original 53 patients considered to be 
refractory to initial therapy, only one is currently alive and free of disease (3 patients 
having been lost to follow-up).  
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Figure 3.1 Outcome of newly diagnosed patients with DLBCL. Numbers in brackets are 
percentages. 
 
 
 
Table 3.4 Response to treatment at diagnosis and recurrence of DLBCL 
 Diagnosis Recurrence 
Response to treatment Number (%) 
N=384 
Number (%) 
N=68 
CR/CRu 
PR 
No response 
Treatment-related death 
241 (63) 
 66 (17) 
 53 (14) 
24 (6) 
37 (54) 
14 (21) 
15 (22) 
2 (3) 
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Table 3.5 Outcome to initial therapy according to age at diagnosis 
Age (years) Outcome Number (%) 
≤30 (n=22) CR/CRu 
PR 
NR 
Treatment-related death 
19 (86) 
0 (0) 
  3 (14) 
                 0 (0) 
31-45 (n=73) CR/CRu 
PR 
NR 
Treatment-related death 
54 (74) 
7 (10) 
11 (15) 
1 (1) 
46-60 (n=106) CR/CRu 
PR 
NR 
Treatment-related death 
63 (59) 
25 (24) 
13 (12) 
5 (5) 
61-70 (n=92) CR/CRu 
PR 
NR 
Treatment-related death 
55 (60) 
17 (18) 
15 (16) 
5 (5) 
>70 (n=91) CR/CRu 
PR 
NR 
Treatment-related death 
50 (55) 
17 (19) 
11 (12) 
13 (14) 
 
Table 3.6 Outcome to initial therapy according to stage at diagnosis 
Stage Outcome Number (%) 
I (n=99) CR/CRu 
PR 
NR 
Treatment-related death 
76 (77) 
11 (11) 
9 (9) 
3 (3) 
II (n=88) CR/CRu 
PR 
NR 
Treatment-related death 
62 (70) 
12 (14) 
11 (13) 
3 (3) 
III (n=55) CR/CRu 
PR 
NR 
Treatment-related death 
34 (62) 
15 (27) 
 6 (11) 
                0 (0) 
IV (142) CR/CRu 
PR 
NR 
Treatment-related death 
69 (49) 
28 (20) 
27 (19) 
18 (13) 
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Table 3.7 Outcome to initial therapy according to IPI score at diagnosis 
IPI score  Outcome Number (%) 
0, 1 (n=189) CR/CRu 
PR 
NR 
Treatment-related death 
141 (75) 
 26 (14) 
               16 (8) 
6 (3) 
2 (n=110) CR/CRu 
PR 
NR 
Treatment-related death 
67 (61) 
24 (22) 
14 (13) 
5 (5) 
3 (n=64) CR/CRu 
PR 
NR 
Treatment-related death 
29 (45) 
11 (17) 
19 (30) 
5 (8) 
4, 5 (n=21) CR/CRu 
PR 
NR 
Treatment-related death 
4 (19) 
5 (24) 
4 (19) 
8 (38) 
 
 
 
Figure 3.2 (a) Remission duration in patients achieving CR/CRu (b) Remission duration 
comparing patients achieving CR and CRu. 
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Figure 3.3 Remission duration according to (a) Age at diagnosis (b) Stage at diagnosis 
(c) IPI score at diagnosis (d) Remission duration in patients initially achieving PR but 
subsequently achieving CR/CRu with additional treatment. 
 
 
3.3.2.4 Patients with ‘composite’ and ‘discordant’ lymphoma at diagnosis 
Twenty-four patients had ‘composite’ lymphoma at diagnosis and their clinical 
characteristics at diagnosis are shown in Table 3.8. The histological subtype present in 
addition to DLBCL was: FL in 22 patients, lymphoplasmacytic lymphoma (LPL) in one, 
and gastric ‘MALT’ lymphoma in another. Seventeen patients (71%) achieved a CR/CRu 
after initial therapy, with a median RD of 2.6 years (Figure 3.4a). The CR/CRu rate was 
not significantly different from those patients with ‘pure DLBCL’ (p=0.5). Six patients 
(25%) had a PR to initial therapy and 1 had no response.  
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Table 3.8 Clinical characteristics of patients with ‘composite’ lymphoma at diagnosis 
Characteristic Number (%) 
Number of patients 24 
Age, years 
     Median 
     Range 
 
58 
29-88 
Male gender 10 (42) 
B symptoms   8 (33) 
Bulky disease
 
  7 (29) 
Stage 
   I 
   II 
   III 
   IV   
 
  5 (21) 
2 (8) 
 6 (25) 
11 (46) 
IPI score 
   Low-risk 
   Low-intermediate 
   High-intermediate 
   High-risk    
 
 8 (33) 
11 (46) 
2 (8) 
  3 (13) 
 
 
Seventeen patients had ‘discordant’ lymphoma at diagnosis; that is, DLBCL in lymph 
node and FL in the bone marrow and their clinical characteristics are shown in Table 3.9. 
Six patients (35%) achieved a CR/CRu to initial therapy. This was significantly lower 
than the CR/CRu rate of patients with ‘pure DLBCL’ (p=0.02). The median RD was 9.5 
years (Figure 3.4b). Five of the 17 patients (29%) had a PR to initial therapy, 2 (12%) had 
no response and 4 (24%) died of treatment-related infection. 
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Table 3.9 Clinical characteristics of patients with ‘discordant’ lymphoma at diagnosis 
Characteristic Number (%) 
Number of patients 17 
Age, years 
     Median 
     Range 
 
60 
46-77 
Male gender 10 (59) 
B symptoms 10 (59) 
Bulky disease
 
7 (41) 
IPI score 
   Low-risk 
   Low-intermediate 
   High-intermediate 
   High-risk    
 
1 (6) 
10 (59) 
5 (29) 
1 (6) 
  
 
 
 
Figure 3.4 Remission duration in patients with (a) ‘composite’ and (b) ‘discordant’ 
lymphoma at diagnosis. 
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3.3.4 Recurrence  
(Figure 3.5) 
Ninety-two of the 241 patients (38%) in whom initial CR/CRu was achieved developed 
recurrent lymphoma, with a median time to recurrence of 10 months (range 2 weeks to 11 
years). Eighty-two patients (89%) had a repeat biopsy at recurrence; histological subtype 
is shown in Table 3.2. Regarding patients with ‘composite’ lymphoma at diagnosis, 12/17 
patients (71%) in whom CR/CRu was achieved subsequently developed recurrent 
disease; 3 with DLBCL, 7 with FL, 1 with ‘composite’ lymphoma (DLBCL and LPL) 
and 1 with gastric ‘MALT’.  Regarding patients with ‘discordant’ lymphoma at diagnosis, 
4/6 patients in whom CR/CRu was achieved subsequently developed recurrent disease; 3 
with DLBCL histology and one with FL. Thus, overall, 12 patients recurred with a 
different histological subtype; 11 with FL and one with gastric ‘MALT’ lymphoma.   
 
Clinical characteristics at recurrence are shown in Table 3.1. Stage and the IPI score were 
assessable in 77/80 patients who recurred with DLBCL.  Forty-one percent of patients 
who recurred with stage I disease had stage I at diagnosis and 73% who recurred with 
stage IV disease have stage IV at diagnosis (Table 3.10). Of the 9 patients who had stage 
I disease at diagnosis and recurrence, the site of disease was the same in 7.  In total, 22 
patients had stage I disease at recurrence and in 17, the site of disease was one which had 
been involved at diagnosis. In 23 patients (10%) recurrence of DLBCL occurred more 
than 2 years after CR/CRu had been achieved and in 14 (6%), after 5 years.  
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Figure 3.5 Outcome of patients with recurrent DLBCL. Numbers in brackets are 
percentages. 
 
 
3.3.4.1 Sites of disease at recurrence 
Seven patients (9%) relapsed with extra-nodal disease alone, the GIT (4%) and tonsil 
(3%) being the commonest sites. In patients relapsing with stage IV disease (n=26), the 
commonest extra-nodal sites of disease were the bone marrow (54%), GIT (42%), liver 
(35%), and lung (12%). Only one patient recurred with disease in the CNS.  
 
3.3.4.2 Response to treatment at recurrence: patients treated with curative intent 
Sixty-eight of the 80 patients (85%) with DLBCL at recurrence received further treatment 
with curative intent (Table 3.3), the most frequently used regimens being etoposide and 
intermediate dose cytosine arabinoside (43%) (Whelan et al, 1992), ‘VAPEC-B’ (18%) 
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(Radford et al, 1994) and ‘MACOP’ (15%) (Dhaliwal et al, 1993). Only four patients 
received regimens containing rituximab.  Five patients with stage I disease received 
radiotherapy alone; all achieved a CR.  
 
Response to treatment at recurrence is shown in Table 3.4. Overall, second CR/CRu was 
achieved in 37/68 patients (54%) [37/80 (46%) if all patients with recurrent DLBCL are 
considered]. Fourteen of 68 patients achieved a PR (21%), 15/68 patients (22%) did not 
respond and only one subsequently responded to an alternative therapy. Two patients 
(3%) died of treatment-related infection. For all patients in whom a second CR/CRu was 
achieved, irrespective of whether HDT was given or not (see below), the median second 
RD was 3 years (range 0.2-23 years; Figure 3.6a).  
 
Seven of the 14 patients in whom only a PR was achieved after the first ‘salvage’ 
treatment went on to receive further treatment, including 3 patients who had HDT, but 
CR/CRu was not achieved in any of them and all died of lymphoma. Five of the seven 
patients who did not receive further treatment died of progressive disease and 2 died of 
non-lymphoma-related causes. Thus, all 14 patients have died; 12 from lymphoma. 
 
Five of the 15 patients who failed to respond to the first ‘salvage’ therapy received 
further treatment but only one went on to have a better response (CRu) which was 
consolidated with HDT. However, the patient subsequently relapsed and died of 
lymphoma. Seven patients did not receive further treatment and all died of progressive 
disease. Therefore overall, 12/15 patients have died of lymphoma (3 lost to follow-up).  
 
3.3.4.3 Patients not treated with curative intent at recurrence 
Twelve of the 80 patients with DLBCL at recurrence were not treated with curative intent. 
All died of progressive disease with a median time to death of 2 weeks (range 2 days-6 
months). Thus, overall only 10/80 patients (13%) with recurrent DLBCL are currently 
alive and disease-free (3 lost to follow-up). 
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3.3.4.4 High-dose therapy with haematopoietic stem cell support 
Forty-six patients were aged 65 years or less at recurrence and therefore would have been 
considered for HDT with autologous haematopoietic stem cell support if a response was 
achieved with ‘salvage’ therapy. However, only nineteen (16 in CR/CRu and 3 in PR) 
with a median age of 46 years actually went on to receive this.  In 10 patients, HDT 
comprised cyclophosphamide and TBI and in 9, ‘BEAM’. None of the three patients 
receiving HDT in PR achieved CR. The median second RD for patients receiving HDT 
was 3.4 years. This, however, was not significantly different from the median second RD 
for patients in whom CR/CRu was achieved with ‘salvage’ chemotherapy but who did 
not receive HDT (2.4 years, p=0.8; Figure 3.6b) 
 
The reasons for not proceeding with HDT in the 22/38 patients in whom a second 
CR/CRu were achieved were: age >65 years (9 patients), co-morbidity (4 patients), failed 
stem cell harvest (2 patients), rapid relapse of disease (2 patients), patient choice (2 
patients) and toxicity of prior therapy (3 patients).  
 
 
 
Table 3.10 Comparison of Stage at diagnosis and at recurrence of DLBCL 
Stage at Diagnosis Stage at recurrence 
 I II III IV NK Total 
I 9 2 3 1 1 16 
II 5 6 8 2 2 23 
III 3 2 6 4  15 
IV 5 1 1 19  26 
Total 22 11 18 26 3 80 
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Figure 3.6 Second remission duration in (a) All patients in whom a second CR/CRu was 
achieved (b) Those patients in second CR/CRu that did and did not receive HDT. 
 
 
3.3.4.5 Recurrence after 5 years 
Fourteen patients (6%) developed recurrent DLBCL after more than 5 years in CR/CRu. 
The characteristics of these patients are shown in Table 3.11. Thirteen of the 14 patients 
had a biopsy at recurrence and in 12 the histology was DLBCL. One patient had 
discordant histology with ‘MALT’ lymphoma present in the duodenum. There were no 
significant differences in the stage or IPI score at diagnosis (p=0.2 and p=0.7 
respectively) or recurrence (p=0.9 and p=0.98 respectively) between patients that 
developed recurrent DLBCL before or after 5 years of CR/CRu. Twelve of the 14 
patients received treatment with curative intent. Two patients received palliative 
treatment only, due to advanced age and co-morbidities. Nine of the fourteen (64%) 
patients have died; 7 of lymphoma, 1 of treatment-related infection and 1 of a second 
malignancy. 
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Table 3.11 Clinical characteristics at diagnosis and recurrence of patients who developed 
recurrent DLBCL greater than 5 years after initial CR/CRu 
 Diagnosis Recurrence 
Characteristic Number (%) Number (%) 
Number of patients 14 14 
Age, years 
     Median 
     Range 
 
61 
21-74 
 
67 
32-83 
Male gender 7 (50) 7 (50) 
B symptoms 3 (21) 2 (14) 
Bulky disease
 
6 (43)           1 (7) 
Stage 
   I 
   II 
   III 
   IV   
 
4 (29) 
       1 (7) 
2 (14) 
7 (50) 
 
5 (36) 
2 (14) 
3 (21) 
4 (29) 
IPI score 
   Low-risk 
   Low-intermediate 
   High-intermediate 
   High-risk    
 
5 (36) 
5 (36) 
4 (29) 
       0 (0) 
 
7 (50) 
5 (36) 
2 (14) 
          0 (0) 
 
3.3.4.6 Outcome of patients with non-DLBCL histology at recurrence 
As mentioned above, 12 patients had recurrent disease with a histological subtype other 
than DLBCL. Eleven patients had FL; 7 of whom had ‘composite’ histology and 
1‘discordant’ histology at diagnosis. The patient with a ‘composite’ histology of gastric 
DLBCL/MALT at diagnosis relapsed with gastric ‘MALT’ lymphoma. The median time 
to relapse for these 12 patients was 18 months. The patient with gastric ‘MALT’ 
lymphoma was treated with Helicobacter pylori eradication resulting in a CR which has 
been maintained for 5 years and 9 months. Nine of the 11 patients who recurred with FL 
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received treatment, some after an initial period of observation. One who was initially 
managed expectantly had progressive disease after 2 years and 3 months but the histology 
at progression was DLBCL and the patient died of lymphoma. One patient was lost to 
follow-up at the time of relapse.  
  
The ‘best outcomes’ in the 9/11 patients with FL who received one or more treatments at 
recurrence were 6 CR and 1 PR. One patient did not respond and in one, the response was 
not recorded. Four patients received HDT with autologous stem cell support. At last 
follow-up, 4 of the 11 are alive, 5 have died (3 of lymphoma, 1 of treatment-related 
infection and 1 of a second malignancy) and 2 have been lost to follow-up. 
 
3.3.5 Survival 
3.3.5.1 Survival in all patients diagnosed with DLBCL 
The median OS for all 461 patients diagnosed with DLBCL was 5.4 years. Seventy-seven 
patients, due to advanced age or co-morbidities, received palliative treatment, because it 
was deemed inappropriate for them to receive intensive, combination chemotherapy with 
curative intent.  The median OS of these patients was 12 weeks (range 3 days to 12 years). 
Of interest, the patient who is currently alive and disease-free 12 years after diagnosis 
had severe Crohn’s disease and developed primary gastrointestinal DLBCL whilst on 
immunosuppression. Following surgical resection, he responded to withdrawal of 
immunosuppression alone. 
 
For the 384 patients treated with curative intent the median OS and cause-specific 
survival were 6 and 12 years respectively (Figure 3.7a). On univariate analysis, OS was 
significantly associated with age (≤45 years vs >45 years p<0.001; Figure 3.7b), stage (I 
vs II vs III vs IV p<0.0001; Figure 3.7c) and the IPI score (0/I vs II vs III vs IV/V 
p<0.0001; Figure 3.7d) at diagnosis. OS was also significantly associated with outcome 
to initial therapy (CR/CRu vs PR vs NR, p<0.0001; Figure 3.8a) but the OS for patients 
in whom CR was achieved versus CRu was not significantly different (p=0.2; Figure 
3.8b).  
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3.3.5.2 Causes of death in patients treated with curative intent   
At last follow-up, 131/384 patients (34%) were alive. Overall, 28/461 patients (6%) have 
been lost to follow-up. The cause of death is known for all but 4 patients and was 
lymphoma-related in 172/384 (45%; Table 3.12). Interestingly, 6 patients died of 
lymphoma-related causes >10 years after diagnosis; 5/6 patients died of recurrent 
DLBCL and 1/6 patients died of AML secondary to receiving cyclophosphamide/TBI.   
 
 
 
Figure 3.7 (a) Overall and cause-specific survival for all 384 patients treated with 
curative intent (b) Cause-specific survival according to age at diagnosis (c) Cause-
specific survival according to the stage at diagnosis (d) Cause-specific survival according 
to the IPI score at diagnosis. 
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Figure 3.8 (a) Overall survival according to outcome to initial therapy (b) Overall 
survival in patients achieving CR and CRu after initial therapy (c) Overall survival and 
cause-specific survival in patients achieving PR after initial therapy (d) OS in patients not 
responding to initial therapy.  
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Table 3.12 Causes of death in patients treated with curative intent 
Cause of death Number  
Lymphoma 134  
Treatment-related infection 38  
Second malignancy 20  
Concurrent malignancy* 1 
Infection 20  
Haemorrhage 4  
Liver failure 3  
Renal failure 3  
Cardiac disease 17  
CVA 3  
Pulmonary disease 3 
Suicide 1 
Old age 2  
Not known 4  
TOTAL 253  
*Laryngeal carcinoma diagnosed at the same time as DLBCL. A CRu was achieved with initial 
therapy of DLBCL but the patient died of laryngeal carcinoma 3 years later. 
 
 
3.3.5.3 Second Malignancies 
Thirty-three second malignancies were diagnosed in 32 patients; 4 skin cancers, 24 solid 
tumours and 5 haematological malignancies (Table 3.13). The 3 patients that developed 
AML had all received cyclophosphamide plus TBI as HDT. Two of the 3 patients that 
developed breast cancer had received mediastinal radiotherapy as part of treatment for 
DLBCL. An additional 5 patients also received radiotherapy as part of treatment, but the 
second malignancy in these patients did not arise in the irradiation field. The median age 
at diagnosis of second malignancy was 65 years (range 34-86 years). The median time 
from the diagnosis of DLBCL to the diagnosis of solid tumour was 5.3 years (range 4 
months-16 years) and to the diagnosis of haematological cancer, 9.7 years (range 2-14 
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years). In 20/32 patients the second malignancy was the cause of death (this includes all 5 
patients who developed therapy-related second malignancies).  
 
Table 3.13 Second malignancies in patients diagnosed with DLBCL 
Site Number Number of 
Deaths 
Basal cell (skin) 3 0 
Breast 3 2 
Colon 4 4 
Ovary 1 1 
Squamous cell (skin) 1 1 
Penile (squamous cell) 1 0 
Tonsil (squamous cell) 1 0 
Conjunctiva (squamous 
cell)* 
1 0 
Squamous cell (site 
unknown) 
1 0 
AML 3 3 
Hodgkin lymphoma 2 1 
Renal 2 2 
Lung 4 3 
Prostate* 1 0 
Liver 2 2 
Bladder 2 1 
Gastric 1 0 
Total 33 20 
* these malignancies occurred in the same patient 
 
3.3.5.4 Survival in patients in whom partial remission was achieved after initial therapy 
The median OS and cause-specific survival for the 66 patients in whom only PR was 
achieved after initial therapy was 2 and 4.8 years respectively (Figure 3.8c). Forty-nine 
patients (74%) have died and in 25 patients (38%) the cause of death was lymphoma and 
in 7 patients (11%), treatment-related infection.  
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3.3.5.5 Survival in patients in whom initial treatment failed 
The median OS for the 53 patients that had no response to initial therapy was 7 months 
(Figure 3.8d). Only one patient is alive and disease-free, 49/53 patients have died; 45 of 
lymphoma (3 patients lost to follow-up).  
 
3.3.5.6 Survival in patients with ‘composite’ and ‘discordant’ lymphoma at diagnosis 
The median OS for patients with ‘composite’ and ‘discordant’ histology at diagnosis was 
3.9 and 3.6 years respectively (Figure 3.9a, b). This was not significantly different from 
the OS of patients with ‘pure DLBCL’ (Figure 3.9c p=0.3). 
 
3.3.5.7 Survival in patients with recurrent DLBCL 
The median OS from recurrence for all 80 patients with recurrent DLBCL was one year 
(Figure 3.10a) and was significantly associated with outcome to first ‘salvage’ therapy 
(CR/CRu vs PR vs NR, p<0.0001; Figure 3.10b), and the IPI score at recurrence (0-II vs 
III-IV p=0.03; Figure 3.10c) but not with age and stage at recurrence or with duration of 
first remission (less than vs greater than 1 year, 2 years or 5 years; Figure 3.11).  
  
In patients with recurrent disease, OS from second remission was not significantly 
different for those who did and those that did not receive HDT (p=0.7; Figure 3.12a). The 
median OS from second remission for all 38 patients was 6 years (Figure 3.12b). 
However, only 10/80 patients (13%; 3 patients lost to follow-up) with recurrent DLBCL 
are alive. The causes of death are shown in Table 3.14 and were lymphoma in 52 patients 
(65%), treatment-related infection in 5 (6%) and treatment-related AML in 2 (3%). In 
patients receiving HDT, 14/19 (74%) have died, the cause of death being lymphoma in 9 
(47%), treatment-related infection in 2 and treatment-related AML in 2 (Table 3.15). 
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Figure 3.9 Overall survival of patients with (a) ‘composite’ and (b) ‘discordant’ 
lymphoma at diagnosis (c) Comparison of the overall survival of patients with 
‘composite’, ‘discordant’ and ‘pure’ DLBCL.  
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Figure 3.10 (a) Overall survival from recurrence (b) Overall survival from recurrence 
according to outcome to first ‘salvage’ chemotherapy (c) Overall survival from 
recurrence according to the IPI score at recurrence. 
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Figure 3.11 Overall survival from recurrence based on length of first RD (a) RD ≤ or > 1 
year (b) RD ≤ or > 2 years (c) RD ≤ or > 5 years. 
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Figure 3.12 Overall survival from second remission in (a) patients that did and did not 
receive HDT (b) all patients achieving a second CR/CRu. 
 
 
 
 
Table 3.14 Causes of death in patients with recurrent DLBCL 
Cause Number 
Lymphoma 52 
Treatment-related infection 5 
2nd malignancy   6* 
infection 1 
Respiratory failure 1 
Cardiac disease 1 
CVA 1 
TOTAL 67/80** 
*including 2 patients who developed AML following cyclophosphamide/TBI. **10 patients are alive and 3 
have been lost to follow-up. 
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Table 3.15 Causes of death in patients receiving high-dose therapy following recurrence 
of DLBCL 
 
Cause Number 
Lymphoma 9 
Treatment-related infection  2* 
2nd malignancy    3** 
TOTAL 14/19 
*1 patient died due to complications of HDT and 1 patient from treatment-related causes following 
subsequent chemotherapy for progressive disease **2 patients developed AML following 
cyclophosphamide/TBI, 1 Hodgkin lymphoma in a patient who had not received previous 
radiotherapy. 
 
 
3.4 DISCUSSION 
This retrospective analysis reports the outcome of DLBCL in an unselected group of 
patients, presenting to a single centre over an 18-year period. The results draw attention 
to the importance of long follow-up. Whilst superficially worse than the outcome usually 
reported in the literature, it is important to remember that the analysis includes everyone 
who was referred for consideration of treatment. In a significant proportion of patients, it 
was deemed inappropriate to give chemotherapy and a palliative approach was taken. 
Therefore, the results truly represent outcome of patients with this illness, albeit prior to 
the introduction of rituximab and draw attention to the appalling prognosis of DLBCL 
following recurrence. In addition, it is presumed that further selection would have taken 
place before some patients were even referred to SBH. 
 
The response rate to first-line therapy and the incidence of recurrence are in keeping with 
those reported (Dana et al, 1990; Fisher et al, 1993; Weick et al, 1991), but the results for 
patients who developed recurrent disease, irrespective of when, starkly demonstrate how 
bad the prognosis is. Seventy-four percent of patients with recurrent disease died of 
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lymphoma or treatment-related causes. The importance of performing a biopsy at the 
time of recurrence is also highlighted by this work as recurrence with a different 
histological subtype of lymphoma, mainly FL, does occur with these patients being 
treated differently.  
 
Of note, the incidence of CNS recurrence in this series was very low, occurring only in 
one patient. When prophylaxis is not given, the incidence of CNS recurrence in DLBCL 
is usually around 5% (Cheung et al, 2005; van Besien et al, 1998). The low rate seen here 
is undoubtedly due to the fact that prior to 2001, the local policy was to give all patients 
CNS prophylaxis. 
 
As reported in other studies, the IPI score at recurrence was significantly associated with 
survival from recurrence (Blay et al, 1998; Guglielmi et al, 2001) but the duration of first 
remission was not. This is in contrast to the results of most other published series in 
which late relapse, usually classified as relapse after more than 2 years in CR/CRu, does 
correlate with better OS (Guglielmi et al, 1998; Hoskins et al, 1997; Sanz et al, 1998). 
However, in a recent retrospective study, the clinical characteristics and outcome in 
patients developing recurrence 5 years or later following diagnosis of DLBCL were 
investigated. Late relapse was rare and occurred in 54/1492 patients (3.6%). The majority 
(83%) did recur with DLBCL histology, and in these patients the outcome was poor with 
a 5 year OS of 27% (Larouche et al, 2010).  
  
Despite the reported cure rate of around 40% for HDT when given as consolidation of 
second remission (Hamlin et al, 2003; Philip et al, 1995), the great majority of such 
studies commence at the point of delivery of HDT and do not take into account the true 
‘denominator’. A significant proportion, (in fact the majority), of patients are not able to 
(or certainly do not) receive HDT following recurrence. The main reason for this is the 
high rate of chemoresistance to conventional second-line regimens; 46% of patients in 
this analysis did not enter CR/CRu after the first ‘salvage’ treatment. In addition, a 
significant proportion of patients with DLBCL are more than 65 years old at diagnosis 
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and thus at recurrence, are usually considered ineligible for HDT. However, recent 
studies have confirmed the feasibility and the promising efficacy of HDT in selected 
older patients (Jantunen et al, 2008).  
 
Perhaps surprisingly, the RD and OS of patients in second CR/CRu was not significantly 
different in patients who did and those that did not receive HDT. Both groups had a poor 
outcome; 28/38 patients have died, 21 from lymphoma-related causes. Again, reflects the 
reality of treating an unselected group of patients with recurrent DLBCL. It is interesting 
to note that during the period of this analysis, 27 other patients with refractory/recurrent 
DLBCL were referred from peripheral hospitals, specifically to receive HDT in second 
remission at SBH. For these patients, by definition a more selected group, the median RD 
and OS were 6.8 and 11.7 years respectively (Figure 3.13).  
 
With the advent of FDG-PET scanning it has become clear that patients with a positive 
FDG-PET scan prior to HDT have a much worse outcome than those in whom the scan is 
negative (Schot et al, 2007). This has led to a change in practice, at SBH and elsewhere, 
thus now, only patients who are FDG-PET negative after second-line ‘salvage’ therapy 
proceed to HDT. Therefore, with better patient selection it is hoped that outcome 
following HDT will improve.     
 
In concordance with the results of other studies, this analysis confirms that further 
conventional chemotherapy is futile in patients with recurrent DLBCL in whom the first 
‘salvage’ regimen fails to induce a response (Ardeshna et al, 2005; Seshadri et al, 2008). 
All patients in whom CR/CRu was not achieved after the first second-line treatment died 
from lymphoma, except for 2 patients who still had disease at the time of death from 
other causes. None had a durable period of remission. It would therefore be reasonable to 
consider such patients for experimental therapies in the context of a clinical trial as soon 
it is apparent that conventional therapy has failed.    
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However, this analysis also demonstrates that there is a group of patients, albeit small, in 
whom, despite only PR being achieved with initial therapy, CR and potential cure can 
still be achieved with an alternative chemotherapy regimen. In addition, there were 3 
patients in PR who did not receive further therapy but are still alive without evidence of 
disease progression after a median follow-up of 9 years. All had evidence of residual 
abnormal lymphoid tissue on CT scanning and in retrospect it is likely that this did not 
represent active disease.  In the era of FDG-PET, these patients would almost certainly 
have been classed as complete responders. In contrast, patients in whom initial therapy 
failed had a very poor outcome despite further therapy and again, this group of patients 
should be offered experimental therapies at that point. 
 
The numbers of patients with ‘composite’ and ‘discordant’ histology in this series are 
small, so it is difficult to draw any firm conclusions. Literature on ‘composite’ lymphoma 
is sparse and consists mainly of case reports and case series. One retrospective study of 
60 patients with DLBCL associated with a ‘low-grade’ component at diagnosis included 
51 patients with two different histological subtypes in the same biopsy; mainly FL and 
marginal zone lymphoma. Compared to a matched control group with de novo DLBCL, 
the study group had a lower CR rate but comparable OS. However, the recurrence rate 
was high with nearly half of patients relapsing with ‘low-grade’ lymphoma (Ghesquieres 
et al, 2006).  In this series, the CR/CRu rate in patients with composite lymphoma was 
similar to the overall rate of CR/CRu, but the recurrence rate was significantly higher 
(71% vs 36%; p=0.004) with 8/12 patients recurring with histology other than DLBCL 
(mainly FL). The OS, however, was not significantly different from the OS of patients 
with ‘pure DLBCL’.  
 
Regarding ‘discordant’ lymphoma, it has been generally been reported that patients with 
a ‘low-grade’ lymphoma component in the bone marrow at diagnosis have a similar 
outcome to patients with no bone marrow involvement (Chung et al, 2007; Conlan et al, 
1990). Some studies have reported a higher rate of recurrence, particularly ‘low-grade’ 
(Robertson et al, 1991), whereas others have not (Hodges et al, 1994). In this series, the 
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rate of CR/CRu was significantly lower than the overall rate of CR/CRu but there were a 
high number of treatment-related deaths (4/17). These treatment-related deaths from 
infection did not occur exclusively in elderly patients, as 2 patients were <60 years and 2 
patients >60 years at diagnosis. The OS of patients with ‘discordant’ lymphoma, however, 
was not significantly different from those patients with ‘pure’ DLBCL.   
 
Regarding the incidence of second malignancies, there were 3 patients who developed 
therapy-related AML secondary to HDT with cyclophosphamide and TBI, all of whom 
died as a consequence. Two of the 3 patients who developed breast cancer had received 
mediastinal radiotherapy as part of their treatment for DLBCL, both died as a 
consequence. Two patients developed Hodgkin lymphoma, neither had received 
radiotherapy as initial therapy. If the therapy-related cases of AML and breast cancer are 
excluded and the incidence of second cancers is only considered relevant to those patients 
that achieved a CR/CRu, (having survived long enough to develop one), then there were 
28 second cancers diagnosed in 264 patients (11%). In 15/264 patients (6%), this was the 
cause of their death. 
 
According to the Office of National Statistics in the UK (www.statistics.gov.uk), the 
incidence rate of newly diagnosed cancer per 100,000 population aged between 65 to 69 
years was 2125 and 1481 for males and females respectively in 2007. That is an 
incidence rate of around 1-2%. Although this is a very crude way of looking at the data, it 
seems that the incidence of second malignancy in this series of patients, with a median 
age of 65 years at diagnosis of their second malignancy, was higher than expected 
compared with that of the general population.  It is difficult to tease out whether this 
statement is supported by published literature regarding second malignancies in patients 
treated for DLBCL. Radiotherapy is a known risk factor for developing a second 
malignancy but taking this into account, the results are conflicting; some studies have 
reported that the risk is not increased (Andre et al, 2004) whilst others have found it to be 
increased.  (Mudie et al, 2006). The problem with the majority of studies addressing this 
issue is that they include all patients with NHL, not distinguishing between different 
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histological subtypes, and also the use of different study designs. However, an Italian 
study reported the incidence of second malignancies in a cohort of 1280 patients with 
DLBCL and found that only patients ≤59 years at diagnosis had an increased risk of 
developing a second cancer whereas patients older than 59 years had the same risk as the 
normal Italian population (Sacchi et al, 2008).  
 
The limitations of this analysis are those associated with a retrospective analysis of any 
kind, which includes: missing data, modification of staging criteria over time and the 
heterogeneity of treatments administered. Data on the molecular subgroup of DLBCL, i.e. 
GCB-like or ABC-like (Alizadeh et al, 2000), at diagnosis and recurrence are also not 
available. In addition, patients in this analysis were treated prior to the routine use of 
rituximab. However, the expectation is that, although the addition of rituximab to initial 
chemotherapy has improved progression-free survival and OS, it will make recurrent 
disease correspondingly more difficult to treat. Interim results of the randomised 
‘CORAL’ trial in patients with relapsed/refractory DLBCL, comparing ‘R-ICE’ with ‘R-
DHAP’, suggest that prior exposure to rituximab results in a worse outcome to ‘salvage’ 
chemotherapy (Giesselbrecht C, 2007; Hagberg & Gisselbrecht, 2006). In addition, a 
recent retrospective analysis evaluating the influence of prior rituximab in patients with 
relapsed/refractory DLBCL who had received ‘R-ESHAP’ as salvage therapy, reported 
inferior progression-free survival and OS in patients previously exposed to rituximab 
(Martin et al, 2008).  
 
Above all, this study highlights the need for new and better first-line treatments, in order 
to prevent recurrence in the first place, particularly in high-risk groups such as patients 
with an unfavourable IPI score or molecular subgroup at diagnosis. Currently, where 
rituximab is readily available, all patients with DLBCL are treated in the same way. 
Additionally, prospective randomised trials which incorporate new agents as treatment 
for patients with recurrent DLBCL are urgently needed. These results also emphasise the 
importance of reviewing outcome for all patients, not just for a selected group, as usually 
reported in the literature about outcome of patients treated in clinical trials. 
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Figure 3.13 (a) Remission duration and (b) Overall survival in patients referred to St 
Bartholomew’s Hospital from peripheral hospitals for high-dose therapy. 
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CHAPTER 4: The activity of selenium in B-NHL cell lines 
 
4.1 INTRODUCTION 
Work from our laboratory has previously demonstrated that Se, in the form of MSA, 
induces apoptosis in DLBCL cell lines but that cell lines differ markedly in their 
sensitivity to MSA (Last et al, 2006). In addition, non-toxic concentrations of MSA were 
found to enhance the cytotoxic effect of conventional chemotherapeutic agents and a 
synergistic interaction was demonstrated with doxorubicin, 4-HC and etoposide. In MSA-
sensitive cell lines (RL and SUD4) a concentration of 1μmol/L MSA was chemo-
sensitising, whilst in MSA-resistant cells lines (DHL4 and DoHH2) a concentration of 
10μmol/L MSA was required. Best results were obtained when MSA was administered 
simultaneously with the cytotoxic drugs. A potential mechanism for the observed 
synergistic interaction was found to be a MSA-induced inhibition of NF-κB activity 
(Juliger et al, 2007). These data complement work by others, in solid tumour cell lines 
and xenograft models, which show that organic Se species increase the efficacy of 
chemotherapeutic agents whilst protecting normal tissue from chemotherapy-induced 
toxicity (Cao et al, 2004; Li et al, 2007b). As described extensively in Chapter 1, Se has 
the potential to affect the function of many cellular proteins and signalling pathways and 
its action differs depending on the cell type, the form of Se and the concentration. 
Therefore, it is likely that other, yet undefined, mechanisms will be important for the 
observed synergy between MSA and cytotoxic agents in DLBCL cell lines. These pre-
clinical studies have led to a proposal for a phase I/II clinical trial combining MSC with 
‘R-ICE’ immunochemotherapy in patients with relapsed/refractory DLBCL. One of the 
aims of this trial will be to achieve a plasma Se concentration of 20µmol/L prior to the 
start of chemotherapy. This plasma concentration has been extrapolated from that 
determined in xenograft models of solid tumours (Azrak et al, 2004).  
 
Potential mechanisms of both the chemo-sensitising and cytotoxic effects of MSA are 
investigated in the experiments reported in this chapter.  
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4.2 AIMS 
1) To determine the activity of MSA in DLBCL cell lines. 
2) To confirm the synergistic interaction between non-toxic concentrations of MSA and 
conventional cytotoxic agents in DLBCL cell lines. 
3) To investigate additional mechanisms by which MSA sensitises DLBCL cell lines to 
chemotherapy. 
4) To investigate the role of p53 in the action of MSA 
5) To determine the activity of MSC in B-NHL cell lines 
 
4.3 MATERIALS AND METHODS 
In these experiments, 4 DLBCL cell lines (RL, DHL4, DoHH2, and SUD4) and 1 MCL 
cell line (JVM2) were used. The activity of MSA and MSC was investigated using the 
ATP assay (Chapter 2, section 2.3.2). The results were expressed relative to the control 
value and were analysed using the GraphPad PRISM
®
 software (version 5.03). The 
activity of MSA and MSC was summarised to an EC50 value which was calculated using 
a sigmoidal concentration-effect model with variable slope. Non-toxic concentrations of 
MSA were combined with cytotoxic agents, doxorubicin and 4-HC, in the RL and DHL4 
cell lines and cell viability was determined using the Guava
®
 viacount assay (Chapter 2, 
section 2.3.3). Intracellular GSH concentration was measured using a 96-well plate-based 
assay kit (Sigma-Aldrich; Chapter 2, section 2.6). Western blotting was used to 
investigate protein changes induced by MSA (Chapter 2, sections 2.4 and 2.5). Flow 
cytometry was used to determine the effect of MSA on cell cycle distribution (Chapter 2, 
section 2.7), MMP (Chapter 2, section 2.9) and the uptake of doxorubicin (Chapter 2, 
section 2.8). The ‘Aktide assay’ which utilises a synthetic Akt substrate peptide, 
RPRAAFT (‘Aktide’), was used to quantify PI3K/Akt activity in whole cell extracts 
(Chapter 2, section 2.13).   
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4.4 RESULTS 
4.4.1 The activity of MSA in DLBCL cell lines 
The activity of MSA was studied in 4 DLBCL cell lines using the ATP assay. Two cells 
lines (RL and SUD4) were relatively sensitive and two cell lines (DoHH2 and DHL4) 
were relatively resistant to the cytotoxic effects of MSA. Figure 4.1 shows the EC50 
concentration-effect curves following 72-hour exposure to MSA, and Table 4.1 
summarises the EC50 values. This confirms previously published results from our group, 
although EC50 values differ slightly due to the use of different methodology (Juliger et al, 
2007; Last et al, 2006). For most subsequent experiments, one MSA-sensitive cell line 
(RL) and one MSA-resistant cell line (DHL4) was chosen.  
 
 
 
0.0 0.5 1.0 1.5 2.0 2.5
0
20
40
60
80
100
120
140
RL
DoHH2
DHL4
SUD4
Log MSA concentration ( M)
%
 c
o
n
tr
o
l
 
Figure 4.1 EC50 concentration-effect curves following 72-hour exposure to increasing 
concentrations of MSA in 4 DLBCL cell lines using the ATP assay. Data points are the 
mean +/- SD of three separate experiments.   
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Table 4.1 EC50 values in 4 DLBCL cells lines exposed to MSA for 72 hours. 
 
Cell line EC50 (μmol/L) 95% CI 
RL 3.9 3.3-4.6 
SUD4 7.7 6.4-9.3 
DHL4 76.6 66.1-88.8 
DoHH2 65.3 56.7-75.2 
 
 
4.4.2 Combining MSA with standard chemotherapeutic agents 
To confirm previously published data from our laboratory (Juliger et al, 2007), the 
chemo-sensitising effect of non-toxic concentrations of MSA was investigated using the 
Guava
®
 viacount assay. Figure 4.2a shows that when the RL cell line was simultaneously 
treated with 1µmol/L MSA and increasing concentrations of doxorubicin for 48 hours, 
the addition of MSA significantly enhanced the cytotoxicity of doxorubicin 50nmol/L, 
100nmol/L and 250nmol/L. For example, the cytotoxicity of 100nmol/L doxorubicin was 
increased from 24.5% (±5.7) to 47.4 (±4.9). Similarly, Figure 4.2b shows that when the 
DHL4 cell line was simultaneously treated with 10µmol/L MSA and increasing 
concentrations of 4-HC for 48 hours, the addition of MSA significantly enhanced the 
cytotoxicity of 4-HC 1µmol/L, 2µmol/L, 3µmol/L and 5µmol/L. For example, the 
cytotoxicity of 3µmol/L 4-HC was increased from 1.7% (±3.4) to 38.9% (±3.1). These 
experiments confirm that non-toxic concentrations of MSA result in a synergistic effect 
when combined with standard chemotherapeutic agents in DLBCL cell lines. In MSA-
sensitive cell lines a concentration of 1μmol/L is chemo-sensitising, whilst a 
concentration of 10µmol/L is chemo-sensitising in MSA-resistant cell lines. 
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Figure 4.2 Cell viability of (a) RL cells exposed to a simultaneous combination of 
1µmol/L MSA and increasing concentrations of doxorubicin (Dox) for 48 hours (b) 
DHL4 cells exposed to a simultaneous combination of 10µmol/L MSA and increasing 
concentrations of 4-HC for 48 hours.  Data points are the mean +/- SD of three separate 
experiments. *p<0.05. 
 
 
4.4.3 The effect of MSA on the generation of DNA damage 
The reason for the difference in sensitivity of DLBCL cell lines to MSA is not clear. 
Although previous work from our laboratory did not identify ROS generation after 
exposure to MSA, (Last et al, 2006) the generation of DNA damage may contribute to 
MSA activity. Therefore the effect of MSA on the generation of DNA damage was 
investigated. Histone H2AX, a variant of the nucleosome core histone H2A, is 
phosphorylated on serine 139 in response to double-stranded DNA breaks and this can be 
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detected by western blotting (Burma et al, 2001). Exposure to UV light was used as a 
positive control. Figure 4.3 shows that in both the RL and DHL4 cell line, 
phosphorylation of histone H2AX was not increased when cells were exposed to MSA 
concentrations up to 50μmol/L for 4 hours, confirming that MSA does not induce DNA 
damage. In contrast, exposure to UV light clearly increased the phosphorylation of 
histone H2AX. 
 
Figure 4.3 Phosphorylated histone H2AX in (a) RL cells and (b) DHL4 cells exposed to 
MSA for 4 hours. Exposure to UV light was used as a positive control.                  
         
 
4.4.4 The effect of MSA on intracellular glutathione concentration 
MSA has been reported to deplete intracellular GSH (Shen et al, 2002). Therefore, the 
effect of a range of MSA concentrations (1-20μmol/L) on intracellular GSH was 
investigated in DLBCL cell lines. There was no difference in basal GSH levels between 
the three cell lines studied. Figure 4.4a shows that after a 2-hour exposure to MSA there 
was no change in intracellular GSH concentration in the DHL4 and RL cells lines. 
However, after 24-hour exposure there was a significant decrease in intracellular GSH 
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levels in RL cells exposed to 10μmol/L and 20μmol/L MSA but not in DHL4 cells 
(Figure 4.4b). Given that DHL4 and RL cells have different sensitivities to MSA, 
intracellular GSH was also measured in another MSA-sensitive cell line, SUD4, after 24-
hour exposure to MSA. Similar results to the RL cell line were obtained, such that 24-
hour exposure to 10μmol/L and 20μmol/L MSA significantly decreased intracellular 
GSH concentration.  
 
Figure 4.4 The effect of MSA on intracellular glutathione concentration in DLBCL cell 
lines after (a) 2-hour and (b) 24-hour exposure. Data points are the mean+/-SD of three 
separate experiments. *p<0.05 is a comparison with control using one-way ANOVA 
followed by Tukey’s test. 
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4.4.5 Mitochondrial membrane potential  
Previously published work from our laboratory has demonstrated that MSA induces 
apoptotic cell death in DLBCL cell lines (Last et al, 2006). To investigate whether non-
toxic concentrations were able to prime cells for apoptosis, MMP was determined by JC-
1 staining and flow cytometry. In non-apoptotic cells the JC-1 dye accumulates in the 
mitochondria forming aggregates, which fluoresce red. During apoptosis, via the intrinsic 
pathway, the MMP collapses, the dye no longer accumulates in the mitochondria but 
remains in the cytoplasm in a monomeric form, which fluoresces green.  
 
RL and DHL4 cell lines were exposed to non-toxic and cytotoxic concentrations of MSA 
for 24 and 48 hours. Doxorubicin was used as a positive control as it is known to induce 
apoptosis via the intrinsic, mitochondrial pathway. Figures 4.5 and 4.6 show the dot plots 
of RL and DHL4 cells respectively exposed to MSA for 24 hours. Figure 4.7 summarises 
the percentage decrease in red fluorescence relative to control in cells treated with MSA. 
In RL cells the chemo-sensitising concentration of 1µmol/L did not alter the percentage 
red fluorescence. However, cytotoxic concentrations of 5µmol/L and 20µmol/L 
significantly decreased the percentage red fluorescence demonstrating loss of MMP. In 
DHL4 cells the chemo-sensitising concentration of 10µmol/L did not result in decreased 
red fluorescence but the cytotoxic concentration of 100µmol/L did. Similar results were 
obtained at 48 hours. Figures 4.8 and 4.9 show the dot plots of RL and DHL4 cell lines 
respectively exposed to MSA for 48 hours and results are summarised in Figure 4.10. The 
experiment of RL cells exposed to MSA for 48 hours was only performed twice and 
therefore statistical analysis is not possible. Therefore, chemo-sensitising concentrations 
in both cell lines did not result in loss of MMP but cytotoxic concentrations did. 
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Figure 4.5 JC-1 staining in RL cells treated for 24 hours. (a) Control (b) Doxorubicin 
250nmol/L (c) MSA 1µmol/L (d) MSA 5µmol/L (e) MSA 20µmol/L. Numbers 
represent % viable cells determined by the Guava
®
 viacount assay. Green fluorescence is 
detected in the FL1 channel and red fluorescence in the FL2 channel. Cells with red 
fluorescence are shown in the right upper quadrant. When red fluorescence is lost, cells 
appear in the right lower quadrant.  
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Figure 4.6 JC-1 staining in DHL4 cells treated for 24 hours. (a) Control (b) Doxorubicin 
500nmol/L (c) MSA 1µmol/L (d) MSA 10µmol/L (e) MSA 100µmol/L. Numbers 
represent % viable cells determined by the Guava
®
 viacount assay. Green fluorescence is 
detected in the FL1 channel and red fluorescence in the FL2 channel. Cells with red 
fluorescence are shown in the right upper quadrant. When red fluorescence is lost, cells 
appear in the right lower quadrant.  
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Figure 4.7 Decrease in red fluorescence in cell lines treated for 24 hours (a) RL cells (b) 
DHL4 cells. Data points are the mean+/-SD of at least 3 separate experiments (except 
DHL4+doxorucibin n=2). The p values are a comparison with control. 
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Figure 4.8 JC-1 staining in RL cells treated for 48 hours. (a) Control (b) Doxorubicin 
100nmol/L (c) MSA 1µmol/L (d) MSA 5µmol/L (e) MSA 10µmol/L. Numbers 
represent % viable cells determined by the Guava
®
 viacount assay. Green fluorescence is 
detected in the FL1 channel and red fluorescence in the FL2 channel. Cells with red 
fluorescence are shown in the right upper quadrant. When red fluorescence is lost, cells 
appear in the right lower quadrant.  
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Figure 4.9 JC-1 staining in DHL4 cells treated for 48 hours. (a) Control (b) Doxorubicin 
500nmol/L (c) MSA 1µmol/L (d) MSA10µmol/L (e) MSA 50µmol/L. Numbers 
represent % viable cells determined by the Guava
®
 viacount assay. Green fluorescence is 
detected in the FL1 channel and red fluorescence in the FL2 channel. Cells with red 
fluorescence are shown in the right upper quadrant. When red fluorescence is lost, cells 
appear in the right lower quadrant.  
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Figure 4.10 Decrease in red fluorescence in cell lines treated for 48 hours (a) RL cells, 
data points are the mean+/-SD of 2 separate experiments (b) DHL4 cells, data points are 
the mean+/-SD of 3 separate experiments. The p value is a comparison with control. 
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4.4.6 Pro-apoptotic signalling 
The induction of apoptosis was further investigated by western blotting. Figure 4.11 
shows that in RL cells, PARP cleavage occurred at the non-toxic concentration of 
1µmol/L MSA after 48-hour exposure, and that the cytotoxic concentration of 5µmol/L 
resulted in a larger increase in cleaved PARP at the earlier time point of 24 hours. In 
DHL4 cells, concentrations of MSA up to 60µmol/L did not result in PARP cleavage. 
Staurosporine (ST) was used as a positive control. 
 
Figure 4.11 PARP cleavage in (a) RL and (b) DHL4 cell lines treated with non-toxic and 
cytotoxic concentrations of MSA. Cells exposed to staurosporine (ST) for 6 hours were 
used as a positive control. 
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To determine whether chemo-sensitisation by MSA was due to enhanced apoptosis, 
PARP cleavage was also investigated in RL and DHL4 cell lines exposed to MSA, 
cytotoxic chemotherapy, or both for 48 hours. Figure 4.12a shows that in DHL4 cells, 
doxorubicin 225nmol/L alone resulted in a small increase in cleaved PARP but MSA 
10µmol/L did not. The combination of both resulted in a less than additive increase in 
cleaved PARP. In RL cells, doxorubicin 100nmol/L resulted in a large increase in 
cleaved PARP but MSA 1µmol/L only produced a small increase. The combination of 
both resulted in an additive increase in the amount of cleaved PARP. Figure 4.12b shows 
DHL4 cells exposed to a synergistic combination of MSA and 4-HC for 48 hours. 
However, neither MSA nor 4-HC alone or in combination resulted in PARP cleavage. It 
should be noted that different antibodies were used in Figures 4.12a and 4.12b as the 
experiments were performed at different times. This may explain why a small amount of 
cleaved PARP is present in DHL4 control cells in Figure 4.12a, but not in Figure 4.12b. 
 
Figure 4.12 PARP cleavage in (a) RL and DHL4 cell lines exposed to MSA, doxorubicin 
or both for 48 hours. Densitometry values are shown. (b) DHL4 cells exposed to MSA, 4-
HC or both for 48 hours. DHL4 cells exposed to staurosporine (ST) 1µmol/L for 6 hours 
were used as a positive control. 
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The effect of MSA on proteins involved in cell survival was investigated. Figure 4.13a 
shows that phosphorylation of Akt did not change in DHL4 and RL cells exposed to 
cytotoxic concentrations of MSA. Figure 4.13b shows that neither the phosphorylation of 
Erk1/2 nor Akt was altered in DHL4 or RL cell lines treated with synergistic 
combinations of MSA and doxorubicin.   
 
 
Figure 4.13 (a) p-Akt in DHL4 and RL cell lines exposed to MSA 60µmol/L and 
5µmol/L respectively (b) p-Erk and p-Akt in RL and DHL4 cells exposed to MSA, 
doxorubicin or both for 48 hours. 
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The effect of chemo-sensitising and cytotoxic concentrations of MSA on the Bcl-2 family 
of proteins was investigated. Figure 4.14 shows that expression of the anti-apoptotic 
protein Bcl-2 was not clearly altered in either the RL or DHL4 cell line. In RL cells, the 
cytotoxic concentration of 5μmol/L increased the expression of the pro-apoptotic protein 
Bax but lower concentrations did not alter its expression. DHL4 cells are known not to 
express Bax protein (Strauss et al, 2007) however, 30µmol/L and 60μmol/L MSA did 
increase the expression of the pro-apoptotic protein Bak at 24 hours, with a further 
increase at 48 hours. In RL cells, the anti-apoptotic protein Mcl-1 was induced after 
exposure to 5µmol/L MSA for 24 hours but this decreased back to baseline by 48 hours. 
In DHL4 cells Mcl-1 was induced at all concentrations. With 30µmol/L and 60µmol/L 
MSA the increase was seen at 24 hours and returned to baseline by 48 hours but at 
10µmol/L MSA the increase was sustained out to 48 hours.   
 
Figure 4.14 The effect of MSA on the expression of Bcl-2 family proteins. (a) RL and 
(b) DHL4 cell lines. Densitometry values are shown. 
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The effect of MSA on the expression of the anti-apoptotic protein survivin was also 
investigated. Figure 4.15 shows that in RL cells, survivin expression decreased in cells 
exposed to 5µmol/L MSA for 24 and 48 hours but lower concentrations did not alter its 
expression. In DHL4 cells, MSA resulted in a concentration and time-dependent decrease 
in survivin expression and this was seen as early as 4 hours and occurred at the chemo-
sensitising concentration of 10µmol/L.  
 
Figure 4.15 Survivin expression in (a) RL and (b) DHL4 cell lines exposed to MSA. 
 
 
4.4.7 Effect of MSA on the p53 wild-type cell line JVM2 
Studies have suggested that the effect of Se, mainly in the form of SLM, is dependent on 
the p53 status of the cell (Goel et al, 2006). The cell lines studied so far all have 
mutations of the p53 gene. Therefore, to investigate where the effect of MSA is also 
dependent on p53, the JVM2 cell line, which is p53 wild-type, was studied. Figure 4.16 
shows that the JVM2 cell line was sensitive to the cytotoxic effect of MSA, with an EC50 
value (ATP assay) after 72-hour exposure of 3.4µmol/L (95% CI 3.1-3.9µmol/L).  
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Figure 4.16 EC50 concentration-response curve following 72-hour exposure to increasing 
concentrations of MSA in the JVM2 cell line. Data points are the mean +/- SD of 8 
separate experiments. 
 
 
Cell cycle analysis was performed in JVM2 cells. Exposure to 3.4µmol/L MSA for 72 
hours significantly increased the sub G1/apoptotic cell population (p=0.003). This was 
associated with a decrease in cells in all other cell cycle phases but without causing cell 
cycle arrest (Figure 4.17).  
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Figure 4.17 Cell cycle analysis of JVM2 cells exposed to 3.4µmol/L MSA for 72 hours. 
(a) Representative DNA histograms (b) Cell cycle distribution. Data points are the mean 
+/- SD of 3 separate experiments.   
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The effect of MSA on intracellular signalling pathways was studied. Figure 4.18a shows 
a concentration-dependent increase in PARP cleavage in JVM2 cells exposed to MSA 
confirming that apoptosis was induced. Staurosporine was used as a positive control. 
Unexpectedly, MSA decreased the expression of p53 and its downstream target p21 in a 
concentration-dependent manner (Figure 4.18b). This is in contrast to the RL and DHL4 
cell lines, which have mutated p53, where MSA did not alter its expression (Figure 
4.18c).  
 
 
Figure 4.18 (a) PARP cleavage and (b) p53 and p21 expression in JVM2 cells exposed to 
MSA (c) p53 expression in RL and DHL4 cell lines exposed to MSA. Staurosporine (ST) 
0.5µmol/L for 6 hours. 
 
The induction of apoptosis was associated with concentration-dependent changes in the 
expression of Bcl-2 family proteins. Figure 4.19 shows that MSA increased the 
expression of the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-xL, whilst 
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decreasing the expression of the anti-apoptotic protein Mcl-1. The expression of Bcl-2 
and Bak was not altered by exposure to MSA. 
 
Figure 4.19 Expression of Bcl-2 family proteins in JVM2 cells exposed to MSA. 
 
In order to confirm results in the RL and DHL4 cell lines that showed no effect of MSA 
on the phosphorylation of Akt, the ‘Aktide assay’, which was being developed in our 
laboratory, was used. This assay uses a synthetic Akt substrate peptide, RPRAAFT 
(‘Aktide’), to quantify PI3K/Akt activity in whole cell extracts and has been described in 
Chapter 2 (section 2.13). Due to the relatively low basal levels of p-Akt in lymphoma cell 
lines, cells were exposed to 100µmol/L pervanadate for 30 minutes prior to exposure to a 
range of MSA concentrations (0.5-10µmol/L) for 30 minutes and 2 hours. Pervanadate is 
a phosphatase inhibitor that leads to the accumulation of phosphorylated proteins, thus 
activating kinases that are normally inactive in the de-phosphorylated state (Ruff et al, 
1997). Thus, pervanadate is a potent activator of PI3K/Akt and increases the amount of p-
Akt. The ability of MSA to inhibit this increase was investigated. Wortmannin 1µmol/L 
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was used as a positive control. Figure 4.20 shows that MSA was unable to inhibit the 
accumulation of p-Akt by pervanadate. Similar results were obtained by western blotting 
(Figure 4.21). Of note, the induction of p-Akt by pervanadate was less in the 2-hour MSA 
experiments compared to the 30-minute experiments, suggesting that the concentration 
used induced only a short term increase in p-Akt.  
 
Figure 4.20 Aktide assay performed in JVM2 cells exposed to pervanadate (P) for 30 
minutes followed by (a) MSA for 30 minutes, data points are the mean+/-SD of 3 
separate experiments and (b) MSA for 2 hours, data points are the mean+/-SD of 2 
separate experiments. *p=0.003 is a comparison with control using one way ANOVA 
followed by Tukey’s test.   
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Figure 4.21 p-Akt in JVM2 cells exposed to pervanadate (P) for 30 minutes followed by 
(a) MSA for 30 minutes and (b) MSA for 2 hours. 
 
 
4.4.8 The effect of MSA on doxorubicin uptake 
To investigate whether MSA altered the uptake of cytotoxic drugs as an explanation for 
the observed synergy, the uptake of doxorubicin by RL and DHL cell lines with and 
without the addition of MSA was investigated after 24-hour exposure.  Doxorubicin 
demonstrates auto-fluorescence and therefore can be detected by flow cytometry. Figures 
4.22a and 4.23a show that exposure to increasing concentrations of doxorubicin for 24 
hours in RL and DHL4 cell lines can be detected by flow cytometry. In RL and DHL4 
cells, simultaneous exposure to doxorubicin and a chemo-sensitising concentration of 
MSA (1µmol/L and 10µmol/L respectively) did not alter the uptake of doxorubicin 
(Figures 4.22 and 4.23). In DHL4 cells, simultaneous exposure to doxorubicin 10nmol/L 
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and MSA 10µmol/L resulted in a consistently small, but statistically significant, 
increased uptake of doxorubicin. This was not apparent at higher doxorubicin 
concentrations. Figure 4.24 shows the increase in mean fluorescence intensity (MFI) 
relative to control. 
 
 
 
 
Figure 4.22 Representation histograms of RL cells exposed to doxorubicin (Dox) for 24 
hours with and without simultaneous exposure to 1µmol/L MSA. (a) Increasing 
concentrations of doxorubicin alone, (b) Doxorubicin 10nmol/L, (c) Doxorubicin 
50nmol/L, (d) Doxorubicin 100nmol/L, (e) Doxorubicin 250nmol/L, (f) Doxorubicin 
500nmol/L. 
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Figure 4.23 Representation histograms of DHL4 cells exposed to doxorubicin (Dox) for 
24 hours with and without simultaneous exposure to 1µmol/L and 10µM MSA. (a) 
Increasing concentrations of doxorubicin alone, (b) Doxorubicin 10nmol/L, (c) 
Doxorubicin 50nmol/L, (d) Doxorubicin 100nmol/L, (e) Doxorubicin 250nmol/L, (f) 
Doxorubicin 500nmol/L. 
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Figure 4.24 MFI in RL and DHL4 cell lines exposed to doxorubicin for 24 hours with 
and without simultaneous exposure to MSA (a) RL cells MSA 1µmol/L  (b) DHL4 cells 
MSA 10µmol/L. *p<0.05. 
 
4.4.9 The activity of methylselenocysteine in B-NHL cell lines 
MSC is the Se compound to be used in the forthcoming clinical trial of Se 
supplementation in patients with DLBCL. Therefore the activity of MSC was 
investigated in 3 lymphoma cell lines; RL, DHL4 and JVM2. Cells were exposed to MSC 
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for 72 hours and cytotoxicity determined using the ATP assay. Figure 4.25 shows the 
concentration-effect curves and Table 4.2 the EC50 values 
 
 
Figure 4.25 EC50 concentration-effect curves following 72-hour exposure to increasing 
concentrations of methylselenocysteine in 3 lymphoma cell lines using the ATP assay. 
Data points are the mean +/- SD of at least 4 separate experiments.   
 
 
Table 4.2 EC50 values in 3 lymphoma cells lines exposed to methylselenocysteine for 72 
hours 
 
Cell line EC50 (μmol/L) 95% CI 
RL 21.6 20.6-22.6 
DHL4 55.8 49.2-63.4 
JVM2 79 65.7-95 
    
 
As MSC is activated in vivo to methylselenol by β-lyase enzymes, the activity of MSC 
plus β-lyase was investigated. The enzyme L-methioninase was purchased from Wako 
Chemical USA, Inc (Richmond, VA) as this had previously been used in publications 
investigating the in vitro effect of MSC (Azrak et al, 2006). However, combining MSC 
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with previously published concentrations of L-methioninase (0.05 units/ml) did not alter 
the activity of MSC in the lymphoma cell lines (data not shown). 
 
4.5 DISCUSSION 
The cytotoxicity of MSA, through induction of apoptosis, has been reported in a number 
of different cancer cell lines and primary cancer samples including lymphoma (Jiang et al, 
2001; Last et al, 2006).  Here, the cytotoxicity of MSA in 4 DLBCL cell lines was 
confirmed using the ATP assay and, in keeping with previously published results, the cell 
lines differed in sensitivity. The reasons for this are not clear. Previous work has 
demonstrated that MSA does not result in the generation of ROS in DLBCL cell lines and 
therefore this is not a mechanism by which apoptosis is induced (Last et al, 2006). An 
alternative hypothesis studied in the experiments presented here was that apoptosis by 
MSA may be due to the generation of DNA damage and the extent may differ between 
sensitive and resistant cell lines. However, the results show that MSA does not induce 
DNA damage in either the RL or DHL4 cell lines as there was no increase in 
phosphorylation of histone H2AX. This is in keeping with previously published results in 
solid tumour cell lines where cytotoxic concentrations of MSA have not been associated 
with DNA damage (Ip et al, 2000).  
 
Previously, it has been reported by our group that low non-toxic concentrations of MSA 
can enhance the cytotoxicity of chemotherapeutic agents in DLBCL cell lines (Juliger et 
al, 2007). Here, limited experiments were conducted to confirm these results before 
investigating additional potential mechanisms for the observed synergy. Thus, synergy 
was observed with the combination of doxorubicin and 1µmol/L MSA in RL cells and 4-
HC and 10µmol/L MSA in DHL4 cells, confirming the published studies. 
 
The effect of MSA on intracellular GSH was investigated for two reasons. Firstly, MSA 
has been reported to deplete intracellular GSH and increasing the intracellular GSH 
concentration, by treating cells with N-acetylcysteine, enhanced MSA-induced apoptosis 
suggesting that GSH was required as a co-factor for MSA-induced apoptosis (Shen et al, 
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2002). This is in keeping with the fact that MSA requires reduction by cellular thiols, 
including GSH, for conversion to its presumed active metabolite, methylselenol. 
However, data from our laboratory showed no effect of N-acetylcysteine on the activity 
of MSA (Last et al, 2006). Secondly, tumour cells have been found to have higher 
concentrations of GSH than non-tumour cells and high GSH concentrations have been 
associated with chemo-resistance (Friesen et al, 2004; Perry et al, 1993). In particular, 
some chemotherapeutic agents, including doxorubicin and cyclophosphamide, are 
inactivated by conjugation with GSH. Thus, GSH depletion by MSA could be responsible 
for its chemo-sensitising effect. 
 
The results reported here show that basal GSH concentration in three DLBCL cell lines 
studied did not differ. MSA concentrations ≤20μmol/L did not alter the intracellular GSH 
concentration after 2-hour exposure. However, after 24-hour exposure there was a 
significant decrease in GSH concentration in both MSA-sensitive cell lines, RL and 
SUD4. This effect was not seen in the MSA-resistant cell line, DHL4. This suggests that 
sensitivity to MSA may be related to the degree of GSH depletion. However, GSH 
depletion was only seen at concentrations of 10μmol/L and 20μmol/L and the 72-hour 
EC50 of both SUD4 and RL cell lines is less than 10μmol/L; 7.7μmol/L and 3.9μmol/L 
respectively. Also, previous results from our laboratory did not observe an effect of 
increasing intracellular GSH levels on MSA activity. The reverse experiment of depleting 
intracellular GSH levels has not been performed and would be valuable. The MSA 
concentrations studied here were chosen because they are clinically relevant and in our 
forthcoming clinical trial the aim is to achieve a plasma Se concentration of 20μmol/l. 
Also, this range included the chemo-sensitising concentrations of 1μmol/L and 10μmol/L 
in MSA-sensitive and MSA-resistant cell lines respectively. It may, however, have been 
useful to study higher concentrations in the DHL4 cell line. In the study reporting the 
GSH-depleting effect of MSA in a hepatoma cell line, these cells were also relatively 
resistant to MSA and concentrations between 20μmol/L and 50μmol/L MSA were found 
to deplete intracellular GSH levels whereas MSA concentrations ≤10μmol/L MSA were 
found to increase GSH levels (Shen et al, 2002). The chemo-sensitising effect of MSA 
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cannot be explained by GSH depletion as concentrations of 1μmol/L in RL and SUD4 
cells and 10μmol/L in DHL4 cells did not alter GSH concentration. 
 
Studies in solid tumour cell lines and in vivo cancer models have reported that synergy 
between MSA and chemotherapeutic agents, is due to enhanced apoptosis (Hu et al, 
2005a; Hu et al, 2008; Wu et al, 2009). Therefore, the induction of apoptosis by chemo-
sensitising and cytotoxic concentrations of MSA in the RL and DHL4 cell lines was 
investigated. Cytotoxic concentrations of MSA were found to reduce the MMP, 
implicating the intrinsic apoptotic pathway in the cytotoxic effect of MSA. However, 
chemo-sensitising concentrations of MSA in both cell lines failed to alter the MMP, 
suggesting that MSA does not prime cells for apoptosis through this mechanism. PARP 
cleavage was studied as the end result of caspase-mediated apoptosis. In RL cells, PARP 
cleavage was apparent at the cytotoxic concentration of 5µmol/L but was also apparent at 
the chemo-sensitising concentration of 1µmol/L. However, when MSA and doxorubicin 
were combined the increase in cleaved PARP was only additive and not synergistic, 
suggesting that enhanced apoptosis is not the mechanism by which MSA sensitises RL 
cells to chemotherapy. In addition, PARP was cleaved in RL cells after exposure to 
1µmol/L MSA but this concentration did not alter the MMP, suggesting that the extrinsic 
apoptotic pathway may also be important in the execution of apoptosis by MSA.  
 
In DHL4 cells, the near EC50 concentration of 60µmol/L did not result in PARP cleavage 
even though similar concentrations resulted in decreased MMP. The lack of PARP 
cleavage in DHL4 cells may appear to be an unexpected result, however, when previous 
results published by our group are considered it is less so. By trypan blue exclusion, the 
DHL4 cell line was very sensitive to the cytostatic effect of MSA with an EC50 value at 
72 hours of 1.7µmol/L, but very resistant to the cytotoxic effect of MSA with an EC50 
value at 72 hours of 166µmol/L (Last et al, 2006). The ATP assay used here reflects both 
the cytostatic and cytotoxic effects of a drug and cannot distinguish between the two, thus 
the EC50 value at 72 hours of 76.6µmol/L is likely to reflect this fact. A synergistic 
combination of doxorubicin and 10µmol/L MSA resulted in a less than additive increase 
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in cleaved PARP and a synergistic combination of 4-HC and 10µmol/L MSA did not 
result in PARP cleavage. Thus, similar to the RL cell line, enhanced apoptosis does not 
appear to be the explanation for the observed synergy in DHL4 cells 
 
Given that cytotoxic concentrations of MSA decrease the MMP, which occurs when the 
intrinsic apoptotic pathway is activated, changes in the expression of Bcl-2 family 
proteins were investigated. These proteins have both anti- and pro-apoptotic members, 
and the balance between them is integral in controlling the intrinsic apoptotic pathway. 
The synergistic interaction between MSA and cytotoxic agents has previously been 
reported to involve altered expression of Bcl-2 family proteins (Hu et al, 2008). The 
expression of the anti-apoptotic protein, Bcl-2, was much higher in the RL cell line 
compared with the DHL4 cell line, consistent with the fact that the RL cell line has the 
t(14;18) translocation. MSA, however, did not alter the expression of Bcl-2 in either cell 
line despite the fact that Bcl-2 is a downstream target of NF-κB, previously shown to be 
inhibited by MSA (Juliger et al, 2007; Tracey et al, 2005). In RL cells, the cytotoxic 
concentration of 5µmol/L MSA increased the expression of the pro-apoptotic protein Bax 
but lower concentrations did not. Bax is not expressed in the DHL4 cell line and therefore 
its expression was not studied (Strauss et al, 2007). In the DHL4 cell line, 30µmol/L and 
60µmol/L MSA resulted in increased expression of the pro-apoptotic protein Bak at 24 
hours and a further increase at 48 hours. In RL cells, Bak protein was not expressed (data 
not shown). The response of the anti-apoptotic protein, Mcl-1, differed between the 2 cell 
lines. In RL cells, 1µmol/L and 3µmol/L MSA had no effect on the expression of Mcl-1 
but 5µmol/L MSA resulted in increased expression at 24 hours with a return to basal 
levels by 48 hours. In DHL4 cells, 10µmol/L MSA resulted in increased expression of 
Mcl-1 at 24 and 48 hours but 30µmol/L and 60µmol/L MSA only increased its 
expression at 24 hours with a return to basal levels by 48 hours.  
 
Clearly, MSA does affect the expression of the Bcl-2 family of proteins but these effect 
seem to differ between the 2 cell lines. The expression of the pro-apoptotic proteins Bax 
and Bak in RL and DHL4 cells respectively are only increased at cytotoxic 
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concentrations of MSA and the anti-apoptotic protein Mcl-1 appears to be induced, 
mainly at 24 hours with a return to basal levels by 48 hours. Mcl-1 has a short half life of 
only a few hours and is degraded by the proteasome, hence it can be down-regulated 
rapidly in response to pro-apoptotic stimuli (Michels et al, 2005). It may be that Mcl-1 is 
induced by MSA at early time-points but once pro-apoptotic proteins are up-regulated, 
such as Bax in the RL cell line and Bak in the DHL4 cell line, it is rapidly degraded. In 
DHL4 cells exposed to 10µmol/L MSA, Mcl-1 expression increased at 24 hours and was 
sustained up to 48 hours, however, this concentration only resulted in a minimal increase 
in Bak expression which may not be enough to suppress Mcl-1 expression.  
 
The effect of MSA on the phosphorylation of Akt and Erk1/2 was also investigated, as 
previous work in solid tumour cell lines have reported that cytotoxic and chemo-
sensitising concentrations of MSA result in the de-phosphorylation of these two proteins, 
thus promoting cell death (Jiang et al, 2002; Li et al, 2007b). However, it appears that in 
the RL and DHL4 cell lines, neither cytotoxic nor chemo-sensitising concentrations of 
MSA de-phosphorylate Akt or Erk. Moreover, combining doxorubicin and MSA at 
synergistic concentrations did not alter the phosphorylation of Akt or Erk.  
 
In contrast, the expression of the pro-survival protein, survivin was decreased by MSA. 
In the RL cell line, a cytotoxic concentration of 5μmol/L decreased survivin expression at 
24 and 48 hours but lower concentrations did not. In DHL4 cell lines 10μmol/L and 
30μmol/L MSA decreased the expression of survivin in a time- and concentration-
dependent manner, and at an earlier time-point of 4 hours. These results are in keeping 
with previously published results in solid tumour cell lines that have reported decreased 
survivin expression by MSA and its role in chemo-sensitisation (Hu et al, 2008). Survivin 
is regulated by NF-κB and therefore these results are also in keeping with those already 
published by our group showing that 5μmol/L and 10μmol/L MSA inhibits the activity of 
NF-κB. However, down-regulation of survivin does not provide a universal explanation 
for the chemo-sensitising effect of MSA in DLBCL cell lines because in RL cells, 1μM 
MSA did not alter survivin expression. Further experiments investigating the expression 
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of survivin following the combination of synergistic concentrations of cytotoxic agents 
and MSA are needed to clarify the role of survivin in the chemo-sensitising effect of 
MSA.  
 
The effect on survivin may be clinically relevant. Survivin is expressed in a large 
proportion of ‘aggressive’ B-cell lymphomas, with virtually no expression of this protein 
in ‘small’ B-cell lymphomas (Tracey et al, 2005). Around 60% of DLBCL cases express 
survivin and this has been associated with a lower OS. Survivin expression remained a 
prognostic factor in multivariate analysis and was independent of the IPI score (Adida et 
al, 2000). Therefore, survivin represents a rational therapeutic target in DLBCL, 
particularly since normal tissue does not express this protein.  
 
To investigate the role of p53 in the action of MSA, the p53 wild-type cell line, JVM2 
was used. The JVM2 cell line was sensitive to the cytotoxic effect of MSA as determined 
by the ATP assay and has a very similar EC50 at 72 hours to the RL cell line. MSA 
induced apoptosis in this cell line as evidenced by PARP cleavage and an increase in the 
sub-G1 population with PI staining. However, MSA did not induce cell cycle arrest 
which is in keeping with results published in p53-mutated DLBCL cell lines where MSA 
did not affect cell cycle distribution (Last et al, 2006). This is in contrast, however,  to a 
number of studies in solid tumour cell lines, in which MSA has been reported to induce 
G1 cell cycle arrest in association with altered expression of cell cycle regulatory proteins 
including p27, p21 and cyclin D1 (Jiang et al, 2002; Zhu et al, 2002). The cyclin-
dependent kinase inhibitor, p21, appears to be particularly important in the G1 cell cycle 
arrest observed in prostate cancer cell lines as knocking-down its expression abolished 
the cell cycle arrest, albeit to different extents in the different cell lines tested. However, 
the induction of p21
 
was independent of p53 as the effect was apparent in p53-mutated 
cell lines (Wang et al, 2010). 
 
The effect of MSA on p53 was further investigated by western blotting. It was anticipated 
that MSA would activate and thus increase the expression of p53 protein in keeping with 
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previous studies that have demonstrated p53 activation by organic Se compounds, such as 
SLM, in the absence of DNA damage (Goel et al, 2006; Seo et al, 2002a).  Surprisingly, 
MSA decreased the expression of p53 in a concentration- and time-dependent manner 
and also decreased the expression of the down-stream protein, p21, suggesting that the 
induction of apoptosis in the JVM2 cell line is not dependent on functional p53 protein. 
The effect of MSA on the Bcl-2 family of proteins was studied in the JVM2 cell line and 
MSA induced a concentration- and time-dependent increase in the expression of the pro-
apoptotic protein Bax but also increased the expression of the anti-apoptotic protein Bcl-
xL. MSA decreased the expression of the anti-apoptotic protein Mcl-1 but had no effects 
on the expression of Bak or Bcl-2. Clearly, MSA alters the expression of Bcl-2 family 
proteins tipping the balance to apoptosis rather than survival but to better understand 
which proteins are crucial, knock-down and over-expression experiments are needed. 
 
To further study the effect of MSA on Akt activity in lymphoma cell lines, 2 methods 
were used with JVM2 cells, the novel ‘Aktide assay’ and western blotting. The ‘Aktide 
assay’ measures the functional activity of Akt, based on the quantitative phosphorylation 
of a synthetic Akt peptide substrate.  MSA, at concentrations up to 10μmol/L, was not 
able to inhibit the PI3K/Akt pathway at 30-minute or 2-hour exposure. Similar results 
were obtained by western blotting. In these experiments, phosphorylation of serine 473 
was studied but full activation of Akt also requires phosphorylation at threonine 308. A 
study in a prostate cancer cell line found that MSA de-phosphorylated Akt as early as 1-
hour post-exposure but the effect was greater at the threonine 308 site than the serine 473. 
It may be that in lymphoma cell lines MSA affects the threonine 308 site, however, the 
‘Aktide assay’, which is an overall measure of Akt activity failed to demonstrate an 
inhibitory effect of MSA on the PI3K/Akt pathway (Wu et al, 2006). 
 
Since these experiments were unable to demonstrate enhanced apoptosis as the 
mechanism by which MSA sensitises cells to cytotoxic agents, the effect of MSA on the 
uptake of doxorubicin was studied in RL and DHL4 cells. There has been an in vivo 
study published suggesting that the organo-Se compound MSC can improve the delivery 
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of doxorubicin to the site of tumours, mainly due to improved vascular functioning 
(Bhattacharya et al, 2008). The direct effect of Se on drug uptake in vitro has not been 
reported. The results reported here show that MSA does not alter doxorubicin uptake as 
determined by flow cytometry. A very small, but statistically significant, increased 
uptake with MSA 10μmol/L and doxorubicin 10nmol/L was not seen at higher 
doxorubicin concentrations. 
 
The activity of MSC in three lymphoma cell lines was investigated, as MSC is the Se 
species to be used in the planned clinical trial.  The EC50 at 72 hours ranged between 
20µmol/L and 80µmol/L. These MSC concentrations were similar to those reported in 
solid tumour cell lines to inhibit cell growth and induce apoptosis (Ip et al, 2000; Yeo et 
al, 2002). The sensitivity of lymphoma cell lines to MSC did not correlate with 
sensitivity to MSA in that the JVM2 cell, which was very sensitive to MSA, was the most 
resistant of the three cell lines to MSC. Since metabolism of MSC by β-lyase enzymes is 
required to generate methylselenol, thought to be responsible for its anti-tumour effects, it 
is likely that the cell lines differ in β-lyase activity. This is addressed further in Chapter 9. 
Tumour cells are thought to have relatively low levels of β-lyase activity (Ip et al, 2000) 
and studies that have combined MSC with the β-lyase enzyme have induced cell death at 
lower concentrations (Azrak et al, 2006).  
 
In summary, MSA is cytotoxic in a number of lymphoma cell lines but this cytotoxicity 
occurs in the absence of DNA damage and as previously reported, in the absence of ROS 
generation (Last et al, 2006). MSA, at cytotoxic concentrations, decreases MMP and 
affects the expression of Bcl-2 family proteins, although the pattern of changes differs 
between the cell lines. The reason for the difference in sensitivity between the cell lines is 
not clear but sensitive and resistant cell lines differ in their ability to deplete GSH in 
response to MSA. The synergy observed between non-toxic concentrations of MSA and 
chemotherapeutic agents cannot be explained by enhanced apoptosis and is not associated 
with effects on the Akt or Erk1/2 pathways. However, MSA does decrease the expression 
of survivin, which may be a downstream effect of the previously reported NF-κB 
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inhibition (Juliger et al, 2007). The effect of MSA appears to be independent of p53, as in 
the p53 wild-type cell line JVM2, both p53 and its downstream target p21, were down-
regulated. In addition, MSA does not alter the uptake of doxorubicin by DLBCL cell 
lines. 
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CHAPTER 5: Cellular stress induction by methylseleninic acid 
 
5.1 INTRODUCTION 
It has been demonstrated that Se induces protein misfolding, a form of cellular stress, 
which results in ER stress and activation of the UPR. This has been extensively discussed 
in Chapter 1 (section 1.3.9.11). With regards to Se in the form of MSA, induction of ER 
stress has been reported to be a mechanism by which high concentrations induce 
apoptosis (Wu et al, 2005; Zu et al, 2006) whilst non-toxic concentrations sensitise cells 
to chemotherapy (Wu et al, 2009). ER stress induction and activation of the UPR has 
recently been recognised as an important mechanism by which other anti-tumour agents, 
such as bortezomib and HSP90 inhibitors, promote tumour cell death (Davenport et al, 
2007; Obeng et al, 2006). However, activation of the UPR is primarily a survival 
response and it is only when the cellular stress cannot be resolved that the cell undergoes 
apoptosis. The precise mechanism by which the cell switches from a pro-survival 
response to apoptosis has not been fully elucidated (Szegezdi et al, 2006). Recently, there 
has been some doubt cast about the mechanistic role of ER stress induction in the action 
of Se in vivo. In a mammary cancer model and a prostate cancer xenograft model, MSA, 
MSC and selenite were all able to inhibit tumour growth and induce apoptosis but this 
occurred in the absence of markers of ER stress (Jiang et al, 2009). Thus, further work is 
required to establish the role of Se-induced ER stress in vivo.  
 
There are two main cellular protein degradation pathways that are activated by ER stress; 
the ubiquitin-proteasome pathway and autophagy. The process of autophagy has been 
discussed in Chapter 1 (section 1.3.9.12) and is generally considered to be a pro-survival 
pathway, but in the face of excessive cellular stress autophagy can result in cell death 
(Levine & Kroemer, 2008). The role of autophagy in cancer is complicated and both the 
induction and inhibition of autophagy has been reported to promote tumour cell death 
(Lambert et al, 2008; Zhu et al, 2010). There are little published data describing the 
effect of Se on autophagy, but it appears that the role of autophagy in the action of Se 
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differs between cell types. The effect of organic Se compounds on autophagy has not 
been investigated (Kim et al, 2007b; Ren et al, 2009).  
 
The hypothesis being tested in the experiments described in this chapter is that Se, in the 
form of MSA, sensitises DLBCL cell lines to chemotherapeutic agents through the 
induction of ER stress.  
 
5.2 AIMS 
1) To investigate whether MSA induces protein misfolding and ER stress in DLBCL cell 
lines.  
2) To investigate the consequences of ER stress induction. 
3) To investigate whether ER stress induction is a mechanism by which MSA sensitises 
DLBCL cell lines to chemotherapy. 
 
5.3 MATERIALS AND METHODS 
The effects of non-toxic, chemo-sensitising and cytotoxic concentrations of MSA were 
investigated in the RL and DHL4 cell lines in time-course experiments. In RL cells this 
was 1μmol/L (chemosensitising), 3μmol/L and 5μmol/L (cytotoxic) MSA and in DHL4 
cells this was 10μmol/L (chemo-sensitising), 30μmol/L and 60μmol/L (cytotoxic) MSA. 
Western blotting was used to investigate protein changes (Chapter 2, sections 2.4 and 2.5) 
and real-time PCR to investigate mRNA expression (Chapter 2, section 2.10). To 
investigate the process of autophagy, immunofluorescence for LC3 protein was 
performed (Chapter 2, section 2.11). In addition, cells were stained with AO and the 
formation of acidic vesicular organelles was quantified by flow cytometry (Chapter 2, 
section 2.12). 
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5.4 RESULTS 
5.4.1 Induction of endoplasmic reticulum stress in RL and DHL4 cell lines exposed 
to MSA 
To establish whether MSA induced protein misfolding, the expression of the enzyme PDI 
was examined. This family of enzymes catalyses protein folding through the formation of 
disulphide bonds and their expression is induced in response to protein misfolding, to 
increase the protein folding capacity of the ER (Ellgaard & Ruddock, 2005). Figure 5.1 
shows that in RL cells, 1μmol/L MSA did not induce PDI expression, but induction was 
seen with 3μmol/L and 5μmol/L MSA at both 24- and 48-hour exposures. In DHL4 cells, 
10-60μmol/L MSA induced a concentration-dependent increase in PDI expression at 24 
and 48 hours.  
 
 
Figure 5.1 PDI expression in (a) RL and (b) DHL4 cell lines exposed to MSA.  
 
 
To investigate whether protein misfolding induced ER stress, the expression of GRP78 
was studied. In general, both the RL and DHL4 cell lines showed basal expression of 
GRP78 although there was some variability between experiments. Figure 5.2 shows that 
in RL cells, MSA induced GRP78 in a concentration-dependent manner. 1μmol/L MSA 
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resulted in only a minimal increase in GRP78 expression but 3μmol/L and 5μmol/L MSA 
resulted in a more obvious increase, which occurred early at 4 hours, was maximal at 6 
hours and then decreased by 24 and 48 hours. 10μmol/L MSA resulted in a more 
sustained increase in GRP78 expression, which was maximal by 24 hours and remained 
at this level out to 48 hours. 
 
 
 
Figure 5.2 GRP78 expression in RL cells exposed to MSA. 
 
 
Figure 5.3 shows that in DHL4 cells, MSA also resulted in a concentration-dependant 
increase in GRP78 expression which was seen as early as 4 hours. At low MSA 
concentrations (1-5μmol/L), the induction was greater than that seen in the RL cell line. 
GRP78 induction was maximal at 6 hours, and then decreased by 24-48 hours. With 
higher MSA concentrations of ≥10μmol/L, expression of GRP78 continued to increase 
with exposure time and was maximal by 24 hours remaining at this level out to 48 hours. 
The induction of GRP78 plateaued, with 10μmol/L, 30μmol/L and 60μmol/L MSA 
producing a similar effect.  
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Figure 5.3 GRP78 expression in DHL4 cells exposed to MSA. 
 
 
 
Protein misfolding activates UPR signalling, a consequence of which is activation of 
PERK and phosphorylation of eIF2α. Phosphorylation of eIF2α was studied in the RL 
and DHL4 cell lines exposed to MSA. Figure 5.4 shows that in RL cells, there was 
increased phosphorylation of eIF2α, which was concentration-dependent and maximal at 
6-24 hours’ exposure. This was due to an increase in the phosphorylation state of the 
protein rather than a general increase in eIF2α, as the increase was apparent when p-
eIF2α was expressed relative to total eIF2α. Although the magnitude of this effect was 
variable, a similar trend was seen in a replicate experiment (Figure 5.4b). 
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Figure 5.4 p-eIF2α in RL cells exposed to MSA. (a) Western blot with fold-change 
corrected to total eIF2α expression (b) Densitometry analysis corrected to total eIF2α 
expression. Data points are the mean+/- SD of two separate experiments. 
 
 
DHL4 cells had a higher basal level of phosphorylated eIF2α compared to RL cells. In 
contrast to the results shown in Figure 5.4 with RL cells, in DHL4 cells there was a clear 
decrease in eIF2α phosphorylation, and possibly total eIF2α, which was maximal by 4-6 
hours, followed by a return towards basal levels by 24-48 hours (Figure 5.5).  
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Figure 5.5 p-eIF2α in DHL4 cells exposed to MSA. (a) Western blot with fold-change 
corrected to total eIF2α expression (b) Densitometry analysis corrected to total eIF2α 
expression. Data points are the mean+/- SD of two separate experiments. 
 
 
5.4.2 Endoplasmic reticulum stress-induced apoptosis 
To investigate whether MSA resulted in ER-stress mediated apoptosis, expression of the 
pro-apoptotic gene GADD153 was studied. Despite many attempts and numerous 
antibodies, the expression of GADD153 in cells treated with MSA was not detected by 
western blotting (data not shown). However, induction of GADD153 by MSA has been 
demonstrated in solid tumour cell lines and therefore expression at the mRNA level was 
investigated by real-time PCR. Figures 5.6 and 5.7 show that MSA resulted in a 
concentration-dependent increase in GADD153 mRNA expression. Figure 5.6 shows that 
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in RL cells, the chemo-sensitising concentration of 1μmol/L MSA did not increase 
GADD153 mRNA expression but 5μmol/L MSA resulted in a significant increase at 4- 
and 6-hour exposure, which then decreased to baseline by 24-48 hours. Figure 5.7 shows 
that in DHL4 cells, there was a similar pattern of increased expression at 5μM MSA but 
higher concentrations (10-60μmol/L) resulted in further significant increases in 
expression of GADD153. A plateau in effect occurred at 30μmol/L with a maximal 
increase at 48 hours. There was no significant difference between the means for cells 
exposed to 30μmol/L and 60μmol/L MSA for 48 hours (p=0.5). 
 
 
 
 
Figure 5.6 Real-time PCR for GADD153 mRNA in the RL cell line. *p=0.02, **p=0.006. 
Data points are the mean +/- SDs of three separate experiments. p values are a 
comparison with control. 
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Figure 5.7 Real-time PCR for GADD153 mRNA in the DHL4 cell line (a) MSA 
5µmol/L and 10µmol/L (b) MSA 30µmol/L and 60µmol/L.  *p<0.05. Data points are the 
mean +/- SDs of three separate experiments except for 10µmol/L 48 hours, which is the 
mean+/-SD of 2 data points. p values are a comparison with control. 
 
 
To establish whether the increase in GADD153 mRNA expression was associated with 
pro-apoptotic signalling at the protein level, Bcl-2 expression, phosphorylation of Jnk and 
PARP cleavage were studied. Staurosporine (ST), a known inducer of apoptosis, was 
used as a positive control for PARP cleavage. In both the RL (Figure 5.8) and DHL4 
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(Figure 5.9) cell lines, expression of Bcl-2 and phosphorylation of Jnk was not altered by 
MSA at concentrations that resulted in increased GADD153 expression. In RL cells, 
PARP was cleaved at concentrations as low as 1μmol/L and 3μmol/L, which did not alter 
GADD153 expression. Therefore, induction of apoptosis in RL cells was independent of 
ER stress-induced pro-apoptotic signalling. In DHL4 cells, PARP was not cleaved up to 
concentrations of 60μmol/L MSA. 
 
 
Figure 5.8 Pro-apoptotic signalling in the RL cell line exposed to MSA. (a) Bcl-2 
expression (b) p-Jnk (c) and (d) PARP cleavage (as shown in Chapter 4, Figure 4.11, and 
repeated here). Cells exposed to staurosporine (ST) were used as a positive control. 
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Figure 5.9 Pro-apoptotic signalling in the DHL4 cell line exposed to MSA. (a) Bcl-2 
expression (b) p-Jnk (c) PARP cleavage (as shown in Chapter 4, Figure 4.11, and 
repeated here). Cells exposed to staurosporine (ST) were used as a positive control. 
 
 
5.4.3 Protein degradation 
Misfolded proteins are degraded by either the proteasome or by autophagy. Experiments 
to assess which mechanism was induced by MSA were conducted. Proteasomal 
degradation requires proteins to be ubiquitinated and therefore the level of ubiquitinated 
proteins in the RL and DHL4 cell lines exposed to MSA was assessed by western blotting. 
Cells were also exposed to bortezomib, a proteasome inhibitor, as a positive control. 
Figure 5.10 shows that there was not a clear increase in the amount of ubiquitinated 
proteins in either the RL or DHL4 cell lines after exposure to MSA, although in DHL4 
cells exposed to 30µmol/L MSA there may have been a small increase. Western blotting, 
however, is not a very sensitive method for assessing small changes in protein levels. 
Exposure to bortezomib did result in a clear increase in ubiquitinated proteins. 
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Figure 5.10 Level of ubiquitinated proteins in the (a) RL and (b) DHL4 cell lines 
exposed to MSA and bortezomib. 
 
 
To assess whether autophagy was induced by MSA, the conversion of LC3-I to LC3-II 
was studied by western blotting. LC3 is microtubule-associated protein 1 light chain 3 
and after post-translational modification is called LC3-I, which resides in the cytosol. 
When autophagy is induced, LC3-I is converted to LC3-II by conjugation to 
phosphatidylethanolamine and relocates specifically to associate with autophagosome 
membranes. There are three human isoforms of LC3; LC3A, LC3B and LC3C (Klionsky 
et al, 2008). Figure 5.11 shows that in the RL cell line, 1µmol/L and 3μmol/L MSA did 
not result in conversion of LC3B-I to LC3B-II but there was a small increase in LC3B-II 
levels in cells exposed to 5μmol/L for 24 and 48 hours. In the DHL4 cell line, exposure 
to 10-60μmol/L MSA did result in the conversion of LC3B-I to LC3B-II, which was 
apparent at 24 and 48 hours. 
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Figure 5.11 LC3B-I and -II in the (a) RL and (b) DHL4 cell lines exposed to MSA. 
 
 
To confirm that autophagy was induced in the DHL4 cell line, immunofluorescence for 
LC3 was performed. When autophagy is induced, the distribution of LC3 protein changes 
from a diffuse to a punctate pattern as the protein relocates to the autophagosomes. 
Figure 5.12 shows that MSA did alter the pattern of LC3B distribution in DHL4 cells, 
with 10μmol/L and 30μmol/L MSA resulting in an increased punctate pattern. 
 
To quantify the increase in autophagy, cells treated with MSA were stained with AO and 
the increase in red fluorescence, indicating an increase in acidic cytoplasmic vesicles, 
was determined by flow cytometry. Thapsigarin (TG), an inhibitor of the ER calcium 
pump and hence an inducer of ER stress and autophagy, was used as a positive control. 
Figure 5.13 shows the flow cytometry plots from one experiment. The numbers indicate 
the percentage of cells present in the upper right and left quadrants with increased red 
fluorescence. Figure 5.14 shows the summary of three separate experiments, 
demonstrating clearly that MSA significantly increased the percentage of red 
fluorescence compared to untreated cells, although there was no clear concentration 
effect.  
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Figure 5.12 Immunofluorescence for LC3B in the DHL4 cell line exposed to MSA 
for 24 hours. (a) Control (b) 10μM (c) 30μM. A punctuate pattern is apparent in cells  
treated with MSA, indicating the formation of autophagosomes.  
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Figure 5.13 Acridine orange staining in the DHL4 cell line exposed to MSA for 24 hours. 
(a) Control (b) Thapsigarin 3μM, (c) MSA 10μM (d) MSA 20μM. FL1 indicates green 
fluorescence and FL3, red fluorescence. Cells above the horizontal line have increased 
red fluorescence.  
 
Figure 5.14 Increase in % of red fluorescent cells in DHL4 cell line stained with acridine 
orange after exposure to MSA or thapsigargin (TG; positive control). Data points are the 
mean+/-SD of 3 separate experiments. p values are a comparison with control.  
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To investigate the consequences of MSA-induced autophagy in the DHL4 cell line, cells 
were exposed to bafilomycin A1. Bafilomycin A1 is a macrolide antibiotic that inhibits 
vacuolar H
+
-ATPase proton pumps, which are required to acidify lysosomes, therefore 
raising lysosomal pH (Yoshimori et al, 1991). It also prevents the fusion of 
autophagosomes with lysosomes (Yamamoto et al, 1998). This results in accumulation of 
autophagosomes and increased levels of LC3-II as LC3-II is also degraded by the process 
of autophagy.  
 
To confirm that 10nmol/L bafilomycin A1 was able to inhibit autophagy, DHL4 cells 
were exposed to bafilomycin A1 alone. Figure 5.15a shows the accumulation of LC3B-II 
at 24 and 48 hours confirming the inhibition of the normal homeostatic process of 
autophagy in DHL4 cells. In this situation the accumulation of LC3B-II occurs because 
bafilomycin inhibits the degradation of autophagosomes. However, an increase in LC3-II 
levels also occurs as a result of autophagy induction, as seen after exposure to MSA 
(Figure 5.11).  
 
DHL4 cells were then exposed to balfilomycin A1 in combination with MSA for 48 
hours and cell viability assessed using the Guava
®
 viacount assay. Figure 5.15b shows 
that 10nmol/L bafilomycin A1 alone did not significantly affect cell viability. However, 
balfilomycin A1 significantly enhanced the cytotoxicity of relatively low, non-toxic 
concentrations of MSA. For example, 10µmol/L MSA alone decreased cell viability by 
6.3% (±1.6) but when combined with bafilomycin A1 the cell viability was decreased by 
46.4% (±4.7). This suggests that autophagy is a pro-survival mechanism activated in 
DHL4 cells exposed to MSA. The effect of 3-methyladenine (3-MA), another inhibitor of 
autophagy, was also assessed in DHL4 cells. However, concentrations known from the 
literature to inhibit autophagy were cytotoxic to DHL4 cells (data not shown). 3-MA, in 
addition to inhibiting autophagy, through its action on class III PI3K, affects other 
signalling pathways, such as class I PI3K and MAPK (Tasdemir et al, 2008). Therefore, 
further experiments would be required to establish which of these affects resulted in 
cytotoxicity to the DHL4 cells. 
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Figure 5.15 (a) Accumulation of LC3B-II in the DHL4 cell line exposed to 10nmol/L 
bafilomycin A1 (b) Cell viability assessed by the Guava
®
 viacount assay in the DHL4 
cell line exposed to MSA and bafilomycin A1. 
 
5.4.4 The effect of MSA on other stress-induced proteins 
The effect of MSA on other stress-induced proteins was investigated. Figure 5.16 shows 
that in the RL and DHL4 cell lines, MSA had no effect on the expression of cytosolic 
HSP70 and HSP90. This is in contrast to the marked increase in GRP78, another member 
of the HSP70 family, in both RL and DHL4 cells. 
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Figure 5.16 Expression of HSP70 and HSP90 in (a) RL cells exposed to 5μM MSA and 
(b) DHL4 cells exposed to 60μM MSA.  
 
 
 
The effect of MSA on the transcription factor Nrf2 and the anti-oxidant protein Prx1 was 
also investigated. As described in Chapter 1 (Section 1.3.9.9), these proteins may be 
differentially affected by Se in normal and tumour cells. Figure 5.17 shows that in RL 
and DHL4 cells MSA had no effect on the nuclear expression of Nrf2 or the expression 
of Prx1 in whole cells extracts. 
 
The Nrf2-Prx1 pathway is modulated by alterations in oxygen conditions (Kim et al, 
2007e). Therefore the effect of hypoxia on the expression of Prx1 in cells exposed to 
MSA was further investigated. Figure 5.18 shows that in DHL4 cells exposed to hypoxia 
for 24 hours followed by MSA for a further 2 and 24 hours, there was no alteration in 
Prx1 expression. 
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Figure 5.17 (a) Nrf2 expression in RL cells exposed to 5μM MSA; nuclear and 
cytoplasmic protein separation (b) Prx1 expression in RL cells exposed to 3μM and 5μM 
MSA (c) Nrf2 expression in DHL4 cells exposed to 60μM MSA; nuclear and 
cytoplasmic protein separation (d) Prx1 expression in DHL4 cells exposed to 30μM and 
60μM MSA. 
 
 
 
 
 
Figure 5.18 Prx1 expression in DHL4 cells exposed to MSA under hypoxic conditions 
(1% O2, 5% CO2, 94% N2).   
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5.5 DISCUSSION 
These experiments show that MSA induces protein misfolding in two DLBCL cell lines, 
resulting in ER stress and activation of the UPR. This was investigated in a MSA-
sensitive (RL) and MSA-resistant (DHL4) cell line. Both cell lines demonstrated basal 
expression of GRP78, although there was some variability in expression between 
experiments. This suggests that the cells lines were already ‘stressed’ at baseline. The 
effect of MSA was concentration-dependent and changes in GRP78 expression and 
GADD153 mRNA levels were seen after only 4-hour exposure. The induction of PDI 
occurred later, at 24 and 48 hours.  
 
In RL cells, the chemo-sensitising concentration of 1μM had very little effect on markers 
of ER-stress and ≥3μmol/L MSA was required to induce expression of PDI and GRP78 
and 5μmol/L MSA was required to induce GADD153 mRNA. Thus, induction of ER 
stress is unlikely to be the mechanism by which MSA sensitises RL cells to 
chemotherapy. Despite the lack of ER stress induction in RL cells exposed to 1μmol/L 
MSA, PARP was cleaved at this concentration, suggesting ER stress is also not the 
mechanism of apoptosis-induction in RL cells. Of interest, 1µmol/L MSA had no effect 
on RL cell viability (Chapter 4, Figure 4.2a), however, PARP cleavage was clearly seen 
at this concentration. 
 
In the DHL4 cell line, the induction of GRP78 at low concentrations of MSA (1-
5μmol/L) was larger than in the RL cell line, but 10μmol/L MSA had a similar effect in 
both cell lines with the increase in GRP78 expression maintained out to 48 hours. In 
DHL4 cells, the increase in GRP78 plateaued at concentrations ≥10μmol/L with no 
further increase in expression with 30μmol/L and 60μmol/L exposure. The induction of 
GADD153 mRNA in DHL4 cells was also concentration-dependent and the effect 
plateaued at 30μmol/L MSA. In both the RL and DHL4 cells lines, 5μmol/L MSA 
resulted in a similar pattern of increased GADD153 mRNA expression.  
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GRP78 is responsible for maintaining ER calcium homeostasis, preventing the 
accumulation of misfolded proteins and controlling UPR signalling. GRP78 is generally 
considered a pro-survival protein and over-expression by tumours both promotes growth 
and has been implicated in chemoresistance. It has been shown that knock-down of 
GRP78 can inhibit the growth of cancer cells and sensitise them to chemotherapy (Pyrko 
et al, 2007). GRP78 is able to bind and inhibit the activation of caspase 7 (Reddy et al, 
2003), inhibit pro-apoptotic members of the Bcl-2 family of proteins and prevent 
cytochrome c release from mitochondria (Fu et al, 2007). The MSA-resistant cell line, 
DHL4, induced GRP78 to a greater extent at low MSA concentrations (1-5μmol/L) 
compared to RL cells, which may represent a mechanism of cytotoxic drug resistance.  
 
ER stress-induced pro-apoptotic signalling was further investigated by examining the 
expression of Bcl-2, phosphorylation of Jnk and cleavage of PARP. It was expected that 
an increase in GADD153 mRNA would decrease the expression of the anti-apoptotic 
protein Bcl-2 but this was not apparent in either cell line. Phosphorylation of Jnk has 
been reported as a downstream effect of UPR signalling via the IRE1 pathway and p-Jnk 
promotes apoptosis. However, increased phosphorylation of Jnk protein was also not 
evident in either cell line. As mentioned, in the RL cell line, PARP was cleaved 
independently of ER-stress induction. In the DHL4 cell line, there was no evidence of 
PARP cleavage even at the highest concentration of 60μmol/L. These results suggest that 
although ER stress is induced by MSA this does not result in pro-apoptotic signalling at 
the concentrations used. In addition, GADD153 mRNA levels were significantly 
increased by MSA but this was not demonstrated at the protein level and its downstream 
target, Bcl-2 was not affected. Expression of GADD153 at the protein level was 
investigated by western blotting on several occasions using different antibodies and 
antibody dilutions. However, GADD153 protein was never detected. A methodological 
problem cannot be excluded as a positive control was not used, but given that its down-
stream targets were also unaffected by MSA it is likely that this was a true result. 
Therefore, in DHL4 cells, the chemo-sensitising concentration of 10μmol/L did induce 
ER stress but this did not appear to push the cells towards apoptosis.  
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Activation of the UPR was investigated further by studying the phosphorylation of eIF2α. 
In the RL cell line 3μmol/L and 5μmol/L MSA increased the phosphorylation of eIF2α in 
a concentration-dependent manner. The increase was apparent by 4-hour exposure and 
had decreased by 48 hours. Although there was some variability between experiments, 
the trend was confirmed in two independent experiments. The baseline level of p-eIF2α 
was higher in the DHL4 cell line compared to the RL cell line but, in contrast, there was a 
clear decrease in phosphorylation of p-eIF2α in DHL4 cells exposed to 10μmol/L and 
30μmol/L MSA at the earliest time-point of 4 hours with a return towards baseline by 24 
and 48 hours. This was an unexpected finding as phosphorylation of eIF2α is generally 
considered a pro-survival response resulting in decreased protein translation and has been 
shown to promote drug resistance (Ranganathan et al, 2006). Given that the DHL4 cell 
line is relatively resistant to MSA, increased phosphorylation of eIF2α was expected. A 
possible explanation for this finding is negative feed-back from GADD34, a target gene 
of GADD153. GADD34 can lead to the dephosphorylation of eIF2α thus removing the 
block on translation and promoting apoptosis (Szegezdi et al, 2006). It may have been 
that if an earlier time point than 4 hours had been investigated, an initial increase in p-
eIF2α would have been seen, followed by dephosphorylation, because by 4 hours, 
10μmol/L MSA had already induced a 15-fold increase in GADD153 mRNA expression. 
In prostate cancer cells lines, MSA increased phosphorylation of eIF2α as early as 1-hour 
post exposure (Wu et al, 2005). However, arguing against this is the observation that at 
the MSA concentrations investigated PARP was not cleaved in DHL4 cells, suggesting 
that apoptosis was not activated.    
 
A recent study has, however, implicated the dephosphorylation of eIF2α in cell survival 
and resistance to bortezomib-induced cell death (Schewe & Aguirre-Ghiso, 2009). 
Bortezomib is known to induce ER stress and this may be one mechanism by which it 
induces cell death. In this study, cells surviving treatment with bortezomib were able to 
decrease phosphorylation of eIF2α, which was associated with a decrease in GADD153 
mRNA expression. When dephosphorylation of eIF2α was inhibited, GADD153 
expression was increased and cell death enhanced. As mentioned previously, UPR 
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signalling can simultaneously activate pro-survival and pro-apoptotic pathways and in 
addition to decreasing general protein translation, the phosphorylation of eIF2α can also 
increase GADD153 expression by increasing translation of the transcription factor ATF4 
(Szegezdi et al, 2006). Again, this mechanism does not fully explain the findings in the 
DHL4 cell line as dephosphorylation of eIF2α was associated with increased expression 
of GADD153 mRNA. 
 
Given that induction of ER stress by MSA in the two DLBCL cell lines was not 
apparently activating pro-apoptotic pathways, further downstream consequences of 
protein misfolding were investigated. MSA did not result in a clear increase in the level 
of ubiquitinated proteins suggesting that the ubiquitin-proteasome pathway may not be 
important in degrading the misfolded proteins. Therefore the protein degradation pathway 
of autophagy was investigated. MSA induced autophagy in both cell lines, but further 
experiments were performed only in DHL4 cells, as in the MSA-sensitive RL cell line 
higher than cytotoxic concentrations were required to induce ER stress and apoptosis was 
activated in the absence of ER stress. 
 
In the DHL4 cell line, the chemo-sensitising concentration of 10μmol/L MSA and higher 
concentrations that had already been shown to induce ER stress also induced autophagy. 
This was shown by the conversion of LC3-I to LC3-II, which occurred later than the 
onset of ER stress signalling, at 24 and 48 hours. The distribution of LC3 protein was 
shown to change from a diffuse to a punctuate pattern by immunofluorescence indicating 
the formation of autophagosomes. Additionally, the increase in acidic cytoplasmic 
vesicles was demonstrated by an increase in AO red fluorescence by flow cytometry. 
When autophagy was inhibited by bafilomycin A1, the cytotoxicity of MSA was 
significantly enhanced, suggesting that MSA-induced autophagy is a pro-survival 
response in the DHL4 cell line. It has been shown that both the PERK-eIF2α and the 
IRE1 arms of UPR signalling can mediate ER stress-induced autophagy (Hoyer-Hansen 
& Jaattela, 2007), however, in DHL4 cells exposed to MSA neither of these pathways 
appeared to be important since MSA inhibited the phosphorylation of eIF2α and did not 
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increase the phosphorylation and hence activation of Jnk, which is required for IRE1-
mediated autophagy.   
 
Monitoring the cellular process of autophagy is complicated and there are drawbacks to 
most of the available methods, requiring several methods to be used in parallel (Klionsky 
et al, 2008). In these experiments, three different methods that are widely reported in the 
literature were used to establish the induction of autophagy by MSA. All of these 
methods demonstrate the accumulation of autophagosomes, which has been interpreted to 
mean increased autophagosome formation due to increased autophagic activity. However, 
an alternative explanation could be that there is reduced turnover of autophagosomes, 
which would give the same experimental results. In addition, the acidotropic dye, AO, is 
not specific for autophagosomes but can be taken up by any acidic vesicles. The 
interpretation of western blotting for LC3 protein is also not straightforward as the 
sensitivity of antibodies to LC3 is greater for LC3-II than LC3-I (Klionsky et al, 2008).  
Ideally, these experiments should be complemented by examining autophagic flux, hence 
studying the flow through the whole process of autophagy. Overall, based on evidence 
that ER stress is known to induce autophagy, it is likely from the data presented here that 
MSA is causing a real increase in autophagic activity.  
 
This is the first report of the induction of autophagy by MSA, which, in the DHL4 cell 
line mediated cell survival and hence may be a mechanism of cellular resistance to MSA. 
Therefore, combining MSA with an inhibitor of autophagy may be a way of sensitising 
resistant cells to the cytotoxic effects of MSA. However, neither the induction of ER 
stress nor autophagy can explain the chemo-sensitising effects of MSA. In the RL cell 
line apoptosis is induced at concentrations that do not induce ER stress and although in 
the DHL4 cell line a chemo-sensitising concentration does induce ER stress and 
autophagy, these responses appear to protect the cell from death. The induction of 
autophagy was only investigated in one cell line and thus to make general conclusions 
these experiments would need to be conducted in more MSA-resistant cell lines. 
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However, these experiments were not pursued further in this work as the primary aim 
was to investigate mechanisms of chemo-sensitisation by MSA. 
 
The effects of MSA on other proteins involved in the cellular response to stress were 
studied.  HSPs are molecular chaperones that are ubiquitously expressed in the cytosol of 
cells and required for the function and stability of proteins implicated in cell growth, 
differentiation and survival. They facilitate normal protein folding and their expression is 
increased in response to cellular stresses such as heat, hypoxia, acidosis and protein 
misfolding and aggregation. HSPs, therefore, represent an adaptive response that 
enhances cell survival.  Increased expression of these chaperone proteins, such as HSP90, 
is seen in many tumour types (Whitesell & Lindquist, 2005). The expression of cytosolic 
HSP70 and HSP90 was investigated but MSA did not alter the expression of either 
protein, although basal expression of at least one of these chaperones was high in both 
cell lines studied. Of note GRP78 is the ER homologue of HSP70 and another ER 
chaperone, GRP94, is the ER homologue of HSP90.   
 
The effect of MSA on the Nrf2-Prx1 pathway was also studied. The relevance of this 
pathway to Se has previously been discussed (Chapter 1, section 1.3.9.9). In addition, 
Nrf2 has been identified as a substrate of PERK and is activated by ER stress, promoting 
cell survival. Nrf2 up-regulates components of the proteasome, thus facilitating protein 
degradation, and also increases the expression of genes involved in protein folding 
(Cullinan & Diehl, 2006). However, MSA did not alter the nuclear expression of Nrf2 or 
the expression of Prx1 in whole cell extracts. Given the hypothesis that the response of 
this pathway to Se may be dependent on oxygen conditions (Kim et al, 2007e), the effect 
of hypoxia on Prx1 expression was investigated. However, neither hypoxia itself nor the 
addition of MSA to cells grown under hypoxic conditions altered the expression of this 
protein. 
 
In summary, MSA induces protein misfolding resulting in ER stress and activation of the 
UPR. However, in the two DLBCL cell lines studied, the induction of ER stress is neither 
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a mechanism by which MSA sensitises cells to chemotherapy nor induces apoptosis. 
Rather, in the MSA-resistance cell line, DHL4, ER stress resulted in the induction of 
autophagy, which was demonstrated to be a mechanism of cell survival in this cell line. 
Thus, combining MSA with an inhibitor of autophagy may represent a way of sensitising 
resistant cells to MSA.  
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CHAPTER 6: Inhibition of histone deacetylase activity by selenium 
 
6.1 INTRODUCTION 
In quiescent cells, DNA exists in a condensed form, wrapped around histones. This 
condensed chromatin structure is less accessible to transcription factors and thus leads to 
a transcriptionally silent state. Chromatin condensation is facilitated by histone 
deacetylase (HDAC) enzymes, which remove acetyl groups from histones. In contrast, 
histone acetylation by histone acetyltransferase (HAT) enzymes leads to a more relaxed, 
‘open’ chromatin structure accessible to transcription factors. Thus, HDAC and HAT 
enzymes are involved in the regulation of gene transcription. In addition, they are 
involved in the regulation of a large number of non-histone proteins, including 
transcription factors, molecular chaperones and proteins involved in DNA repair, cell 
signalling and apoptosis. Protein acetylation can also affect the stability of proteins and 
protein-protein interactions (Glozak & Seto, 2007). Eighteen HDAC enzymes, grouped 
into four classes and two families, have been identified in humans. The members of the 
classical family comprise class I (HDAC 1, 2, 3 and 8), class II (HDAC 4, 5, 6, 7, 9, and 
10) and class IV (HDAC 11). They share similarities in structure and sequence and 
require a zinc ion for their deacetylase activity. Class III HDACs belong to the sirtuin 
family and have seven members, which do not share structural or sequence similarities to 
members of the classical family and require NAD
+
 for their activity. HDAC enzymes are 
not functionally redundant. Class I HDACs are localised mainly to the nucleus and are 
widely expressed, whereas class II HDACs are localised mainly to the cytoplasm but can 
move between the nucleus and cytoplasm and have tissue-specific expression. HDACs 
function as components of large multi-protein complexes, which are recruited to specific 
regions of DNA and regulate the expression of various genes (Minucci & Pelicci, 2006; 
Xu et al, 2007).  
 
As the list of non-histone protein targets of HDACs continues to grow, it has become 
clear that these HDAC substrates are involved in many critical cellular processes, 
including the regulation of cell proliferation, differentiation and death. In addition, 
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dysregulation and over-expression of HDACs have been found in many cancers 
(Halkidou et al, 2004; Wilson et al, 2006). Therefore, inhibition of HDAC activity as a 
target for cancer therapy has been an area of intensive investigation in recent years and a 
large number of compounds are at various stages of clinical development (Figure 6.1). 
The HDAC inhibitor (HDACi) vorinostat is the most advanced in clinical development 
and has been approved by the Federal Drug Administration (FDA) in the United States 
for the treatment of patients with cutaneous T-cell lymphoma (Mann et al, 2007). HDACi 
are derived from both natural and synthetic routes and the main structural classes are; 
short chain fatty acids (e.g. valproic acid), hydroxamic acids (e.g. vorinostat), cyclic 
tetrapeptides (e.g. depsipeptide), aminobenzamides (e.g. MS-275) and electrophilic 
ketones (e.g. α-ketoamides) (Xu et al, 2007).  HDACi are mainly directed against class I 
and II HDACs. Although HDACi currently in clinical trial show some differences in 
specificity for different HDAC isoforms, they are not particularly selective. Isoform 
specific HDACi are currently being developed (Marks & Xu, 2009). 
 
The mechanism of action of HDACi is complex as these agents affect multiple cellular 
pathways. Studies using DNA array have found that the transcription of up to 20% of 
expressed genes can be altered in cells exposed to HDACi with similar numbers of genes 
being up- and down-regulated (Glaser et al, 2003; Peart et al, 2005). Some of the 
demonstrated mechanisms of action include the induction of cell cycle arrest (Ungerstedt 
et al, 2005), activation of both the intrinsic (Shao et al, 2004) and extrinsic apoptotic 
pathways (Insinga et al, 2005), induction of both mitotic (Robbins et al, 2005) and 
autophagic cell death (Shao et al, 2004) and the accumulation of ROS (Ungerstedt et al, 
2005). In addition, inhibition of HDAC6 leads to the acetylation of HSP90, disrupting its 
chaperone function with consequences such as Akt dephosphorylation (Bali et al, 2005). 
HDAC6 is also a component of the aggresome, a cellular structure involved in the 
degradation of misfolded proteins, and thus HDAC inhibition disrupts this pathway 
(Kawaguchi et al, 2003). It appears normal cells, in contrast to tumour cells, are relatively 
resistant to the cytotoxic effects of HDACi (Insinga et al, 2005; Kim et al, 2003). As well 
as their single agent activity, HDACi have been shown to interact synergistically with a 
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number of conventional therapeutic drugs (Kim et al, 2003) and novel targeted agents 
(Yu et al, 2003) 
 
 
Figure 6.1 Simplified diagram representing the action of HDAC inhibitors.  
Histone acetylation, through the inhibition of HDAC activity, results a more ‘open’ 
chromatin structure accessible to transcription factors.  
 
 
Another potentially important property of HDACi is their ability to inhibit angiogenesis, 
which is required to promote tumour growth. Inhibition of new blood vessel formation is 
therefore a logical and promising target for cancer therapy. Angiogenesis is enhanced by 
hypoxia, which is commonly found in central regions of solid tumours. Hypoxia in turn 
regulates a number of transcription factors including HIF-1, a heterodimeric protein 
consisting of the subunits HIF-1α and HIF-1β. HIF-1β is constitutively expressed and not 
regulated by oxygen levels whilst HIF-1α expression is tightly regulated. Under 
normoxic conditions, certain post-translational modifications of HIF-1α and its 
interaction with VHL protein leads to its ubiquitination and proteasomal degradation. 
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However, under hypoxic conditions, HIF-1α is stabilised and moves from the cytoplasm 
to the nucleus of cells, where it heterodimerises with HIF-1β and initiates the 
transcription of a number of target genes. VEGF is one such gene whose expression is 
regulated by HIF-1α and is crucial in promoting angiogenesis (Semenza, 2003). HIF-1α 
has been found to be over-expressed in many tumour types (Zhong et al, 1999) and in 
some, but not all studies, has been associated with an inferior outcome (Birner et al, 
2000).  
 
Hypoxia has been found to increase the expression of HDAC proteins and it has been 
demonstrated that HDACs regulate HIF-1α activity through both indirect and direct 
mechanisms. Over-expression of HDACs leads to reduced expression of the two tumour 
suppressor proteins, p53 and VHL, which results in over-expression of HIF-1α and 
VEGF. HDAC inhibition was able to reverse this effect (Kim et al, 2001). HDAC 
inhibition can also result in HIF-1α degradation through a VHL-independent mechanism 
(Qian et al, 2006). In addition, the inhibition of HDAC6 results in acetylation of HSP90 
and thus degradation of its client protein, HIF-1α (Kong et al, 2006). A number of studies 
have also found that various HDACs directly interact with HIF-1α regulating its stability 
and transcriptional activity (Kato et al, 2004; Kim et al, 2007c). 
 
Se has recently been found to inhibit HDAC activity. This was first reported in the human 
prostate cancer cell line LNCaP, exposed to a non-cytotoxic concentration (1.5µmol/L) of 
the inorganic Se compound selenite for 7 days. Western blotting revealed that selenite 
increased levels of acetylated histone H3 without altering the levels of HDAC proteins 
and inhibition of HDAC activity was demonstrated using a cell-free fluorescence activity 
assay (Xiang et al, 2008). This study also found that selenite decreased the levels of 
methylated histone H3 and decreased general DNA methylation. In LNCaP cells, this led 
to the re-expression of two tumour suppressor genes known to be silenced by DNA 
hypermethylation. Thus, epigenetic modifications induced by Se may be important in 
explaining its anti-tumour effects. 
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The organic Se compounds, MSC and SLM, have also been reported to inhibit HDAC 
activity in human prostate and colon cancer cell lines (Lee et al, 2009a; Nian et al, 2009). 
However, it is the α-keto acid metabolites of MSC and SLM that have been shown to be 
responsible for this effect. As mentioned previously, the anti-cancer properties of organic 
Se compounds are thought to be due to the generation of methylselenol (Ip et al, 2000).  
Methylselenol is generated from MSC and SLM by the action of pyridoxal 5’-phosophate 
(PLP)-dependent β-lyases and γ-lyases respectively (Okuno et al, 2006; Suzuki et al, 
2007). However, in addition to undergoing β- and γ-elimination, MSC and SLM are 
substrates for aminotransferases and L-amino oxidases resulting in the formation of α-
keto acid analogues. Methylselenopyruvate (MSP) is formed by transamination and or/L-
amino acid oxidase reaction of MSC and α-keto-γ-methylselenobutyrate (KMSB) is 
formed from SLM. Both these compounds resemble butyrate, a known HDACi, in 
structure (Pinto et al, 2010). The studies in prostate and colon cancer cell lines found that 
direct exposure to MSP and KMSB, generated in vitro, resulted in a concentration-
dependent increase in histone H3 acetylation. The two studies examined different 
exposure times and in colon cancer cell lines, an increase in histone H3 acetylation was 
detected as early as 30 minutes and persisted for at least 48 hours, whereas in the prostate 
cancer cell lines, 5- and 24-hour exposure were examined and an increase in histone H3 
acetylation was detected by 5 hours. In addition, both metabolites were able to inhibit 
HDAC activity in a cell-free system with an EC50 for HDAC inhibition around 30-
50µmol/L. Much higher concentrations of MSC were required to demonstrate a similar 
effect, whereas SLM had no effect.  
 
The reason for the lack of HDAC inhibitory activity of SLM was studied in prostate 
cancer cells and it was found that the cells contain the enzyme glutamine transaminase K 
(GSK), which is an aminotransferase enzyme that can convert MSC to MSP. However, 
SLM is a very poor substrate for this enzyme and hence the active metabolite KMSB was 
not produced.  GSK is an enzyme that is widely distributed in mammalian tissue whereas 
enzymes that catalyse SLM to MSP such as glutamine transaminase L have tissue-
specific expression (Pinto et al, 2010). These results add support to the notion that MSC 
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is likely to be a better anti-cancer compound than SLM. In addition to HDAC inhibition, 
MSP and KMSB were found to inhibit cell growth, induce cell cycle arrest and induce the 
expression of the cell cycle regulator p21, a known target of HDAC inhibition. From the 
in vitro studies conducted to date, it is not possible to establish whether sufficient levels 
of α-keto acid metabolites can be achieved in vivo following the administration of either 
MSC or SLM. Most tissues do contain aminotransferases that could potentially convert, 
in particular, MSC to the active metabolite but further pharmacokinetic and 
pharmacodynamic studies are required to confirm this. L-amino oxidases may 
theoretically also play a role in vivo in generating MSP and KMSB from MSC and SLM 
and enzymatic activity has been found to be present in liver, kidney and lymphoid cells 
however, this requires further investigation (Pinto et al, 2010).  
 
In addition to naturally occurring Se compounds, two Se analogues modelled on the 
structure of vorinostat have been synthesised.  One compound contained a Se dimer and 
the other selenocyanide. It was assumed that within the cell, Se would be reduced to yield 
selenol (SeH) which would be the active species. Both compounds were found to be more 
potent in their HDAC inhibitory activity in a cell-free assay than vorinostat (Desai et al, 
2010).  
 
6.2 AIMS 
1) To determine whether MSA, a precursor of methylselenol, is able to inhibit HDAC 
activity in DLBCL cell lines.  
2) If HDAC inhibition is observed, then to investigate downstream targets.  
 
6.3 METHODS 
The DHL4, RL and SUD4 cell lines were exposed to a range of MSA (1-30µmol/L) and 
MSC (20-200µmol/L) concentrations for 2, 24 and 48 hours. In addition, PBMCs 
harvested from healthy volunteers were exposed to MSA (1-20µmol/L) for 24 hours. 
Western blotting was performed to determine changes in acetylation of histone H3 and α-
tubulin and expression of p21 (Chapter 2, sections 2.4 and 2.5). Cell lines were also 
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cultured under hypoxic conditions as described in Chapter 2 (section 2.1.2) and then 
exposed to MSA in order to investigate changes in HIF1α expression, by western blotting, 
and VEGF production, by an electrochemiluminescence assay (see below, section 6.3.3). 
The effect of MSA on HDAC activity in the DLBCL cell lines was investigated using a 
cell-free and cell-based activity assay (see below, section 6.3.1). SAHA was used as a 
positive control at a concentration of 1µmol/L and 3µmol/L 
 
6.3.1 Measurement of histone deacetylase activity 
HDAC activity was measured using the HDAC fluorimetric assay/discovery and the 
HDAC fluorimetric cellular activity kits (Biomol, Plymouth Meeting, PA, USA) 
according to the manufacturers’ instructions. Both assays are based on the Fluor de LysTM 
(Fluorogenic Histone deAcetylase Lysyl substrate/developer) system. The Fluor de Lys
TM 
substrate has an acetylated lysine side chain, so when it is incubated with a source of 
HDAC activity, deacetylation occurs and sensitises the substrate. When the Fluor de 
Lys
TM 
developer is subsequently added, a fluorescent signal is produced. The addition of 
an HDACi to the assay system inhibits deacetylation of the Fluor de Lys
TM 
substrate thus 
decreasing the fluorescent signal. The assays were performed in a white 96-well format 
plate with each condition performed in duplicate.  
 
For the fluorimetric assay/discovery assay, HeLa nuclear extract (provided in the assay 
kit) was used as the source of HDAC activity and Trichostatin A (TSA) was used as a 
positive control. The concentration of HeLa nuclear extract used per well was 3-4.5µg of 
protein. Each assay run had two blank wells (no HeLa extract added) and two control 
wells (no HDACi added). The HeLa extract, MSA (possible HDACi) and Fluor de Lys
TM 
substrate, at a final concentration of 50µmol/L, were added to each well and the plate 
incubated at room temperature for 30 minutes. After this, the Fluor de Lys
TM 
developer 
was added and the plate incubated at room temperature for a further 10-15 minutes. Of 
note, TSA, at a final concentration of 2µmol/L, was added to the developer to ensure that 
HDAC activity stopped when it was added to the wells. Fluorescence (excitation 350-
380nm, emission 440-460nm) was then measured on the POLARstar OPTIMA plate 
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reader (BMG Labtech). The values from the blank well were deducted from the test wells 
and the results expressed relative to the no inhibitor control. 
 
For the HDAC fluorimetric cellular activity assay, 1x10
5
 cells were plated in a 96-well 
plate. Different concentrations of MSA were added to the wells and TSA was used as a 
positive control. Plates were placed at 37°C in a cell culture incubator for 30 minutes. 
The Fluor de Lys
TM 
substrate, which is cell-permeable, was then added to each well at a 
final concentration of 200µmol/L. The plates were once again placed at 37°C in a cell 
culture incubator for a further 2 hours. For this assay, the Fluor de Lys
TM 
developer was 
diluted in cell lysis buffer (provided in the kit) and again TSA, at a final concentration of 
2µmol/L, was added to ensure that HDAC activity was stopped when the developer was 
added to the wells. After addition of the Fluor de Lys
TM 
developer, the plate was 
incubated at room temperature for a further 10-15 minutes. Fluorescence (excitation 350-
380nm, emission 440-460nm) was then measured on the POLARstar OPTIMA plate 
reader (BMG Labtech). The values from the blank well were deducted from the test wells 
and the results expressed relative to the no inhibitor control. 
 
6.3.2 Preparation of DHL4 cell lysates as a source of histone deacetylase activity 
4x10
6
 cells were pelleted by centrifugation at 210g for 6 minutes at room temperature and 
the supernatant discarded. Cells were then washed once in HBSS by centrifugation at 
210g for 6 minutes. 200µl of lysis buffer [0.394g Tris HCl, 0.146g NaCl, 0.357g MgCl2, 
25mls glycerol, 250µl Triton X-100 made up to 250ml with deionised water, pH set to 
7.4, stored at 4°C] was then added to the cell pellet and the samples sonicated in an 
ultrasonic bath (Grant, Cambridge, UK) for 10 minutes at room temperature. Following 
sonication, the sample was centrifuged at 20,800g for 10 minutes to remove insoluble 
cellular debris and the supernatant collected into a fresh tube. The cell lysate was diluted 
1:1 in the HDAC kit assay buffer and used immediately. Protein concentration of the 
lysate was determined using the BCA™ protein assay kit as described in Chapter 2 
(section 2.4.5).  
249 
 
6.3.3 Measurement of vascular endothelial growth factor 
VEGF levels in cellular supernatants were measured using the MSD
® 
cytokine assay 
(Meso Scale Discovery, Maryland, USA). This is an electrochemiluminescence assay. 
The custom-made 96-well microtitre plates have electrodes integrated into the bottom of 
the plate. The wells are pre-coated with one or several ‘capture antibodies’ which bind 
the cytokine of interest. The detection antibody has an electrochemiluminescent label 
(MSD SULFO-TAG™) which emits light at 620nm when electrochemically stimulated. 
The detection process is initiated at the electrode and only labels near the electrode are 
excited and detected.  The light emitted is detected using a SECTOR™ Imager (Meso 
Scale Discovery) which uses a charge coupled device camera.  
 
To measure VEGF levels, 25µl of the supernatant was added to each well. Samples were 
added in duplicate. The plate was sealed with an adhesive cover and incubated at room 
temperature for 1 hour with vigorous shaking (1000rpm). Following this, 25µl of the 
detection antibody solution (1µg/ml) was added to each well and the plate again 
incubated at room temperature for 1 hour with vigorous shaking. The plate was then 
washed 3 times with PBS and 150µl of 2x read buffer was added to each well. The plate 
was then analysed on a SECTOR™ Imager. A standard curve was prepared from the 
cytokine calibrator solution provided with the assay kit. A range of 2.4pg/ml to 
1000pg/ml was used. An example of the standard curve generated is shown below 
(Figure 6.2, r=0.99). 
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Figure 6.2 An example of the standard curve obtained for vascular endothelial growth 
factor using the MSD
 
cytokine assay. 
 
 
6.4 RESULTS 
6.4.1 The effect of MSA on protein acetylation 
A preliminary experiment was conducted in DHL4 cells to establish whether MSA 
induced protein acetylation. Figure 6.3 shows that MSA increased the acetylation of 
histone H3 at 24 hours. With 10µmol/L MSA, the effect was lost by 48 hours, whereas 
with 30µmol/L, the increase was sustained up to 48 hours. MSA also increased the 
acetylation of α-tubulin but to a lesser degree than histone H3. In addition, MSA induced 
the expression of the cyclin-dependent kinase inhibitor p21, a known target of HDAC 
inhibition. p21 expression was increased at 24 hours but by 48 hours the effect was less 
marked (Figure 6.3).                       
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Figure 6.3 Protein acetylation and p21
 
expression in DHL4 cells exposed to MSA and 
SAHA.                                                        
  
 
Further time- and concentration-dependent experiments were conducted in SUD4, RL 
and DHL4 cells. Similar results were obtained in all three cell lines when exposed to 
MSA 1-30µmol/L for 2 and 24 hours (Figure 6.4). MSA concentrations as low as 
1µmol/L increased the acetylation of histone H3 and α-tubulin as early as 2 hours, and 
this was sustained until 24 hours. However, the induction of acetylated histone H3 was 
greater at 24 hours than at 2 hours, whereas the reverse was true for acetylated α-tubulin. 
In addition, MSA induced the expression of p21 in RL and SUD4 cells (Figure 6.5). 
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Figure 6.4 Representative western blots of protein acetylation in (a) RL, (b) SUD4 (c) 
DHL4 cell lines exposed to MSA for 2 and 24 hours. These experiments were performed 
twice.                                       
 
Figure 6.5 p21 expression (a) SUD4 and (b) RL cells exposed to MSA and SAHA 
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6.4.2 The effect of MSA on histone deacetylase activity 
The effect of MSA on HDAC activity was investigated. To validate the assay kit, TSA, a 
known HDACi (provided in the assay kit) was first tested. TSA showed a concentration-
dependent inhibition of Fluor de Lys
TM
 substrate deacetylation by HeLa nuclear extract 
after 30 minutes incubation (Figure 6.6). 
 
Figure 6.6 TSA inhibition of Fluor de Lys
TM 
substrate deacetylation by HeLa nuclear 
extract. Data points are the mean+/-SD of 5 separate experiments. 
 
 
However, when MSA was incubated with HeLa nuclear extract for 30 minutes, there was 
no inhibition of Fluor de Lys
TM
 substrate deacetylation, suggesting that MSA, in this cell-
free assay system, was not able to inhibit HDAC activity (Figure 6.7). 
 
Figure 6.7 Effect of MSA on Fluor de Lys
TM 
substrate deacetylation by HeLa nuclear 
extract. Data points are the mean+/-SD of 3 separate experiments. 
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Therefore, the effect of MSA on HDAC activity was tested in a cell-based assay. In this 
assay, MSA was able to inhibit HDAC activity in a concentration-dependent manner in 
all three cell lines after 2-hour exposure (Figure 6.8). 30μmol/L MSA in all three cell 
lines inhibited HDAC activity by around 50%. This suggests that cellular metabolism of 
MSA is required to generate an active metabolite.  
 
 Figure 6.8 Deacetylation of Fluor de Lys
TM 
substrate in (a) DHL4, (b) SUD4 and (c) RL 
cell lines incubated with MSA or TSA for 2 hours. Data points are the mean+/-SD of at 
least 3 separate experiments except in the SUD4 cells where experiments were only 
performed in duplicate. *p<0.05. p values are comparisons with control.  
 
 
To confirm that HDAC inhibition did not occur in the cell-free assay even with prolonged 
exposure to MSA, or using an alternative HDAC source, MSA was incubated with HeLa 
nuclear extract and DHL4 cell lysates for 2 hours. Initially, to confirm the protein 
concentration of DHL4 cell lysate that produced the same fluorescence signal as the 
HeLa nuclear extract, different protein concentrations were used in the assay (Figure 6.9). 
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8µg of protein produced an equivalent fluorescence signal and therefore this 
concentration was used in the subsequent experiments 
 
Figure 6.9 Fluorescence signal produced after incubation of Fluor de Lys
TM 
substrate 
with different concentrations of DHL4 cell lysate compared with HeLa nuclear extract. 
AFU=arbitrary fluorescence units. 
 
When MSA was incubated with either HeLa nuclear extract or DHL4 cell lysate for 2 
hours there was no inhibition of Fluor de Lys
TM 
substrate deacetylation. This was in 
contrast to incubation with TSA used as a positive control (Figure 6.10). 
 
Figure 6.10 Deacetylation of Fluor de Lys
TM 
substrate by HeLa nuclear extract and 
DHL4 cell lysate after incubation with MSA or TSA. Data points are the mean+/-SD of 2 
separate experiments. 
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To further investigate whether a cellular metabolite of MSA was responsible for the 
observed HDAC inhibitory effect, medium from DHL4 cells incubated with MSA for 2 
hours was tested in the cell-free HDAC assay kit. Medium from DHL4 cells incubated 
with 10µmol/L MSA was not able to inhibit Fluor de Lys
TM 
substrate deacetylation but 
medium from DHL4 cells incubated with 30µmol/L MSA had a small but significant 
inhibitory effect of 20.6% (±4.7; Figure 6.11). This supports the hypothesis that a cellular 
metabolite of MSA is responsible for the effect seen.  
 
  
Figure 6.11 Deacetylation of Fluor de Lys
TM
 substrate by HeLa nuclear extract after 
incubation with cell medium from DHL4 cells exposed to MSA. Data points are the 
mean+/-SD of 3 separate experiments. *p=0.02 is a comparison with control.  
  
 
6.4.3 The effect of MSC on protein acetylation 
MSC will be the Se compound used in the forthcoming clinical trial and therefore its 
effect on protein acetylation was also investigated. RL and DHL4 cell lines were exposed 
to EC50 and higher than EC50 concentrations of MSC for 24 hours (EC50 values of MSC 
shown in Chapter 4, Table 4.2). MSC increased the acetylation of histone H3 and α-
tubulin and the expression of p21 in a concentration-dependent manner, suggesting that 
MSC also inhibits HDAC activity (Figure 6.12). A higher than EC50 concentration was 
required in RL cells to observe this effect. 
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Figure 6.12 Protein acetylation and p21 expression in RL and DHL4 cell lines exposed 
to MSC for 24 hours. RL cells were also exposed to SAHA 3µmol/L for 24 hours 
 
 
6.4.4 Effect of MSA on HIF-1α expression and vascular endothelial growth factor 
production 
The effect of MSA on HIF-1α expression and VEGF production was investigated after 
culture of RL and DHL4 cells under hypoxic conditions for 24 hours. Western blotting 
for HIF-1α in nuclear extracts showed that hypoxia induced the expression of HIF-1α but 
this induction was suppressed by MSA (Figure 6.13). Hypoxia also increased the 
production of VEGF by RL and DHL4 cell lines, but this was also inhibited by MSA in a 
concentration-dependent manner (Figure 6.14) 
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Figure 6.13 HIF-1α expression in (a, b) DHL4 cells and (c, d) RL cell lines exposed to 
hypoxia and MSA. Western blot and densitometry combining 2 separate experiments; 
data points are mean+/-SD. 
 
 
Figure 6.14 Vascular endothelial growth factor levels in the supernatant of (a) DHL4 and 
(b) RL cell lines exposed to hypoxia and MSA. Data points are the mean+/-SD of 2 
separate experiments. Values are expressed relative to control and are corrected for cell 
number (1x10
6
 cells). 
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6.4.5 Acetylation of Histone H3 in peripheral blood mononuclear cells 
The effect of MSA in PBMCs from 3 individuals was investigated. Concentrations of 
5µmol/L and above increased the acetylation of histone H3 (Figure 6.15). Unexpectedly, 
the expression of total histone H3 also increased. 
 
 
                                                         
Figure 6.15 Histone H3 acetylation in peripheral blood mononuclear cells exposed to 
MSA for 24 hours. 
 
 
6.5 DISCUSSION 
These experiments have demonstrated that MSA can inhibit HDAC activity in three 
DLBCL cell lines. MSA increased the acetylation of histone H3 and α-tubulin in a 
concentration-dependent manner and the effect was apparent at concentrations as low as 
1µmol/L. The pattern of protein changes was similar in all three cell lines despite the fact 
that RL and SUD4 cells are relatively sensitive and DHL4 cells relatively resistant to the 
cytotoxic effects of MSA. The increase in acetylated α-tubulin was greater at 2 hours than 
24 hours and the increase in acetylated histone H3 greater at 24 hours. Acetylation of α-
tubulin occurs as a result of the inhibition of HDAC6, a class II HDAC. This suggests 
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that MSA inhibits both class I and II HDACs but the time-course differs with an earlier 
effect on class II HDACs. MSA also induced the expression of p21, a cyclin-dependent 
kinase inhibitor, which is a well known target of HDAC inhibition. This occurs 
independently of p53 and is due to acetylation of histones in its gene promoter (Richon et 
al, 2000). The induction of p21 would be expected to result in cell cycle arrest, however, 
in these DLBCL cell lines MSA does not induce cell cycle changes (Last et al, 2006).    
 
The HDAC inhibitory action of MSA was confirmed by an HDAC activity assay. 
However, in the cell-free assay, MSA was not able to inhibit the HDAC activity of HeLa 
nuclear extract.  HDAC inhibition was only apparent when MSA was exposed to cells 
and activity measured in a cell-based assay. This is likely to be due to the intracellular 
activation of MSA to methylselenol, which is the metabolite thought to be responsible for 
its anti-tumour effect. The metabolism of MSA also results in the production of other 
reactive metabolites such as dimethylselenide and dimethyldiselenide (Juliger et al, 
2007); this will be discussed further in Chapter 9. Medium from DHL4 cells exposed to 
10µmol/L and 30µmol/L MSA, which in the cellular activity assay produced 34% and 
50% inhibition HDAC activity respectively, was used in the cell-free assay. Only 
medium from DHL cells exposed to 30µmol/L MSA inhibited HDAC activity in the 
HeLa nuclear extract and only by 21% (p=0.02). This is probably due to the volatile 
nature of MSA metabolites which are not retained in the cell medium. These novel 
findings suggest that it is not only the α-keto acid metabolites of organic Se compounds 
that are capable of inhibiting HDAC activity but that the volatile methylated species are 
likely to play a role. For completeness, it would have been useful to confirm that MSA 
does not decrease the expression of HDAC enzymes at the protein level, which could also 
explain the decrease in HDAC activity. However, this is less likely, as changes in protein 
translation usually take longer than 2 hours. In addition, further time-course experiments 
are required to establish the duration of HDAC inhibition. This could include using class-
specific HDAC assays to investigate the time-course of class I and class II HDAC 
inhibition.  
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MSC was also found to increase the acetylation of histone H3 and α-tubulin in two 
DLBCL cell lines, however, high concentrations were required. The EC50 of RL cells to 
MSC at 72 hours was 22µmol/L but concentrations higher than this were required to 
induce protein acetylation. The DHL4 cell line has a higher EC50 at 72 hours of 56µmol/L 
and exposure to 50µmol/L MSA did induce protein acetylation. Western blots were only 
performed at one time point, 24 hours, and it may be that if an earlier time point had been 
studied a greater effect may have been seen. However, these results are similar to those of 
studies in colon and prostate cancer cells in which western blotting was performed in 
cells exposed to 50µmol/L and 200µmol/L MSC for 24 hours (Lee et al, 2009a; Nian et 
al, 2009). As previously discussed, metabolism of MSC to its active metabolites 
methylselenol and MSP requires β-lyases and aminotransferases respectively which are 
likely to be present at low levels in tumour cells.  
 
HDAC inhibition as a therapeutic strategy in lymphoma has proven to be a useful one, 
although it appears that T-cell lymphomas are more sensitive than B-cell lymphomas to 
HDAC inhibition. The best results have been seen in patients with cutaneous T-cell 
lymphoma (CTCL) for which vorinostat now has FDA approval.  Thirty-three patients 
with refractory CTCL, who had received a median of 5 previous treatments, took part in a 
phase II trial of vorinostat. The RR rate was 24% with 8 patients achieving a PR. In 
addition, 11 patients had improvement in their symptoms, stable disease or both (Duvic et 
al, 2007). In DLBCL, the response to HDAC inhibition has been less impressive. A phase 
II study of vorinostat in 18 patients with relapsed DLBCL had only 2 responders (1 CR 
and one stable disease) and the remaining 16 patients discontinued treatment due to 
progressive disease (Crump et al, 2008). Although these results are disappointing, it may 
be, as with other targeted therapies, that combination with conventional chemotherapy, or 
with other novel agents may be required to achieve better responses.  
 
There is a scientific rationale for the use of HDACi in DLBCL. It has been demonstrated 
by IHC staining that class I HDACs are over-expressed in tumours when compared with 
normal lymphoid tissue. There is, however, some discrepancy in the data about the 
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expression of class II HDACs, particularly HDAC6, with one study showing that it is 
very rarely expressed in primary tumours (Gloghini et al, 2009) and another showing that 
HDAC6 is expressed (Marquard et al, 2009). Furthermore, in the latter study, patients 
with moderate and high expression had a better outcome than patients with low 
expression. Class I HDACs also appear to be widely expressed in other lymphoid 
tumours including Hodgkin lymphoma which, in clinical trials, is more responsive than 
DLBCL to the HDACi MGCD0103 (Younes et al, 2007).  HDAC expression in tumours 
does not however appear to be a good predictive marker for treatment response to 
HDACi (Gloghini et al, 2009). An additional role for HDAC inhibition in DLBCL is that 
acetylation of the transcriptional repressor, Bcl-6, inhibits its function (Bereshchenko et 
al, 2002). This protein is frequently involved in translocations and over-expressed in 
DLBCL thus being implicated in the pathogenesis of the disease (Swerdlow SH, 2008).   
 
HDAC inhibition by MSA requires relatively high concentrations, with 30µmol/L for 2 
hours resulting in 40-50% inhibition of activity across the three cell lines tested. HDACi 
currently in clinical trials inhibit activity in vitro at nanomolar concentrations (Khan et al, 
2008). However, this Se concentration is potentially clinically achievable. In the phase 
I/II dose escalation study of SLM in patients with solid tumours, the highest dose level of 
7200µg twice daily resulted in a mean plasma Se concentration after 8 days of 31µmol/L 
(Fakih et al, 2008). In the forthcoming clinical trial at SBH, the aim will be to achieve a 
plasma Se concentration of 20µmol/L. Despite the relatively high concentration required 
to inhibit HDAC enzyme activity by 50%, there is evidence (at the protein level) of an 
effect at concentrations as low as 1µmol/L, which resulted in increased acetylation of 
histone H3 and α-tubulin. However, in PBMCs, ≥5µmol/L MSA was required to increase 
acetylation of histone H3. It would be valuable to study an earlier time-point in PBMCs, 
such as 2-hour exposure, in case low concentrations of MSA increase protein acetylation 
early without sustaining the response to 24 hours. Acetylation of histone H3 in PBMCs at 
24 hours is concentration-dependent between 5-20µmol/L and therefore may serve as a 
useful biomarker of Se activity in the forthcoming clinical trial. Histone acetylation in 
PBMCs has already been successfully used as a biomarker in clinical trials of HDACi, 
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however, in most studies this does not appear to be a predictive marker of response 
(Garcia-Manero et al, 2008). 
 
Se may have a role in inhibiting angiogenesis and as described previously in Chapter 1, 
this has been extensively demonstrated in solid tumour xenograft models (Bhattacharya 
et al, 2008; Yin et al, 2006). In DLBCL cell lines exposed to hypoxia, MSA was able to 
suppress the induction of HIF-1α, demonstrated by western blotting of nuclear extracts, 
and the production of VEGF, demonstrated by an electrochemiluminescence assay of 
cellular supernatants. This occurred at similar concentrations to those required to inhibit 
HDAC activity and at concentrations that are clinically achievable. HDACi appear to 
target tumour angiogenesis and in addition to the pre-clinical data, there are clinical data 
from the phase II trial of vorinostat in CTCL to support this (Duvic et al, 2007). Paired 
skin biopsies of lymphoma lesions before and after vorinostat therapy showed a 
significant reduction in microvessel density in patients who responded to treatment. 
Although the role of hypoxia and angiogenesis in tumour progression is better established 
in solid tumours, these factors may also be important in lymphoma.  
 
The most important mediator of angiogenesis is VEGF, which has several family 
members, including VEGF-A –B –C and –D, that interact with receptor tyrosine kinases 
VEGFR1 and VEGFR2. VEGF-A is produced by tumours cells and surrounding stromal 
cells, promoting angiogenesis through interaction with receptors on endothelial cells and 
bone marrow-derived endothelial precursors. In addition, VEGF-A can interact with 
receptors on tumour cells, resulting in cell survival and proliferation in an autocrine 
manner. Tumour-associated stromal cells also produce a number of other pro-angiogenic 
factors (Ferrara et al, 2003). Regarding DLBCL, it has been demonstrated that the tumour 
cells express both VEGF and VEGF receptors and the degree of VEGF expression 
correlates with the receptor expression, suggesting that autocrine and paracrine VEGF 
signalling may be important in lymphoma progression (Gratzinger et al, 2007). Targeting 
VEGF receptors was found to inhibit tumour growth in a xenograft model of DLBCL and 
both paracrine and autocrine signalling was shown to be important through the use of 
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species-specific VEGF receptor antibodies (Wang et al, 2004). The tumour 
microenvironment is important in lymphoma progression.  A study analysing gene 
expression in tumour samples from patients with DLBCL found that the gene expression 
signature of the non-malignant cells influenced survival, such that tumours expressing 
genes related to angiogenesis, also shown to be associated with increased tumour blood-
vessel density, conferred an inferior prognosis (Lenz et al, 2008a). When microvessel 
density of DLBCL samples has been studied in isolation, there have been conflicting data 
as to whether the degree of vascularity correlates with tumour VEGF expression and also 
outcome (Gratzinger et al, 2007; Gratzinger et al, 2008; Jorgensen et al, 2007).  Most 
studies have shown that serum VEGF levels are increased in patients with NHL 
compared to controls (Passam et al, 2008) but whether the degree of elevation correlates 
with outcome is unclear, with some studies reporting an inferior outcome in patients with 
high serum VEGF levels at diagnosis (Salven et al, 2000) whereas others have not found 
an association (Giles et al, 2004). However, most studies have included patients with 
different types of B-cell NHL and therefore the impact on specific NHL subtypes needs 
to be further investigated.    
 
There is increasing interest in targeting angiogenesis in lymphoma and bevacizumab, the 
humanised monoclonal antibody targeting VEGF-A, has been used in clinical trials. A 
phase II trial of single agent bevacizumb in 52 patients with recurrent DLBCL and MCL 
resulted in disease stabilisation in 25% of patients with a median time to progression of 
5.2 months (Stopeck et al, 2009). These results are not particularly impressive but single 
agent therapy in patients with chemo-resistant DLBCL is unlikely to yield significant 
responses given the numerous pathogenic pathways involved. Therefore, bevacizumab in 
being investigated in combination with ‘R-CHOP’ in phase II/III trials. The safety and 
feasibility of the combination has already been established (Ganjoo et al, 2006). 
 
The role of HIF-1α in lymphoma has not been extensively investigated but from the 
available data it appears that about 60% of tumours from patients with DLBCL express 
HIF-1α, with most exhibiting moderate to high expression and no difference in 
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expression based on the cell of origin assessed by IHC (Evens et al, 2008; Evens et al, 
2010). The one study to investigate the prognostic significance of HIF-1α expression 
found it to be an independent predictor of good progression-free and OS in patients 
treated with ‘R-CHOP’ but not in those who received  ‘CHOP’ without rituximab (Evens 
et al, 2010). Correlation with gene expression revealed that increased HIF-1α gene 
expression was associated with expression of genes forming part of the favourable 
stromal-1 gene signature as defined by Lenz et al (Evens et al, 2010; Lenz et al, 2008a). 
This study suggests that rituximab has a beneficial effect on HIF-1α or its downstream 
target genes. Further studies are required to fully understand this interaction. 
 
Given that MSA can inhibit the induction of HIF-1α expression and the production of 
VEGF by DLBCL cell lines, it may have the ability to inhibit angiogenesis and other 
downstream targets of HIF-1α in vivo. However, the mechanism by which MSA inhibits 
HIF-1α and VEGF in DLBCL cell lines is not clear. Although MSA has been found to be 
an HDACi and HDACi have anti-angiogenic properties, these two observations have not 
been mechanistically linked by the current experimental data. In solid tumours, MSA and 
MSC have been reported to inhibit HIF-1α through effects on PHDs (Chintala et al, 
2010). In order to establish whether MSA inhibits HIF-1α in DLBCL cell lines through 
HDAC inhibition, the experiment to perform would be to over-express HDACs and see 
whether this prevented the inhibition of HIF-1α expression. In addition, for the purposes 
of the forthcoming clinical trial, it may be possible to use plasma VEGF levels as a 
biomarker of Se activity.  
 
In summary, this work has demonstrated the novel finding that a cellular metabolite of 
MSA is able to inhibit HDAC activity in DLBCL cell lines. MSA also inhibited the 
induction of HIF-1α expression and the production of VEGF in these cell lines. In 
addition, two potential biomarkers of Se activity have been identified that may be of 
value in the forthcoming clinical trial; acetylated histone H3 in PBMCs and plasma 
VEGF levels. 
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CHAPTER 7: The activity of methylseleninic acid in non-malignant 
cells 
 
7.1 INTRODUCTION 
There is ample evidence in the literature supporting a cyto-protective role for Se. Of 
particular interest to cancer medicine is its ability to protect normal cells from 
chemotherapy-and radiation-induced toxicity, an effect that has been demonstrated in 
vitro (Rafferty et al, 2003a; Santos & Takahashi, 2008), in xenograft models of human 
cancer (Cao et al, 2004) and in clinical trials (Muecke et al, 2010). However, the exact 
mechanism by which Se protects normal cells is not clear and it is apparent that different 
chemical forms act by different mechanisms. Evidence for the cyto-protective role of Se, 
and potential mechanisms by which it exerts this effect, have already been discussed in 
Chapter 1, but some additional points relating to organic Se compounds will be 
summarised here. 
 
A number of studies have demonstrated that Se, mainly in the form of SLM, is able to 
activate DNA repair mechanisms when cells are exposed to DNA-damaging agents and 
that this is p53-dependent. p53 is mutated and non-functional in a large proportion of 
human cancers. In the absence of functional p53, Se is unable to activate DNA repair 
mechanisms, leaving cells vulnerable to apoptosis (Fischer et al, 2007; Seo et al, 2002a; 
Seo et al, 2002b). SLM can also activate p53 by a redox mechanism in the absence of 
DNA damage, requiring the redox factor Ref-1 (Seo et al, 2002a). In addition, Ref-1 has 
also been found to be important in the activation of p53 in response to DNA damage 
(Jeong et al, 2009). Thus the functional status of p53 may be one reason for the observed 
differential effect of Se in malignant and non-malignant cells. However, this may not be 
as relevant in haematological cancers because, compared to solid tumours, p53 mutations 
are less common. The frequency of p53 mutations in lymphoid malignancies at diagnosis 
has been reported to be 12.5% (Newcomb, 1995) although in some lymphoma subtypes 
this is higher, with one study in ‘aggressive’ B-cell lymphomas reporting a frequency of 
22% (Ichikawa et al, 1997).  
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Other mechanisms that may be important include differential responses of malignant and 
non-malignant cells to cellular stress and, as discussed in Chapter 5, Se can induce ER 
stress. It has been proposed that because malignant cells, through the nature of the tumour 
environment, are already under a degree of cellular ‘stress’, any additional ‘stress’, such 
as protein misfolding in the case of Se, is tolerated less well, making them more 
susceptible to apoptosis. In contrast, normal cells are exposed to less ‘stress’ and 
therefore, in response to ER stress induced by Se, can mount a survival response and 
have a higher threshold for apoptosis (Zu et al, 2006).  
Another cellular stress response pathway that may be differentially modulated by Se is 
the Nrf2-Prx1 pathway. As discussed in Chapter 1, it has been suggested that differences 
in oxygen conditions between the environment of normal and malignant cells may affect 
the cells’ response to Se, with inhibition of the Nrf2-Prx1 pathway in tumour cells, thus 
promoting apoptosis, but induction of the  pathway in normal cells, thus promoting cell 
survival (Kim et al, 2007e).  In addition to cellular stress-response pathways, other 
survival pathways may be activated by normal cells in response to Se. A study examining 
the effect of MSA on tumour stage-specific mouse prostate cell lines found that tumour 
cells dephosphorylated Akt and Erk1/2 in response to MSA but that the non-tumourigenic 
cell line increased phosphorylation of Akt and Erk1/2, thus promoting cell survival 
(Gonzalez-Moreno et al, 2007).  
The response of non-malignant cells to MSA has been investigated in the experiments 
presented in this chapter, with the aim of determining further mechanisms by which Se 
may protect these cells from chemotherapy-induced toxicity. The concentration of MSA 
used, particularly in PBMC experiments, was determined by the fact that in the 
forthcoming clinical trial in patients with DLBCL the aim is to achieve a plasma Se 
concentration of 20μM. This concentration was determined from the xenograft study by 
Cao et al, in which plasma Se concentrations of >14μmol/l and >23μmol/l were required 
to achieve maximum protection against chemotherapy-induced toxicity and potentiation 
of anti-tumour activity, respectively. These concentrations were established following 
SLM administration and it is likely that lower plasma Se concentrations will be adequate 
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following MSC administration given its more efficient conversion to methylselenol 
(Azrak et al, 2004). 
7.2 AIMS 
1) To investigate the activity of MSA in non-malignant cells. 
2) To investigate the effect of combining MSA with cytotoxic agents in non-malignant 
cells. 
3) To investigate mechanisms of Se-resistance in non-malignant cells. 
 
7.3 MATERIALS AND METHODS 
In these experiments, normal cells (keratinocytes, fibroblasts and PBMCs) were exposed 
to a range of MSA concentrations for various time points. Keratinocytes and fibroblasts 
were also exposed to 4-HC, the active metabolite of cyclophosphamide, and doxorubicin. 
Trypan blue exclusion and the ATP assay (described in Chapter 2, sections 2.3.1 and 
2.3.2) were used to assess cytotoxicity. The results of the ATP assay were expressed 
relative to the control value and were analysed using the GraphPad PRISM
®
 software 
(version 5.03). The drug activity was summarised to an EC50 value which was calculated 
using a sigmoidal concentration-effect model with variable slope. 
 
Western blotting was performed to identify protein changes induced by MSA (described 
in Chapter 2, sections 2.4 and 2.5). The effect of MSA on cell cycle distribution in 
keratinocytes was determined by flow cytometric analysis of cells stained with PI 
(described in Chapter 2, section 2.7). In addition, the effect of MSA on NF-κB activity in 
PBMCs was determined using an ELISA kit. 
 
7.3.1 Cell lines 
Normal human keratinocytes immortalised by transfection of hTERT, the catalytic 
subunit of the enzyme telomerase, were purchased from Dr J. Rheinwald (Brigham and 
Women’s Hospital and Harvard Skin Disease Centre, Harvard Medical School, MA, 
USA) (Dickson et al, 2000). These were maintained in keratinocyte serum-free medium 
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(GIBCO
®
 Invitrogen™) supplemented with bovine pituitary extract (final concentration 
25μg/ml), 1% penicillin (10,000units/ml) and streptomycin (10,000μg/ml), epidermal 
growth factor (final concentration 0.2ng/ml) and 0.3mM calcium chloride (all 
supplements from Invitrogen™). The HFFF2 cell line (human foetal foreskin fibroblast) 
was a kind gift from Dr J. Marshall (Institute of Cancer, Barts Cancer Centre, London, 
UK). These cells were maintained in Dulbecco’s Modified Eagle Medium with high 
glucose (4500mg/l) and GlutaMax™ (GIBCO® Invitrogen™) supplemented with 7.6mls 
of GlutaMax™ (GIBCO® Invitrogen™),1% penicillin (100units/ml) and streptomycin 
(100μg/ml) and 10% foetal calf serum (Sigma-Aldrich). Both cell lines were kept at 37°C 
in a humidified atmosphere and 5% CO2.  Cell medium was changed every 2-3 days and 
cells were passaged once 70% confluence was reached. Cells were detached using 
trpsin/EDTA solution (Trypsin 0.05%, EDTA 0.01% in PBS, GIBCO
®
 Invitrogen™). 
 
7.3.2 Chemicals 
Recombinant tissue necrosis factor alpha (TNFα; R&D systems, Europe, Ltd) was 
supplied as a lyophilized sample. This was reconstituted in PBS to prepare a stock 
solution of 100µg/ml, which was stored at -20°C. Prior to use, it was further diluted in 
cell culture medium to obtain a final concentration of 10ng/ml.  
 
7.3.3 NF-κB activity in peripheral blood mononuclear cells treated with MSA 
Activated NF-κB in PBMCs treated with MSA was measured by ELISA (enzyme-linked 
immunosorbent assay) using the TransAM™ NF-κB p65 transcription factor assay kit 
(Active Motif North America, Carlsbad, CA), according to the manufacturers’ 
instructions. Six µg of protein from cell lysates was incubated in 96-well plates on which 
the oligonucleotide containing the NF-κB consensus (5’-GGACTTTCC-3’) binding site 
had been immobilised. NF-κB binding to the target was detected by incubation with a 
primary antibody to the p65 subunit that recognised an epitope on p65 that is accessible 
only when NF-κB is activated and bound to its target DNA. An anti-IgG-horseradish 
peroxidise-conjugated secondary antibody was then added and the reaction was 
quantified by adding a chemiluminescent reagent and reading luminescence at a 
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wavelength of 450nm on the POLARstar OPTIMA plate reader (BMG Labtech). For 
each experiment a negative and positive control was used. The assay kit provided a 
positive control in the form of Jurkat nuclear extract. In addition, to monitor specificity of 
the assay, a wild-type consensus oligonucleotide was provided as a competitor for NF-κB 
binding that prevented NF-κB in the experimental sample from binding. The effect of 
MSA on NF-κB activation by TNFα was also studied. All samples and controls were 
analysed in duplicate and results were expressed relative to the control values obtained 
for untreated PBMCs. 
 
 
7.4 RESULTS 
7.4.1 The activity of MSA in three in vitro models of normal cells 
The activity of MSA was investigated in PBMCs, hTERT-immortalised keratinocytes 
and the HFFF2 cell line. Previously published results from our laboratory have shown 
that PBMCs are relatively resistant to the cytotoxic effect of MSA with an EC50 at 72 
hours of 84.2μmol/l (Juliger et al, 2007). To confirm that the concentrations of MSA to 
be used in subsequent PBMC experiments were not cytotoxic, cell viability of PBMCs 
exposed to 5μmol/L, 10μmol/L and 20μmol/L MSA for 24 and 48 hours was determined 
by trypan blue exclusion. Figure 7.1 shows that at these concentrations there was minimal 
toxicity to the cells, with 20μmol/L MSA at 48 hours reducing cell viability by 12.3% (± 
3.0; p=0.02).  
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Figure 7.1 Perpipheral blood mononuclear cell viability determined by trypan blue 
exclusion after exposure to MSA. Data points are mean+/-SD of at least 3 separate 
experiments. *p<0.05. p values are a comparison with control. 
 
The activity of MSA in keratinocytes and HFFF2 cells is shown in Figure 7.2. Both cell 
lines were very sensitive to the cytotoxic effect of MSA as determined by the ATP assay. 
For keratinocytes the EC50 at 48 hours was 2.4μmol/L (95% CI 2.2-2.6μmol/L) and for 
HFFF2 cells was 7.2μmol/L (95% CI 6.0-8.7μmol/L). 
 
Figure 7.2 EC50 concentration-effect curves following 48-hour exposure to increasing 
concentrations of MSA in (a) Keratinocytes and (b) HFFF2 cells. Data points are the 
mean +/- SD of three separate experiments.   
272 
 
7.4.2 The activity of chemotherapeutic agents in keratinocytes and HFFF2 cells 
To establish whether keratinocytes and HFFF2 cells were sensitive to other cytotoxic 
agents or whether this was a specific effect of MSA, cells were exposed to doxorubicin 
and 4-HC for 48 hours. Figure 7.3 shows that keratinocytes were relatively sensitive to 
both drugs. The 48-hour EC50 for 4-HC was 13.2μmol/L (95% CI 11.6-15.0μmol/L) and 
doxorubicin was 214nmol/L (95% CI 179.5-255.2nmol/L) as determined by the ATP 
assay. HFFF2 cells were more resistant than the keratinocytes to chemotherapeutic agents 
with 20μmol/L 4-HC only reducing cell viability relative to control by 19.3% (±7.3). The 
48-hour EC50 for doxorubicin was 429.9nmol/L (95% CI 297.8-620.4nmol/L). 
 
Figure 7.3 EC50 concentration-effect curves following 48-hour exposure to increasing 
concentrations of 4-HC and doxorubicin in (a, b) Keratinocytes and (c, d) HFFF2 cells. 
Data points are the mean +/- SD of three separate experiments.   
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As a comparison, the activity of doxorubicin and 4-HC in the RL cell line is shown in 
Figure 7.4. Although this has been performed using the Guava
®
 viacount assay, it can be 
seen that the activity of the two chemotherapeutic agents in RL cells is similar to that 
seen in the keratinocytes and HFFF2 cells with the exception of 4-HC in HFFF2 cells. 
For RL cells, the 48-hour EC50 values for 4-HC and doxorubicin were 9.1μmol/L (95% 
CI 7.2-11.6μmol/L) and 314.4nmol/L (95% CI 254.7-388.2nmol/L) respectively. 
 
Figure 7.4 EC50 concentration-effect curves following 48-hour exposure to increasing 
concentrations of (a) 4-HC and (b) Doxorubicin in the RL cell line. Data points are the 
mean +/- SD of three separate experiments.   
 
7.4.3 Cell cycle analysis in keratinocytes exposed to MSA 
MSA does not induce cell cycle arrest in lymphoma cell lines. To determine whether this 
is the case in normal cells, the effect of MSA on cell cycle distribution in keratinocytes 
was investigated. Figure 7.5 shows that exposure to increasing concentrations of MSA for 
24 and 48 hours increased the sub-G1 apoptotic population but did not result in cell cycle 
arrest. 
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Figure 7.5 Cell cycle analysis of keratinocytes exposed to MSA (a) 24-hour exposure (b) 
Representative histogram of 24-hour exposure (c) 48-hour exposure (d) Representative 
histogram of 48-hour exposure. Data points are the mean+/-SD of at least 3 separate 
experiments. 
 
7.4.4 Combining MSA and chemotherapeutic agents in keratinocytes 
Given that Se has been reported to protect normal cells from chemotherapy-induced 
cytotoxicity, keratinocytes were treated simultaneously with a non-toxic concentration of 
MSA (0.5μmol/L) and either 4-HC or doxorubicin for 48 hours. However, Figure 7.6 
shows that 0.5μmol/L MSA did not alter the cytotoxicity of either 4-HC or doxorubicin 
as determined by the ATP assay. Therefore, keratinocytes were pre-treated with 
0.5μmol/L MSA for 7 days prior to exposure to either 4-HC or doxorubicin for 48 hours. 
Figure 7.7 shows that pre-treatment with MSA was unable to alter the cytotoxicity of 
either 4-HC or doxorubicin as determined by the ATP assay. 
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Figure 7.6 Keratinocytes exposed simultaneously to MSA 0.5μM and (a) 4-HC or (b) 
Doxorubicin for 48 hours. Data points are the mean+/-SD of 3 separate experiments. 
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Figure 7.7 Keratinocytes pre-treated with MSA 0.5μM for 7 days followed by 48-hour 
exposure to (a) 4-HC or (b) Doxorubicin. Data points are the mean+/-SD of 3 separate 
experiments. 
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7.4.5 Induction of endoplasmic reticulum stress in peripheral blood mononuclear 
cells exposed to MSA 
Given the lack of evidence for a cyto-protective action of MSA in keratinocytes and 
HFFF2 cells, further experiments were performed in PBMCs. Previous experiments, 
reported in Chapter 5, demonstrated that MSA induced ER stress and activated the UPR 
in DLBCL cell lines. To determine whether the response of PBMCs to MSA-induced ER 
stress differed, cells were exposed to a range of MSA concentrations. Initially 24- and 48- 
hour exposures were investigated. Figure 7.8 shows that unlike DLBCL cell lines, 
PBMCs have virtually no basal expression of GRP78. After 24-hour exposure to 1μmol/L 
MSA, there was a large increase in GRP78 expression, although a further increase in 
expression with higher concentrations of MSA was not apparent. A 4-hour time-point 
was therefore studied using 5μmol/L, 10μmol/L and 20μmol/L MSA to determine if there 
was a concentration effect.  Figure 7.9 shows that there was induction of GRP78 at 4 
hours but to a lesser extent than at 24 hours. There was also a small concentration effect 
between 5μmol/L and 10μmol/L MSA but between 10μmol/L and 20μmol/L the effect 
plateaued in some individuals. 
 
 
Figure 7.8 GRP78 expression in peripheral blood mononuclear cells from 3 different 
individuals exposed to MSA (a) 1μM and 3μM MSA for 24 and 48 hours (b) 5μM, 10μM 
and 20μM MSA for 24 hours. 
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Figure 7.9 GRP78 expression in peripheral blood mononuclear cells from 6 different 
individuals exposed to MSA for 4 hours. 
 
To investigate whether MSA induced the apoptotic branch of the ER stress response in a 
similar way to DLBCL cell lines, real-time PCR for GADD153 mRNA expression was 
performed in PBMCs exposed to 20μmol/L MSA. Figure 7.10 shows that GADD153 
mRNA expression was induced by MSA in a time-dependent manner with the highest 
increase apparent at 24 hours. However, there was variability amongst individuals in the 
degree of induction ranging from a 4.7-fold to a 16.1-fold increase at 24 hours.   
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Figure 7.10 Real-time PCR for GADD153 expression in peripheral blood mononuclear 
cells exposed to 20μM MSA. Data points are the mean+/-SD of at least 8 separate 
experiments using peripheral blood mononuclear cells harvested from 10 different 
individuals.  The p values are a comparison with control. 
 
7.4.6 Effect of MSA on NF-κB activity in peripheral blood mononuclear cells 
The effect of MSA on NF-κB was investigated for two reasons. Firstly, published results 
from our laboratory have demonstrated that minimally toxic concentrations of MSA can 
decrease NF-κB activity in DLBCL cell lines after 4-hour exposure (Juliger et al, 2007) 
and secondly, because ER stress has been reported to activate NF-κB (Nozaki et al, 2001; 
Schapansky et al, 2007). NF-κB activity was initially determined using the TransAM™ 
NF-κB p65 assay kit. The kit was first validated and Figure 7.11a shows an example of 
the controls used when performing the assay. Jurkat nuclear extract was provided as a 
positive control and produced a concentration-dependent increase in luminescence 
expressed as relative light units (RLU). The wild-type consensus oligonucleotide is a 
competitor for NF-κB binding and prevents NK-κB binding to the consensus binding site 
immobilised on the plate. Figure 7.11a shows that the wild-type oligonucleotide 
prevented an increase in luminescence. Figure 7.11b shows that increasing concentrations 
280 
 
of protein from PBMC whole cell lysates could produce a concentration-dependent 
increase in luminescence.  
 
Figure 7.11 NF-κB binding activity using the TransAM™ assay kit (a) Positive and 
negative controls (b) Increasing protein concentration of PBMC whole cell extracts (c) 
Whole cell extracts of PBMCs exposed to MSA for 24 hours. Data points are the mean+/-
SD of at least 2 separate experiments. 
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PBMCs were then exposed to a range of MSA concentrations for 24 hours and whole cell 
protein was extracted. Figure 7.11c shows that when whole cell lysates were used in this 
assay kit, there was no change in NF-κB activity. Therefore nuclear protein extracts were 
used for subsequent experiments.  
It was expected that NF-κB activity in nuclear extracts would be relatively low and given 
the expectation that MSA might inhibit NF-κB activity, as seen in DLBCL cell lines, 
cells were first stimulated with TNFα for 1 hour prior to treating with MSA for a further 
4 hours. Figure 7.12 shows experiments using PBMCs from 3 different individuals. 
Nuclear protein extracts were used in the TransAM™ assay kit and correlated with 
western blotting performed using both nuclear and cytoplasmic protein extracts. The 
experiments show 3 different patterns of response. In all 3 experiments TNFα increased 
the activity of NF-κB. In Figure 7.12a MSA further increased NF-κB activity in a 
concentration-dependent manner, in Figure 7.12b MSA did not further increase NF-κB 
activity and in Figure 7.12c MSA did further increase NF-κB activity but the effect was 
not concentration-dependent.  In none of the 3 samples did MSA inhibit the TNFα-
mediated increase in NF-κB activity. The western blotting experiments correlated very 
well with the results from the TransAM™ assay kit, therefore for subsequent experiments 
western blotting was used to confirm these preliminary results.  
Since MSA activated NF-κB in PBMCs, pre-stimulation with TNFα was felt not to be 
necessary. Further PBMCs were exposed to 20μM MSA for 4 hours and western blotting 
performed on nuclear protein extracts. Figure 7.13a shows 3 examples of the results 
obtained. Densitometry was performed to correct for protein loading and the results of 8 
separate experiments using PBMCs from 8 different individuals were combined. Figure 
7.13b shows that 20μmol/L MSA for 4 hours significantly increased NF-κB activity in 
nuclear extracts by 2.5-fold (p=0.02). However, there was variability in the observed 
effect and in PBMCs from 2 of the 8 individuals NF-κB activity was not increased, but in 
none of the samples was NF-κB activity inhibited. 
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Figure 7.12 NF-κB binding activity in nuclear extracts of peripheral blood mononuclear 
cells exposed to TNFα 10ng/ml for 1 hour followed by MSA for a further 4 hours. 
Experiments on peripheral blood mononuclear cells from 3 separate individuals are 
shown. Data points are the mean+/-SD of one experiment performed in duplicate. Below 
each graph is the corresponding western blot. 
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Figure 7.13 (a) NF-κB expression in nuclear extracts of peripheral blood mononuclear 
cells from 3 healthy subjects after exposure to MSA 20µmol/L or TNFα 10ng/ml for 4 
hours (b) Densitometric analysis of western blots of 8 separate PBMC samples exposed 
to 20µmol/L MSA. *p=0.02. 
 
To investigate the mechanism by which MSA activated NF-κB, phosphorylation of eIF2α 
and expression of IκB were determined by western blotting. It has been reported that 
phosphorylation of eIF2α is necessary for activation of NF-κB (Jiang et al, 2003) and 
given that IκB inhibits NF-κB activity it was expected that MSA might result in IκB 
degradation. However, Figure 7.14 shows that exposure to 20μmol/L MSA for 4 and 24 
hours did not clearly alter the amount of phosphorylated eIF2α or the expression of IκB 
in PBMCs from 2 individuals. 
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Figure 7.14 p-eIF2α and IκB in peripheral blood mononuclear cells exposed to 20μM 
MSA. 
 
7.4.7 The effect of MSA on other stress-induced proteins in peripheral blood 
mononuclear cells 
The effect of MSA on other cellular stress-induced proteins was investigated. Similar to 
the results obtained in DLBCL cell lines, Figure 7.15 shows that MSA did not alter the 
expression of HSP70, HSP90 or Prx1 in PBMCs harvested from 3 different individuals. 
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Figure 7.15 (a) HSP70 and HSP90 expression in peripheral blood mononuclear cells 
exposed to MSA for 24 hours (b) Peroxiredoxin-1 expression in peripheral blood 
mononuclear cells exposed to a range of MSA concentrations for 24 and 48 hours.  
 
7.5 DISCUSSION 
Three models of normal, non-malignant cells have been investigated. PBMCs, a mixture 
of lymphocytes and monocytes derived from normal volunteers, are widely used to test 
the cytotoxicity of novel agents in normal cells (Paoluzzi et al, 2010; Sterz et al, 2010). 
They have the advantage of being easily accessible, however they have the disadvantage 
that they are terminally differentiated and do not divide and hence may not truly reflect 
the action of a drug in proliferating ‘normal’ cells. hTERT-immortalised human 
keratinocytes have been reported to retain normal growth and differentiation 
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characteristics (Dickson et al, 2000) and therefore were felt to be a good model for 
normal proliferating cells. In addition, the HFFF2 cell line was obtained as an alternative 
normal cell model.  
 
PBMCs are relatively resistant to the cytotoxic effect of MSA. Previous work published 
from our laboratory found that the EC50 for PBMCs exposed to MSA for 72 hours was 
84.2μmol/L (Juliger et al, 2007). In the experiments reported here, MSA concentrations 
of up to 20μM were investigated and exposure to 20μmol/L for 48 hours resulted in 
minimal toxicity, reducing cell viability relative to control by 12.3%. In contrast, it was 
found that the keratinocytes and HFFF2 cells were relatively sensitive to the cytotoxic 
effect of MSA, with EC50 values at 48-hour exposure of 2.4μmol/L and 7.2μmol/L 
respectively. These cells also showed similar sensitivity to doxorubicin and 4-HC as the 
MSA-sensitive DLBCL cell line, RL, with the exception of HFFF2 cells exposed to 4-
HC. The reason that trypan blue exclusion rather than the ATP assay was used to 
determine the cytotoxicity of MSA in PBMCs was to limit the number of cells required 
for experiments. Cell counts were performed just prior to cell lysis on a small aliquot of 
cells obtained from samples that had been set up for western blotting. 
 
Most studies in the literature that have investigated the cyto-protective effect of Se in 
normal cells have reported the effects of selenite and SLM (Fischer et al, 2007; Rafferty 
et al, 2003a; Rafferty et al, 2003b). In addition, non-tumourigenic cell lines have been 
reported to be more resistant than tumour cell lines to the induction of apoptosis by MSC 
(Jariwalla et al, 2009). Very few studies have examined the effect of MSA in normal 
cells. In those that have, the cells studied have also been very sensitive to the cytotoxic 
effect of MSA. Examples include a study investigating the effect of MSA on mouse 
embryonic fibroblasts which found that concentrations >1μmol/L induced significant 
apoptosis (Fischer et al, 2007). In HUVECs, MSA concentrations >5μmol/L induced 
significant apoptosis (Wang et al, 2008) and human bronchial epithelial cells were also 
found to be very sensitive to MSA (Poerschke et al, 2008). In contrast, one study has 
reported that the non-tumourigenic prostate cell line, Pr111 was less sensitive to MSA 
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than prostate cancer cell lines, however, the EC50 for growth inhibition was 0.92μmol/L, 
which makes it more sensitive that any of the DLBCL cell lines studied here (Gonzalez-
Moreno et al, 2007).  
 
In the work presented here, MSA clearly induced apoptosis in keratinocytes at 
concentrations ≤5μmol/L as evidenced by the results of the ATP assay, and confirmed by 
an increase in the sub-G1/apoptotic population during cell cycle analysis. This suggests 
that the response to MSA may be cell-type dependent and that normal cells do not all 
respond in the same way. On the other hand, MSA may not be the correct form of Se to 
be studying in normal cells. MSA is highly reactive and volatile with conversion to 
methylselenol immediately after uptake into the cell. However, SLM and MSC require 
enzymatic conversion to methylselenol. In vivo, metabolism of SLM and MSC to 
methylselenol occurs predominantly in the liver and kidney, as this is where high 
concentrations of the relevant β- and γ-lyase enzymes are found. Other cell types 
generally have lower β- and γ-lyase activity and therefore conversion of SLM and MSC 
to methylselenol in in vitro cell models other than liver and kidney cells is likely to be 
less efficient (Cooper et al, 2010; Cooper & Pinto, 2006). In fact, in vitro studies 
demonstrating anti-tumour effects of SLM and MSC often supplement cultures with γ- 
and β-lyase respectively (Azrak et al, 2006; Kim et al, 2007a). Studies demonstrating the 
cyto-protective effects of SLM and MSC have not supplemented in vitro cell cultures 
with the relevant lyase enzymes suggesting that perhaps the monomethylated metabolites 
may not be responsible for the observed effects (Fischer et al, 2007). As discussed in 
Chapter 6, SLM and MSC can also form α-keto acid metabolites (Lee et al, 2009a) and 
therefore other metabolites could be responsible for the differing effects between MSA 
and other organo-Se compounds, but this requires further investigation.  
In contrast, MSA has been found to be superior to SLM and selenite in respect to in vivo 
tumour growth inhibition in two xenograft models of prostate cancer. When comparing 
MSC and MSA in the same in vivo models, MSC was able to inhibit tumour growth in 
only one of the two xenograft models. Tumour growth inhibition by MSC was associated 
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with increased apoptosis whereas tumour growth inhibition by MSA was not, but instead 
appeared to affect angiogenesis. This suggests that although both compounds are thought 
to act through their common metabolite methylselenol, they appear to affect different 
intracellular signalling pathways (Li et al, 2008a). Therefore, it may be an over 
simplification to suggest that all Se compounds that are metabolised to methylselenol act 
in the same way, and it may be that other, as yet unknown, properties of these compounds 
are also important in mediating the effects observed.   
To further investigate the effect of MSA in hTERT-immortalised keratinocytes, a non-
cytotoxic concentration of MSA, 0.5μmol/L, was used. MSA was combined 
simultaneously with increasing concentrations of either doxorubicin or 4-HC for 48 
hours. The addition of MSA did not alter the cytotoxicity of either chemotherapeutic 
agent. Although a cyto-protective effect of MSA was not observed, these results differed 
from those obtained when combining non-toxic concentrations of MSA with 
chemotherapeutic agents in DLBCL cell lines where a synergistic interaction was 
observed, as shown in Chapter 4. This suggests a differential effect between DLBCL cell 
lines and this normal cell line, with chemo-sensitisation observed in malignant cells, but 
not in normal cells. In the xenograft study that reported the protective effect of Se on 
chemotherapy-induced toxicity, seven days pre-treatment with Se prior to the 
commencement of chemotherapy was required (Cao et al, 2004). Therefore, 
keratinocytes were pre-treated with 0.5μmol/L MSA for seven days prior to treatment 
with increasing concentrations of doxorubicin and 4-HC for a further 48 hours. However, 
results were similar to those obtained after simultaneous exposure and MSA did not alter 
the effect of either chemotherapeutic agent. Given these negative results, further 
experiments were not conducted in either the hTERT immortalised keratinocytes or the 
HFFF2 cell line.  
Further experiments were performed using PBMCs given that they appear to represent 
‘normal’ cells that are relatively resistant to MSA. To establish whether the response to 
ER stress differed between normal cells and DLBCL cell lines, GRP78 expression and 
GADD153 mRNA expression was investigated in PBMCS exposed to MSA. In contrast 
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to DLBCL cell lines, PBMCs had virtually no basal expression of GRP78. Following 
exposure to 1μmol/L MSA for 24 hours, there was a marked increase in expression of 
GRP78, much larger than the effect of the same concentration in either the RL or DHL4 
cell lines. In the RL cell line, 1μmol/L MSA produced a minimal increase in GRP78 
expression (Chapter 5, Figure 5.2), while in DHL4 cells, 1μmol/L MSA did increase 
expression of GRP78 at 4- and 6-hour exposures but the effect was lost by 24 hours 
(Chapter 5 Figure 5.3). In PBMCs, the increase in GRP78 expression at 24 hours was 
maximal after exposure to only 1μmol/L MSA, with no concentration effect. 
Concentrations >1μmol/L MSA induced GRP78 expression to the same extent and this 
induction was sustained out to 48-hour exposure. In the RL and DHL4 cell lines, a 
maximal sustained effect in GRP78 induction was observed only after exposure to 
concentrations ≥10μmol/L MSA (Chapter 5, Figures 5.2 and 5.3).  
Given the plateau in GRP78 expression at 24 hours with concentrations as low as 
1μmol/L MSA, PBMCs were exposed to 5μmol/L, 10μmol/L and 20μmol/L MSA for 4 
hours. GRP78 expression was clearly induced following 4-hour exposure but the 
induction was less compared with 24-hour exposure. There was a concentration effect 
between 5μmol/L and 10μmol/L MSA but between 10μmol/L and 20μmol/L MSA the 
effect was maximal in PBMCs from some but not all individuals. These results 
demonstrate that in PBMCs, MSA produced a larger, more sustained increase in GRP78 
than in DLBCL cell lines at equivalent concentrations. Given that induction of GRP78 by 
cells is generally considered a pro-survival response and has been associated with chemo-
resistance (Lee, 2007; Pyrko et al, 2007), these results suggest that PBMCs are able to 
induce a larger pro-survival response than DLBCL cell lines in response to MSA.  
Differences were also observed in the induction of GADD153 mRNA expression by 
MSA between PBMCs and DLBCL cell lines. GADD153 expression was studied in 
PBMCs exposed to 20μmol/L MSA for 4, 6 and 24 hours. Induction of GADD153 
expression was time-dependent with a maximal 11-fold increase observed at 24 hours. 
Although the concentrations investigated in the DHL4 cell line differed, the induction of 
GADD153 in PBMCs was less. In the DHL4 cell lines, 10μmol/L MSA for 24 hours 
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increased GADD153 expression by 23-fold and 30μmol/L MSA by 35-fold (Chapter 5, 
5.7). Hence, it appears that the apoptotic response to ER stress induced by MSA in 
normal PBMCs is less than that seen in DLBCL cell lines. 
Pre-conditioning of cells through the induction of ER stress has been demonstrated to 
protect cells from toxic agents. This has mainly been examined in renal cell lines and it 
has been reported that pre-treatment of cell lines for 16-24 hours with agents such as 
tunicamycin and thapsigarin, which are known inducers of ER stress, can protect cells 
from oxidative stress following H2O2 exposure and from cytotoxicity following exposure 
to known nephrotoxins, such as cisplatin. In these studies, ER stress induction was 
demonstrated by the induction of GRP78 and GRP94 and inhibiting the expression of 
GRP78 was found to prevent the cyto-protective response to pre-treatment with inducers 
of ER stress (Hung et al, 2003; Peyrou & Cribb, 2007). There were, however, differences 
between the extent of cyto-protection afforded between cell lines and the different ER 
stress inducers and toxic agents investigated, with the level of GRP78 induction not 
always correlating with the extent of cyto-protection (Bedard et al, 2004; Peyrou & 
Cribb, 2007). Thus, the mechanism of ER stress-induced cyto-protection is not fully 
understood and is likely to involve other molecular pathways. The MAPK and PI3K/Akt 
pathways have been implicated in the survival response.  In renal epithelial cells, ER 
stress induced protection from oxidative stress caused by H2O2 was found to be 
dependent on phosphorylation and thus activation of Erk1/2 and suppression of Jnk 
activation, but was not dependent on the activity of the PI3K/Akt pathway (Hung et al, 
2003). In solid tumour cell lines, ER stress-induced cell survival required 
phosphorylation and thus activation of Akt and Erk1/2 and also the induction of two anti-
apoptotic proteins, cIAP-2 and XIAP (Hu et al, 2004). In addition, the induction of 
autophagy by ER stress may be important in the survival response. A study investigating 
the effect of the known nephrotoxic agent cyclosporine A reported that it induced ER 
stress in human renal epithelial cells and this directly led to the induction of autophagy. 
Inhibition of autophagy increased the cytotoxicity of cyclosporine A, implicating this 
pathway in cell survival (Pallet et al, 2008). The induction of autophagy in PBMCs by 
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MSA has not been investigated but given the findings in DLBCL cell lines it would be 
valuable to do so. 
A further pro-survival protein that is activated by ER-stress is NF-κB and this is distinct 
from the activation of the UPR (Pahl & Baeuerle, 1995). The exact mechanism by which 
NF-κB is activated is not clear but phosphorylation of eIF2α is thought to be required 
(Jiang et al, 2003). NF-κB activation has been shown to inhibit the expression of 
GADD153 and hence promote cell survival (Nozaki et al, 2001; Schapansky et al, 2007). 
Given that our laboratory has demonstrated inhibition of NF-κB by MSA in DLBCL cell 
lines, NF-κB activity was investigated in PBMCs. The results reported here demonstrate, 
by two different methods, that MSA activates NF-κB. Although there was some 
variability in the observed effect, when results of western blotting experiments were 
combined, it was demonstrated that MSA increased NF-κB nuclear expression by a 2.5-
fold. This may therefore explain why the induction of GADD153 was less when 
compared to DLBCL cell lines in which NF-κB activity is inhibited by MSA. However, 
the role of ER stress-induced NF-κB activation is complex and it has been reported that 
NF-κB can also mediate ER stress-induced cell death (Hu et al, 2006). To further 
investigate how NF-κB is activated by MSA, phosphorylation of eIF2α and expression of 
IκB were investigated. However, MSA did not alter the level of either protein. Further 
work is required to define the mechanism and role of NF-κB activation by MSA in 
PBMCs. 
The effect of MSA on other stress-induced proteins was studied. Similar to the findings 
in DLBCL cells lines, MSA did not affect the expression of HSP70, HSP90 or Prx1.  
The results presented in this chapter have demonstrated clear differences in the responses 
of PBMCs to MSA when compared with DLBCL cell lines. This was not the case with 
all normal cell types, with the HFFF2 cell line and normal keratinocytes showing 
sensitivity similar to that of some lymphoma cell lines. These results may be dependent 
on the Se compound used, and may reflect altered uptake or activation of MSA in normal 
cells compared to lymphoma cells. This is further investigated in Chapter 9. 
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CHAPTER 8: Combining methylseleninic acid and bortezomib in 
mantle cell lymphoma cell lines 
 
8.1 INTRODUCTION 
Bortezomib is a dipeptide boronic acid, ‘first-in class’, proteasome inhibitor (Adams et 
al, 1999). It is a specific, reversible inhibitor of the 26S proteasome, a large multi-subunit 
protein complex present in all eukaryotic cells. The ubiquitin-proteasome pathway (UPP) 
is an essential one, responsible for the degradation of intracellular proteins. To be 
recognised for degradation by the proteasome, proteins require the attachment of a 
polyubiquitin chain (Navon & Ciechanover, 2009). Proteins degraded by the UPP include 
those involved in key intracellular processes such as cell cycle regulation, cell growth, 
proliferation and survival. Therefore, inhibition of the proteasome affects multiple 
cellular pathways, ultimately resulting in cell death (Adams, 2004). Despite the fact that 
the proteasome is crucial to the functioning of all cells, it appears that malignant cells are 
more sensitive than normal, non-malignant cells to the cytotoxic effects of proteasome 
inhibition (Hideshima et al, 2001). The reasons for this are not entirely clear, but may 
include the fact that malignant cells often have abnormalities in cell cycle regulation and 
thus are rapidly proliferating, which may lead to the accumulation of defective proteins at 
a higher rate than in normal cells. Thus, malignant cells may be more dependent on the 
normal functioning of the UPP (Masdehors et al, 2000). 
 
It has been demonstrated that bortezomib induces cell death through multiple 
mechanisms and that these differ depending on the tumour type. Bortezomib has been 
investigated most extensively in multiple myeloma and has demonstrated impressive 
clinical efficacy, both as a single agent and in combination with other conventional and 
novel agents. It is now approved in the UK and the United States for the treatment of 
patients with relapsed/refractory myeloma (Richardson et al, 2003). Initially it was 
thought that the key mechanism involved in the activity of bortezomib was the inhibition 
of NF-κB activation. The NF-κB family of transcription factors are kept in an inactive 
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state in the cytoplasm through binding to the inhibitor protein IκB. In order to activate 
NF-κB and allow its translocation to the nucleus, IκB must be phosphorylated, 
ubiquitinylated and degraded by the 26S proteasome. The degradation of IκB is inhibited 
by bortezomib, thus preventing activation of NF-κB. NF-κB activation in turn promotes 
cell survival, growth, proliferation and angiogenesis, by mechanisms such as induction of 
pro-apoptotic Bcl-2 family members, cell cycle regulators, caspase inhibitors and VEGF 
(Navon & Ciechanover, 2009).  However, it has become apparent that bortezomib also 
has a number of NF-κB-independent effects. These include disruption of cell cycle 
progression (An et al, 2000), generation of ROS (Ling et al, 2003), activation of the 
extrinsic, death receptor, apoptotic pathway (Kabore et al, 2006), induction of ER stress 
and the UPR (Obeng et al, 2006) and cell death as a result of mitotic catastrophe (Strauss 
et al, 2007). Interestingly, a recent study has shown that bortezomib can actually induce 
NF-κB activation in multiple myeloma cell lines and patient-derived tumour cells through 
induction of IκB phosphorylation. In this study, bortezomib was still cytotoxic, 
suggesting that the inhibition of NF-κB activation is not the most important mechanism 
of bortezomib action (Hideshima et al, 2009). A study in endometrial cancer cell lines 
and primary patient samples had previously demonstrated a similar finding when 
examining the effects of four proteasome inhibitors, including bortezomib (Dolcet et al, 
2006). 
The other disease for which bortezomib has been approved by the FDA in the United 
States is for the treatment of relapsed/refractory mantle cell lymphoma (MCL). MCL is a 
distinct subtype of B-cell NHL and comprises about 6% of all NHL. The median age at 
presentation is around 60 years, it is more common in men and most patients present with 
advanced stage disease. It is an aggressive malignancy with a poor prognosis and 
currently, no curative therapy (Anon, 1997; Swerdlow SH, 2008). With the recent 
addition of rituximab to first-line combination chemotherapy, improvements have been 
made in response rates (Lenz et al, 2005). Impressive results have been achieved at the 
M.D.Anderson Cancer Centre using the intensive ‘hyper-CVAD’ (fractionated 
cyclophosphamide/vincristine/doxorubicin/ dexamethasone) regimen, alternating with 
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high-dose methotrexate/cytarabine plus rituximab as first-line treatment. 87% of patients 
achieved a CR/CRu and the 5-year OS was 65% (Fayad et al, 2007). However, this 
regimen is too toxic for the majority of patients and therefore ‘CHOP’ plus rituximab is 
the ‘standard of care’ in most centres. Moreover, the real problem is that the great 
majority of patients develop recurrent disease and bortezomib has proved to be a useful 
treatment option in this setting. An updated analysis (with longer follow-up) of the phase 
II ‘PINNACLE’ study, using bortezomib as a single agent in patients with 
relapsed/refractory MCL has recently been published. The overall response rate was 32% 
(CR/CRu 8%), with a median duration of response of 9.2 months. The OS was 23.5 
months. In patients who responded, the median time to progression was 1 year and the 
OS, 3 years.  These results are all the more impressive considering that almost half the 
patients were treated at second recurrence. (Goy et al, 2009).  
MCL is characterised by over-expression of the protein cyclin D1, which controls cell 
cycle progression from G1 to S phase.  MCL is characterised by the presence of the 
t(11;14)(q13;32) which results in the juxtaposition of the cyclin D1 gene with the 
immunoglobulin heavy-chain joining region.  A large number of other, secondary 
molecular alterations have also been reported in MCL, including the constitutive 
activation of the NF-κB pathway (Obrador-Hevia et al, 2009). A study in MCL cell lines 
and patient-derived tumour cells reported that both bortezomib and the NF-κB inhibitor 
BAY 11-7082 could induce apoptosis in MCL cells and that a similar effect was observed 
when NF-κB activation was inhibited using a super-repressor form of IκB (Pham et al, 
2003). Therefore, inhibition of the NF-κB pathway seems a promising therapeutic target 
in MCL and appears to be the main mechanism of action for bortezomib in this disease.  
Bortezomib may also be of use in the treatment of DLBCL. The ABC-like molecular 
subgroup of DLBCL (unlike the GCB-like subgroup) is characterised by constitutive 
activation of the NF-κB pathway. It has a significantly worse outcome compared to the 
GCB-like subgroup. A recent study reported that although bortezomib had no clinical 
activity as a single agent in patients with relapsed/refractory DLBCL, when combined 
with conventional chemotherapy, it resulted in a significantly higher response rate and 
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OS in patients with the ABC-like subgroup compared with the GCB-like subgroup 
(Dunleavy et al, 2009). 
The hypothesis being investigated by the experiments presented in this chapter is that the 
combination of MSA and bortezomib in MCL cell lines may lead to a synergistic 
interaction. The rationale is based on the following:  both drugs inhibit NF-κB activity 
(Juliger et al, 2007) and both induce ER stress, through the accumulation of misfolded 
proteins (Wu et al, 2005). Furthermore, it has been reported that combining bortezomib 
and ER stress-inducing agents results in enhanced cell death (Hill et al, 2009; Kraus et al, 
2008).  
8.2 AIMS 
1) To investigate the activity of MSA in MCL cell lines. 
2) To investigate the combination of MSA and bortezomib in MCL cell lines. 
 
8.3 METHODS 
8.3.1 Cell lines, cell culture and treatment of cell lines 
Two MCL cell lines were used in these experiments; JeKo-1 and Granta-519 obtained 
from Cancer Research UK cell services (Amin et al, 2003). They were maintained in 
suspension in RPMI-1640 culture medium (Sigma-Aldrich) supplemented with 10% 
foetal calf serum (Sigma Aldrich), and 1% penicillin (100units/ml) and streptomycin 
(100µg/ml) (Invitrogen™, California, USA) at 37°C in a humidified atmosphere with 5% 
CO2. Cells were passaged twice weekly and reset at 2x10
5
/ml.  
 
The cell lines were exposed to range of MSA and bortezomib concentrations and cell 
viability and number were determined using the Guava
®
 viacount assay (described in 
Chapter 2, section 2.3.3). The results were expressed relative to the control value and 
were analysed using the GraphPad PRISM
®
 software (version 5.03). The activity of MSA 
and bortezomib were summarised to an EC50 value, which was calculated using a 
sigmoidal concentration-effect model with variable slope. 
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Cell lines were then exposed to a combination of a non-toxic concentration of MSA and 
increasing concentrations of bortezomib. MSA and bortezomib were initially combined 
simultaneously for 48 hours. Subsequently, cells were pre-treated with MSA for 48 hours 
followed by treatment with bortezomib for a further 48 hours. Cell viability was 
determined using the Guava
®
 viacount assay. 
Western blotting was used to investigate protein changes induced by the combination of 
MSA and bortezomib. 
 
8.3.2 Proteasome activity assay 
Proteasome activity in whole cell extracts was determined by measuring the release of the 
fluorophore 7-amino-4-methylcoumarin (AMC) from a synthetic peptide Suc-Leu-Leu-
Val-AMC (S-LLV-AMC; Alexis Biochemicals, Nottingham, UK), which is hydrolysed 
by the chymotryptic activity of the 20S proteasome. The assay was performed in a 96-
well plate and samples analysed in triplicate. 
 
JeKo-1 and Granta-519 cells were exposed to MSA, Bortezomib or both and then 
pelleted by centrifugation at 210g for 6 minutes. Cell were washed once in ice-cold PBS 
and then lysed in ‘assay buffer’ (20mM PIPES-KOH, pH 7.4, 10mM DTT, 10% sucrose, 
1mM EDTA) to which 0.1% 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS; Sigma-Aldrich) was added just prior to use. Samples were 
incubated on ice for 20 minutes and then centrifuged at 20,800g for 10 minutes to remove 
insoluble cellular debris. The supernatant was transferred to fresh tubes and the protein 
concentration measured using the BCA™ protein assay kit (described in Chapter 2, 
section 2.4.5).  
50µg of protein was diluted to 95µl in assay buffer. The reaction was initiated by the 
addition of 5µl of 400mmol/L (final concentration 40µmol/L) S-LLV-AMC fluorescent 
substrate. After incubation at 37°C for 15 minutes, fluorescence (excitation 350-360nm, 
emission 460nm) was measured on the POLARstar OPTIMA plate reader (BMG 
298 
 
Labtech). Measurements were calibrated against a standard linear regression curve of 
AMC (Sigma-Aldrich). Proteasome activity was defined as µmol/L AMC released per 
milligram protein per hour (µM/mg/hr). An example of the standard curve is shown in 
Figure 8.1 (r=0.99) 
 
Figure 8.1 An example of a standard curve for AMC. AFU=arbitrary fluorescence units. 
 
 
8.4 RESULTS 
8.4.1 The effect of MSA and bortezomib on cell viability and number 
JeKo-1 and Granta-519 cell lines were exposed to MSA and bortezomib for 48 hours and 
cell viability and number was determined. Figure 8.2 shows the EC50 concentration-effect 
curves for cell viability and number. The EC50 values for cell viability and cell number 
are summarised in Table 8.1. MSA is clearly more cytostatic than cytotoxic. This is also 
true for bortezomib but to a lesser degree.  
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Figure 8.2 EC50 concentration-effect curves following 48-hour exposure to increasing 
concentrations of MSA and bortezomib using the Guava
®
 viacount assay. (a) MSA cell 
viability (b) Bortezomib cell viability (c) MSA cell number (d) Bortezomib cell number. 
Data points are the mean +/- SD of three separate experiments. 
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Table 8.1 MSA and bortezomib EC50 values for cell viability and number in JeKo-1 and 
Granta-518 cell lines after 48-hour exposure. EC50 values are the mean of 3 separate 
experiments. 
Drug Cell lines Cell viability 
EC50  
95% CI Cell number 
EC50  
95% CI 
MSA 
(µmol/L) 
JeKo-1 38.9 33.2-45.5 3.2 1.6-6.1 
 Granta-519 51.8 43.2-62.2 2.8 0.9-8.9 
Bortezomib 
(nmol/L) 
JeKo-1 72.2 62.3-83.7 29.4 24-36 
 Granta-519 82.8 67.1-102.1 33.6 26.6-42.4 
 
 
8.4.2 Simultaneous combination of MSA and bortezomib  
A non-cytotoxic concentration of MSA was combined simultaneously with increasing 
concentrations of bortezomib for 48 hours. 10µmol/L MSA was chosen as it had minimal 
effect on cell viability and was the concentration in the MSA-resistant DLBCL cell lines, 
DHL4 and DoHH2, that resulted in a synergistic interaction with cytotoxic agents. 
Unexpectedly, at the highest bortezomib concentration, 50nmol/L, there was an 
antagonistic interaction in the combination resulting in increased cell viability compared 
with bortezomib alone in both MCL cell lines. In the JeKo-1 cell line, 50nmol/L 
bortezomib decreased the cell viability by 48.5% (±8.3) but when combined with MSA 
the cell viability was only decreased by 32% (±5.1). In the Granta-519 cell line, 
50nmol/L bortezomib decreased the cell viability by 37.3% (±4.3) but when combined 
with MSA the cell viability was only decreased by 28.7% (±2.2). These effects were 
statistically significant (Figure 8.3 and 8.4).  
301 
 
 
Figure 8.3 JeKo-1 cells exposed to a simultaneous combination of MSA 10µmol/L and 
increasing concentrations of bortezomib. (a) Cell viability with bortezomib alone and in 
combination with MSA (b) The expected and observed cell viability from the 
combination of MSA and bortezomib. Guava
®
 viacount assay used. Data points are the 
mean +/- SD of three separate experiments. *p=0.006.  
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Figure 8.4 Granta-519 cells exposed to a simultaneous combination of MSA 10µmol/L 
and increasing concentrations of bortezomib. (a) Cell viability with bortezomib alone and 
in combination with MSA (b) The expected and observed cell viability from the 
combination of MSA and bortezomib. Guava
®
 viacount assay used. Data points are the 
mean+/-SD of three separate experiments *p=0.01. 
 
 
8.4.3 Pre-treatment with MSA followed by the addition of bortezomib 
In order to investigate whether the scheduling of the two agents affected the observed 
antagonistic interaction, JeKo-1 and Granta-519 cells were pre-treated with MSA 
10µmol/L for 48 hours followed by the addition of increasing concentrations of 
bortezomib for a further 48 hours. The results show that pre-treatment with MSA 
enhanced the antagonistic interaction with the effect now apparent at bortezomib 
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concentrations of 20nmol/L and 50nmol/L (Figure 8.5 and 8.6).  In JeKo-1 cells, 
bortezomib 20nmol/L and 50nmol/L decreased cell viability by 15% (±2.9) and 54.5% 
(±7.8) respectively but when pre-treated with MSA, these bortezomib concentrations only 
decreased cell viability by 3.7% (± 1.0) and 14.7% (±5.7) respectively. In Granta-519 
cells, bortezomib 20nmol/L and 50nmol/L decreased cell viability by a mean 17.5% 
(±3.0) and 68.8% (±1.5) respectively but when pre-treated with MSA these bortezomib 
concentrations only decreased cell viability by 3.1% (±0.6) and 12.6% (±3.4) 
respectively. MSA 10µmol/L alone for 96 hours decreased cell viability by <2%. 
 
Figure 8.5 JeKo-1 cells pre-treated with MSA 10µmol/L for 48 hours, followed by 
increasing concentrations of bortezomib for a further 48 hours. (a) Cell viability with 
bortezomib alone and pre-treatment with MSA (b) The expected and observed cell 
viability from the combination of MSA and bortezomib. Guava
®
 viacount assay used. 
Data points are the mean +/- SD of three separate experiments. *p=0.01 **p=0.04 
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Figure 8.6 Granta-519 cells pre-treated with MSA 10µmol/L for 48 hours, followed by 
increasing concentrations of bortezomib for a further 48 hours. (a) Cell viability with 
bortezomib alone and pre-treatment with MSA. (b) The expected and observed cell 
viability from the combination of MSA and bortezomib. Guava
®
 viacount assay used. 
Data points are the mean +/- SD of three separate experiments. *p=0.007 **p=0.002. 
 
 
8.4.4 Protein changes associated with the antagonistic combination of MSA and 
bortezomib 
To investigate the mechanism by which MSA antagonises the effect of bortezomib, 
western blotting was performed. Cells were exposed to MSA 10µmol/L alone at several 
time points (6-72 hours) and bortezomib 50nmol/L alone for 6 and 24 hours. For the 
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combination, cells were pre-treated with MSA for 48 hours followed by bortezmib for a 
further 6 and 24 hours. The results in both JeKo-1 (Figure 8.7) and Granta-519 (Figure 
8.8) cells were similar. Cleavage of PARP was used to investigate the induction of 
apoptosis. MSA alone did not result in PARP cleavage but bortezomib at 24 hours did. 
However, when cells were pre-treated with MSA followed by 24 hours of bortezomib, 
the amount of cleaved PARP decreased, suggesting that MSA inhibits apoptosis. These 
results are in keeping with the cell viability data. 
 
Both MSA and bortezomib are known to induce ER stress and autophagy which are both 
mechanisms of cell survival. Therefore western blotting for the ER chaparone GRP78 
and the down-stream target p-eIF2α was performed and the conversion of LC3B-I to 
LC3B-II, as a marker of autophagy induction, was investigated. Figures 8.7 and 8.8 show 
that in JeKo-1 and Granta-519 cells MSA alone induced expression of GRP78 with 
maximal induction at 24 hours, followed by decreasing expression, although the levels 
did not return to baseline by 72 hours. Bortezomib also induced expression of GRP78 but 
the combination resulted in a less than additive increase.  Both cell lines displayed 
phosphorylation of eIF2α at baseline. MSA alone decreased the phoshorylation of eIF2α 
at 6-hour exposure, which was unexpected, as induction of ER stress usually increases 
phosphorylation.  By 24 hours, there was a return of p-eIF2α towards baseline levels. 
Bortezomib alone increased the phoshorylation of eIF2α as did the combination with 
MSA. Both MSA and Bortezomib led to the conversion of LC3B-I to LC3B-II. The 
amount of LC3B-II in MSA-treated cells was maximal at 24 hours. Pre-treatment with 
MSA prior to bortezomib actually decreased LC3B-II levels compared with bortezomib 
alone, suggesting that although each drug induces autophagy, the combination decreased 
this induction.  
 
306 
 
 
Figure 8.7 Induction of apoptosis, endoplasmic reticulum stress and autophagy in JeKo-1 
cells exposed to MSA 10µmol/L and bortezomib 50nmol/L alone and in combination. 
Densitometry values are shown where relevant. 
 
 
 
 
Figure 8.8 Induction of apoptosis, endoplasmic reticulum stress and autophagy in 
Granta-519 cells exposed to MSA 10µmol/L and bortezomib 50nmol/L alone and in 
combination. Densitometry values are shown where relevant. 
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To further investigate how MSA inhibits bortezomib-induced apoptosis, the expression of 
two anti-apoptotic members of the Bcl-2 family of proteins was investigated. JeKo-1 and 
Granta-519 cells were exposed to MSA 10µmol/L alone for 72 hours, bortezomib 
50nmol/L alone for 24 hours and a combination of MSA pre-treatment for 48 hours 
followed by bortezomib for 24 hours. Figure 8.9 shows that MSA alone, but not 
bortezomib, induced the expression of Bcl-2 and the combination resulted in a larger 
increase in expression. Both MSA and bortezomib increased Mcl-1 expression and again 
the combination resulted in a further increase. This suggests that MSA inhibits 
bortezomib-induced apoptosis through the induction of anti-apoptotic Bcl-2 family 
proteins. 
 
 
Figure 8.9 Bcl-2 and Mcl-1 expression in JeKo-1 and Granta-519 cells exposed to MSA 
10µmol/L alone for 72 hours, bortezomib alone 50nmol/L for 24 hours and combined 
pre-treatment with MSA for 48 hours followed by bortezomib for 24 hours. Densitometry 
values are shown. 
 
8.4.5 Proteasome inhibition  
A further mechanism by which MSA could inhibit the action of bortezomib is by 
antagonising its effect on the proteasome. To investigate whether MSA prevented 
bortezomib from inhibiting the proteasome, two methods were used. Firstly, western 
blotting for total ubiquitinated proteins was performed and secondly, a proteasome 
activity assay was used.  Figure 8.10 shows the full western blot of JeKo-1 and Granta-
519 cells treated with MSA and bortezomib, in the same experiment described for 
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Figures 8.7 and 8.8. The blot was incubated with an anti-ubiquitin antibody. MSA did not 
increase the amount of ubiquitinated proteins but bortezomib did. When cells were pre-
treated with MSA followed by treatment with bortezomib the amount of ubiquitinated 
proteins appeared the same as with bortezomib alone. 
 
Figure 8.10 Total ubiquitinated proteins in JeKo-1 and Granta-519 cells treated with 
10µmol/L MSA alone, bortezomib 50nmol/L alone and combined pre-treatment with 
MSA for 48 hours followed by bortezomib. 
 
Western blotting is not a very sensitive or specific method of assessing proteasome 
function, therefore a proteasome activity assay was used. Cells were treated with MSA 
10µmol/L alone for 72 hours, bortezomib 20nmol/L or 50nmol/L alone for 24 hours and 
a combination of pre-treatment with MSA for 48 hours followed by bortezomib 
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20nmol/L or 50nmol/L for a further 24 hours. Figure 8.11 shows that bortezomib 20 and 
50nmol/L completely inhibited proteasome activity and pre-treatment with MSA did not 
prevent this inhibition. 
 
 
Figure 8.11 Proteasome activity assay in cells treated with MSA 10µmol/L and 
bortezomib alone and in combination. Bortezomib 20nmol/L, data points are the mean +/- 
SD of three separate experiments, Bortezomib 50nmol/L, data points are the mean +/- SD 
of two separate experiments. 
 
8.5 DISCUSSION 
The JeKo-1 and Granta-519 cell lines have constitutive activation of NF-κB (Shishodia et 
al, 2005) suggesting that they may be sensitive to MSA and bortezomib. Both cell lines, 
however, were found to be relatively resistant to the cytotoxic effects of both MSA and 
Bortezomib with 48-hour EC50 values for cell viability of >30μmol/L and >70nmol/L 
respectively. In comparison, the 72-hour EC50 value for cell viability for bortezomib in a 
panel of 5 B-NHL cell lines was reported to be between 6-25nmol/L (Strauss et al, 2007). 
MSA was cytostatic at much lower concentrations with EC50 values for cell number of 
3.2µmol/L and 2.8µmol/L for JeKo-1 and Granta-519 cells respectively. Bortezomib also 
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had a larger effect on cell number than cell viability but not to the same degree as MSA 
and EC50 values for cell number were approximately half those for cell viability.  In 
JVM2 cells, another MCL cell line, the 72-hour EC50 for MSA was found to be 3.4μM 
(Chapter 4, Figure 4.16). However, these results are not directly comparable to those for 
JeKo-1 and Granta-519 cell lines because the ATP and not the Guava
®
 viacount assay 
was used. The ATP assay reflects both the cell number and viability whereas the Guava
®
 
viacount assay can assess both parameters separately. Nonetheless, in JVM2 cells, PARP 
cleavage was observed in cells exposed to ≥3µmol/L MSA (Chapter 4, Figure 4.18) and 
exposure to an EC50 concentration significantly increased the sub-G1/apoptotic 
population when performing cell cycle analysis (Chapter 4, Figure 4.17). These results 
suggest that the JVM2 cell line was more sensitive to the cytotoxic effects of MSA than 
the JeKo-1 and Granta-519 cell lines. This is the first time that the activity of MSA in 
MCL cell lines has been reported. 
 
It was expected that the combination of MSA and bortezomib in MCL cell lines would 
result in a synergistic interaction. Unexpectedly, it was found that the opposite was true, 
such that MSA inhibited bortezomib-induced cell death. This was apparent when cells 
were treated with both drugs simultaneously but only with the highest concentration of 
bortezomib, 50nmol/L. However, when cells were pre-treated with MSA 10µmol/L for 
48 hours and then bortezomib added for a further 48 hours the interaction was enhanced 
such that MSA inhibited the action of bortezomib at 20nmol/L and at 50nmol/L. In both 
cell lines, MSA alone for 96 hours decreased cell viability by <2%. In JeKo-1 cells, pre-
treatment with MSA increased cell viability by 12.7% and 41.2% in cells treated with 
20nmol/L and 50nmol/L bortezomib respectively when compared with the expected cell 
viability of the combination. In Granta-519 cells, pre-treatment with MSA increased cell 
viability by 15% and 56.8% in cells treated with 20nmol/L and 50nmol/L bortezomib 
respectively when compared with the expected cell viability of the combination. 
Decreased apoptosis was confirmed in the combination by western blotting which 
showed decreased PARP cleavage when cells were pre-treated with MSA compared with 
bortezomib alone. 
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There have been reports in the literature of potential therapeutic agents inhibiting the 
cytotoxic effect of bortezomib and the mechanism of interaction has been a chemical one 
with the boronic acid group of bortezomib. This has been reported for flavonoids (Liu et 
al, 2008) and polyphenols (Golden et al, 2009). The interaction between MSA and 
bortezomib is not a chemical one as pre-treatment of cells with MSA enhances the 
antagonism and MSA did not prevent inhibition of proteasome activity as demonstrated 
by western blotting and a proteasome activity assay.  
 
Other mechanisms of resistance to bortezomib have also been reported, including the 
induction of GRP78. As already discussed, GRP78, a molecular chaperone found mainly 
in the ER, promotes cell survival and has been implicated in chemo-resistance (Lee, 
2007). In addition, it has been demonstrated that GRP78 is expressed on the cell surface 
of tumour cells (Arap et al, 2004) and it can also be secreted by tumour cells (Kern et al, 
2009). Thus, targeting GRP78 is being explored as a therapeutic option (Lee, 2007).  It 
was recently reported that certain solid tumour cell lines secrete GRP78 and this resulted 
in resistance to bortezomib both in vitro and in vivo. Knockdown of GRP78 restored 
sensitivity to bortezomib and the addition of recombinant GRP78 to bortezomib-sensitive 
cell line cultures induced resistance. Direct interaction of GRP78 and bortezomib was 
excluded as the mechanism of resistance but it was shown that the addition of GRP78 to 
cell cultures induced pro-survival intracellular signalling proteins such as p-Erk and p-
Akt, suggesting that GRP78 may interact with cell surface receptors (Kern et al, 2009).     
 
GRP78 expression was therefore investigated in JeKo-1 and Granta-519 cells. These cell 
lines had a low level of basal GRP78 expression but at concentrations that resulted in 
antagonism both MSA and bortezomib alone resulted in induction of GRP78 expression, 
the mechanism of which is the accumulation of unfolded proteins (Obeng et al, 2006; 
Park et al, 2005). The induction by MSA was maximal at 24 hours but GRP78 had not 
returned to baseline by 72 hours. The combination of MSA pre-treatment followed by 
bortezomib resulted in a less than additive increase in GRP78 expression, although the 
increase was more than that with bortezomib alone. Thus, this may be a mechanism by 
312 
 
which MSA antagonises the effect of bortezomib. To confirm this, further experiments to 
knockdown the expression of GRP78 would be required.  
 
Induction of ER stress leads to activation of the three transducers of the UPR (Szegezdi et 
al, 2006). When PERK is activated it leads to phosphorylation of eIF2α. Depending on 
the degree of cellular stress, phosphorylation of eIF2α can promote cell survival, by 
reducing the rate of protein translation and inducing growth arrest, or apoptosis, through 
the induction of pro-apoptotic proteins such as GADD153 (Rutkowski & Kaufman, 
2007). A recent study of bortezomib in multiple myeloma reported that bortezomib-
resistance was associated with eIF2α dephosphorylation and suppression of its 
downstream target GADD153.  Treatment of myeloma cells with a chemical that induced 
phosphorylation of eIF2α enhanced bortezomib-induced cytotoxicity. Similar effects 
were seen with the proteasome inhibitor MG-132 (Schewe & Aguirre-Ghiso, 2009). 
Phosphorylation of eIF2α was therefore examined in the MCL cell lines and both JeKo-1 
and Granta-519 cells displayed phosphorylation of eIF2α at baseline. MSA decreased the 
phosphorylation of eIF2α with a maximal effect at 6 hours and a return to baseline levels 
with longer exposure times. Bortezomib alone increased the phosphorylation of eIF2α as 
did the combination of MSA pre-treatment followed by bortezomib. It is difficult to know 
how to interpret these results without further experiments. Clearly, the combination of 
MSA and bortezomib increases the phosphorylation of eIF2α but pre-treatment with 
MSA initially decreases this. The cellular effects of this would have to be studied by 
either over-expressing or inhibiting p-eIF2α to see whether this reversed the protective 
effect of MSA. 
 
ER stress activates autophagy, which is mainly a mechanism of cell survival whereby 
cells degrade long-lived proteins and protein aggregates (Ogata et al, 2006). However, 
like ER stress and the UPR, autophagy has been implicated both in cancer cell death and 
survival. Bortezomib has been shown to induce autophagy and in human prostate cancer 
cell lines this was a protective cellular response mediated by p-eIF2α. When bortezomib 
was combined with inhibitors of autophagy, cell death was enhanced (Zhu et al, 2010).  
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Similarly, in human breast cancer cell lines, induction of autophagy was shown to be a 
mechanism of resistance to bortezomib (Milani et al, 2009). However, the consequence 
of bortezomib-induced autophagy is not clear cut as some studies have reported it to 
result in cell death and thus the effect may be cell-type dependent (Belloni et al, 2010; 
Hoang et al, 2009). Both MSA and bortezomib induced autophagy in JeKo-1 and Granta-
519 cells, demonstrated by an increase in LC3-II levels by western blotting. The increase 
in LC3-II was maximal at 24 hours in MSA treated cells and then returned to baseline. 
Unexpectedly, the combination of MSA pre-treatment followed by bortezomib resulted in 
less of an increase in LC3-II compared with bortezomib alone, suggesting that MSA 
inhibits bortezomib-induced autophagy. Again, the consequences of this require further 
investigation, for example, by combining a known inhibitor of autophagy with 
bortezomib to assess the effect on cell death.     
 
Bortezomib-induced cytotoxicity is associated with altered expression of Bcl-2 family 
proteins although these effects differ depending on the cell type. For example, in multiple 
myeloma cell lines, bortezomib-induced apoptosis was associated with down-regulation 
of Bcl-2 (Mitsiades et al, 2002). However, in MCL cell lines, bortezomib did not alter 
Bcl-2 expression (Perez-Galan et al, 2006). The expression of two anti-apoptotic Bcl-2 
family members, Bcl-2 and Mcl-1, was investigated by western blotting. Of note, Mcl-1 
is degraded by the proteasome, so bortezomib results in its accumulation, at least in the 
short term (Nencioni et al, 2005). MSA 10µmol/L alone for 72 hours resulted in 
increased expression of Bcl-2 but bortezomib 50nmol/L alone for 24 hours did not. The 
combination of MSA pre-treatment for 48 hours, followed by bortezomib, further 
increased Bcl-2 expression. Both MSA and bortezomib alone increased the expression of 
Mcl-1 and the combination showed a larger increase. Therefore, modulation of Bcl-2 
family proteins by MSA may explain, in part, the antagonism seen with bortezomib.  
 
In summary, pre-treatment of MCL cell lines with MSA antagonises the cytotoxic effect 
of bortezomib. This is not through a chemical interaction as proteasome inhibition is not 
prevented, but may be through the modulation of Bcl-2 family proteins. Although both 
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drugs induce ER-stress and autophagy in the MCL cell lines it is not entirely clear from 
the experiments performed what role these cellular responses play in cell survival. 
However, it can be concluded that Se supplementation, in patients with MCL treated with 
bortezomib, should be avoided. 
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CHAPTER 9: The investigation of methylseleninic acid uptake and 
metabolism by diffuse large B-cell lymphoma cell lines and peripheral 
blood mononuclear cells. 
 
9.1 INTRODUCTION 
Methylselenol is thought to be the metabolite responsible for the anti-tumour effects of 
Se compounds but, because of its high volatility, it cannot be directly measured or 
quantified (Ip et al, 2000). In this thesis, the compound MSA has been used as a 
precursor of methylselenol to study its effects in lymphoma cell lines and normal cells. 
Once taken up by cells, MSA is reduced by enzymatic and non-enzymatic reactions to 
methylselenol. MSA reacts with cellular thiols, compounds that contain the functional 
group composed of a sulfur-hydrogen bond (-SH), such as GSH and cysteine-containing 
molecules. Intermediate compounds are formed such as methylselenenylsulfide, which is 
reduced to methylselenol in the presence of excess thiol, and reaction with GSH results in 
methylselenoglutathione, which undergoes NADPH-dependent reduction by glutathione 
reductase to methylselenol (Ip et al, 2000). Other seleno-sulphur conjugates have been 
detected as a result of spontaneous reaction of MSA with thiols, including S-
methylselenocysteine and S-methylselenoglutathione (Gabel-Jensen et al, 2008). Once 
formed, methylselenol can be further methylated to form dimethylselenide, which in vivo 
is excreted in breath, and trimethylselenonium, which in vivo is excreted in urine (Ohta et 
al, 2009). Additionally, methylselenol can be demethylated to form hydrogen selenide 
which is the essential metabolite for the incorporation of Se into selenoproteins (Rayman 
et al, 2008; Suzuki et al, 2006b). Hydrogen selenide, that is not required for selenoprotein 
synthesis, is converted to selenosugars, which are the main Se metabolites excreted in 
urine after ingestion of Se compounds (Kuehnelt et al, 2007; Ohta et al, 2009).  Other 
metabolites of MSA have also been identified. When rat hepatocytes were exposed to 
MSA, the major metabolite identified was MSC, with SLM identified as a minor 
metabolite. MSC was formed via the intermediates S-methylselenocysteine and S-
methylselenoglutathione (Gabel-Jensen et al, 2009b). Volatile metabolites, other than 
methylselenol, have also been identified in the head-space of cells exposed to MSA. 
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These have been identified as dimethylselenide and dimethyldiselenide (Gabel-Jensen et 
al, 2009a; Goenaga-Infante et al, 2007a). Of interest, dimethyldiselenide can be formed 
by combining MSA with GSH in aqueous solution in the absence of cells indicating that 
it is a reaction product rather than a metabolic product (Gabel-Jensen et al, 2009a). 
Experiments, in which methylselenol was produced in situ, demonstrated that 
dimethyldiselenide is spontaneously formed by oxidation of methylselenol and hence 
may be a good indicator for the production of methylselenol in vitro (Gabel-Jensen et al, 
2010). As an aside, these volatile species have a pungent garlic odour when working with 
Se compounds in the laboratory. 
 
MSC seems to be the most promising compound for clinical use, as compared with other 
organic Se compounds it is more efficiently converted to methylselenol and has more 
potent anti-tumour properties (Ip et al, 1991; Ohta et al, 2009; Suzuki et al, 2006a). MSC 
can be directly converted to methylselenol by cysteine S-conjugate β-lyase (β-lyase) 
enzymes and the subsequent metabolic reactions are the same as those described above 
for MSA (Rayman et al, 2008). In addition, MSC can be oxidised to MSC-selenoxide and 
this can be converted to MSA by β-lyase enzymes (Ganther, 1999).  β-lyase enzymes are 
pyridoxal 5’-phosophate (PLP)-dependent enzymes that primarily are involved in amino 
acid metabolism but catalyse β-elimination reactions as a secondary function. At least 13 
mammalian enzymes with β-lyase activity have been identified, most showing a wide 
distribution in mammalian tissue, but with highest activity in the liver and kidney 
(Cooper et al, 2010; Cooper & Pinto, 2006). In addition, it has been demonstrated that 
commonly found bacterial species in the human intestine possess β-lyase activity and 
may play a role in the activation of selenocysteine derivatives (Schwiertz et al, 2008). 
Studies investigating the metabolism of orally administered MSC in rats have reported 
that MSC is taken up, intact, by a number of organs and then converted to methylselenol 
(Suzuki et al, 2006a; Suzuki et al, 2008). It is not clear, however, how much β-lyase 
activity tumour cells possess as this has not been extensively investigated.  One study 
measured the β-lyase activity in normal and tumour tissue from patients with renal 
carcinoma. The enzyme activity in a large proportion of tumours was significantly higher 
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than in the adjacent normal tissue (Nelson et al, 1995). The β-lyase activity in the T-cell 
leukaemia cell line, Jurkat, was indirectly determined by incubating cells with MSC and 
measuring the generation of dimethyldiselenide, as a marker of methylselenol production, 
in the headspace of the cells. However, dimethyldiselenide was not detected suggesting 
these cells do not possess β-lyase activity (Gabel-Jensen et al, 2010). β-lyase activity in 
other human malignancies has not been reported.  
 
The in vitro metabolism of MSA is, therefore, relevant to the in vivo use of MSC and has 
been investigated by our laboratory in DLBCL cell lines (Goenaga-Infante et al, 2007a; 
Juliger et al, 2007). This has been described in Chapter 1 (section 1.3.12) but will be 
briefly summarised again. These experiments used very high concentrations of MSA, 
200µmol/L. Differences in baseline Se concentration were found between cell lines, with 
the MSA-sensitive cell line RL having a higher baseline level than two MSA-resistant 
cell lines (DHL4 and DoHH2). After exposure to MSA for 4 hours, the intracellular Se 
concentration of the DHL4 cell line increased by a larger amount compared to the RL cell 
line. Intracellular Se metabolites were studied in DHL4 cells and the main metabolite 
formed after 4-hour exposure to MSA was MSC, but SLM and γ-glutamyl-MSC were 
also detected as minor metabolites. In the headspace of DHL4 cells exposed to MSA, the 
main volatile metabolite detected was dimethyldiselenide and after longer exposure 
times, dimethylselenide was detected as a minor metabolite (Goenaga-Infante et al, 
2007a; Juliger et al, 2007). 
 
The experiments reported in this chapter were performed to investigate and compare the 
uptake and metabolism of a clinically relevant concentration of MSA (20µmol/L) in 
DLBCL cell lines and PBMCs collected from healthy volunteers. Given that the action of 
Se differs in tumour and normal cells, the hypothesis being tested in this chapter was that 
the uptake and metabolism of MSA may differ between lymphoma cell lines and PBMCs. 
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9.2 AIMS 
1) To investigate the uptake of MSA in DLBCL cell lines and PBMCs. 
2) To compare the intracellular metabolites of MSA in DLBCL cell lines and PBMCs 
using a clinically relevant concentration. 
3) To compare the generation of volatile Se species in the DHL4 cell line and PBMCs. 
4) To establish the feasibility of measuring intracellular Se metabolites as a 
pharmacokinetic end-point in patients receiving MSC in the planned clinical trial. 
 
9.3 METHODS 
9.3.1 Sample preparation for total selenium determination and intracellular 
selenium species 
Sample preparation was performed at the Institute of Cancer, Barts Cancer Centre. 
Harvested PBMCs were set in culture medium at 1x10
6 
cells/ml and 10 million cells were 
used for each experimental condition. The DHL4 and RL cell lines were reset in fresh 
culture medium at 5x10
5
/ml and 10 million cells were used for each experimental 
condition. Cells were exposed to 20µmol/L MSA for different time periods between 10 
minutes and 24 hours. This concentration of MSA was chosen because in the forthcoming 
clinical trial the aim is to achieve a plasma Se concentration of 20µmol/L. Cells were 
then lysed as described for western blot sample preparation (Chapter 2, section 2.4.3) and 
the lysates stored at -80°C until analysis.  
 
9.3.2 Determination of total intracellular selenium concentration 
These experiments were performed at LGC (Teddington, London, UK). The high-
performance liquid chromatography (HPLC) and MS conditions are described in Table 
9.1. To quantify total Se in the cell lysates the sample was initially diluted 1:1 with 2% 
nitric acid (LGC standards) in deionised water. 10µl of the diluted sample was then 
injected by flow injection into an Agilent 1200 HPLC (Agilent Technologies, Palo Alto, 
CA, USA). Each sample was injected in triplicate in a stream of ultra-pure water (ELGA 
water purification unit, ELGA, Marlow, UK) as the sample carrier. This was coupled on-
line to an Agilent 7500i inductively coupled plasma (ICP)-MS for the detection of Se 
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isotopes. Calibration standards of Se at concentrations of 1, 2, 5, 25 and 100µg/kg were 
prepared in lysis buffer (the same as that used to lyse the original cell sample) and diluted 
1:1 with 2% nitric acid in deionised water.  
 
There are 6 naturally occurring isotopes of Se, and 5 are stable (
74
Se, 
76
Se, 
77
Se, 
78
Se, 
80
Se). 
80
Se is the most abundant isotope, but the dimer 
40
Ar2
+ 
overlaps with its mass signal 
resulting in interference (B'Hymer & Caruso, 2006). Therefore, quantification was 
performed using the peak area measurements of the chromatographic signals for the Se 
isotope 
78
Se, the second most abundant isotope. Rhodium was used as the internal 
standard. An example of a standard curve using 
78
Se is shown below (Figure 9.1; r=1). 
Lysis buffer diluted 1:1 with 2% nitric acid in deionised water was used as a reagent 
blank. The lower quantification limit was set as 2.5µg/kg Se, representing 10 times the 
SD of at least four blank replicates. Figure 9.2 shows the chromatographic peak of one 
PBMC control sample in comparison with the reagent blank. Similar results were 
obtained for the two DLBCL cell lines, thus the basal Se concentration of the cell lines 
and PBMCs was below the lower quantification limit.  
 
 
Figure 9.1 Standard curve of the Se isotope 
78
Se, obtained by the standard addition 
technique (cps; counts per second).  
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Figure 9.2 Chromatographic peak of reagent blank (black line) and 2 replicates of a 
peripheral blood mononuclear cell control sample (green and yellow lines). 
 
 
9.3.3 Measurement of intracellular selenium species  
These experiments were performed at LGC (Teddington, London, UK). HPLC and MS 
conditions are described in Table 9.1. Cell lysates were analysed by reverse-phase HPLC-
ICP-MS. The Agilent 1200 HPLC system was used for chromatographic separations and 
the Agilent 7500i quadrupole ICP-MS for element-specific detection. Chromatographic 
data were analysed using Agilent Technologies ICP-MS chromatographic software 
(G1824C version C.01.00). Se standards, which included sodium selenite, SLM, MSC, 
dimethylselenide and dimethyldiselenide, were purchased from Sigma-Aldrich and γ-
glutamyl-MSC was purchased from PharmaSe
®
, Inc. SLM stock solution was prepared 
using 0.1M hydrochloric acid. All other standards were diluted in ultra pure water and 
stored at 4°C. The chromatographic signal for 
78
Se was monitored. 
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Verification of the presence of S-methylselenoglutathione by HPLC-ESI MS/MS 
To identify an unknown Se-containing chromatographic peak, electrospray ionisation 
(ESI) followed by MS/MS was performed. An Agilent 1200 HPLC system coupled to an 
Agilent 6300 Ion Trap LC-MS were used. HPLC and MS conditions are described in 
Table 9.1. The cell lysate was injected into the reversed-phase column and the effluent 
was fed directly into the electrospray source. For ions containing Se, product ion spectra 
were acquired in the collision-induced dissociation mode. Confirmation of S-
methylselenoglutathione was based on the MS/MS data obtained by fragmentation of the 
parent ion, m/z 402, using collision-induced dissociation. Data acquisition and processing 
were performed using the Agilent 6300 Ion Trap software, version 6.2.  
 
 
Table 9.1 HPLC-ICP-MS and the HPLC-ESI-MS/MS operating conditions   
HPLC conditions 
Column 
 
 
Injection loop 
Flow rate  
Mobile phase 
 
Zorbax microbore 300SB-C18 
(250mm length x1.0mm id x 5µm particle 
size) 
5µl 
50µl/min (30µl/min for ESI) 
0.1% TFA (formic acid for ESI) in 2% 
methanol/98% ultrapure H2O 
ICP-MS settings 
RF power 
Plasma argon flow rate 
Make-up argon flow rate 
Nebuliser argon flow rate 
 
1300W 
15 l/min 
0.31 l/min 
0.81 l/min 
ESI-MS/MS setting 
ESI mode 
Capillary voltage 
Dry gas 
Nebulisation gas 
Collision energy 
Collision gas 
m/z range 
 
Positive 
4.0 kV 
12 l/min 
39 psi 
20 eV 
N2 
200-1000 
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9.3.4 Measurement of volatile selenium compounds 
Sample preparation 
Harvested PBMCs and DHL4 cells were set in culture medium at 1x10
6
/ml and 10 
million cells were used for each experimental condition. The cells were transferred into a 
15ml glass vial and exposed to 20µmol/L MSA. The glass vials were placed in a cell 
culture incubator at 37°C in a humidified atmosphere with 5% CO2 for a range of time-
points. 
 
Solid phase microextraction capture of volatile selenium compounds 
These experiments were performed at LGC. In order to capture the volatile selenium 
species generated by MSA treatment, a 75µm Carboxen polydimethylsiloxane solid 
phase microextraction (SPME) fibre (Supelco, Sigma-Aldrich) was passed through the 
septum of the glass vial and placed in the 5ml headspace above the PBMCs and DHL4 
cells for the last 10 minutes of the exposure. Prior to this the SPME fibre had been 
exposed to a conditioning temperature of 230°C for 30 minutes. The fibre was then held 
in the inlet liner of the gas chromatogram for the duration of the chromatographic run. 
 
Identification of volatile Se species by Cryogenic Oven Cooling (COC) Gas 
Chromatography (GC) and Time of Flight Mass Spectrometry (TOFMS) 
COC enables the trapping of volatile compounds on the GC column by cooling the whole 
oven down to temperatures as low as -60°C. GC-TOFMS measurements were performed 
using an Agilent 6890 GC coupled to the Leco Pegasus III TOFMS (Leco, St Joseph, 
Michigan, USA). The GC and TOFMS conditions are described in Table 9.2. For 
separation of the volatile species, a HP Ultra2 column was used. TOF mass calibration 
was performed using perfluorotributylamine. A splitless injection mode was used with 
helium as the carrier gas. The initial temperature of the column was set at -35°C for 3 
minutes and reached a final temperature of 250°C with a gradient of 15°C/min. Mass 
spectra were recorded over a m/z range of 40 to 500. The LECO ChromaTOF™ software 
version 2.25 (optimized for Pegasus) was used for data acquisition and processing.  
Dimethylselenide and dimethyldiselenide were used as standards.  
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Table 9.2 GC-TOFMS operating conditions 
GC conditions 
Column 
 
Carrier gas 
Helium flow rate 
Injector temperature 
Splitless time 
Purge flow 
Transfer line temperature 
Oven programme 
 
HP ultra 2 (25m length x 0.2mm id x 
0.33µm particle size) 
Helium 
1 ml/min 
230°C 
3 minutes 
20 ml/min 
280°C 
-35°C, 3 minutes isothermal; then 
15°C/min to 250°C; then 2 minutes 
isothermal 
TOFMS settings 
m/z range 
Acquisition rate 
Ion source temperature 
 
50-400 
5 spectra/second 
230°C 
 
 
9.3.5 Tumour selenium measurements 
Samples 
The request to measure Se concentration in stored tumour biopsy samples from patients 
with lymphoma received a favourable ethical opinion from the East London and City HA 
Local Research Ethics Committee. Se concentration in biopsy samples from 16 patients 
with DLBCL was determined. These were samples obtained from patients who were 
diagnosed with DLBCL at SBH between 1986 and 1996, in whom the presentation serum 
Se had previously been determined (Last et al, 2003). Fresh frozen samples had been 
stored in liquid nitrogen and approximately 0.1g of tissue (the weight was recorded 
accurately to two decimal places) was cut from the original biopsy sample, placed into 
glass vials and used for analysis. Further sample preparation and analysis was performed 
at LGC (Teddington, London, UK). 
 
1ml of nitric acid/hydrogen peroxide (1:1) solution was added to each tumour tissue. 
Samples were digested in a microwave oven (CEM, UK) using the standard programme 
(150˚C for 10 min). Digested samples were diluted up to 10g with ultra-pure water before 
analysis. Certified reference material (CRM) were mineralised and analysed in duplicate 
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in parallel with the tumour samples to evaluate the accuracy of the procedure. The CRM 
used were DORM-2 dogfish muscle (National Research Council of Canada) and bovine 
liver (National Institute of Standards and Technology, USA) with certified concentrations 
for Se of 1.40  0.09mg/kg and 0.73  0.06mg/kg respectively. 
 
Sample analysis 
20µl of each sample was injected, in triplicate, into the Agilent 1200 HPLC (without an 
LC column). This was combined on-line to an Agilent 7500i ICP-MS for detection of Se 
isotopes. Quantification was performed by external calibration, monitoring the Se isotope 
78
Se, and rhodium was used as the internal standard. Peak area was used for 
quantification. 
 
9.3.6 β-lyase activity in lymphoma cell lines 
β-lyases are PLP-dependent enzymes involved in the bioactivation of selenocysteine 
conjugates into selenols. β-lyase activity in lymphoma cell lines was determined by 
measuring the formation of pyruvate after incubating cell lyastes with MSC and PLP as 
per the reaction shown below. The method used was modified from a previous 
publication (Zhang & Hanigan, 2003). 
 
MSC                                      selenol + ammonia + pyruvate 
  
 
Preparation of whole cell lysates  
Cell lysates were prepared from 40 million cells. DHL4, RL and JVM2 cells were used in 
these experiments. The renal adenocarcinoma cell line, ACHN (ATCC, VA, USA) was 
used as a positive control. Cells were pelleted by centrifugation at 210g for 6 minutes at 
room temperature. The supernatant was discarded and the cells washed twice in HBSS by 
centrifugation at 210g for 6 minutes at room temperature. The cells were resuspended in 
250µl lysis buffer as per the western blotting protocol for cell lysis (Chapter 2, section 
2.4.3). Samples were left on ice for 20 minutes and then centrifuged at 20,800g for 10 
β-lyase 
PLP 
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minutes at 4°C to remove insoluble cellular debris. The supernatant was removed and 
placed into fresh tubes. 
 
Preparation of the ‘reaction mix’ (RM) 
The RM consisted of PLP, MSC and potassium phosphate buffer pH 7.2 (K2HPO4). The 
following stock solutions were prepared and stored at -20°C until further use: 25mg/ml 
PLP (Sigma-Aldrich) in 1M HCl, 5mM MSC (PharmaSe
®
 Inc.) in deionised water and 
100mM K2HPO4  in deionised water and the pH adjusted to 7.2 with phosphoric acid. 
From these stock solutions 10mls of the RM was prepared by mixing 9.1ml K2HPO4, 
910µl MSC and 1µl PLP.  
 
β-lyase assay 
200µl of the cell lysate was placed into fresh eppendorf tubes. 40µl of the RM was added 
to this. As a control, water was added to the cell lysate instead of the RM. The samples 
were then incubated for 15 minutes at 37°C. Following this, the pyruvate released was 
converted to pyruvate 2,4-dinitrophenylhydrazone by the addition of 2µl of 0.2M 2,4-
dinitrophenylhydrazine phosphoric acid solution (Sigma-Aldrich). The samples were 
incubated again for 15 minutes at 37°C. This was followed by the addition of 320µl of 
2M potassium hydroxide (Sigma-Aldrich). 100µl of each sample was transferred 
immediately to a 96-well plate and the absorbance of pyruvate 2,4-
dinitrophenylhydrazone at 450nm was measured on the POLARstar OPTIMA plate 
reader (BMG Labtech). A standard curve was prepared using sodium pyruvate (Sigma-
Aldrich) with a concentration range of 31.25 to 1000µmol/L. An example of a pyruvate 
standard curve is shown below (Figure 9.3; r=0.99). Results were expressed as a 
percentage of control. 
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Figure 9.3 Standard curve for sodium pyruvate used to quantify β-lyase activity in cell 
lines. 
 
 
9.4 RESULTS 
9.4.1 Total intracellular selenium concentration in DLBCL cell lines and peripheral 
blood mononuclear cells exposed to MSA 
Total intracellular Se concentration was determined in the RL and DHL4 cell lines and 
PBMCs exposed to 20µmol/L MSA for a range of time-points. Figure 9.4 shows the total 
intracellular Se concentration in the two DLBCL cell lines and Figure 9.5 shows the total 
intracellular Se concentration in PBMCs. The data were variable, but it appears that in the 
DLBCL cell lines MSA was taken up rapidly by the cells, with the maximum 
intracellular Se concentration reached after only 10-minute exposure. There was then a 
trend towards a decrease in Se concentration at 6- and 24-hour exposure, particularly in 
the DHL4 cell line. In contrast, the intracellular Se concentration in PBMCs increased 
more slowly with a maximum concentration reached at 4- to 6-hour exposure, followed 
by a decrease by 24 hours. The mean values at each time point were, in general, lower 
than those obtained in the lymphoma cell lines. In addition, the area under the curve 
(calculated using the GraphPad PRISM
® 
software) for PBMCs (2236µg/kg.hrs) was 
0
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lower than that for the DLBCL cell lines (RL, 3367µg/kg.hrs; DHL4, 3102µg/kg.hrs), 
suggesting that overall Se uptake by PBMCs was less. However, meaningful statistical 
analysis was not possible due to limited data. Of note, the Se concentration in all the 
control samples were below estimated quantification limits, therefore these values should 
not be considered as exact values.  
 
 
 
 
Figure 9.4 Total intracellular selenium concentration in RL and DHL4 cell lines exposed 
to 20µmol/L MSA. Data points are the means+/-SD of 2 separate experiments. 
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Figure 9.5 Total intracellular selenium concentration in PBMCs exposed to 20µmol/L 
MSA. Data points are the mean+/-SD of 5 separate experiments. *p=0.03 comparing 2- 
and 6-hour exposure. 
 
 
9.4.2 Intracellular selenium species in DLBCL cell lines and peripheral blood 
mononuclear cells 
DHL4 and RL cell lines exposed to 20µmol/L MSA for 1 and 2 hours 
In the DHL4 cell line exposed to 20µmol/L MSA for 1 and 2 hours, three main Se-
containing peaks were detected. These are shown in Figure 9.6. The peak with the highest 
intensity was dimethylselenide, which had a retention time of around 35 minutes (peak 
C). Peak A, which had a retention time of around 5 minutes, was MSC. The identity of 
peak D, which had a retention time of around 60 minutes, was unknown. There was also 
a very small peak (peak B) with a retention time of around 11 minutes, which was SLM. 
In the RL cell line, the same peaks were detected with the exception of MSC, which was 
not present in any sample (Figure 9.7). The peak with the highest intensity was again 
dimethylselenide. 
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Figure 9.6 Representative chromatograms demonstrating intracellular selenium species 
generated in the DHL4 cell line exposed to 20µmol/L MSA (a) Control (b) 1-hour 
exposure (c) 2-hour exposure. Peak A is MSC, peak B is SLM, peak C is 
dimethylselenide and peak D is unknown. Experiments have been performed in duplicate. 
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Figure 9.7 Representative chromatograms demonstrating intracellular selenium species 
generated in the RL cell line exposed to 20µmol/L MSA (a) Control (b) 1-hour exposure 
(c) 2-hour exposure. Peak B is SLM, peak C is dimethylselenide and peak D is unknown. 
 
 
PBMCs exposed to 20µmol/L MSA for 1 and 2 hours 
In PBMCs exposed to 20µmol/L MSA, three Se-containing peaks were detected (Figure 
9.8). The peak with the highest intensity was peak D whose identity was not known. 
Dimethylselenide (peak C) and a small amount of SLM (peak B) were detected but 
similar to the RL cell line, MSC was not detected. The intensity of the dimethylselenide 
peak compared to the DLBCL cell lines was at least 10 times lower. 
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Figure 9.8 Representative chromatograms demonstrating intracellular selenium species 
generated in peripheral blood mononuclear cells exposed to 20µmol/L MSA (a) Control 
(b) 1-hour exposure (c) 2-hour exposure. Peak B is SLM, peak C is dimethylselenide and 
peak D is unknown. Experiments have been performed in duplicate. 
 
Identification of the unknown peak 
The unknown peak with a retention time around 60 minutes was identified using HPLC-
ESI-MS/MS. In this method, the unknown Se-containing species is ionised by electro-
spray and after detection of the parent ion, the parent ions are further fragmented. The 
fragment ions that are generated are then detected, so there are two mass detection steps, 
hence the MS/MS terminology. Based on the masses of the fragment ions it is possible to 
identify unknown elemental species by matching them with published mass spectra 
libraries. Figure 9.9 shows the fragmentation pattern of the unknown parent ion, m/z 402, 
which was subsequently identified as S-methylselenoglutathione. 
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Figure 9.9 Fragmentation pattern of the unknown parent ion, m/z 402, consistent with S-
methylselenoglutathione. 
 
 
Ratio of dimethylselenide to S-methylselenoglutathione in DLBCL cell lines and 
PBMCs 
The two Se species with the highest intensity detected in both DLBCL cell lines and 
PBMCS were dimethylselenide and S-methylselenoglutathione. However, in the DLBCL 
cell lines, dimethylselenide was the peak with the highest intensity whereas in PBMCs, 
S-methylselenoglutathione was the peak with the highest intensity, although the intensity 
was similar to that in the DLBCL cell lines. Therefore, the ratio of these 2 peaks differed 
between DLBCL cell lines and PBMCs, as shown in Table 9.3. 
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Table 9.3 The ratio of dimethylselenide to S-methylselenoglutathione in DLBCL cell 
lines and peripheral blood mononuclear cells 
 
Cell type 
MSA 
20µmol/L 
Ratio of dimethylselenide:S-
methylselenoglutathione 
(mean+/-SD) 
DHL4 cell line 1 hour (n=2) 12.5+/-6.5 
 2 hours (n=2) 10.6+/-5.6 
RL cell line 1 hour (n=1) 8.1 
 2 hours (n=1) 7 
PBMCs 1 hour (n=2) 0.8+/-0.3 
 2 hours (n=3) 1.6+/-1.2 
 
 
DHL4 and RL cell lines exposed to 20µmol/L MSA for 24 hours 
In Chapter 4 (Figure 4.4) it was demonstrated that 24-hour exposure to MSA depleted 
intracellular GSH in the RL cell line but not in the DHL4 cell line. This difference could 
be explained by differences in the formation of S-methylselenoglutathione. Therefore, the 
intracellular Se species generated in the RL and DHL4 cell lines after exposure to 
20µmol/L MSA for 24 hours was determined (Figure 9.10).  However, in both cell lines 
the intensity of the S-methylselenoglutathione peak was similar at 24 hours and the peak 
intensity was not different from that at 1- and 2-hour exposure. Of note, both cell lines 
have similar basal levels of GSH (Chapter 4, Figure 4.4). The intensity of the 
dimethylselenide peak increased markedly at 24 hours compared with 1- and 2-hour 
exposure. MSC was now detected in both cell lines whereas at 1- and 2-hour exposure it 
was only present in the DHL4 cell line. SLM was still detected at 24 hours but at a 
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similar intensity to that at 1- and 2-hour exposure. An additional peak was present at 24 
hours (peak C), which was identified as γ-glutamyl-MSC. Due to time constraints, 
PBMCs exposed to 20µmol/L MSA for 24 hours has not been analysed. 
 
 
Figure 9.10 Representative chromatograms demonstrating intracellular selenium species 
generated in DLBCL cell lines exposed to 20µmol/L MSA for 24 hours (a) DHL4 control 
(b) DHL4 24 hours (c) RL control (d) RL 24 hours. Peak A is MSC, peak B is SLM, peak 
C is γ-glutamyl-MSC, peak D is dimethylselenide, peak E is S-methylselenoglutathione. 
 
 
9.4.3 Cell lysates spiked with MSA 
MSA is reduced by thiols, such as GSH, into various Se metabolites/species as described 
in the introduction. To determine which species were generated as a reaction product and 
which actually required cellular metabolism, cell lysates prepared from untreated DHL4 
cells and PBMCs were spiked with MSA and then analysed by HPLC-ICP-MS. Figure 
9.11 shows that when DHL4 cell lysates were spiked with MSA at a concentration of 
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20µmol/L, the main reaction products detected were S-methylselenoglutathione, which 
had the highest peak intensity, and SLM. In addition, MSA was detected early at a 
retention time of 3-4 minutes and a very small peak of dimethylselenide was also 
detected. In PBMCs, the main peak was S-methylselenoglutathione, which was present at 
a similar intensity to the DHL4 cell line. A very small peak of dimethylselenide was 
detected and SLM was also possibly formed, but because of a long tail on the peak of 
MSA, which extended out to the retention time of SLM, it was difficult to be certain of 
the presence of SLM.  
 
 
 
Figure 9.11 Representative chromatograms demonstrating Se species generated when 
cell lysates were spiked with MSA (a) DHL4 cell line (b) Peripheral blood mononuclear 
cells. Peak A is MSA, peak B is SLM, peak C is dimethylselenide, peak D is S-
methylselenoglutathione. Experiments were performed in duplicate. 
 
 
9.4.4 Volatile species generated by DHL4 cells and peripheral blood mononuclear 
cells exposed to 20µmol/L MSA 
The volatile species generated by DHL4 and PBMCs were dimethyldiselenide and 
dimethylselenide. However, there were differences in the rate of generation. All 
experiments were performed at least in duplicate. Figure 9.12a shows the standards, 
dimethylselenide and dimethyldiselenide. Figure 9.12b shows the chromatogram 
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generated after the SPME fibre was held above the headspace of control/untreated DHL4 
cells for 10 minutes.  
 
In the DHL4 cell line exposed to MSA for 10 minutes there was generation of both 
volatile species, but dimethyldiselenide was the peak with the greatest intensity with only 
a very small peak of dimethylselenide. However, there was variability in the intensity of 
the dimethyldiselenide peak between replicates as shown in Figure 9.13. 
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Figure 9.12 Representative chromatograms (a) Standards, dimethylselenide and 
dimethyldiselenide (b) Control/untreated DHL4 cells. SPME fibre held above the 
headspace of untreated cells and then subjected to COC-GC-TOFMS.  
338 
 
 
Figure 9.13 Representative chromatograms demonstrating the generation of volatile Se 
species in DHL4 cells exposed to 20µmol/L MSA for 10 minutes. Two replicates shown 
(a, b) to demonstrate the variability in the peak intensity of dimethyldiselenide. 
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However, in PBMCs exposed to MSA for 10 minutes only very small amounts of the 
volatile species were generated (Figure 9.14; note the change in scale). 
 
 
 
Figure 9.14 Representative chromatogram demonstrating the generation of volatile Se 
species in peripheral blood mononuclear cells exposed to 20µmol/L MSA for 10 minutes. 
 
After exposure of DHL4 cells to MSA for 30 minutes, the dimethyldiselenide peak 
plateaued. This was either because the SPME fibre had been saturated or that the 
generation of this volatile species was maximal (Figure 9.15a). The dimethylselenide 
peak had increased in intensity compared with 10-minute exposure. In PBMCs exposed 
to MSA for 30 minutes (Figure 9.15b) there was an increase in intensity of the 
dimethyldiselenide peak compared with 10-minute exposure but dimethylselenide was 
still only present at a very low level. 
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Figure 9.15 Representative chromatograms demonstrating the generation of volatile 
species in (a) DHL4 cells and (b) PBMCs exposed to 20µmol/L MSA for 30 minutes. 
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In DHL4 cells exposed to MSA for 1 hour, the dimethyldiselenide peak was stable but 
the dimethylselenide peak had again increased in intensity compared with 30-minute 
exposure (Figure 9.16a). In PBMCs exposed to MSA for 1 hour, the dimethyldiselenide 
peak reached the same maximum level as that generated by the DHL4 cell line. While the 
dimethylselenide peak had increased in intensity compared with 30-minute exposure, it 
was present at a much lower intensity than in the DHL4 cell line (Figure 9.16b). 
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Figure 9.16 Representative chromatograms demonstrating the generation of volatile 
species in (a) DHL4 cell line and (b) PBMCs exposed to 20µmol/L MSA for 1 hour.  
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9.4.5 β-lyase activity in lymphoma cell lines 
The generation of MSC differed between the DHL4 and RL cell lines after exposure to 
MSA and the two cell lines also differed in sensitivity to MSC. These differences may be 
due to differences in β-lyase activity between the cell lines and therefore this was 
determined in the DHL4, RL and JVM2 cell lines. In addition, the renal adenocarcinoma 
cell line, ACHN, was used as a positive control. The 72-hour EC50 of MSC in the 3 
lymphoma cell lines is shown in Chapter 4 (Table 4.2).  The EC50 values were 
55.8µmol/L, 21.6µmol/L and 79µmol/L for DHL4, RL and JVM2 cells respectively. 
Figure 9.17 shows that the 3 lymphoma cell lines differed in their β-lyase activity as 
determined by pyruvate generation. The RL cell line, which was relatively sensitive to 
MSC, had a significant increase in pyruvate concentration after addition of the ‘reaction 
mix’ (51%±13.5 increase; p=0.005). However, there was no detectable increase in 
pyruvate concentration in the DHL4 and JVM2 cell lines, which were relatively resistant 
to MSC. The ACHN cell line had a 383% (±114.4) increase (p=0.03) in pyruvate 
concentration after addition of the ‘reaction mix’. 
 
Figure 9.17 β-lyase activity in three lymphoma cell lines and the renal adenocarcinoma 
cell line, ACHN. Data points are the mean+/-SD of at least 3 separate experiments. 
*p=0.005 **p=0.03. p values are a comparison with the relevant controls. 
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To confirm that the sensitivity of cell lines to MSC correlated with β-lyase activity, the 
72-hour EC50 of MSC in the ACHN cell line was determined using the ATP assay. Figure 
9.18 shows that that EC50 was 16.4µmol/L (95% CI 14.5-18.5), which makes it the most 
sensitive cell line tested. The 72-hour EC50 for MSC and the corresponding β-lyase 
activity is summarised in Table 9.4. 
 
 
Figure 9.18 EC50 concentration-response curve following 72-hour exposure to increasing 
concentrations of MSC in the ACHN cell line. Data points are the mean+/-SD of three 
separate experiments.  
 
 
Table 9.4 Summary of MSC EC50 and β-lyase activity in three lymphoma cell lines and 
the ACHN cell line 
Cell line 72-hour MSC EC50 
(µmol/L) 
% increase in pyruvate generation 
(Mean+/-SD) 
DHL4 55.8 3.1+/-7.9 
RL 21.6 50.8+/-13.5 
JVM2 79 17.2+/-18.7 
ACHN 16.4 382.5+/-114.4 
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9.4.6 Tumour selenium concentration at diagnosis in patients with DLBCL 
Our laboratory has previously reported that the serum Se concentration at diagnosis is 
independently predictive of treatment response and long-term survival in patients with 
‘aggressive’ B-cell lymphoma (Last et al, 2003). However, it is not known whether the 
serum Se reflects the tumour Se concentration. Therefore, the tumour Se concentration 
was measured in diagnostic samples from the original cohort of patients for which serum 
Se had already been determined. The results are shown in Table 9.5 
 
Table 9.5 Tumour selenium concentration in presentation tumour biopsy samples in 
patients with DLBCL 
Sample No. Biopsy site Serum Se (µmol/L)*# Tumour Se (ng/g) 
1 Lymph node 0.84 177.4 
2 Spleen 1.05 362 
3 Lymph node 0.6 177 
4 Lymph node 1.19 160 
5 Lymph node 0.97 129.9 
6 Spleen 0.79 455.4 
7 Lymph node 1.51 274.3 
8 Mediastinal mass 0.89 156.3 
9 Lymph node 0.92 248.3 
10 Lymph node 1.06 306.1 
11 Lymph node 0.97 72.4 
12 Lymph node 0.54 82.0 
13 Lymph node 0.97 268.5 
14 Lymph node 1.34 190.1 
15 Spleen 1.05 343.6 
16 Lymph node 0.4 343.6 
*numbers in italics denote values below the UK reference range (1-1.88µmol/L) 
#serum Se values were those obtained from Last et al, 2003 
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Figure 9.19 shows that there was no correlation between serum and tumour Se at 
diagnosis (r=0.17). 
 
Figure 9.19 Correlation between serum and tumour selenium at diagnosis in 16 patients 
with DLBCL. 
 
9.5 DISCUSSION 
The results reported in this chapter have identified a number of differences in the 
handling of Se, in the form of MSA, between two DLBCL cell lines and PBMCs, a 
model for ‘normal cells’. The concentration of MSA used in these experiments was 
20µmol/L because in the forthcoming clinical trial, the aim is to achieve a plasma Se 
concentration of 20µmol/L. However, it is not entirely clear if an MSA concentration of 
20µmol/L would be equivalent to a plasma Se concentration of 20µmol/L. MSA has only 
been used in vivo in rats, both orally and intravenously (Suzuki et al, 2006b; Suzuki et al, 
2008). It appears that in rats, orally administered MSA and MSC produces an equivalent 
rise in plasma Se (Suzuki et al, 2008).  
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The predominant method used in this chapter was ICP-MS, which is a well established, 
robust and highly sensitive method for trace element and elemental speciation analysis. 
With ICP-MS it is possible to quantify elemental species even if their structure is 
unknown, but identification then requires matching the retention time with a known 
standard compound. This is because the extremely high temperature of the plasma ion 
source completely destroys the organic molecules present in a sample and thus ICP-MS 
only detects elemental ions. Therefore, it is the best method to use when quantitative data 
are required and reference compounds are available. However, in order to identify an 
unknown species for which a standard is not available, a commonly used method is ESI-
MS. This is less sensitive than ICP-MS for the detection of elements but is able to 
provide molecular information about the elemental species and the fragmentation pattern 
therefore allowing identification in the absence of a standard reference compound. 
However, for quantification, a standard would be required. Therefore, both these methods 
are complimentary and together are powerful tools in the field of elemental speciation 
(B'Hymer & Caruso, 2006; Francesconi & Sperling, 2005; Gammelgaard et al, 2008). In 
addition to investigating differences in Se metabolism between DLBCL cell lines and 
PBMCs, the aim of these experiments was to establish a method for analysing and 
quantifying Se species in small volume samples, similar to those that will be obtained by 
the collection of PBMCs from patients entered into the forthcoming clinical trial. 
 
For analysis of volatile Se species, SPME fibres were used to absorb the species as this 
has been demonstrated to improve the sensitivity of GC-based methods (Meija et al, 
2002). When using conventional GC, Se compounds, such as dimethylselenide, are 
poorly retained because of their relatively low boiling point (58°C). Therefore COC was 
used to trap the volatile compounds on the GC column. This involves cooling the whole 
oven down to temperatures as low as -60°C (Watanabe-Suzuki et al, 2002).  
 
Total intracellular Se concentration was determined in the DLBCL cell lines and PBMCs 
after exposure to MSA. MSA appears to be taken up into PBMCs at a slower rate than in 
the DLBCL cell lines. In the DLBCL cell lines, the maximum intracellular Se 
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concentration was reached by the earliest exposure time, 10 minutes, whereas in PBMCs 
the Se concentration did not plateau until 4-6 hours. In addition, it appears that the 
maximum intracellular concentration obtained in PBMCs was lower than in the DLBCL 
cell lines. However, because of the time and complexity of these experiments, analysis of 
DLBCL cell lines was only performed in duplicate and therefore meaningful statistical 
comparisons with PBMCs are not possible. The uptake of MSA by the RL and DHL4 cell 
lines appeared similar. This is in contrast to previously published data by our laboratory 
in which the DHL4 cell line accumulated more Se (Juliger et al, 2007). However, these 
previous experiments used higher concentrations of Se and thus it may be that the uptake 
mechanism (see below) is saturable in the RL cell line. 
 
The results for intracellular concentration were highly variable in both the cell lines and 
PBMCs and thus the SD for the data points is large. It is difficult to explain the reason for 
this. For each experimental condition 10 million cells were lysed in the same volume of 
lysis buffer. There may have been variation in the degree of cell lysis between 
experiments and therefore it may have been prudent to have determined the protein 
concentration in each sample and correct the final Se concentration for protein content. It 
is unlikely that the method of analysis, ICP-MS, is responsible for the variation, as this is 
a robust method that involves the complete fragmentation of molecules into elemental 
ions without the need for an extraction or separation step which can contribute to 
variability. The calibration curves for Se were also very reproducible. It may be that the 
variability is actually real and that uptake of MSA by cells is variable. In addition, there 
may have been efflux of MSA from the cells that could have resulted in the variability.  
 
The mechanism of MSA uptake by cells has not been extensively investigated and it is 
not known whether uptake is dependent on active mechanisms or is merely by diffusion. 
When rats were administered intravenous MSA labelled with a stable isotope, this was 
not detected in the plasma even at the earliest time-point post administration, 10 minutes. 
Instead, immediately after administration, the concentration in red cells increased 
dramatically suggesting that MSA was taken up rapidly. However, the Se concentration 
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in red cells decreased back to control levels within 30 minutes suggesting there was 
efflux of  MSA or its metabolites (Suzuki et al, 2006b). Further experiments to establish 
the exact mechanism by which MSA is taken into cells may help to understand better the 
differences observed in uptake between the DLBCL cell lines and PBMCs and the data 
variability. These could include experiments to inhibit various cellular transporters to 
establish which, if any, are required for MSA uptake. To establish whether uptake is ATP 
dependent, membrane-bound ATPases could be inhibited. In addition, measuring the Se 
concentration in the culture medium to investigate efflux of MSA by cells would be 
valuable.   
 
An unexpected finding was that the baseline Se concentration in both the DLBCL cell 
lines and PBMCs was below the lower quantification limit. However, when the same 
experiments were performed previously by our laboratory, it was possible to quantify the 
baseline Se level and differences between cell lines were reported (Goenaga-Infante et al, 
2007a; Juliger et al, 2007). The reason for this is not clear as the experimental conditions 
used were identical to those previously reported. It is unlikely that the ICP-MS itself is 
responsible for these differences as it is a highly sensitive method with an extremely low 
detection limit. However, foetal calf serum used to supplement cell culture medium 
contains Se and this may differ from batch to batch depending on where the cattle are 
from. RPMI-1640 cell culture medium itself does not contain Se. In addition, the original 
experiments were only performed once and it is possible that these cell lysates could have 
been contaminated with Se, for example when preparing the standards for the calibration 
curve.  
 
The intracellular Se species generated after exposure to MSA were determined in the 
DLBCL cell lines and PBMCs. Neither MSA nor methylselenol were detected. However, 
in DLBCL cell lines, the main intracellular species was dimethylselenide which is formed 
by methylation of methylselenol, suggesting that methylselenol is, as expected, the main 
metabolite of MSA. Dimethylselenide increased in intensity with time, being present at a 
higher concentration at 24 hours compared to that at 1- and 2-hour exposure. In addition, 
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there were other Se species detected in the DLBCL cell lines. In the DHL4 cell line, as 
previously reported by our laboratory, MSC and SLM were detected. In addition, a Se-
containing peak, later identified as S-methylselenoglutathione was also detected. The 
concentration of SLM and S-methylselenoglutathione remained fairly constant between 
the three exposure times studied (1, 2 and 24 hours). However, there was an increase in 
the intensity of MSC between 1/2-hour exposure and 24 hours. At 24-hour exposure, γ-
glutamyl-MSC was also detected but this was not present after 1- and 2-hour exposure. 
The findings were similar in the RL cell line except that MSC was not detected at 1- and 
2-hour exposure but only at 24-hour exposure. In the work previously published by our 
group, dimethylselenide and S-methylselenoglutathione, were not detected because the 
chromatograms were only run for 15 minutes and these species have retention times of 
around 35 minutes and 60 minutes respectively. This is the first report of the detection of 
dimethylselenide as an intracellular, soluble metabolite of MSA. The formation of MSC, 
SLM and S-methylselenoglutathione have all been reported previously in hepatocytes 
exposed to MSA (Gabel-Jensen et al, 2009b).  
 
Further experiments, involving spiking untreated DHL4 cell lysates with MSA, 
demonstrated that SLM and S-methylselenoglutathione were both formed as a reaction 
product and their production did not require intact cells. S-methylselenoglutathione was 
the main reaction product formed. As discussed in the introduction to this chapter, MSA 
is reduced by GSH and other thiols to intermediate metabolites other than methylselenol 
and the formation of these metabolites clearly do not require intact cells. It was thought 
that the extent of GSH conjugate formation may differ between the DHL4 and the RL 
cell lines as MSA depletes GSH in RL but not in DHL4 cells. However, both the cell 
lines generated the same amount of S-methylselenoglutathione, which remained 
relatively constant between 1/2-hour exposure and 24 hours. Therefore the generation of 
GSH conjugates, as a result of MSA exposure, does not explain the difference in GSH 
depletion observed between the two cell lines. 
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The chromatographic profile of PBMCs differed from that of the DLBCL cell lines. 
Although the same species were detected, with the exception of MSC, which was not 
detected, the intensity of the peaks differed. S-methylselenoglutathione was the main 
peak detected but this was present at a similar intensity to that seen in the DLBCL cell 
lines. Dimethylselenide, however, was present at a much lower intensity and the ratio of 
dimethylselenide to S-methylselenoglutathione was reversed in PBMCs as compared 
with the DLBCL cell lines. Of note, cell lysates of PBMCs exposed to MSA for 24 hours 
have not been analysed. Given that dimethylselenide is formed downstream of 
methylselenol, this suggests that PBMCs may generate less methylselenol than DLBCL 
cell lines. As discussed in the introduction, methylselenol can also be demethylated to 
hydrogen selenide, which can be used for selenoprotein synthesis. It may be that in 
PBMCs, methylselenol generated from MSA is metabolised through a different pathway 
and incorporated into selenoproteins rather than being available as methylselenol per se. 
This could be an explanation for the observed differences in effect of methylselenol 
precursors in normal and tumour cells. However, this hypothesis needs to be investigated 
further with additional experiments. It would be useful to determine the baseline levels of 
selenoproteins, such as GPx and TrxR, in harvested PBMCs and compare them to those 
in DLBCL cell lines. The rise in selenoprotein levels could then be measured after 
exposure to MSA.  In addition, PBMCs may have lower concentrations of GSH than 
DLBCL cell lines and thus MSA is not reduced as efficiently. When cell lysates of 
PBMCs were spiked with MSA, the main peak detected was that of S-
methylselenoglutathione confirming that this was generated as a reaction product and 
does not require the presence of intact cells. 
 
Given that the generation of MSC differed between the DHL4 and RL cell lines and that 
they had differing sensitivities to MSC, it was hypothesised that this may be due to 
differences in β-lyase activity. The DHL4 cell line was relatively resistant to MSC (EC50 
55.8µmol/L) compared to the RL cell line, which was relatively sensitive (EC50 
21.6µmol/L). Therefore it was assumed that RL cells would have higher β-lyase activity 
than DHL4 cells. In addition, MSC was formed at 1 and 2 hours exposure to MSA in 
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DHL4 cells but not in RL cells and it was hypothesised that if RL cells had higher β-lyase 
activity, MSC would be metabolised to methylselenol and not be detected. The results 
clearly demonstrate that RL cells have higher β-lyase activity than DHL4 and JVM2 cells 
(another relatively MSC-resistant cell line). After exposure of cell lysates to MSC and 
PLP (‘reaction mix’), RL cells had a 51% increase in pyruvate concentration indicating 
the conversion of MSC by β-lyases to methylselenol and pyruvate. In the DHL4 and 
JVM2 cells, there was no detectable increase in pyruvate concentration. These cell lines 
must possess some β-lyase activity as MSC is cytotoxic at high concentrations and it may 
be that the assay used was not sensitive enough to pick up these smaller increases in 
pyruvate. The other explanation may be that MSC is metabolised to its α-ketometabolite, 
MSP, by aminotransferases and L-amino oxidases as discussed in Chapter 6 and this 
metabolite may be responsible for the cytotoxicity observed at high concentrations (Pinto 
et al, 2010). It was demonstrated that the β-lyase activity of the cell lines did correlate, to 
a certain degree, to sensitivity to MSC. The ACHN cell line, which had high β-lyase 
activity demonstrated by a 383% increase in pyruvate concentration, was more sensitive 
than any of the lymphoma cell lines to MSC (EC50 16.4µmol/L). The 95% confidence 
intervals for the EC50 of RL and ACHN cells do not overlap suggesting that the ACHN 
cell line is significantly more sensitive to MSC. β-lyase activity in lymphoma cell lines 
has not been previously reported. 
 
The volatile species detected after exposure of the DHL4 cell line to MSA were the same 
as those reported previously by our laboratory (Goenaga-Infante et al, 2007a; Juliger et 
al, 2007). The main volatile species detected was dimethyldiselenide, which was rapidly 
formed after 10-minute exposure to MSA. It has been previously reported that this Se 
species is a reaction product and does not require the presence of intact cells as 
combining MSA and GSH in aqueous solution leads to rapid generation of 
dimethyldiselenide (Gabel-Jensen et al, 2009a; Gabel-Jensen et al, 2010). However, 
dimethyldiselenide is an oxidation product of methylselenol and therefore a marker of its 
generation (Gabel-Jensen et al, 2010). The intensity of the dimethyldiselenide peak was 
highly variable at 10-minute exposure and this was repeated at least four times with 
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differing results. The reason for this was felt to be the fact that dimethyldiselenide is 
generated so rapidly that any small variation in the time for which the SPME fibre is held 
in the headspace could lead to large differences in the amount of dimethyldiselenide 
absorbed. By 30-minute exposure, the intensity of the dimethyldiselenide peak had 
plateaued. A very small amount of dimethylselenide was detected at 10-minute exposure 
and this peak continued to increase with increasing exposure time but did not reach the 
maximum level of the dimethyldiselenide peak.  
 
In PBMCs, the same volatile species were detected but the rate of generation was much 
slower. At 10-minute exposure there were only very tiny amounts of dimethylselenide 
and dimethyldiselenide detected and although the peaks had increased by 30 minutes, 
with the main one being dimethyldiselenide, they were present at a much lower intensity 
than in DHL4 cells. By 1 hour, the dimethyldiselenide peak had reached the same 
maximum level generated by DHL4 cells but the dimethylselenide peak was still present 
at a much lower intensity than in DHL4 cells. The results in PBMCs are in keeping with 
the other observations made in this chapter. Firstly, uptake of MSA by PBMCs is less and 
occurs at a slower rate than DLBCL cell lines and hence the formation of reaction 
products such as dimethyldiselenide is also slower. Secondly, PBMCs form less 
dimethylselenide than DLBCL cell lines and hence the amount of volatile 
dimethylselenide detected is also less. Combined with the observation that 
dimethyldiselenide is also formed at a slower rate in PBMCs, these results demonstrate 
that PBMCs form methylselenol less efficiently than DLBCL. The proposed metabolism 
of MSA is shown in Figure 9.20. 
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Figure 9.20 The proposed cellular metabolism of MSA. 
Adapted from Gabel-Jensen, C et al., J. Anal. At. Spectrom, 2009 (Gabel-Jensen et al, 
2009b). The dashed lines represent steps that would require the relevant lyase enzymes 
and therefore would be dependent on the cell type. 
 
Although not directly related to the rest of the work presented in this chapter, tumour Se 
concentration has been included as its measurement required similar methods to those 
used for determining total intracellular Se concentration in cell lines and PBMCs. 16 
diagnostic biopsy samples were available from the original 100 patients in whom 
presentation serum Se concentration had been reported (Last et al, 2003). In this 
relatively small number of samples, there was no correlation between serum Se and 
tumour Se at diagnosis. As discussed in Chapter 1, most studies that have reported 
tumour Se levels have actually found that a low serum Se concentration is associated with 
a significantly increased tumour Se concentration when compared with adjacent non-
neoplastic tissue (Charalabopoulos et al, 2006a; Charalabopoulos et al, 2006b). Se 
concentration in normal or neoplastic lymphoid tissue has not previously been reported 
and in this study there was no non-neoplastic tissue available. Clearly it would be useful 
to determine tumour Se in a larger number of patients with DLBCL and this may be 
possible in patients entered into the forthcoming clinical trial. However, from these 
limited results it appears that the serum Se concentration does not reflect what is 
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occurring in the tumour itself which may actually support the argument that serum Se is 
merely a reflection of tumour burden and an acute phase response (Beguin et al, 1989; 
Sakr et al, 2007).  
 
In summary, the uptake of MSA by DLBCL cell lines and PBMCs differs with slower 
uptake by PBMCs. In addition, PBMCs form methylselenol less efficiently than DLBCL 
cell lines. These differences may explain, in part, why the action of organic Se 
compounds differs between normal and tumour cells.  
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CHAPTER 10: A proteomics approach to investigating the chemo-
sensitising action of methylseleninic acid 
 
10.1 INTRODUCTION 
The work presented so far in this thesis has demonstrated that Se, in the form of MSA, 
affects a number of cellular pathways in DLBCL cell lines. However, a unifying 
mechanism by which MSA sensitises these cell lines to conventional chemotherapeutic 
agents has not been established. Therefore, a more global approach was taken, in the 
form of proteomics analysis of cell lines exposed to chemo-sensitising concentrations of 
MSA. 
 
A number of studies have used a genomics approach to identify molecular mechanisms of 
Se action. DNA microarray analysis has most frequently been performed in prostate and 
breast cancer cell lines exposed to organic Se compounds, precursors of mono-
methylated Se species. These studies have identified a large number of genes, expression 
of which is altered by Se, but the results often differ depending on the form and 
concentration of Se used. Also, the effects of Se are dependent on the tissue type 
investigated. However, there are similarities in the genes identified, and commonly they 
are genes involved in cell cycle regulation, apoptosis and anti-oxidant function, 
implicating Se in the prevention of cancer initiation, progression and metastasis (El-
Bayoumy & Sinha, 2005). Gene expression in prostate biopsy samples of men with 
prostate cancer, supplemented prior to prostatectomy with SLM, vitamin E or a 
combination (in a similar way to the SELECT trial), has been performed (Tsavachidou et 
al, 2009). Laser capture micro-dissection of these biopsies was used to isolate normal 
epithelial, normal stromal and tumour cells. The study was able to identify over 500 
differentially expressed genes in the three cell types, including cell-type specific effects, 
thus demonstrating the potential global effect of Se in vivo, even at nutritional doses. 
There have been no studies published that have investigated gene expression in 
lymphoma cell lines exposed to Se. The disadvantage of a genomics approach is that 
mRNA expression does not always correlate with protein expression or activity. Reasons 
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for this include, alternative splicing of RNA, post-translational modification of proteins 
and protein degradation.   
 
Like genomics, proteomics is a rapidly expanding field. It is the study of the complete 
protein complement of a cell/organism and MS has become the method of choice for 
analysing complex protein mixtures (Aebersold & Mann, 2003). A few studies have used 
a proteomics approach to investigate the cellular effect of Se, but again this is 
predominantly in prostate cancer cell lines and has not been performed in lymphoma cell 
lines. Although these studies have used different forms and concentrations of Se, they 
have all identified novel Se-targets (Roveri et al, 2008; Sinha et al, 2008). Proteomics has 
also been able to identify protein changes in the plasma of rats supplemented with 
different forms of Se and these novel proteins have the potential to be useful as 
biomarkers of Se intake (Mahn et al, 2009a; Mahn et al, 2009b). A study using a display 
thiol-proteomics approach to identify protein redox modifications by MSA has already 
been discussed in Chapter 1 (section 1.3.9.11) (Park et al, 2005). Again, this study 
demonstrates the large number of cellular proteins that are susceptible to modification by 
Se. 
 
In addition to protein identification, MS can be used to identify post-translational 
modifications and this has most widely been used to study protein phosphorylation 
(Thingholm et al, 2009). Phosphorylation is one of the most common mechanisms of 
protein regulation, affecting both structure and function. The amino acids that are most 
frequently phosphorylated are serine, threonine and tyrosine and multiple residues can be 
phosphorylated within a protein. Protein phosphorylation is involved in the regulation of 
critical and diverse cellular functions such as cell division, proliferation, enzyme activity, 
intracellular signalling, transcription and translation (Graves & Krebs, 1999). The large 
numbers of protein kinases present within a cell are responsible for the phosphorylation 
of specific proteins and deregulated kinase activity is found in many cancers (Hunter, 
1995). Thus, ‘phospho-proteomics’ has the potential to yield valuable information about 
the functioning of a cell, pathways that may be active or de-regulated within a cell and, 
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like proteomics itself, may identify novel therapeutic targets and biomarkers for use in 
cancer therapy. Interestingly, a study investigating the effect of MSA exposure on protein 
kinases in a mouse mammary epithelial tumour cell line found that MSA resulted in the 
differential expression of a number of proteins kinases, with both up- and down-
regulation being observed (Singh et al, 2008). 
 
A phospho-proteomics approach has been used here to study the molecular affects of 
MSA in DLBCL cell lines. This has not previously been reported for the investigation of 
Se-induced changes. This approach, however, is not without its challenges. Firstly, 
proteins and phospho-proteins need to be isolated from a cellular sample. Cell lysis can 
activate proteases and protein phosphatases making proteins susceptible to degradation 
and dephosphorylation. Therefore, a mixture of protease and phosphatase inhibitors is 
added to samples to prevent this, the choice of which is crucial. Once the isolated 
proteins have been digested into peptides, the sample needs to be enriched for phospho-
peptides in order to improve the sensitivity of MS detection. This is because phospho-
peptides are particularly difficult to analyse by MS as they are not as efficiently ionised 
as non-phosphorylated peptides. Thus, MS signal intensities for phospho-peptides will be 
lower than those for the non-phosphorylated peptides present within a sample. There are 
a number of methods available for phospho-enrichment of samples, each requiring 
validation by individual user groups prior to conducting large scale experiments.  The 
method used in this study was immobilised metal ion affinity chromatography (IMAC). 
This makes uses of positively charged metal ions, such as Fe
3+
, chelated to either 
nitrilotriacetic acid or iminodiacetic acid coated beads, which can bind the negatively 
charged phospho-peptides (Paradela & Albar, 2008; Thingholm et al, 2009). In addition, 
it has been demonstrated that larger numbers of phospho-peptides are obtained by IMAC 
if samples are first pre-fractionated by strong cation exchange (SCX) (Trinidad et al, 
2006). 
 
Samples enriched for phospho-peptides are then separated by LC and identified by 
tandem MS (LC-MS/MS). However, identification of phospho-peptides is not as 
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straightforward as the identification of non-phosphorylated peptides due to their low 
abundance and low ionisation efficiency, requiring very sensitive detection methods, and 
the potential loss of labile phosphate groups. Additionally, this results in a low number of 
peptide fragment ions for identification. For protein identification it is normally possible 
to match several MS/MS spectra to a given protein. However, for phospho-peptide 
identification, only one or two ion species are detected and matched to a given phospho-
peptide. Thus, good quality MS/MS spectra are required to have full confidence in the 
findings (Alcolea et al, 2009; Paradela & Albar, 2008; Thingholm et al, 2009). The MS 
used in these experiments was the LTQ-Orbitrap XL (Thermo Fisher Scientific, Hemel 
Hempstead, UK). This is an ion-trap analyser which has the advantages of high 
sensitivity, resolution, mass accuracy and dynamic range in addition to performing full 
scans very rapidly (Aebersold & Mann, 2003). To identify the phospho-peptides present 
within a sample, the mass to charge ratio (m/z ratio) generated is compared to the m/z 
ratio within spectral reference databases to match the amino acid sequences to known 
peptides. However, the spectral databases for phospho-peptides are not as robust or 
comprehensive as those for non-phosphorylated peptides (Alcolea et al, 2009).  
 
Although technically challenging for the reasons outlined above, these proteomic studies 
were performed to identify potentially novel mechanisms underlying the chemo-
sensitising effect of MSA. 
 
10.2 AIM 
To identify novel protein changes induced by chemo-sensitising concentrations of MSA 
in a MSA-sensitive (RL) and MSA-resistant (DHL4) DLBCL cell line. A phospho-
proteomics approach has been used to provide functional information about the signalling 
pathways targeted by MSA. 
 
10.3 METHODS 
A full description of the method is given in the appendix. Figure 10.1 summarises the 
steps involved. 
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Figure 10.1 Summary of the steps involved in the phospho-proteomics experiments 
(UPLC; ultra high-performance liquid chromatography) 
 
10.3.1 Sample preparation 
The RL and DHL4 cell lines were exposed to 1μmol/L and 10μmol/L MSA respectively 
for 24 hours. Following this, 10 million cells were washed in PBS supplemented with 
Na3VO4 and NaF. Cells pellets were then snap-frozen on dry ice and stored at -20°C until 
further use. These experiments were performed on three separate occasions to obtain 
independent triplicate samples. 
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10.3.2 Cell lysis 
The cell pellets were thawed, resuspended in 1ml of lysis buffer and the cell suspension 
was sonicated. Samples were centrifuged to remove cellular debris and the supernatant 
was recovered into protein Lobind
®
 tubes (Eppendorf UK Limited). Where possible, 
samples were kept in protein LoBind
®
 tubes from this stage onwards. Cellular proteins 
were reduced with DTT followed by alkylation with iodoacetamide. Protein extracts were 
then diluted in 20mM HEPES pH 8.0 (1:4 dilution).  
 
10.3.3 Protein digestion 
Immobilised L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-trypsin beads 
(Thermo Fisher Scientific, Cramlington, UK) were used for protein digestion. 80μl of the 
beads were used per sample and beads were conditioned prior to use according to the 
manufacturers’ instructions. Following addition of the beads, samples were incubated for 
16 hours at 37°C with shaking. Digestion was stopped by adding TFA (LGC Standards) 
at a final concentration of 1%. The beads were removed by centrifugation. 
 
10.3.4 Peptide desalting 
Sep-Pak
® 
C18 cartridges (Waters UK Ltd., Manchester, UK) were used to desalt the 
peptide samples.  
 
10.3.5 Phospho-peptide enrichment by immobilised metal ion affinity 
chromatography 
IMAC sepharose
TM
 high performance beads (GE healthcare) were used to separate the 
phospho-peptide component of the peptide sample. Firstly, the beads were conditioned 
and charged with Fe
3+
. The beads (300µL/sample) were then added to each sample and 
placed on a rotatory mixer for 1 hour. Following this, samples were centrifuged and the 
supernatant recovered (i.e. non-phosphorylated peptides). The phospho-peptides were 
eluted using ammonia water (LGC standards). Both the fractions containing the non-
phosphorylated and phospho-enriched peptides were dried down in a vacuum centrifuge 
(Christ rotational vacuum concentrator, Osterode, Germany). 
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10.3.6 Nanoflow-UPLC
®
 coupled to tandem mass spectrometry (LC-MS/MS) 
Samples for analysis were reconstituted in 11μl of 0.1% FA in LC-MS grade H2O. 
Samples were analysed using a nanoflow UPLC
®
 system (nanoAquity, Waters/ 
Micromass UK Ltd. Manchester) coupled to a LTQ-Orbitrap XL MS (Thermo Fisher 
Scientific, Hemel Hempstead, UK). 3µl of each sample were injected in duplicate. The 
MS was operated to automatically acquire MS and MS/MS spectra. Initially, full scan 
survey spectra (m/z 375-1800) were acquired and then the five most intense ions in each 
full scan (every 0.6 of a second) were sequentially isolated and fragmented. Data were 
acquired using the Xcalibur software version 2.0.7 (Thermo Fisher Scientific).  
 
10.3.7 Data analysis 
For protein identification, the processed files were searched against the Swiss-Prot 
database of protein sequences using the Mascot search engine (Mascot Daemon, v2.3.0; 
Matrix Science). For quantitative analysis of the MS data, a program written by the 
Analytical Signalling Group (Institute of Cancer, Barts Cancer Centre, London, UK) 
known as Pescal was used (Cutillas & Vanhaesebroeck, 2007). This program generates 
peak intensity values for each of the peptide sequences identified by Mascot. Each 
experiment was performed in triplicate and therefore for each peptide the mean peak 
intensities for control and MSA-treated samples were calculated. If more than one 
peptide belonging to the same protein was present, then the peak intensity values for all 
peptides were combined and the mean calculated. A paired t-test was used to determine 
significant differences in peptide intensities between control and MSA-treated samples. 
p<0.05 was considered statistically significant. Peptides that did not change in intensity 
between control and MSA-treated samples were excluded from further analysis. These 
quantitative data were then analysed using the MetaboAnalyst software 
(www.metaboanalyst.ca) which performs both univariate (t-test and fold change) and 
multivariate analysis (principle component analysis and hierarchical cluster analysis). 
Network and pathway analysis was performed using Ingenuity Pathway Analysis (IPA) 
software™ v8.6 (Ingenuity® Systems, www.ingenuity.com). The fold-change (FC) was 
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calculated for the peptides that changed significantly between control and MSA-treated 
samples and peptides with a ≥2 FC in intensity were used in pathway analysis. 
 
10.4 RESULTS 
More than 3000 proteins were identified in each of the RL and DHL4 cell samples.  
 
10.4.1 DHL4 cell line 
In the DHL4 cell line exposed to 10µmol/L MSA, 299 proteins were identified that were 
differentially expressed (p<0.05) between control and MSA-treated samples. There were 
an additional 13 peptides that were differentially expressed but could not be identified. Of 
these 299 proteins, 87 were phosphorylated proteins (29%). 98/299 proteins had a ≥2-fold 
difference in expression, either up- or down-regulated, of which 39/98 (40%) were 
phosphorylated.  
 
Using the MetaboAnalyst software, univariate analysis of the data was performed. FC 
and t-tests were calculated for the peptides identified and Figure 10.2 shows the ‘volcano 
plot’ which combines this information. The x-axis shows the FC with a threshold of +/-1-
FC, and the y-axis shows the p value with a threshold of p=0.1. Note that both axes are 
log-transformed. The red circles represent peptides above the set thresholds for both FC 
and statistical significance. 
 
Principal component analysis (PCA) was performed using the MetaboAnalyst software. 
This is an unsupervised, multivariate statistical method which provides a graphical 
representation of multi-dimensional data to determine how well calculated summary 
‘component’ values describe differences between samples (Ringner, 2008). This is done 
by reducing the dimensionality of the data by identifying variables, [principal 
components (PC)], that account for as much of the variability in the data as possible. 
Thus, PC1 is associated with the greatest variation in the data and subsequent PCs for the 
remaining variability. Figure 10.3 shows the PCA analysis for DHL4 cells using two PCs. 
It shows that using these 2 summary components, the control and MSA-treated samples 
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can be grouped and are clearly separated, with PC1 accounting for 81% of the variability 
within the data and PC2, 10.2%. 
 
 
Figure 10.2 Volcano plot showing fold change and p values of peptides identified in 
DHL4 cells exposed to 10µmol/L MSA. 
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Figure 10.3 Principal component analysis plot for DHL4 cells exposed to 10µmol/L 
MSA. 
 
 
Hierarchical cluster analysis was also performed using the MetaboAnalyst software. This 
again is an unsupervised analysis which begins by considering each sample as a single 
cluster. These clusters are then combined based on similarities until all samples belong to 
one cluster. Figure 10.4 shows the hierarchical clustering for the DHL4 cell line 
represented as a heat map. Again, the control and MSA-treated samples are clearly 
different and can be separated by this clustering method. The shades of blue represent 
peptides that are down-regulated and shades of red represent peptides that are up-
regulated relative to the mean signal intensity across all samples for each peptide. 
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Figure 10.4 Unsupervised hierarchical clustering, shown as a heat map, of DHL4 cells 
exposed to 10µmol/L MSA 
 
The data shown above clearly demonstrate that MSA results in distinct changes in 
peptide/protein expression in the DHL4 cell line. The top up-regulated proteins as 
identified by the Mascot search engine are shown in Table 10.1 and the top down-
regulated proteins are shown in Table 10.2. The full list of differentially expressed 
proteins is shown in the appendix. Some of the protein changes were expected and 
confirm some of the data presented in earlier chapters. For example TrxR1, a known 
selenoprotein, was up-regulated. In addition, the ER chaperones GRP78 and GRP94, and 
the enzyme PDI were all up-regulated.   
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Table 10.1 The top most up-regulated proteins in DHL4 cells exposed to 10µmol/L MSA 
Gene Symbol Protein Phospho* FC p value 
PTPLAD1 Protein tyrosine phosphatase-like protein  ST 38.4 0.004 
HNRNPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 
 23.7 0.02 
TUBB3 Tubulin beta-3 chain  13.5 0.002 
CCT8 Chaperonin containing T complex protein 
1, subunit 8 (theta) 
 12.1 0.002 
TXNRD1 Thioredoxin reductase 1  9.7 0.004 
RCTPI1 Triosephosphate isomerase  9 0.02 
CCT4 Chaperonin containing T complex protein 
1, subunit 4  (delta) 
 8.5 0.02 
SYNE2 Isoform 1 of Nesprin-2  7.7 0.02 
PDCD4 Programmed cell death 4 isoform 2  7.3 0.009 
SOD1 Superoxide dismutase  7.1 0.03 
HSPA5 GRP78  6.6 0.02 
HSP90B3P GRP94  6.0 0.01 
*ST, serine/threonine 
 
Table 10.2 The top most down-regulated proteins in DHL4 cells exposed to 10µmol/L 
MSA 
Gene Symbol Protein Phospho* FC  p value 
C1QBP Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
 229 0.001 
MCM7 Isoform 1 of DNA replication licensing 
factor MCM7 
 98.4 0.03 
VEPH1 Isoform 1 of Ventricular zone-expressed 
PH domain-containing protein homolog 1 
ST 55.2 0.001 
ALDOA Fructose-bisphosphate aldolase A  25.8 0.008 
RRM2 Ribonucleotide reductase, subunit M2 ST 14.4 0.01 
GLO1 Glyoxalase 1  11.6 0.01 
CDC2 Cyclin-dependent kinase 1 ST, Y 8.7 0.02 
HMGCS1 Hydroxymethylglutaryl-CoA synthase, ST 7.6 0.01 
HSPH1 Heat shock protein 105 kDa (Isoform β)  6.6 0.045 
RPLP0 60S acidic ribosomal protein P0 2ST 5.9 0.03 
*ST, serine/threonine, Y, tyrosine 
368 
 
To further analyse the protein changes induced by MSA, the IPA software was used to 
study protein networks and signalling pathways. The proteins identified could be grouped 
into 3 main networks. The top network was termed ‘DNA replication, recombination and 
repair, cell cycle and cell death’ and 14 of the differentially expressed proteins could be 
incorporated into this network (Figure 10.5). The second network was termed ‘cell-
mediated immune response, cellular development, function and maintenance’ and 13 
proteins could be incorporated into this network (Figure 10.6). The third network was 
termed ‘cellular growth and proliferation, cellular development and cancer’ and 8 
proteins could be incorporated into this network (Figure 10.7).  The proteins identified 
were associated with a large number of canonical pathways. The three main pathways 
identified were glycolysis/gluconeogenesis (5 proteins), pyrimidine metabolism (5 
proteins), and Nrf2-mediated oxidative stress response (5 proteins). The molecular and 
cellular functions of the proteins were grouped and 28 proteins were involved in cell 
death, 24 in cellular growth and proliferation, 7 in post-translational modification and 5 
in protein folding.  
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Figure 10.5 ‘DNA replication, recombination and repair, cell cycle and cell death’ 
network identified by the IPA software in DHL4 cells exposed to 10µmol/L MSA. 
Shades of red represent proteins that were up-regulated and shades of green represent 
proteins that were down-regulated. The intensity of the red and green colour relates to the 
degree of change. 
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Figure 10.6 ‘Cell-mediated immune response, cellular development, function and 
maintenance’ network identified by the IPA software in DHL4 cells exposed to 
10µmol/L MSA. Shades of red represent proteins that were up-regulated and shades of 
green represent proteins that were down-regulated. The intensity of the red and green 
colour relates to the degree of change. 
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Figure 10.7 ‘Cellular growth and proliferation, cellular development and cancer’ network 
identified by the IPA software in DHL4 cells exposed to 10µmol/L MSA. Shades of red 
represent proteins that were up-regulated and shades of green represent proteins that were 
down-regulated. The intensity of the red and green colour relates to the degree of change. 
 
 
10.4.2 RL cell line 
In the RL cell line exposed to 1µmol/L MSA, 151 proteins were identified that were 
differentially expressed (p<0.05) between control and MSA-treated samples. There were 
an additional 3 peptides that were differentially expressed but were unable to be 
identified. Of these 151 proteins, 57 were phosphorylated proteins (38%). 29/151 proteins 
had a ≥2-FC in expression, either up- or down-regulated, between control and MSA-
treated cells of which 8/29 (28%) were phosphorylated. The same analysis using the 
MetaboAnalyst software was performed as for the DHL4 cell line. FC and t-tests were 
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calculated for the peptides identified and Figure 10.8 shows the ‘volcano plot’ which 
combines this information. The x-axis shows the FC with a threshold of +/-1-FC, and the 
y-axis shows the p value with a threshold of p=0.1. Note that both axes are log 
transformed. The red circles represent peptides above the set thresholds for both FC and 
statistical significance. 
 
 
Figure 10.8 Volcano plot showing fold change and p values of peptides identified in RL 
cells exposed to 1µmol/L MSA. 
 
Figure 10.9 shows the PCA analysis for RL cells using two PCs. It shows that using these 
2 summary components the control and MSA-treated samples can be grouped and are 
clearly separated, with PC1 accounting for 75.3% of the variability within the data and 
PC2, 13%. 
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Figure 10.9 Principal component analysis plot for RL cells exposed to 1µmol/L MSA. 
 
 
Figure 10.10 shows the hierarchical clustering for the RL cell line represented as a heat 
map.  The control and MSA-treated samples are clearly different and can be separated by 
this clustering method. The shades of blue represent peptides that are down-regulated and 
shades of red represent peptides that are up-regulated relative to the mean signal intensity 
across all samples for each peptide. 
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Figure 10.10 Unsupervised hierarchical clustering shown as a heat map of RL cells 
exposed to 1µmol/L MSA. 
 
Compared to the DHL4 cell lines, far fewer proteins were differentially expressed by ≥2-
fold between control and MSA-treated in the RL cell line. This is likely to be due to the 
fact that cells were exposed to only a very low concentration of MSA, 1µmol/L. 
However, none of the experiments performed up until this point, described in other 
chapters, had revealed any proteins that were altered in expression by the exposure of RL 
cells to 1µmol/L MSA, despite its ability to sensitise RL cells to chemotherapeutic 
agents. All the up-regulated proteins as identified by the Mascot search engine are shown 
in Table 10.3 and the down-regulated proteins are shown in Table 10.4. There were some 
similarities with the findings in the DHL4 cell line (see below).  
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Table 10.3 Up-regulated proteins in RL cells exposed to 1µmol/L MSA   
Gene Symbol Protein Phospho* FC p value 
NPM1 Isoform 1 of Nucleophosmin  33.4 0.047 
GRHPR Glyoxylate reductase/hydroxypyruvate 
reductase 
 25.4 0.03 
EIF3B Isoform 1 of Eukaryotic translation 
initiation factor 3 subunit B 
 17.8 0.008 
ACTB Beta actin  7.2 0.03 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
ST 6.8 0.045 
RPL6 60S ribosomal protein L6  4.5 0.0004 
HDGF Hepatoma-derived growth factor 
isoform C 
2 ST 4.4 0.02 
C14orf43 49 kDa protein ST 3.9 0.045 
PPIB Peptidyl-prolyl cis-trans isomerase B  3.7 0.04 
RPLP1 60S acidic ribosomal protein P1 2 ST 3.6 0.01 
DHX38 Pre-mRNA-splicing factor ATP-
dependent RNA helicase PRP16 
 3.1 0.01 
TXNRD1 Thioredoxin reductase 1  2.9 0.007 
CDC2 Cyclin-dependent kinase 1 ST, Y 2.8 0.04 
DHX9 ATP-dependent RNA helicase A  2.5 0.03 
HSP90AB2P Similar to Heat shock protein HSP 90-
beta 
ST 2.3 0.02 
RPS5 40S ribosomal protein S5  2.2 0.02 
HIST1H2BL Histone H2B type 1-L  2.2 0.03 
ZNF828 Zinc finger protein 828 ST 2.1 0.01 
*ST, serine/threonine, Y, tyrosine 
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Table 10.4 Down-regulated proteins in RL cells exposed to 1µmol/L MSA  
Gene Symbol Protein Phospho* FC p value 
RPS14 40S ribosomal protein S14  85.8 0.001 
RPS8  40S ribosomal protein S8  76.2 0.03 
YWHAG 14-3-3 protein gamma  34.4 0.01 
CAPZB Isoform 1 of F-actin-capping protein 
subunit beta 
 33.5 0.04 
ALDOA Fructose-bisphosphate aldolase A  20 0.0001 
PADI3 Protein-arginine deiminase type-3 ST 16.3 0.03 
PHGDH D-3-phosphoglycerate dehydrogenase  4.7 0.04 
NSUN2 tRNA (cytosine-5-)-methyltransferase 
NSUN2 
 4.1 0.048 
SFPQ Isoform Long of Splicing factor, 
proline- and glutamine-rich 
 4.0 0.04 
HIST1H2BN Histone H2B type 1-N  3.0 0.04 
FUS Isoform Short of RNA-binding protein 
FUS 
 2.8 0.04 
*ST, serine/threonine 
 
 
The IPA software was used to group the proteins into networks and pathways. The 
proteins identified appeared to be spread across a large number of pathways. The proteins 
could be grouped into one main network termed ‘cell death, cell cycle, connective tissue 
development and function’ (Figure 10.11). The three main canonical pathways identified 
were Nrf2-mediated oxidative stress response (3 proteins), glycine, serine, threonine 
metabolism (2 proteins) and glycolysis/gluconeogenesis (2 proteins). Thus, 2 out of the 3 
of these pathways are the same as those identified in the DHL4 cell line. The molecular 
and cellular functions of the proteins were grouped and 5 proteins were involved in 
protein synthesis, 6 in gene expression and 3 in cell cycle regulation.   
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Figure 10.11 ‘Cell death, cell cycle, connective tissue development and function’ 
network identified by the IPA software in RL cells exposed to 1µmol/L MSA. Shades of 
red represent proteins that were up-regulated and shades of green represent proteins that 
were down-regulated. The intensity of the red and green colour relates to the degree of 
change.  
 
 
10.4.3 Classification of the differentially expressed proteins by function 
It is possible to group the differentially expressed proteins in both the cell lines based on 
their function. This is shown in Table 10.5 and proteins common to both cell lines are 
shown in italics. 
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Table 10.5 Differentially expressed proteins in DHL4 and RL cell lines after exposure to 
MSA, based on protein function. 
Function  DHL4 cell line FC RL cell line FC 
Protein 
folding  
 GRP78 
 GRP94  
 PDI 
 DnaJ (HSP40) homologue 
 HSP60 
 HSP105 (β-isoform) 
 Peptidyl-prolyl cis-trans 
isomerase FKBP1A 
 T-complex-1 (α-subunit) 
 Chaperonin containing 
TCP1, subunit 4 
 Chaperonin containing 
TCP1, subunit 8 
 Chaperonin containing 
TCP1, subunit 7 
↑6.6 
↑6.0 
↑2.3 
↑2.3 
↓5.0 
↓6.6 
 
↑2.5 
↑4.4 
 
↑8.5 
 
↑12.1 
 
↓5.3 
 Peptidyl-propyl cis-
trans isomerase B 
 Protein similar to 
HSP90 
↑3.7 
 
↑2.3 
Protein 
Synthesis 
 60S acidic ribosomal 
      protein P0 
 60S acidic ribosomal 
protein P1 
 60S ribosomal protein L21 
 60S ribosomal protein L15 
 Nucleolin 
 Nucleolar RNA helicase 2 
 Mitochondrial Tu 
translation elongation 
factor 
 Bifunctional aminoacyl-
tRNA synthetase 
 Heterogeneous nuclear 
ribonucleoprotein A3 
 Heterogeneous nuclear 
ribonucleoprotein U 
 Heterogeneous nuclear 
ribonucleoprotein M 
 Heterogeneous nuclear 
ribonucleoprotein A2/B1 
 Heterogeneous nuclear 
ribonucleoprotein H 
↓5.9 
 
↓2.7 
 
↑3.4 
↑3.1 
↑4.3 
↓3.7 
 
↑2.0 
 
↓2.3 
 
 
↑23.7 
 
↑3.9 
 
↑2.8 
 
↓2.6 
 
↓2.2 
 60S ribosomal protein 
L6 
 60S acidic ribosomal 
protein P1 
 40S ribosomal protein 
S5 
 40S ribosomal protein 
S14 
 40S ribosomal protein 
S8 
 Eukaryotic translation 
initiation factor 3 
 Pre-mRNA-splicing 
factor ATPase RNA 
helicase PRP16 
 ATP-dependent RNA 
helicase A 
 Nucleophosmin 
↑4.5 
 
↑3.6 
 
↑2.2 
 
↓85.8 
 
↓76.2 
 
 
↑17.8 
 
↑3.1 
 
 
↑2.5 
 
↑33.4 
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Table 10.5 continued 
Function  DHL4 cell line FC RL cell line FC 
Metabolism  Fructose bisphosphate 
aldolase A 
 GAPDH 
 Triosephosphate isomerase 
 Enolase 1 
 Enolase 3 
 Pyruvate Kinase 
 Asparagine synthetase 
 Hydroxymethylglutaryl-
CoA synthase 
↓25.8 
 
↑2.0 
↑9.0 
↑2.4 
↓2.0 
↑2.2 
↑2.2 
 
↓7.6 
 Fructose bisphosphate 
aldolase A 
 GAPDH 
 Glyoxylate 
reductase/hydroxypyr-
uvate reductase 
 D-3-phosphoglycerate 
dehydrogenase 
↓20 
 
↑6.8 
↑25.4 
 
 
↓4.7 
DNA 
synthesis, 
replication 
and repair 
 Cyclin-dependent kinase 1 
 Ribonucleotide reductase, 
M2 
 Deoxyuridine 
triphosphatase 
 Carbamoyl-phosphate 
synthetase 2 
 Dyskeratosis congenita 1 
 MCM2 
 MCM4 
 MCM5 
 MCM7 
 Mediator of DNA damage 
1 
 DNA damage-binding 
protein 1 
↓8.7 
↓14.4 
 
↓3.3 
 
↓4.1 
 
↓2.1 
↓2.4 
↓2.4 
↓3.2 
↓98.4 
 
↓2.1 
 
↓2.0 
 Cyclin-dependent 
kinase 1 
 
↑2.8 
Cytoskeletal/
structural 
proteins 
 Tubulin beta-3 chain 
 Tubulin alpha-1C 
 Stathmin 2 
 Stathmin 
 Nesprin 2 
 Cofilin 2 
 Ezrin 
↑13.5 
↓4.0 
↑3.1 
↓3.0 
↑7.7 
↑4.5 
↑2.5 
 Actin 
 F-actin capping 
protein subunit β 
↑7.2 
↓33.5 
Epigenetic  Histone H4 
 Histone H1.5 
↑3.2 
↓5.5 
 Histone  H2B type 1L 
 Histone  H2B type 1N 
↑2.2 
↓3.0 
Anti-oxidant  TrxR1 
 SOD1 
↑9.7 
↑7.1 
 TrxR1 ↑2.9 
Lymphoma-
related 
 Bcl-6 
 Glycolase 1 
↓3.2 
↓11.6 
 Nucleophosmin ↑33.4 
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Protein folding 
As mentioned above, these results confirmed some of the earlier work presented in 
Chapter 5. In the DHL4 cell line the ER chaperones, GRP78 and GRP94, and the enzyme 
PDI were all up-regulated. These proteins are involved in the cellular response to protein 
misfolding. In addition, other proteins not previously studied that are involved in protein 
folding, were also differentially expressed. These included HSPs, mitochondrial HSP60, 
and HSP105 (β-isoform), which were down-regulated, and DnaJ (HSP40) homologue 
which was up-regulated. The enzyme peptidyl-prolyl cis-trans isomerase FKBP1A, and 
three members of the chaperonin containing T-complex protein (TCP) family [T-
complex-1 (α-subunit), chaperonin containing TCP1, subunit 8 and chaperonin 
containing TCP1, subunit 4] were up-regulated, and chaperonin containing TCP1, subunit 
7 was down-regulated.  
 
In the RL cell line, two proteins that may also play a role in protein folding were up-
regulated. These were the ER enzyme peptidyl-propyl cis-trans isomerase B and a protein 
similar to HSP90. Additionally, the phosphorylated enzyme, protein-arginine deiminase 
3, was down-regulated. This enzyme is one member of a family of enzymes that catalyse 
the conversion of arginine in a protein to citrulline. This post-translational modification 
can modify the structure and function of proteins (Gyorgy et al, 2006). 
 
Protein synthesis 
Ribosomal proteins were differentially expressed in both cell lines. Two components of 
the 60S subunit were up-regulated in the RL cell line. In the DHL4 cell line, two 
components of the 60S subunit were down-regulated and one up-regulated. The two 
proteins with the largest fold-change in the RL cell line were components of the 40S 
ribosomal subunit and these proteins were down-regulated.  In addition, the nucleolar 
protein, nucleophosmin, was the most up-regulated protein in the RL cell line and this 
protein, amongst other functions, is involved in ribosomal biogenesis (Grisendi et al, 
2006). In the DHL4 cell line, nucleolin, another nucleolar protein involved in ribosomal 
biogenesis (Ginisty et al, 1999) , was up-regulated and nucleolar RNA helicase 2, which 
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is involved in the processing of ribosomal RNA, was down-regulated. Other proteins 
involved in protein synthesis identified included, in the RL cell line, eukaryotic 
translation initiation factor 3 (subunit B), pre-mRNA-splicing factor ATPase RNA 
helicase PRP16 and ATP-dependent RNA helicase A, which were all up-regulated. In the 
DHL4 cell line, mitochondrial Tu translation elongation factor was up-regulated and 
bifunctional aminoacyl-tRNA synthetase was down-regulated. In addition, five members 
of the heterogenous nuclear ribonucleoprotein family were found to be differentially 
expression, These proteins bind RNA and are involved in the processing of RNA 
however, 3 of these proteins were up-regulated and 2 down-regulated (Swanson & 
Dreyfuss, 1988). 
 
Metabolism 
A pathway identified by the IPA software, which was common to both cell lines was that 
of glycolysis/gluconeogenesis. Fructose bisphosphate aldolase A, which catalyses the 
reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and 
dihydroxyacetone phosphate, was down-regulated and GAPDH, which catalyses the 
conversion of glyceraldehyde 3-phosphate to D-glycerate 1,3-bisphosphate, was up-
regulated in both cell lines. However, in the RL cell line phosphorylated GAPDH was 
detected whereas in the DHL4 cell line non-phosphorylated GAPDH was detected. 
Phosphorylation may alter the function of GAPDH (see discussion). Additionally, in the 
DHL4 cell line four other enzymes in the glycolytic pathway were altered in expression; 
triosephosphate isomerase, enolase 1 and pyruvate kinase were up-regulated and enolase 
3 was down-regulated. 
 
Proteins involved in other cellular metabolic pathways were also differentially expressed 
in both cell lines. In the DHL4 cell line, asparagine synthetase was up-regulated and 
hydroxymethylglutaryl-CoA synthase, an enzyme involved in cholesterol synthesis, was 
down-regulated. In the RL cell line, the enzyme glyoxylate reductase/hydroxypyruvate 
reductase which catalyses the reduction of
 
hydroxypyruvate to D-glycerate, the reduction 
of glyoxylate to glycolate
 
and the oxidation of D-glycerate to hydroxypyruvate, was the 
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second most highly induced protein. The enzyme D-3-phosphoglycerate dehydrogenase, 
which catalyses the rate limiting step in serine biosynthesis, was down-regulated. 
 
Two subunits of mitochondrial ATP synthase were up-regulated in the DHL4 cell line. 
This enzyme catalyses the phosphorylation of ADP to ATP (Hong & Pedersen, 2008), 
suggesting that in the presence of MSA there is increased generation of cellular energy. 
  
DNA synthesis, replication and repair 
In the DHL4 cell line, enzymes involved in both pyrimidine and purine synthesis, were 
differentially expressed. This included down-regulation of the M2 subunit of 
ribonucleotide reductase. This enzyme catalyses the formation of deoxyribonucleotides 
from ribonucleotides, hence is critical for the synthesis of DNA (Nocentini, 1996). In 
addition, deoxyuridine triphosphatase, carbamoyl-phosphate synthetase 2, dyskeratosis 
congenita 1, all proteins involved in pyrimidine metabolism, were down-regulated. 
 
In the DHL4 cell line, four members of the mini-chromosome maintenance (MCM) 
family of proteins were down-regulated; MCM 2, 4, 5, and 7. This family of proteins play 
a critical role in DNA replication (Bochman & Schwacha, 2009). There was also down-
regulation of phosphorylated mediator of DNA damage checkpoint 1 (MDC1). This 
protein is phosphorylated in response to DNA damage and forms complexes with 
phospho-histone H2AX, localising to sites of DNA damage and recruiting proteins 
involved in DNA repair. MDC1 also mediates both the S-phase and G2/M damage-
activated cell-cycle checkpoints (Stewart et al, 2003). Another protein involved in DNA-
damage repair, DNA damage-binding protein 1 (DDB1), was also down-regulated in the 
DHL4 cell line. This is a heterodimeric protein consisting of 2 subunits, the larger subunit 
is DDB1 and the smaller subunit is DDB2 (Dualan et al, 1995).   
 
In both cell lines, there was altered expression of the cell cycle regulatory protein, CDK1, 
which is required mainly for transition between the G2 and mitotic phases of the cell 
cycle (Salaun et al, 2008). Phosphorylation of this kinase inactivates its activity 
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(Potapova et al, 2009); in the RL there was increased expression and in the DHL4 cell 
line decreased expression of the phosphorylated protein. 
 
Cytoskeletal/structural proteins 
Cytoskeletal proteins were another group of proteins that were differentially expressed in 
both cell lines. In the DHL4 cell line, tubulin beta-3 chain was up-regulated and the 
alpha-1C chain down-regulated. Tubulin is the main constituent of microtubules which 
are components of the cytoskeleton (Verhey & Gaertig, 2007). Stathmins are a family of 
proteins that bind to tubulin and inhibit microtubule formation. The proteins are regulated 
by phosphorylation which reduces its binding to tubulin, one consequence of which is 
progression of cells through mitosis (Curmi et al, 1999). In the DHL4 cell line, the 
expression of phosphorylated stathmin 1 was down-regulated and that of stathmin 2 (non-
phosphorylated) was up-regulated. Actin is another component of the cytoskeleton that 
polymerises to form microfilaments. In the DHL4 cell line, the expression of cofilin 2, an 
actin-binding protein that disrupts actin assembly (Huang et al, 2006), was up-regulated. 
The protein, ezrin, was also up-regulated in DHL4 cells. This protein has a number of 
cellular functions including regulation of the actin cytoskeleton, control of cell shape, 
adhesion and motility (Brambilla & Fais, 2009). In the RL cell line β-actin was up-
regulated and there was down-regulation of the β-subunit of F-actin-capping protein 
which binds to the growing end of actin microfilaments (Schafer et al, 1996). In the 
DHL4 cell line nesprin-2, a nuclear membrane associated protein which maintains 
nuclear organisation and structural integrity (Warren et al, 2005), was up-regulated.  
 
Epigenetic changes 
In both cell lines, histone proteins were differentially expressed, some being increased 
and some decreased in expression. DNA is wrapped around histones which are the main 
protein component of chromatin and modification of histones plays an important role in 
chromatin regulation, including gene transcription (Jenuwein & Allis, 2001). 
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Anti-oxidant enzymes 
The selenoprotein, TrxR1, was up-regulated in both cell lines. Its function has been 
discussed in Chapter 1. In addition, in the DHL4 cell line, SOD1 expression was 
increased. SOD1 belongs to a family of superoxide dismutase enzymes which act to 
eliminate superoxide anion radicals thus combating oxidative stress (Miao & St Clair, 
2009). 
 
Lymphoma-related proteins 
Two proteins associated with lymphoma pathogenesis were differentially expressed, In 
the DHL4 cell line phosphorylated Bcl-6 was down-regulated. This protein is a 
transcription factor that is frequently involved in translocations and over-expressed in 
DLBCL and its function is regulated by phosphorylation (Moriyama et al, 1997). In the 
RL cell line, the most up-regulated protein was nucleophosmin. This protein is frequently 
involved in translocations or over-expressed in a number of cancers including 
haematological malignancies (Grisendi et al, 2006). Another protein related to cancer 
pathogenesis, glyoxalase 1, was down-regulated in the DHL4 cell line. This enzyme 
catalyses the conversion of reactive α-oxoaldehydes to corresponding α-hydroxyacids 
(Thornalley, 2003) The gene encoding this protein, GLO1, has been found to be over-
expressed, due to gene amplification, in a number of human cancers (Santarius et al, 
2010). 
 
10.5 DISCUSSION 
This study has not been without its challenges, however, it has potentially identified 
novel proteins and pathways involved in the action of MSA in DLBCL cell lines. The 
main problem was that, despite several attempts, the phospho-enrichment procedure was 
not optimal. In these experiments, the percentage of phosphorylated peptides in enriched 
samples was around 30%. Previously published work using similar techniques has 
reported around 60% enrichment of samples (Alcolea et al, 2009). There are several 
potential reasons for this and some of these were seemingly addressed. As mentioned 
already, phosphate groups are labile and proteins are easily dephosphorylated. Therefore, 
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precautions need to be taken during sample processing such as the use of a broad range of 
phosphatase inhibitors and processing samples mainly at 4°C. One of the problems may 
have been the phospho-enrichment strategy chosen, which was the use of IMAC beads. 
This technique is known to have the problem of non-specific binding when complex 
peptide samples are used and non-phosphorylated peptides may also bind to the beads. 
Thereafter, when samples are analysed by MS the non-phosphorylated peptides are more 
efficiently ionised resulting in lowered sensitivity for phosphorylated peptides 
(Thingholm et al, 2009). There are ways to address this problem, such as sample 
acidification prior to IMAC enrichment and adequately raising the pH, with ammonia 
solution, during phospho-peptide elution, but despite these measures optimal 
improvements in phospho-peptide yield were not obtained (Thingholm et al, 2009). If 
these experiments are to be repeated, it may be best to use an alternate method of 
phospho-peptide enrichment, such as titanium dioxide chromatography, which has been 
reported to be a superior method to IMAC (Larsen et al, 2005). In addition, pre-
fractionation of samples by SCX, prior to phospho-enrichment, has been shown to 
improve the phospho-peptide recovery, therefore this may be a useful step to add for 
future experiments (Trinidad et al, 2006). 
 
Despite these problems, some interesting observations were made. These are, however, 
based mainly on the non-phosphorylated peptides present within the samples that were 
analysed. More differentially expressed proteins were identified in the DHL4 cell line 
than in the RL cell line. This is likely to be because of the higher MSA concentration 
used for the DHL4 cell line. Prior to these experiments, the exposure of RL cells to 
1µmol/L MSA had not resulted in any detectable changes in protein expression by 
western blotting. However, the use of the more sensitive MS-based method has clearly 
demonstrated that this concentration of MSA does indeed alter protein expression. It may 
be that the proteins with the largest FC would also show altered expression by western 
blotting.  
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The results from the DHL4 cell line confirmed some of the work presented in earlier 
chapters. Mainly, that MSA alters the expression of proteins required for protein folding. 
In addition to identifying known targets of MSA such as ER-chaperones, other molecular 
chaperones including, HSPs, and enzymes required for protein folding were also 
identified. Of note, GADD153 was not identified as a protein that was differentially 
expressed, again confirming earlier results in which induction of GADD153 was only 
detected at the mRNA level (Chapter 5).   
 
The IPA software identified changes within the Nrf2-mediated oxidative stress pathway 
as being important in both cell lines. This pathway was previously investigated by 
western blotting (discussed in Chapter 4) and neither the expression of Nrf2 nor its target 
Prx1 were altered by MSA. Nrf2 and Prx1 were not identified in these proteomics 
experiments either but, in the DHL4 cell line, five other down-stream targets of Nrf2 
were; T-complex protein 1, subunit 7, DnaJ (HSP40) homologue, protein tyrosine 
phosphatase-like protein, SOD1 and TrxR1. All, except the T-complex protein 1, subunit 
7, were up-regulated by MSA. However, Nrf2-mediated signalling may not be the only 
explanation for altered expression of these proteins. TrxR is a selenoprotein and therefore 
its expression is likely to be increased due to the increased availability of Se rather than 
being a target of Nrf2.  DnaJ (HSP40) homologue expression may be related to the 
overall protein folding capacity of the cell. Members of the DnaJ (HSP40) homologue 
family have been found to be up-regulated in genomics studies of the LNCaP prostate 
cancer cell line exposed to MSA (Zhang et al, 2005; Zhao et al, 2004). These proteins, 
which are members of the HSP40 family, are co-chaperones that regulate the formation 
of complexes between HSP70 and its client proteins (Fan et al, 2003). Different SOD 
enzymes have also previously been identified as targets of Se in genomics studies (Dong 
et al, 2001; El-Bayoumy & Sinha, 2005) and considering that MSA results in widespread 
redox modifications of proteins, it is not unexpected that the expression of proteins with 
an antioxidant function, which themselves are redox-regulated, should be induced (Park 
et al, 2005).  
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In RL cells, the IPA software identified three proteins belonging to the Nrf2-mediated 
oxidative stress pathway, one being up-regulation of TrxR. The other two proteins which 
were also up-regulated, β-actin and peptidylpropyl isomerase B, could also belong to 
other signalling pathways. Actins are essential cytoskeletal proteins required for cell 
motility, structure and integrity and as mentioned above, peptidylpropyl isomerase B, in 
addition to other functions, is involved in protein folding. Therefore, although the Nrf2-
pathway was identified as being important, many of the proteins could also belong to 
other pathways.  
 
A common feature between the two cell lines was the altered expression of ribosomal 
proteins and other proteins involved in protein translation, suggesting that MSA affects 
general protein synthesis. However these proteins were both up- and down-regulated and 
therefore it is not entirely clear whether overall, MSA increases or decreases protein 
synthesis. Similar observations have been made in other genomics and proteomics studies 
investigating the action of Se. In a study that analysed gene expression in lymphocytes 
isolated from healthy volunteers supplemented with sodium selenite, there was up-
regulation of genes involved in protein synthesis, including constituents of the 60s and 
40S ribosomal subunits (Pagmantidis et al, 2008).  The authors hypothesised that this 
may be due to enhanced incorporation of Sec into selenoproteins, several of which were 
also found to be up-regulated. Another study reported the down-regulation of genes 
coding for 40S ribosomal subunits in mammary epithelial cells in rats given MSC in 
addition to the carcinogen nitrosomethylurea (Dong et al, 2001). Two proteomics studies 
of LnCaP cells exposed to selenite (Roveri et al, 2008) and SLM (Sinha et al, 2008) 
identified up-regulation of heterogenous nuclear ribonucleoproteins. These proteins 
contain functional cysteine residues and are thus susceptible to redox modification by Se 
compounds. In the DHL4 cell lines, heterogenous nuclear ribonucleoproteins were both 
up- and down-regulated. 
 
The most up-regulated protein in RL cells was nucleophosmin, a nucleolar 
phosphoprotein involved in many cellular functions including ribosomal biogenesis. This 
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protein also has a well established role in the pathogenesis of a number of cancers, 
including anaplastic large B-cell lymphoma and other haematological malignancies. 
However, evidence supports its role in both tumour promotion and tumour suppression 
(Grisendi et al, 2006). Therefore, to understand its role in the action of MSA, 
experiments to over-express and knockdown this protein need to be performed.  In the 
DHL4 cell line, the protein nucleolin which is also involved in ribosomal biogenesis was 
up-regulated (Ginisty et al, 1999). Interestingly, this protein has recently been found to 
bind to the SECIS elements (secondary RNA stem-loop structures required for the 
incorporation of Sec into proteins) of a subset of selenoprotein mRNAs, including TrxR1, 
and positively regulate their translation. Knockdown of nucleolin resulted in decreased 
TrxR1 protein levels (Miniard et al, 2010). Therefore, the up-regulation seen in the 
DHL4 cell lines may be related to increased translation of TrxR.  
 
MSA appears to affect cellular metabolic processes and a pathway, which was common 
to both cell lines was that of glycolysis/gluconeogenesis. Similar findings were reported 
in a proteomics study of the LNCaP cell line exposed to sodium selenite for 3 days. Here, 
GAPDH and enolase 1 were amongst the most differentially expressed proteins, both 
being up-regulated (Roveri et al, 2008).  Another study reported up-regulation of enolase 
2 gene expression by MSA in the prostate cancer cell line,  PC-3 (Zhang et al, 2005). In 
the work presented here, enzymes involved in other metabolic pathways were also 
differentially expressed. These findings are supported by genomics studies reported in the 
literature that have identified a number of differentially expressed genes involved in 
several metabolic pathways in prostate cancer cell lines exposed to MSA (Gonzalez-
Moreno et al, 2007; Zhang et al, 2005). However, the results presented here only overlap 
with respect to glycolysis.  
 
Targeting tumour metabolic pathways for cancer therapy is currently being investigated 
and several compounds are in clinical trial (Tennant et al, 2010). It is apparent that 
tumour cells have altered metabolism which supports cell proliferation and survival. For 
example, glucose utilisation is higher compared to normal cells and inhibitors of 
389 
 
glycolysis have been shown to sensitise tumours to chemotherapy (Maschek et al, 2004). 
Tumour cells also utilise more amino acids and targeting of amino acid metabolism is 
already being used in cancer therapy. The enzyme asparaginase, which reduces plasma 
asparagine levels, is an integral part of therapy for acute lymphoblastic leukaemia 
(Masetti & Pession, 2009). Inhibitors of fatty acid metabolism have also shown promise 
in xenograft tumour models (Kridel et al, 2004). Thus, the effects of MSA on cellular 
metabolism could account, in part, for its chemo-sensitising effect. However, from the 
results obtained it is not possible to establish the exact consequences of the differentially 
expressed proteins as changes in pathways such as glycolysis are not consistent, with 
some enzymes up-regulated and some down-regulated. Further experiments, including 
over-expression and knock-down of these differentially expressed proteins, are required. 
 
DNA synthesis and replication appears to be inhibited by MSA in the DHL4 cell line. 
Ribonucleotide reductase (M2 subunit), enzymes involved in pyrimidine synthesis and 
four members of the MCM family of proteins were all down-regulated. MCM proteins 
play a critical role in DNA replication. In particular they function as replicative helicases, 
unwinding double-stranded DNA into single-stranded DNA ready for the action of DNA 
polymerases. However, MCM proteins are crucial to all stages of the cell cycle 
(Bochman & Schwacha, 2009). These results are in keeping with previous data published 
from our laboratory demonstrating that MSA has a profound cytostatic effect in the 
DHL4 cell line with the 72-hour EC50 for cell number being 1.7µmol/L (Last et al, 2006), 
compared to a cytotoxic EC50, as determined by the ATP assay, of 76.6µmol/L.  
 
In both cell lines, there was altered expression of the cell cycle regulatory protein, CDK1, 
which is required mainly for transition between the G2 and mitotic phases of the cell 
cycle (Salaun et al, 2008). However, the consequences of this are difficult to explain as 
MSA decreased the expression of the phosphorylated/inactivated protein in DHL4 cells 
but increased its expression in RL cells. In addition, MSA does not result in clear cell 
cycle changes in either cell line (Last et al, 2006). A number of different cell cycle 
regulatory proteins, including CDK1, have been identified as targets of MSA in other 
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tumour cell lines but often this has been associated with cell cycle arrest (El-Bayoumy & 
Sinha, 2005). In the DHL4 cell line, two proteins important in maintaining genomic 
stability in response to DNA damage, phosphorylated MDC1 and DDB1, were down-
regulated (Dualan et al, 1995; Stewart et al, 2003). MSA may therefore impair the 
cellular response to DNA damage, making cells more susceptible to apoptosis induced by 
DNA damaging agents such as doxorubicin and 4-HC.  
 
MSA appears to result in epigenetic modifications suggested by the altered expression of 
histone proteins. Genomics studies of prostate cancer cell lines exposed to MSA have 
also described differential expression of histone proteins (Zhang et al, 2005; Zhao et al, 
2004) and epigenetic modification as a mechanism of selenite action in the LnCaP cell 
line has also been reported (Xiang et al, 2008).  Cytoskeletal proteins were another group 
of proteins that were differentially expressed in both the RL and DHL4 cell lines. 
Genomics studies in prostate cancer cell lines exposed to MSA also identified a number 
of differentially expressed genes encoding cytoskeletal proteins, none however 
overlapping with those identified here (Gonzalez-Moreno et al, 2007; Zhang et al, 2005). 
However, a proteomics study in the LNCaP cell line exposed to SLM identified the 
protein cofilin 2 as being up-regulated (Sinha et al, 2008). This protein was up-regulated 
in the DHL4 cell line and contains functional cysteine residues making it susceptible to 
redox modification. In addition, translocation of cofilin proteins from the cytosol to the 
mitochondria occurs during apoptosis and inhibition of these proteins using siRNA, have 
been found to inhibit cytochrome c release and apoptosis (Chua et al, 2003). 
 
Of particular relevance to DLBCL was the finding that MSA decreased levels of 
phosphorylated Bcl-6 in the DHL4 cell line. Bcl-6 is a transcriptional repressor which is 
frequently over-expressed in DLBCL. This promotes cell survival, proliferation and 
blocks differentiation, thus targeting Bcl-6 is being investigated as a therapeutic approach 
in DLBCL (Parekh et al, 2008). Phosphorylation of the protein is known to regulate its 
function (Moriyama et al, 1997). The protein, glyoxalase 1 was also down-regulated in 
the DHL4 cell line. The gene encoding this protein, GLO1, is over-expressed in a number 
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of human cancers and recently this has been shown to be due to gene amplification 
(Santarius et al, 2010). Although GLO1 over-expression has most frequently been 
detected in solid tumours, it has also been reported in haematological tumours, including 
lymphoma (Sakamoto et al, 2000; Santarius et al, 2010). Over-expression of GLO1 is 
associated with drug resistance and knock-down of GLO1 or inhibition of the glyoxalase 
1 inhibits cell proliferation, increases apoptosis and reverses chemo-resistance (Sakamoto 
et al, 2000; Santarius et al, 2010). 
 
Of concern in these results is the finding that MSA induces the expression of GAPDH, as 
this has been used as a loading control in all western blotting experiments. In the RL cell 
line it was the phosphorylated form of the enzyme that was detected but in the DHL4 cell 
line it was the non-phosphorylated protein. GAPDH is phosphorylated by protein kinase 
C ι/λ. GAPDH is known to associate with tubulin and it has been shown that recruitment 
of β-tubulin to the Golgi and ER membranes is dependent on phosphorylated GAPDH 
which therefore plays a role in microtubule dynamics (Tisdale, 2002). It may be that 
induction of GAPDH by MSA is related to its cytoskeletal function rather than its role in 
glycolysis. Clearly, if levels of the phosphorylated form are increased, total levels should 
remain the same and can still be used as a control in western blotting. The western blots 
presented in this thesis do not appear to show increased expression of total GAPDH 
therefore further western blotting experiments need to be performed to assess 
phosphorylated levels. This issue also highlights a limitation of the IPA software in that it 
does not consider the post-translational modification of proteins when performing 
pathway mapping. This, however, is a problem with all commercially available protein 
analysis software. 
 
In summary, these results demonstrate that at chemo-sensitising concentrations, MSA 
alters the expression of proteins belonging to many different cellular pathways. Despite 
the limitations of this study, several changes reported in earlier chapters, using a western 
blotting approach, have been confirmed by this LC-MS method. Moreover, novel 
differentially expressed proteins, belonging to previously un-investigated pathways have 
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been identified in two DLBCL cell lines. Some of these findings are supported by 
published studies that have mainly investigated gene expression in solid tumour cell lines 
exposed to different forms of Se (El-Bayoumy & Sinha, 2005; Zhang et al, 2005). 
However, it is apparent that although there is some overlap in the functions of the 
genes/protein targets of Se, the effects are also very much dependent on the cell-type and 
the chemical form of Se. These experiments clearly need to be repeated and it would be 
valuable to optimise phospho-enrichment of samples to establish the effect of MSA on 
protein function and signalling pathways. In addition, confirmatory experiments, such as 
western blotting, need to be performed to be fully confident in the proteins identified in 
these experiments. Finally, to determine the cellular consequences of the protein changes 
identified, over-expression and knock-down experiments need to be conducted. 
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CHAPTER 11: Conclusions and future studies 
DLBCL is a disease that is potentially curable with combination chemotherapy (DeVita 
et al, 1975). The addition of rituximab to first-line treatment has significantly improved 
both response rates and OS (Coiffier et al, 2002; Feugier et al, 2005). The work presented 
here analysed the outcome and patterns of survival of 384 patients, presenting to SBH 
over an 18-year period, for whom treatment with curative intent was deemed appropriate. 
Although the response rates to initial treatment were in keeping with those from other 
published series, the results clearly demonstrate that, in an unselected group of patients, 
the prognosis for those who develop recurrent disease is exceedingly poor. The median 
OS for the 80 patients with recurrent DLBCL was only one year. Similarly, for patients in 
whom CR was not achieved with the first ‘salvage’ therapy, the outcome was particularly 
poor, with none experiencing a durable period of remission following subsequent 
treatment. All, except two patients (who still had active lymphoma at the time of death), 
died of disease.  
 
Despite the curative potential of HDT with autologous haematopoietic stem cell support 
in recurrent DLBCL, a significant proportion of patients, for several reasons, were not 
able to receive this treatment. Surprisingly however, in patients in whom a second 
CR/CRu was achieved, there was no significant difference in RD or OS between those 
who did and those who did not receive HDT. Clearly, this is at odds with published data 
that have demonstrated the superiority of HDT over standard-dose chemotherapy alone in 
the treatment of recurrent disease (Philip et al, 1995). These results, however, likely 
reflect the reality of treating an unselected group. The results for patients referred to SBH 
from peripheral hospitals, specifically to receive HDT in second remission, were 
considerably better and more in keeping with those achieved in clinical trials. However, 
most clinical trials in patients with recurrent DLBCL commence at the point of delivery 
of HDT and do not take into account the true ‘denominator’.   
This work also highlights the importance of long follow-up, as late recurrences of 
DLBCL do occur. In this series, recurrence of DLBCL occurred in 14 patients (6%) after 
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5 years of CR/CRu and these patients had a similarly poor prognosis to those in whom 
recurrence occurred earlier. In addition, 6 patients died of lymphoma-related causes more 
than 10 years after the diagnosis of DLBCL. The importance of performing a biopsy at 
the time of disease recurrence is also evident, as recurrence with a different histological 
subtype of lymphoma, mainly FL, does occur and these patients need to be treated 
differently.  
Overall, this analysis confirms the need for new and better first-line treatments, in order 
to prevent recurrence in the first place. Additionally, prospective randomised trials, which 
incorporate new agents as treatment for patients with recurrent DLBCL, are urgently 
needed. With this is mind, and against this background, the remainder of the work 
presented has concentrated on the potential therapeutic role of Se as an adjunct to 
treatment for patients with DLBCL.  The rationale for this project came from 
observational and in vitro studies performed in our Department. Serum Se concentration 
at presentation was found to be an independent prognostic factor, predicting for dose 
delivery, treatment response and long-term survival in patients with ‘aggressive’ B-cell 
NHL (Last et al, 2003). Additionally, in vitro studies using MSA, a precursor of 
methylselenol, in DLBCL cell lines demonstrated that whilst high concentrations induced 
apoptosis, non-cytotoxic concentrations could enhance the efficacy of a number of 
cytotoxic agents (Juliger et al, 2007; Last et al, 2006). Repeat experiments presented here 
confirm these published data. This work complements that of others, in solid tumour cell 
lines and xenograft models, which show that organic Se species increase the efficacy of 
chemotherapeutic agents, whilst protecting normal tissue from chemotherapy-induced 
toxicity (Cao et al, 2004; Hu et al, 2008).    
MSA was shown to inhibit the activation of NF-κB in DLBCL cell lines thus providing a 
potential mechanism to explain its chemo-sensitising action (Juliger et al, 2007). 
However, as described extensively in Chapter 1, Se has the potential to affect the function 
of many cellular proteins and signalling pathways. In addition, a differential response to 
Se has been demonstrated in tumour and normal cells (Cao et al, 2004). Therefore, 
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further mechanisms by which Se may mediate these differential effects, was one of the 
main aims of the laboratory studies in this thesis.    
It is perhaps surprising that the observed synergy between MSA and cytotoxic agents was 
not associated with increased apoptosis, as studies in solid tumour cell lines have 
demonstrated the ability of non-toxic concentrations of MSA to enhance apoptosis (Hu et 
al, 2005a; Hu et al, 2008; Wu et al, 2009). There are three main types of cell death; 
apoptosis, autophagy and necrosis. Other atypical forms of cell death exist, such as 
‘mitotic catastrophe’ and ‘anoikis’, but in general, these eventually demonstrate features 
of apoptosis or autophagy (Kroemer et al, 2009). In this work, both apoptosis and 
autophagy were investigated. Although cytotoxic concentrations of MSA induced cell 
death by apoptosis (Last et al, 2006), non-toxic concentrations did not enhance apoptosis 
when combined with cytotoxic agents. The Guava
®
 viacount assay was used to 
demonstrate synergy between MSA and cytotoxic drugs. This assay makes use of two 
dyes, one that is membrane permeable and stains all nucleated cells and one that is 
membrane impermeable and only enters cells when the membrane has been 
compromised, thus identifying apoptotic/dead cells. Cell death by necrosis could, 
therefore, be responsible for the observed increase in cell death as this process involves 
swelling of the cell with early cell membrane permeabilisation followed by membrane 
rupture (Kroemer et al, 2009). Necrosis has not been previously reported as a mechanism 
of cell killing by organic Se compounds, however further investigation seems warranted. 
Necrosis has traditionally been considered an ‘accidental’, unregulated form of cell death, 
but recent studies suggest that, under certain circumstances, it can also be a carefully 
regulated process (Festjens et al, 2006; Golstein & Kroemer, 2007). Autophagy was 
excluded as a mechanism of cell death in experiments reported in Chapter 5. MSA did 
induce autophagy but this appears, at least in one cell line, to be a mechanism of cell 
survival rather than cell death.  
At cytotoxic concentrations, MSA activated the intrinsic apoptotic pathway as evidenced 
by loss of MMP and downstream effects on members of the Bcl-2 family of proteins. 
However, the pattern of protein changes induced by MSA differed between cell lines. In 
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the RL cell line, MSA increased the expression of the pro-apoptotic protein Bax and in 
the DHL4 cell line, the expression of the pro-apoptotic protein Bak was increased. In the 
JVM2 cell line, MSA increased the expression of Bax and the anti-apoptotic protein Bcl-
xL, but decreased the expression of the anti-apoptotic protein Mcl-1. In all three cell 
lines, the expression of Bcl-2 was not altered by MSA. Of note, PARP was cleaved in the 
RL cell line after exposure to 1µmol/L MSA, but this concentration did not result in a 
loss of MMP suggesting that the extrinsic apoptotic pathway may also be involved in 
executing cell death. What triggers apoptosis in lymphoma cell lines exposed to MSA is 
not clear. Previous work from our laboratory excluded generation of ROS (Last et al, 
2006). The generation of DNA damage and induction of ER stress (discussed further 
below) by MSA have now also been excluded.  
The effect of MSA on intracellular GSH was investigated. MSA-resistant and MSA-
sensitive DLBCL cell lines did not differ in basal GSH levels. However, in two MSA-
sensitive cell lines (RL and SUD4), exposure to MSA concentrations ≥10µmol/L for 24 
hours resulted in a significant decrease in GSH concentration. This effect was not 
observed in the MSA-resistant cell line, DHL4. The consequence of the observed MSA-
induced decrease in GSH levels in RL and SUD4 cells is not entirely clear. Previous 
work from our laboratory has demonstrated that increasing intracellular GSH 
concentration, by treating DLBCL cell lines with N-acetyl cysteine, had no effect on the 
activity of MSA (Last et al, 2006). This is in contrast to a study in a hepatoma cell line, 
which demonstrated that N-acetylcysteine enhanced MSA-induced apoptosis (Shen et al, 
2002). This latter finding is consistent with the fact that reduction of MSA by thiols, such 
as GSH, is required for its metabolism to methylselenol. To further investigate the role of 
GSH in determining the sensitivity of DLBCL cell lines to MSA, treatment of cells with 
the inhibitor of GSH synthesis, buthionine sufoxamine, would be useful. However, higher 
than apoptotic concentrations were required to decrease the GSH concentration in RL and 
SUD4 cells and this effect was not apparent at the chemo-sensitising concentration of 
1µmol/L MSA. Moreover, in the DHL4 cell line, the chemo-sensitising concentration of 
397 
 
10µmol/L did not alter GSH levels. Therefore it is unlikely that a decrease in GSH levels 
is critical to the apoptotic or chemo-sensitising action of MSA in these cell lines. 
A number of intracellular signalling pathways were studied in the DLBCL cell lines and 
JVM2 cells. Exposure to MSA did not affect the PI3K/Akt or the MAPK pathways. 
However, MSA decreased the expression of the anti-apoptotic protein, survivin. This 
protein is a target of NF-κB and its expression was suppressed at similar concentrations 
to those reported by our group to inhibit the activation of NF-κB; ≥5µmol/L MSA 
(Juliger et al, 2007). In RL cells, survivin expression was not altered by the chemo-
sensitising concentration of 1µmol/L, therefore the effect of MSA on this protein does 
not provide a unifying explanation for the chemo-sensitising activity of MSA. Survivin 
expression in cells exposed to a combination of MSA and cytotoxic agents at synergistic 
concentrations was not investigated but would be valuable in order to completely exclude 
its role in chemo-sensitisation. The effect on survivin expression may be a clinically 
relevant one, as the proposed clinical trial aims to achieve a plasma Se concentration of 
20µmol/L. In addition, survivin is expressed in a large proportion of ‘aggressive’ B-cell 
lymphomas with virtually no expression in normal tissue (Tracey et al, 2005). 
p53 was not found to be important in determining the sensitivity, or action, of MSA in the 
lymphoma cell lines studied. All the DLBCL cell lines used have mutated p53 and they 
exhibited differing sensitivities to MSA. The three MCL cell lines used, JVM2, JeKo-1 
and Granta-519, all have wild-type p53. The JVM2 cell line was relatively sensitive to 
MSA with a 72-hour EC50 of 3.4µmol/L, whereas both the JeKo-1 and Granta-519 cell 
lines were relatively resistant, with 48-hour EC50 values for cell viability of 38.9µmol/L 
and 51.8µmol/L respectively. However, MSA had a greater cytostatic effect in these cell 
lines, with 48-hour EC50 values for cell number in JeKo-1 and Granta-519 cell of 
3.2µmol/L and 2.8µmol/L respectively. It should be noted that different assays were used 
in JVM2 cells compared with JeKo-1 and Granta-519 cells. The ATP assay, which 
reflects both cell viability and cell number, without the ability to distinguish between 
these two effects, was used in experiments with JVM2 cells. For experiments with JeKo-
1 and Granta-510 cells, the Guava
®
 viacount assay was used. This assay measures cell 
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viability and number separately, therefore distinguishing between the cytotoxic and 
cytostatic effects of a drug. Given that in JVM2 cells, MSA resulted in PARP cleavage at 
concentrations as low as 3µmol/L and that the EC50 concentration of 3.4µmol/L 
significantly increased the sub-G1, apoptotic population, when cell cycle analysis was 
performed, it can be assumed that MSA was in fact cytotoxic to JVM2 cells. In JeKo-1 
and Granta-519 cells, 10µmol/L MSA (the only concentration used in western blotting 
experiments) did not result in PARP cleavage. 
Despite the presence of wild-type p53, MSA did not result in cell cycle arrest in JVM2 
cells but rather there was a concentration-dependent decrease in p53 and p21 expression. 
This was unexpected, as it has been demonstrated that the organic Se compound, SLM, 
can activate p53 and induce cell cycle arrest in solid tumour cell lines with wild-type p53 
in the presence or absence of DNA damage (Fischer et al, 2007; Goel et al, 2006; Seo et 
al, 2002a). Of note, SLM itself is not genotoxic. Thus, it can be concluded that in 
lymphoma cell lines, p53 function does not have a major impact on MSA activity.  
MSA was shown to induce protein misfolding and ER stress in two DLBCL cell lines. 
This was demonstrated by an MSA-induced increase in expression of the enzyme PDI 
and the ER chaperone GRP78, along with increased mRNA expression of GADD153. 
However, in contrast to published work in solid tumour cell lines, the induction of ER 
stress is unlikely to be responsible for the apoptotic or chemo-sensitising effects of MSA 
in DLBCL cell lines (Wu et al, 2009). The chemo-sensitising concentration of 1µmol/L 
MSA in RL cells had virtually no effect on markers of ER stress but this concentration 
did result in PARP cleavage suggesting that the induction of ER stress was not 
responsible for inducing apoptosis. In the MSA-resistant cell line, DHL4 cell line, low 
concentrations of MSA (1-5µmol/L) resulted in a much larger increase in GRP78 
expression compared to equivalent concentrations in the RL cell line. GRP78 is generally 
considered a pro-survival protein and over-expression by tumours both promotes growth 
and has been implicated in chemo-resistance (Pyrko et al, 2007; Reddy et al, 2003). 
Thus, ER stress induction may represent a mechanism of MSA-resistance in this cell line. 
In fact, the chemo-sensitising concentration of 10µmol/L MSA, in DHL4 cells, led to the 
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induction of autophagy, a downstream consequence of ER stress, and this was shown to 
be a mechanism of cell survival. This work would need to be extended to other MSA-
resistant cell lines to draw any firm conclusions, but identifying mechanisms of resistance 
to MSA may be useful if MSC shows value in the clinic. 
A novel finding presented in this work is the observation that MSA inhibits HDAC 
activity in DLBCL cell lines. However, cellular metabolism of MSA was required for this 
effect as MSA, in a cell-free assay, was unable to inhibit the HDAC activity of HeLa 
nuclear extracts. It was only in a cell-based activity assay that HDAC inhibition was 
observed. Additionally, cell culture medium from DHL4 cells exposed to MSA had a 
small, but statistically significant, inhibitory effect on HDAC activity in a cell-free assay. 
Thus, the data demonstrate that a cellular metabolite of MSA is responsible for HDAC 
inhibition. It has recently been demonstrated that α-keto acid metabolites of SLM and 
MSC are capable of inhibiting HDAC activity in solid tumour cell lines (Lee et al, 2009a; 
Nian et al, 2009), however, the ability of monomethylated Se species to inhibit HDAC 
activity has not been reported. The main metabolite of MSA is presumed to be 
methylselenol, but it is difficult to detect and quantify due to its volatility.  
In Chapter 9, further Se-containing metabolites of MSA were investigated. After 2-hour 
exposure to MSA, the same time-point as that studied for HDAC inhibition, the main 
intracellular metabolite detected in RL and DHL4 cells was dimethylselenide, with SLM 
and S-methylselenoglutathione present as minor components. Dimethylselenide is formed 
from the methylation of methylselenol and thus provides evidence for the conversion of 
MSA into its active form. This is the first time that this metabolite has been detected in 
solution in cells exposed to MSA. Dimethyldiselenide was the main volatile Se species 
detected after exposure of DHL4 cells to MSA, being detected at the earliest time-point 
studied, 10 minutes, when using a system that traps volatile species in the head space 
above cells in culture. Dimethyldiselenide is formed by the oxidation of methylselenol, 
thus providing further evidence for the rapid conversion of MSA to methylselenol. It is 
therefore assumed that either methylselenol or its methylation product, dimethylselenide, 
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itself a very reactive compound, may be responsible for the HDAC inhibitory activity of 
MSA.   
The downstream consequences of HDAC inhibition were investigated. p21 expression 
was induced by both MSA and MSC in DLBCL cell lines, following a similar pattern to 
the acetylation of histone H3. This is clearly in contrast to the effect of MSA on p21 in 
JVM2 cells where its expression was down-regulated. The effect of MSA on HDAC 
activity in JVM2 cells or other MCL cell lines was not studied and it may be that this 
effect, like many other effects of MSA, is cell-type specific. It is also possible that the 
down-regulation of p53 by MSA and the resultant inhibition of p21 may exceed the 
opposing HDAC inhibitory effect of MSA in JVM2 cells. In DLBCL cell lines, 
significant HDAC inhibition in the activity assay was observed at concentrations 
≥10µmol/L, whereas in the JVM2 cell, the effect on p53 was observed at concentrations 
≥3µmol/L. Further work is required to clarify this.  
MSA was also shown to inhibit the induction of HIF-1α and the production of VEGF in 
RL and DHL4 cells exposed to hypoxic conditions. Similar findings have been reported 
in solid tumour cell lines and xenograft models (Bhattacharya et al, 2008; Jiang et al, 
2000; Yin et al, 2006). The mechanism by which MSA exerts these effects in DLBCL 
cell lines is not clear from the experiments performed. It may be a direct consequence of 
HDAC inhibition but further experiments would be required to confirm this. Hypoxia is 
known to increase the expression of several HDACs, which results, either directly or 
indirectly, in the deacetylation of HIF-1α, thus promoting its activity (Kim et al, 2001).  
Alternatively, HDAC inhibition may not be responsible as in solid tumours, MSA and 
MSC have been reported to inhibit HIF-1α through effects on prolyhydroxylases 
(Chintala et al, 2010).  
The results of the experiments performed in normal cells suggest that MSA may not have 
been the correct Se compound to study the cyto-protective effects of Se.  Most studies 
reporting the cyto-protective effect of organic Se compounds in normal cells have used 
SLM (Fischer et al, 2007; Seo et al, 2002b), with some using MSC (Cao et al, 2004; 
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Cuello et al, 2007). In general, when these Se compounds have been used in vitro, 
cultures have not been supplemented with the relevant lyase enzyme suggesting that 
formation of methylselenol would not have been maximal. A cyto-protective effect of 
MSA has not been reported in the literature whereas its superior in vivo anti-tumour 
effect has (Li et al, 2008a). It may therefore be that metabolites, other than methylselenol, 
are important in the cyto-protective action of Se compounds, including α-keto acid 
metabolites (Pinto et al, 2010). It is likely to be an over simplification to suppose that all 
Se compounds that are metabolised to methylselenol act in the same way and it may be 
that other, yet unknown, properties of these compounds are also important in their 
mechanism of action.  
It has also been demonstrated that the mechanism of action of Se compounds that are 
precursors of methylselenol i.e. MSA, MSC and SLM may differ, and that their effects 
are cell-type dependent. An example is a study that compared MSC and MSA in the same 
in vivo models of prostate cancer. MSC was able to inhibit tumour growth in only one of 
the two xenograft models. Tumour growth inhibition by MSC was associated with 
increased apoptosis, whereas tumour growth inhibition by MSA was not, instead 
affecting angiogenesis (Li et al, 2008a). In contrast, in a human head and neck cancer 
xenograft model, MSC was found to potentiate the activity of irinotecan and hence 
dramatically increase cure rates but this was not associated with increased markers of 
apoptosis, instead, the observed synergy correlated with inhibition of angiogenesis (Yin 
et al, 2006). This demonstrates that although both MSA and MSC are thought to act 
through their common metabolite methylselenol, they affect different intracellular 
signalling pathways depending on the tumour-type or on other oncogenic alterations in 
the same tumour type.  
It was found that PBMCs, a model for normal cells, were relatively resistant to the 
cytotoxic effects of MSA and were able to mount a better survival response when 
compared to DLBCL cell lines. Expression of GRP78, a pro-survival chaperone, was 
increased to a greater extent at equivalent concentrations in PBMCs than in DLBCL cell 
lines. In addition, MSA increased NF-κB activation in PBMCs whereas our group has 
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shown that MSA inhibits NF-κB activation in DLBCL cell lines (Juliger et al, 2007). 
Conversely, keratinocytes and HFFF2, two cell lines commonly used as models for 
normal cells, were very sensitive to the cytotoxic effects of MSA, and a non-toxic 
concentration of MSA was not able to protect keratinocytes from chemotherapy-induced 
toxicity. However, MSA did not increase the activity of cytotoxic agents in normal cells, 
even with 7 days’ pre-exposure. It should be noted that MSA is not going to be the Se 
compound used in the forthcoming clinical trial, rather it will be MSC. The use of MSC 
in vitro is limited by its requirement for activation by β-lyase enzymes, which in vivo 
occurs mainly in the liver.   
The experiments performed to investigate uptake and metabolism of MSA by DLBCL 
cell lines and PBMCs, identified differences between these cell types. In the RL and 
DHL4 cell lines, MSA was taken up rapidly and total intracellular Se concentration was 
maximal at the earliest time-point studied, 10 minutes. However, MSA was taken up at a 
slower rate in PBMCs with the maximal Se concentrations being achieved between 4-6 
hours’ exposure. In addition, the mean Se concentration at each time-point was, in 
general, lower in PBMCs compared with those obtained in the DLBCL cell lines. 
Conversion of MSA to methylselenol was found to occur less efficiently in PBMCs than 
in DLBCL cell lines. The formation of dimethylselenide, the methylation product of 
methylselenol, was less in PBMCs and the generation of volatile dimethyldiselenide, the 
oxidation product of methylselenol, was slower. The reason for these differences needs to 
be investigated further but may be because tumour cells, in general, have higher levels of 
GSH or because PBMCs use the Se in MSA to form selenoproteins via the intermediate 
hydrogen selenide. Although these experiments in themselves may not be directly 
clinically relevant, it has allowed the optimisation of methods to determine total 
intracellular Se and Se species in PBMCs. These measurements will be used to quantitate 
intracellular Se species in plasma and PBMCs collected from patients in the proposed 
clinical trial. 
For clinical relevance, the conversion of MSC to methylselenol by normal and tumour 
cells needs to be studied. The experiments reported here show that the sensitivity of 
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tumour cells to MSC differs, most likely due to differences in β-lyase activity. The RL 
cell line and the renal adenocarcinoma cell line, ACHN, were relatively sensitive to the 
cytotoxic effect of MSC and these cell lines had higher β-lyase activity. Whether the β-
lyase activity in lymphoma cell lines reflects that in primary lymphoma samples is not 
known. It is assumed that in vivo, MSC is converted to methylselenol, mainly in the liver 
and this is enough to exert its anti-tumour effect. However, there is evidence from 
experiments conducted in rats to suggest that MSC can also be delivered, intact, to other 
organs and then converted to methylselenol (Suzuki et al, 2008). The contribution of 
tumour metabolism of MSC would be interesting to investigate and it would be possible 
to measure β-lyase activity in tumour samples from patients entered into the proposed 
clinical trial. However, the current assay would have to be optimised to increase its 
sensitivity as 40 million cells were used per experimental condition. Additionally, it 
would be valuable to determine the in vivo anti-tumour effect of MSC in a xenograft 
model of lymphoma in order to confirm the results obtained in xenograft models of solid 
tumours.  
The experiments conducted in the first part of this project did not identify further 
unifying mechanisms to explain the chemo-sensitising action of MSA in DLBCL cell 
lines. Thus, a more global approach was taken in the form of phospho-proteomics. 
Despite the limitations of these experiments, novel proteins and pathways of Se action 
were identified. In addition, in the DHL4 cell line, some of the differentially expressed 
proteins were those that had been identified by western blotting in earlier experiments, 
such as GRP78 and PDI. Further experiments are required to investigate the relevance of 
the more novel findings. For example, the protein nucleophosmin was the most up-
regulated, by 33.4-fold, in the RL cell line. This needs to be confirmed by an alternative 
technique, such as western blotting, and the consequences of this up-regulation require 
further investigation through knock-down and over-expression experiments.  
One of the aims of this work was to identify potential biomarkers for the clinical use of 
Se. Four such markers were identified; GRP78 expression and acetylated histone H3 by 
western blotting of PBMC whole cell extracts, NF-κB activity by western blotting of 
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PBMC nuclear extracts and plasma VEGF levels. After 24-hour exposure to MSA, 
GRP78 expression was maximal at 1µmol/L MSA. However, there was a concentration 
effect of MSA after 4-hour exposure, (mirroring the time-point of maximal Se uptake), 
suggesting that this potential biomarker may need to be used at early time-points in 
patients receiving Se supplementation. Obtaining nuclear extracts from PBMCs for NF-
κB activity requires a large number of cells, around 10 million, which may limit its value. 
In addition, not all patients with DLBCL will have elevated VEGF levels, potentially 
limiting the value of this protein as a biomarker. Therefore, the true value of these 
potential biomarkers will have to be assessed in the forthcoming clinical trial. 
Differentially expressed proteins identified in the proteomics experiments may also serve 
as potential biomarkers but further work is required to confirm these preliminary 
findings.      
In addition to the work performed in DLBCL cell lines, the combination of Se and 
bortezomib was investigated in MCL cell lines. Despite a sound rationale to suggest that 
this interaction would be synergistic, including the fact that both drugs inhibit the 
activation of NF- B and induce ER stress, a clear antagonistic interaction was 
demonstrated. One potential mechanism identified for this antagonism was the induction 
by MSA and bortezomib of the anti-apoptotic proteins, Bcl-2 and Mcl-1. In addition, both 
drugs were shown to induce ER stress and autophagy in the cell lines but the role of these 
pathways in promoting cell survival requires further investigation. This would include 
over-expression and knock-down of GRP78 and combining MSA and bortezomib with an 
inhibitor of autophagy. However, these experiments demonstrate that the effect of MSA 
is dependent on cell-type and that its combination with some anti-tumour agents may in 
fact be detrimental. Thus, similar to its use in cancer prevention, careful selection of 
patients who may benefit from Se supplementation is required, since Se is clearly not 
going to benefit all patients receiving treatment for cancer.  
In conclusion, organic Se compounds have the potential to benefit patients with DLBCL 
without increasing, but possibly decreasing, the toxicity of chemotherapeutic agents. Se 
has multiple mechanisms of action and this work has endeavoured to provide a better 
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understanding of its activity in DLBCL. It is hoped that this work will contribute to the 
successful therapeutic use of Se in patients with DLBCL.   
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APPENDIX 
 
Appendices to Chapter 4 
MSA μmol/L Set 1 Set 2 Set 3 Mean +/- SD 
0 100 100 100 100 0 
0.5 108 115.8 83.5 102.4 16.9 
1 111.9 106.8 74.8 97.8 20.1 
3 63.7 82.4 55.2 67.1 13.9 
5 20.5 33.6 45.9 33.3 12.7 
10 0.5 3.2 5.1 2.9 2.3 
Table 1 Concentration-effect of the RL cell line exposed MSA for 72 hours. Results 
expressed relative to control values. 
 
MSA μmol/L Set 1 Set 2 Set 3 Mean +/- SD 
0 100 100 100 100 0 
10 100.9 123.8 93.8 106.2 15.7 
50 57.3 77 72.4 68.9 10.3 
100 19.3 10.9 35.2 21.8 12.3 
200 2 3.2 4.6 3.3 1.3 
400 0.4 2.7 1.9 1.7 1.2 
Table 2 Concentration-effect of the DoHH2 cell line exposed to MSA for 72 hours. 
Results expressed relative to control values. 
 
MSA μmol/L Set 1 Set 2 Set 3 Mean +/- SD 
0 100 100 100 100 0 
0.5 109.2 111.5 112.3 111 1.6 
1 107.4 125.6 94.9 109.3 15.4 
3 97.6 90.3 123.1 103.7 17.2 
5 87.7 82.2 73.2 81 7.3 
10 37.7 37.1 11.4 28.7 15 
Table 3 Concentration-effect of the SUD4 cell line exposed to MSA for 72 hours. 
Results expressed relative to control values. 
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MSA μmol/L Set 1 Set 2 Set3 Mean +/- SD 
0 100 100 100 100 0 
10 95.5 126.9 92 104.8 19.2 
50 77.7 104 77.7 86.5 15.2 
100 21.2 24 25.2 23.5 2.1 
200 6.9 5.9 14 8.9 4.4 
400 2.5 2.4 7.1 4 2.7 
Table 4 Concentration-effect of the DHL4 cell line exposed to MSA for 72 hours. 
Results expressed relative to control values. 
 
Doxorubicin nmol/L Set 1 Set 2 Set 3 mean SD+/- 
0 100 100 100 100 0 
10 92.3 86.1 96.2 91.5 5.1 
50 79.2 76.4 75.0 76.9 2.2 
100 68.0 81.4 77.0 75.5 6.9 
250 56.4 70.1 58.5 61.6 7.4 
Doxorubicin+1μmol/L MSA     
MSA alone 101.2 98.7 100.4 100.1 1.3 
10 91.7 89.0 99.1 93.3 5.2 
50 74.4 66.7 64.5 68.5 5.2 
100 54.8 56.2 47.1 52.7 4.9 
250 27.8 33.2 37.1 32.7 4.7 
Doxorubicin+ 1µmol/L MSA Expected cell viability    
MSA alone 101.2 98.7 100.4 100.1 1.3 
10 93.5 84.8 96.6 91.6 6.1 
50 80.4 75.1 75.4 77.0 3.0 
100 69.2 80.1 77.4 75.6 5.7 
250 57.6 68.8 58.9 61.7 6.1 
Table 5 Cell viability of RL cells exposed to doxorubicin alone and in combination with 
MSA 1µmol/L for 48 hours. Results expressed relative to control. 
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4-HC µmol/L Set 1 Set 2 Set 3 Mean SD+/- 
0 100 100 100 100 0 
0.5 99.6 99.5 100.1 99.7 0.3 
1 99.7 99.7 99.8 99.7 0.0 
2 99.4 99.0 99.1 99.2 0.2 
3 99.3 98.0 97.8 98.4 0.8 
5 97.5 81.4 81.3 86.8 9.3 
4-HC+10μmol/L MSA     
control 92.8 96.6 90.1 93.2 3.3 
0.5 87.0 94.5 79.9 87.1 7.3 
1 79.7 89.8 75.9 81.8 7.2 
2 65.6 75.8 65.4 68.9 5.9 
3 50.8 56.6 55.6 54.3 3.1 
5 30.0 28.4 21.6 26.7 4.5 
4-HC+10μmol/L MSA Expected cell viability    
0 92.8 96.6 90.1 93.2 3.3 
0.5 92.4 96.1 90.2 92.9 3.0 
1 92.5 96.3 89.9 92.9 3.2 
2 92.2 95.6 89.2 92.3 3.2 
3 92.1 94.6 87.9 91.5 3.4 
5 90.3 78.0 71.4 79.9 9.6 
 Table 6 Cell viability of DHL4 cells exposed to 4-HC alone and in combination with 
MSA 10µmol/L for 48 hours. Results expressed relative to control. 
 
MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 255.0 252.6 244.5 250.7 5.5 
1 248.4 270.6 245.1 254.7 13.8 
3 303.9 294.8 251.4 283.4 28.0 
5 280.2 278.3 298.6 285.7 11.2 
10 279.3 257.2 260.1 265.5 12.0 
20 305.0 270.2 271.3 282.2 19.8 
Table 7 GSH concentration in DHL4 cells exposed to MSA for 2 hours. Results 
expressed as pmoles/million cells. 
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MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 223.8 229.4 209.2 220.8 10.4 
1 215.1 222.1 219.4 218.8 3.5 
3 272.9 240.2 242.7 251.9 18.2 
5 246.4 212.5 258.5 239.1 23.8 
10 197.7 184.8 226.2 202.9 21.2 
20 197.2 155.9 239.7 197.6 41.9 
Table 8 GSH concentration in DHL4 cells exposed to MSA for 24 hours. Results 
expressed as pmoles/million cells. 
  
MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 142.5 212.3 176.9 177.2 34.9 
1 259.8 247.3 219.5 242.2 20.6 
3 253.8 221.1 266.7 247.2 23.5 
5 260.2 200.1 132.5 197.6 63.9 
10 219.3 196.4 233.5 216.4 18.7 
20 187.0 179.9 252.8 206.5 40.2 
Table 9 GSH concentration in RL cells exposed to MSA for 2 hours. Results expressed 
as pmoles/million cells. 
 
MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 253.5 260.7 237.3 250.5 11.9 
1 224.1 229.2 237.7 230.3 6.9 
3 280.7 209.7 310.6 267.0 51.8 
5 241.4 210.5 275.9 242.6 32.7 
10 163.8 94.1 156.4 138.1 38.3 
20 149.7 82.0 121.9 117.9 34.0 
Table 10 GSH concentration in RL cells exposed to MSA for 24 hours. Results 
expressed as pmoles/million cells. 
 
MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 225.6 259.7 208.8 231.4 25.9 
1 214.9 226.3 213.5 218.2 7.0 
3 240.4 231.6 223.0 231.7 8.7 
5 188.0 215.0 220.2 207.7 17.3 
10 57.5 137.4 118.0 104.3 41.7 
20 17.0 24.7 25.0 22.3 4.5 
Table 11 GSH concentration in SUD4 cells exposed to MSA for 24 hours. Results 
expressed as pmoles/million cells 
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MSA µmol/L Set 1 Set 2 Set 3 Set 4 Mean +/-SD 
0 0 0 0 0 0 0 
1 -11.3 -0.9 -4.5 -1.3 -4.5 4.8 
5 4.7 12.4 16.9 13.1 11.8 5.1 
20 28.7  47.4 54.9 43.7 13.5 
Doxorubicin 250nmol/L 18.3 22.7 14.1  18.4 4.3 
Table 12 JC-1 staining in RL cells exposed to MSA and doxorubicin for 24 hours. 
Results are % decrease in red fluorescence relative to control. 
 
MSA µmol/L Set 1 Set 2 Set 3 Set 4 Mean SD+/- 
0 0 0 0 0 0 0 
1 -2.8 0.2 -3.3 -1.6 -2.0 1.6 
10 1.4 5.5 4.8 9.0 3.9 3.1 
100 39.9  36.6 46.2 38.3 4.9 
Doxorubicin 500nmol/L 15.3 21.5   18.4 4.4 
Table 13 JC-1 staining in DHL4 cells exposed to MSA and doxorubicin for 24 hours. 
Results are % decrease in red fluorescence relative to control. 
 
MSA µmol/L  Set 1 Set 2 Mean +/-SD 
0 0 0 0 0 
1 -3.3 -0.1 -1.7 2.3 
5 15.8 8.0 11.9 5.5 
10 53.8 62.4 58.1 6.1 
Doxorubicin 100nmol/L 47.4 36.6 42.0 7.6 
Table 14 JC-1 staining in RL cells exposed to MSA and doxorubicin for 48 hours. 
Results are % decrease in red fluorescence relative to control. 
 
MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 0 0 0 0 0 
1 -3.5 -1.6 0.7 -1.5 2.1 
10 1.6 7.4 3.0 4.0 3.0 
50 25.0 39.9 25.9 30.3 8.4 
Doxorubicin 500nmol/L 16.6 17.4 5.2 17.0 6.8 
Table 15 JC-1 staining in DHL4 cells exposed to MSA and doxorubicin for 48 hours. 
Results are % decrease in red fluorescence relative to control. 
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MSA µmol/L Set 
1 
Set 
2 
Set 
3 
Set 4 Set 
5 
Set 
6 
Set 
7 
Set 
8 
Mean +/-
SD 
0 100 100 100 100 100 100 100 100 100 0 
0.5 100.
1 
96.2  123.3     106.5 14.7 
1 91.1 76.6 67.5  76.8 93.7 88.3  82.3 10.2 
3 75.7 60.5 71.5 65.7 40.7 41.6 49.6 48.2 56.6 13.6 
5 44.6 38.4 46.6 42.7 22.9 22.3 30.9 28.4 34.5 9.8 
10 21.3 18.9 21.4 24.4 13.6 12.2 16.9 17 18.1 4.2 
20     8.3 6.6 9.7 9.2 8.3 1.2 
Table 16 Concentration-effect of the JVM2 cell line exposed to MSA. Results expressed 
relative to control. 
 
MSA µmol/L Phase of cell cycle Set 1 Set 2 Set 3 Mean +/-SD 
0 A 2.1 2.5 2.6 2.4 0.2 
 G1 54.4 50.9 52.2 52.5 1.8 
 S 6.8 8.6 7.3 7.5 0.9 
 G2 13.1 10.5 9.7 11.1 1.8 
3.4 A 16.7 29.2 30.9 25.6 7.8 
 G1 26.4 43.9 41.5 37.3 9.5 
 S 7.7 7.1 6.4 7.1 0.6 
 G2 7.7 9.2 9.4 8.8 0.9 
Table 17 Cell cycle analysis of JVM2 cells exposed to MSA for 72 hours. Results are % 
of cells in each phase of the cell cycle. 
 
 Set 1 Set 2 Set 3 Mean +/-SD 
Control 100.0 100.0 100.0 100.0 0.0 
Pervanadate 100µmol/L 478.3 535.2 511.3 508.3 23.3 
Pervanadate + MSA 0.5µmol/L 458.9 477.5 483.7 473.4 10.6 
Pervanadate + MSA 1µmol/L 459.5 465.9 461.9 462.4 2.6 
Pervanadate +MSA 3µmol/L 443.3 541.6 441.5 475.5 46.8 
Pervanadate + MSA 5µmol/L 454.0 591.5 436.8 494.1 69.2 
Pervanadate + MSA 10µmol/L 410.7 463.9 426.2 433.6 22.4 
Pervanadate + Wortmannin 1µmol/L 290.9 346.9 335.5 324.4 24.2 
Table 18 Aktide assay in JVM2 cells exposed to pervanadate for 30 minutes followed by 
MSA for a further 30 minutes. Results are expressed relative to control. 
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 Set 1 Set 2 Mean +/-SD 
Control 100.0 100.0 100.0 0.0 
Pervanadate 100µmol/L  160.3 182.9 171.6 16.0 
Pervanadate + MSA 0.5µmol/L 183.7 149.1 166.4 24.5 
Pervanadate + MSA 1µmol/L 175.6 173.0 174.3 1.8 
Pervanadate +MSA 3µmol/L  154.9 142.1 148.5 9.1 
Pervanadate + MSA 5µmol/L  138.4 153.9 146.1 10.9 
Pervanadate + MSA 10µmol/L  153.9 135.7 144.8 12.9 
Pervanadate + Wortmannin 1µmol/L 117.0 134.8 125.9 12.6 
Table 19 Aktide assay in JVM2 cells exposed to pervanadate for 30 minutes followed by 
MSA for a further 2 hours. Results are expressed relative to control. 
 
Doxorubicin nmol/L Set 1 Set 2 Set 3 Mean SD+/- 
0 1 1 1 1 0 
10 1.9 1.2 1.4 1.5 0.4 
50 4.5 3.9 3.8 4.1 0.4 
100 7.7 7.1 8.3 7.7 0.6 
250 17.3 15.7 17.7 16.9 1.1 
500 32.1 29.0 23.4 28.2 4.4 
Doxorubicin+1µmol/LMSA     
0 1 1 1 1 0 
10 2.1 1.2 1.4 1.5 0.4 
50 5.0 3.7 4.2 4.3 0.7 
100 8.1 7.4 7.7 7.7 0.4 
250 18.3 15.1 17.5 17.0 1.7 
500 33.1 27.6 25.9 28.9 3.7 
Table 20 Intracellular doxorubicin in RL cells exposed to doxorubicin alone and in 
combination with 1µmol/L MSA. Results are expressed as fold change in mean 
fluorescence relative to control. 
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Doxorubicin nmol/L Set 1 Set 2 Set 3 Mean SD+/- 
0 1 1 1 1 0 
10 1.3 1.2 1.2 1.2 0.1 
50 3.8 3.0 3.2 3.3 0.4 
100 6.7 5.6 5.5 5.9 0.6 
250 14.5 12.4 11.7 12.9 1.5 
500 24.2 22.3 18.6 21.7 2.8 
Doxorubicin+10µmol/L MSA     
0 1 1 1 1 0 
10 2.0 1.8 1.7 1.8 0.1 
50 4.9 4.0 3.6 4.1 0.6 
100 7.7 6.5 5.9 6.7 0.9 
250 14.5 13.4 11.9 13.3 1.3 
500 26.1 23.1 21.7 23.6 2.2 
Table 21 Intracellular doxorubicin in DHL4 cells exposed to doxorubicin alone and  in 
combination with 10µmol/L MSA. Results are expressed as fold change in mean 
fluorescence relative to control. 
 
MSC  μmol/L Set 1 Set 2 Set 3 Set 4 Set 5 Set 6 Set 7 Mean +/-SD 
0 100 100 100 100 100 100 100 100 0 
1 98.3 99.2 114.7 100    103.1 7.8 
3 97.1 93.9 117.8 118.8    106.9 13.2 
5 97.4 89.8 116.3 119    105.6 14.3 
10 97.3 91.1 110.4 116    103.7 11.5 
20   70.2 86 81.1 93 95.7 85.2 10.2 
30   55.7 69.2 72.2 72.3 70 67.9 6.9 
40   53.6 57.2 60.7 62 59.5 58.6 3.3 
50   48.1 49.5 52.4 53.8 51.4 51 2.3 
100   37.2 33.3 41 36.7 34.9 36.6 2.9 
Table 22 Concentration-effect of the DHL4 cell line exposed to MSC for 72 hours. 
Results expressed relative to control. 
 
 
 
 
 
 
 
 
 
 
 
470 
 
MSC  μmol/L Set 1 Set 2 Set 3 Set 4 Mean +/-SD 
0 100 100 100 100 100 0 
1 109 102 107.8 116.6 108.9 6 
3 100.6 102.2 106.7 113.5 105.8 5.8 
5 97.8 96.6 102.4 112.4 102.3 7.2 
10 95.6 90 99.5 107.2 98.1 7.2 
15   83.1 94.3 88.7 7.9 
20 53.3 59.5 58 68.3 59.8 6.3 
30   14.8 13.4 14.1 1 
40   5.3 5.4 5.4 0.1 
50   3.9 3.1 3.5 0.6 
100   2.2 1.6 1.9 0.4 
Table 23 Concentration-effect of the RL cell line exposed to MSC for 72 hours. Results 
expressed relative to control. 
 
MSC  μmol/L Set 1 Set 2 Set 3 Set 4 Set 5 Mean +/-SD 
0 100 100 100 100 100 100 0 
1 112 124.6 117.2 121.8 117.8 118.7 4.8 
3 125.9 125.1 119.9 131.2 116.2 123.7 5.8 
5 125.2 121.3 123.7 126.6 122.1 123.7 2.2 
10 116.2 106.6 123.8 109 115.7 114.3 6.8 
15 96.6 99.1 112.7 124 101.7 106.8 11.4 
20  97 90.6 94.9 107.1 97.4 7 
30  87.8 86.2 97.1 95.7 91.7 5.5 
40  79.1 82.9 98.1 79.5 84.9 9 
50  77.6 77.1 94.4 65 78.5 12.1 
100  63 38.4 38.7 26.2 34.9 5.9 
Table 24 Concentration-effect of the JVM2 cell line exposed to MSC for 72 hours. 
Results expressed relative to control. 
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Appendices to Chapter 5 
MSA µmol/L Time (hrs) Experiment 1 Experiment 2 Mean +/-SD 
0 Control 1.0 1.0 1.0 0.0 
3 4 1.3 0.8 1.1 0.3 
3 6 1.8 1.2 1.5 0.5 
3 24 1.8 1.0 1.4 0.6 
3 48 1.5 0.9 1.2 0.4 
5 4 1.8 0.9 1.3 0.6 
5 6 2.0 1.6 1.8 0.3 
5 24 2.9 1.3 2.1 1.1 
5 48 2.4 1.3 1.8 0.8 
Table 25 Densitometry values for western blots of p-eIF2α in RL cells exposed to MSA. 
Results expressed as fold change relative to total eIF2α. 
 
MSA µmol/L Time (hrs) Experiment 1 Experiment 2 Mean +/-SD 
0 Control 1.0 1.0 1.0 0.0 
30 4 0.5 0.6 0.6 0.1 
30 6 0.4 0.4 0.4 0.0 
30 24 0.7 0.7 0.7 0.0 
30 48 1.2 1.0 1.1 0.1 
0 Control 1.0 1.0 1.0 0.0 
60 4 0.4 0.5 0.4 0.0 
60 6 0.4 0.6 0.5 0.2 
60 24 0.7 1.1 0.9 0.3 
60 48 0.8 2.2 1.5 0.9 
Table 26 Densitometry values for western blots of p-eIF2α in DHL4 cells exposed to 
MSA. Results expressed as fold change relative to eIF2α.  
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MSA μmol/L Time 
(hrs) 
Set 
1 
Set 
2 
Set 
3 
Set 
4 
Mean +/-
SD 
0 Control 1 1 1 1 1 0 
1 4  1.7 1.1 1.1 1.3 0.3 
1 6  1 1.1 1 1 0 
1 24  1.8 1.6 0.9 1.4 0.4 
1 48  1.6 1.3 1.3 1.4 0.1 
3 4  1.8 1.5 1.4 1.6 0.1 
3 6  1.9 1.3 1.3 1.6 0.3 
3 24  1.8 0.8 0.8 1.1 0.5 
3 48  1.9 1.2 1.2 1.5 0.3 
5 4 3.5 5 4.5  4.3 0.7 
5 6 4.3 4.7 5.3  4.8 0.4 
5 24 1.4 1.2 1.4  1.4 0.1 
5 48 0.9 1.1 1  1 0.1 
Table 27 GADD153 mRNA expression in RL cells exposed to MSA. Results expressed 
as fold change relative to control. 
 
MSA μmol/L Time (hours) Set 1 Set 2 Set 3 Mean +/-SD 
0  1 1 1 1 0 
5 4 8.8 11 10.5 9.9 1.5 
5 6 5.2 4.1 4.4 4.7 0.8 
5 24 0.7 0.7 1.1 0.7 0 
5 48 0.8 1.1 1.6 1.1 0.2 
10 4 18.1 7.7 18.5 14.7 5 
10 6 15.5 8.2 22.2 15.3 5.7 
10 24 28.4 14.2 26.2 22.9 6.2 
10 48 27.4 18.7  23 4.4 
30 4 14.6 11.3 19.6 15.2 3.4 
30 6 15.4 19.8 26 20.1 4.4 
30 24 39.4 21.9 42.3 34.6 9.1 
30 48 129.2 72 104.1 101.7 23.4 
60 4 13.5 11.9 14.5 13.3 1.1 
60 6 16 10.2 16.3 14.2 2.8 
60 24 41.1 32.8 56.8 43.6 10 
60 48 85.3 65.3 115.9 88.8 20.8 
Table 28 GADD153 mRNA expression in DHL4 cells exposed to MSA. Results 
expressed as fold change relative to control. 
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 Set 1 Set 2 Set 3 Mean +/-SD 
Control 5.7 4.7 2.7 4.4 1.5 
TG 3μmol/L 9.2 8.5 8.9 8.9 0.3 
MSA 10μmol/L 17.5 19.4 18.3 18.4 1.0 
MSA 20μmol/L 29.4 35.6 20.4 28.5 7.6 
Table 29 Acridine orange staining in DHL4 cells exposed to MSA and Thapsigargin 
(TG) for 24 hours. Results represent the % increase in red fluorescence. 
 
MSA μmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
10 94.3 94.9 92.0 93.7 1.6 
20 76.6 75.0 65.8 72.4 5.8 
MSA+Bafilomycin 10nmol/L     SD+/- 
Bafilomycin alone 99.6 99.0 96.3 98.3 1.7 
10 55.6 57.1 48.2 53.6 4.7 
20 22.4 35.5 37.1 31.7 8.1 
Table 30 Cell viability of the DHL4 cell line exposed to MSA alone and combined with 
bafilomycin A1 for 48 hours. Results expressed relative to control.  
 
Appendices to Chapter 6 
TSA nmol/L Set 1 Set 2 Set 3 Set 4 Set 5 Mean +/-SD 
0 100.0 100.0 100.0 100.0 100.0 100.0 0.0 
0.5 88.7 92.6 93.2 97.9 93.8 93.2 3.3 
5 47.8 60.3 60.6 43.9 51.0 52.7 7.5 
50 9.9 4.3 5.8 1.7 3.2 5.0 3.1 
Table 31 TSA inhibition of Fluor de Lys
TM 
substrate deacetylation by HeLa nuclear 
extract after 30-minute exposure. Results expressed relative to control. 
 
MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
Control 100.0 100.0 100.0 100.0 0.0 
5 102.6 92.6 91.5 95.6 6.1 
10 96.0 97.1 100.2 97.8 2.2 
20 97.3 90.5 99.9 95.9 4.9 
Table 32 Effect of MSA on Fluor de Lys
TM 
substrate deacetylation by HeLa nuclear 
extract after 30-minute exposure. Results expressed relative to control. 
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 Set 1 Set 2 Set 3 Mean +/-SD 
Control 100.0 100.0 100.0 100.0 0.0 
MSA 10µmol/L 58.2 71.0 69.5 66.2 7.0 
MSA 30µmol/L 36.4 60.0 55.1 50.5 12.4 
TSA 100nmol/L 25.2 43.8 33.5 34.2 9.3 
Table 33 Deacetylation of Fluor de Lys
TM 
substrate in DHL4 cells exposed to MSA and 
TSA for 2 hours using the cellular HDAC activity assay. Results expressed relative to 
control. 
 
 Set 1 Set 2 Mean +/-SD 
Control 100.0 100.0 100.0 0.0 
MSA 5µmol/L 73.1 80.5 76.8 5.3 
MSA 10µmol/L 61.0 64.5 62.7 2.5 
MSA 30µmol/L 46.7 57.4 52.0 7.5 
TSA 100nmol/L 35.2 50.9 43.1 11.1 
Table 34 Deacetylation of Fluor de Lys
TM 
substrate in SUD4 cells exposed to MSA and 
TSA for 2 hours using the cellular HDAC activity assay. Results expressed relative to 
control. 
 
 Set 1 Set 2 Set 3 Set 4 Mean +/-SD 
Control 100.0 100.0 100.0 100.0 100.0 0.0 
MSA 5µmol/L 75.8 90.8 97.5 72.1 84.1 12.0 
MSA 10µmol/L 77.8 67.8 54.2 70.7 67.6 9.9 
MSA 30µmol/L 63.6 65.3 41.9 63.3 58.5 11.1 
TSA 100nmol/L 67.1 59.2 32.9 43.9 50.8 15.4 
Table 35 Deacetylation of Fluor de Lys
TM 
substrate in RL cells exposed to MSA and 
TSA for 2 hours using the cellular HDAC activity assay. Results expressed relative to 
control. 
 
HeLa extract Set 1 Set 2 Mean +/-SD 
Control 100.0 100.0 100.0 0.0 
MSA 10µmol/L 110.2 109.1 109.7 0.7 
MSA 30µmol/L 103.9 102.0 103.0 1.4 
TSA 50nmol/L 12.1 5.4 8.8 4.7 
DHL4 lysates     
Control 100.0 100.0 100.0 0.0 
MSA 10µmol/L 108.1 108.5 108.3 0.3 
MSA 30µmol/L 101.7 108.3 105.0 4.6 
TSA 50nmol/L 11.9 4.4 8.2 5.3 
Table 36 Effect of MSA and TSA on Fluor de Lys
TM 
substrate deacetylation by HeLa 
nuclear extract and DHL4 lysates after 2-hour exposure. Results expressed relative to 
control. 
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MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100.0 100.0 100.0 100.0 0.0 
10 92.3 112.4 100.2 101.6 10.1 
30 77.6 84.7 75.8 79.4 4.7 
Table 37 Effect of medium from DHL4 cells exposed to MSA for 2 hours on Fluor de 
Lys
TM 
substrate deacetylation by HeLa nuclear extract. Results expressed relative to 
control. 
 
MSA µmol/L Experiment 1 Experiment 2 Mean +/-SD 
Control O2 1.0 1.0 1.0 0.0 
Control hypoxia 2.0 1.6 1.8 0.3 
5 0.6 0.3 0.5 0.3 
20 1.0 0.4 0.7 0.4 
60 0.0 0.2 0.1 0.1 
Table 38 Densitometry values for western blots of HIF1α expression in DHL4 cells 
exposed to hypoxia and MSA. Results expressed as fold change relative to control O2. 
 
MSA µmol/L Experiment 1 Experiment 2 Mean +/-SD 
Control O2 1.0 1.0 1.0 0.0 
Control hypoxia 1.8 1.4 1.6 0.3 
1 1.6 1.4 1.5 0.1 
5 0.5 1.2 0.8 0.3 
20 0.7 1.0 0.6 0.2 
Table 39 Densitometry values for western blots of HIF1α expression in RL cells exposed 
to hypoxia and MSA. Results expressed as fold change relative to control O2. 
 
MSA µmol/L Set 1 Set 2 Mean +/-SD 
Control O2 100.0 100.0 100.0 0.0 
Control hypoxia 281.4 286.1 283.8 3.4 
5 139.0 199.2 169.1 42.5 
20 78.2 80.6 79.4 1.7 
60 46.9 57.1 52.0 7.2 
Table 40 VEGF production in DHL4 cells exposed to hypoxia and MSA. Results 
expressed relative to control and have been corrected for cell number (1x10
6
). 
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MSA µmol/L Set 1 Set 2 Mean +/-SD 
Control O2 100.0 100.0 100.0 0.0 
Control hypoxia 322.9 363.8 343.3 28.9 
1 268.6 300.7 284.6 22.7 
5 177.9 206.1 192.0 19.9 
20 54.3 75.2 64.7 14.8 
Table 41 VEGF production in RL cells exposed to hypoxia and MSA. Results expressed 
relative to control and have been corrected for cell number (1x10
6
). 
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MSA µmol/L Time (hrs) Set 1 Set 2 Set 3 Set 4 Set 5 Mean +/-SD 
0 Control 98.9 98.0 97.0   98.0 1.0 
5 24 94.4 96.5 95.3   95.4 1.1 
5 48 91.5 94.9 93.2   93.2 1.7 
0 Control 94.4 92.9 92.9 99.2 97.3 95.3 2.8 
10 24 88.1 89.2 92.9 98.0 94.1 92.5 4.0 
10 48 79.2 83.3  90.0 91.5 86.0 5.8 
0 Control 97.0 96.3 95.1   96.1 1.0 
20 24 96.5 94.2 92.2   94.3 2.2 
20 48 86.9 80.9 83.7   83.8 3.0 
Table 42 Cell viability of PBMCs exposed to MSA. 
  
MSA μmol/L Set 1 Set 2 Set 3 Mean SD+/- 
0 100 100 100 100 0 
0.5 98.8 100.7 94.7 98.1 3.1 
1 83.9 88.9 88.3 87.0 2.7 
2 49.7 61.3 65 58.7 8.0 
3 27.4 36 36.9 33.4 5.2 
5 20.2 20.7 24 21.6 2.1 
10 9.1 10.7 9.5 9.8 0.8 
15 6.4 6.4 5.8 6.2 0.3 
20 4.2 4.9 4.6 4.6 0.4 
Table 43 Concentration-effect of keratinocytes exposed to MSA for 48 hours. Results 
expressed relative to control. 
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MSA µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
0.5 94.4 91.7 83.4 89.8 5.7 
1 80.5 88 87.6 85.4 4.2 
3 78.3 62.8 69.6 70.2 7.8 
5 67 71.6 60.3 66.3 5.7 
7.5 49.8 67 62.1 59.6 8.9 
10 24.2 29.6 24.6 26.1 3.0 
15 26.1 36.5 35.1 32.6 5.6 
20 30.8 27.6 22.3 26.9 4.3 
Table 44 Concentration-effect of HFFF2 cells exposed to MSA for 48 hours. Results are 
expressed relative to control. 
 
4-HC μmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
1 99.9 93.2 100.2 97.8 4.0 
3 83.5 94.9 96.7 91.7 7.1 
5 75.4 86.0 86.7 82.7 6.3 
10 56.4 67.5 64.4 62.8 5.7 
20 42.6 25.7 29.3 32.6 8.9 
Table 45 Concentration-effect of keratinoyctes exposed to 4-HC for 48 hours. Results are 
expressed relative to control. 
 
Doxorubicin nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100.0 100.0 100.0 100.0 0.0 
10 99.5 90.2 99.5 96.4 5.4 
50 83.5 80.1 87.7 83.8 3.8 
100 74.9 61.9 70.0 68.9 6.5 
250 57.1 37.2 44.4 46.2 10.0 
500 36.9 21.1 26.3 28.1 8.1 
Table 46 Concentration-effect of keratinocytes exposed to doxorubicin for 48 hours. 
Results are expressed relative to control. 
 
4HC µmol/L Set 1 Set 2 Set 3 Set 4 Mean +/-SD 
0 100 100 100 100 100.0 0.0 
1 81.7  93.8 86.3 87.3 6.1 
3 80 103.5 105.3 95.3 96.0 11.5 
5 84 86.9 92 99.5 90.6 6.8 
10 91 99.8 82.9 101.8 93.9 8.7 
20 74.9 80.7 76.2 90.9 80.7 7.3 
Table 47 Concentration-effect of HFFF2 cells exposed to 4-HC for 48 hours. Results are 
expressed relative to control. 
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Doxorubicin nmol/L Set 1 Set 2 Set 3 Set 4 Set 5 Mean +/-SD 
0 100 100 100 100 100 100.0 0.0 
10 81.4 78.7  83 80.3 80.9 1.8 
50 83.1 75.9 84.4 82.4 81.2 81.4 3.3 
100 76.3 76 68.5  86.3 76.8 7.3 
250 61.3 72.2 59.5 59.5 67.5 64.0 5.6 
500 32.5 51.8 37.5 39.5 44.6 41.2 7.4 
Table 48 Concentration-effect of HFFF2 cells exposed to doxorubicin for 48 hours. 
Results are expressed relative to control. 
 
 
Doxorubicin nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
10 95.2 89.7 93.3 92.7 2.8 
50 76.6 77 72.3 75.3 2.6 
100 75.2 65.3 72 70.8 5.1 
250 53.8 57.7 63.6 58.4 4.9 
500 35.6 37.7 42.1 38.5 3.3 
Table 49 Cell viability of RL cells exposed to doxorubicin for 48 hours. Results are 
expressed relative to control. 
 
 
4-HC µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
0.5 97.9 98.2 96.3 97.5 1.0 
1 95.7 91.1 96.0 94.3 2.7 
2 90.4 89.1 90.4 90.0 0.7 
3 82.4 78.0 85.8 82.0 3.9 
5 70.7 62.9 73.8 69.1 5.6 
Table 50 Cell viability of RL cells exposed to 4-HC for 48 hours. Results are expressed 
relative to control. 
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MSA µmol/L Phase of cell cycle Set 1 Set 2 Set 3 Mean +/-SD 
0 A 1.0 0.7 4.6 2.1 2.2 
 G1 58.4 58.8 68.4 61.9 5.6 
 S 11.6 14.3 6.1 10.7 4.2 
 G2 23.1 17.4 14.4 18.3 4.4 
0.5 A 0.38 0.48 3.28 1.38 1.65 
 G1 44.4 65.5 66.8 58.9 12.6 
 S 21.8 12.5 7.2 13.8 7.3 
 G2 16.4 15.6 15.4 15.8 0.5 
1 A 0.8 0.2 3.7 1.6 1.9 
 G1 64.4 76.4 69.7 70.2 6.0 
 S 13.6 8.2 6.1 9.3 3.9 
 G2 11.2 9.3 12.8 11.1 1.8 
2 A 2.3 2.8 5.7 3.6 1.8 
 G1 80.1 76.7 66.5 74.4 7.1 
 S 3.7 6.5 3.7 4.7 1.6 
 G2 10.5 8.5 14.5 11.2 3.1 
3 A 13.1 14.5 18.2 15.3 2.7 
 G1 66.6 63.4 62.9 64.3 2.0 
 S 7.2 7.1 4.0 6.1 1.8 
 G2 11.7 13.7 13.4 12.9 1.0 
5 A 19.8 11.5 25.2 18.8 6.9 
 G1 53.1 59.8 52.4 55.1 4.1 
 S 10.5 11.7 6.6 9.6 2.7 
 G2 12.0 13.9 12.4 12.8 1.0 
Table 51 Cell cycle analysis of keratinocytes exposed to MSA for 24 hours. Results 
expressed as % of cells in each phase of the cell cycle. 
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MSA µmol/L Phase of 
cell cycle 
Set 1 Set 2 Set 3 Set 4 Mean +/-SD 
0 A 2.2 1.8 0.9 1.4 1.6 0.6 
 G1 63.6 61.4 65.2 64.3 63.6 1.6 
 S 10.0 16.7 11.8 12.0 12.6 2.8 
 G2 19.9 15.1 18.6 16.9 17.7 2.1 
0.5 A 1.4 2.2 0.9  1.5 0.6 
 G1 65.9 66.6 65.7  66.1 0.5 
 S 9.7 11.1 12.6  11.2 1.5 
 G2 18.7 16.3 15.2  16.7 1.8 
1 A 1.7 2.3 2.3  2.1 0.4 
 G1 67.7 68.6 70.1  68.8 1.2 
 S 14.7 10.7 8.9  11.5 3.0 
 G2 11.9 15.1 13.7  13.6 1.6 
2 A 3.6 3.2 14.5 25.6 11.7 10.6 
 G1 70.9 68.5 65.3 50.2 63.7 9.3 
 S 11.0 7.9 5.4 7.8 8.0 2.3 
 G2 10.4 13.4 11.7 9.1 11.1 1.8 
3 A 12.4 12.1 37.8 32.1 23.6 13.3 
 G1 67.0 69.9 39.9 42.5 54.8 15.8 
 S 7.6 6.1 5.7 7.4 6.7 0.9 
 G2 10.1 6.6 8.4 7.4 8.1 1.5 
5 A 34.4 22.5 44.3 48.6 37.5 11.6 
 G1 47.5 56.1 40.6 36.3 45.1 8.6 
 S 8.0 8.6 3.7 10.4 7.7 2.8 
 G2 8.1 8.6 6.6 4.1 6.8 2.0 
Table 52 Cell cycle analysis of keratinocytes exposed to MSA for 48 hours. Results 
expressed as % of cells in each phase of the cell cycle. 
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4-HC µmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
1 104.3 101.3 105.1 103.5 2.0 
3 89.3 86.1 94.2 89.9 4.1 
5 77.7 80.0 87.2 81.6 4.9 
10 58.7 64.3 68.4 63.8 4.9 
20 37.2 45.1 52.9 45.1 7.8 
4-HC+MSA 0.5µmol/L      
MSA alone 102.2 100.0 101.8 101.3 1.2 
1 97.2 91.6 92.8 93.8 2.9 
3 89.7 81.0 87.9 86.2 4.6 
5 80.9 74.6 80.8 78.8 3.6 
10 65.6 67.3 65.5 66.1 1.0 
20 47.0 55.3 53.4 51.9 4.4 
Table 53 Concentration-response of keratinocytes exposed to 4-HC alone and in 
combination with MSA for 48 hours. Results are expressed relative to control. 
 
Doxorubicin nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
10 98.2 109.8 108.2 105.4 6.3 
50 82.8 96.3 88.6 89.2 6.8 
100 71.1 84.6 76.9 77.6 6.8 
250 52.4 70.5 51.6 58.2 10.7 
500 31.9 41.4 34.8 36.1 4.8 
Doxorubicin+MSA 0.5µmol/L      
MSA alone 94.1 100.9 105.1 100.0 5.6 
10 91.9 105.8 103.8 100.5 7.5 
50 78.0 96.6 93.3 89.3 9.9 
100 69.4 87.1 84.1 80.2 9.5 
250 54.4 70.2 61.3 62.0 7.9 
500 31.5 44.7 34.1 36.8 7.0 
Table 54 Concentration-response of keratinocytes exposed to doxorubicin alone and in 
combination with MSA for 48 hours. Results expressed relative to control. 
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4-HC μmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
1 104.3 101.3 105.1 103.5 2.0 
3 89.3 86.1 94.2 89.9 4.1 
5 77.7 80.0 87.2 81.6 4.9 
10 58.7 64.3 68.4 63.8 4.9 
20 37.2 45.1 52.9 45.1 7.8 
7 days pre-treatment with 0.5µmol/L MSA   
0 102.2 100.0 101.8 101.3 1.2 
1 97.2 91.6 92.8 93.8 2.9 
3 89.7 81.0 87.9 86.2 4.6 
5 80.9 74.6 80.8 78.8 3.6 
10 65.6 67.3 65.5 66.1 1.0 
20 47.0 55.3 53.4 51.9 4.4 
Table 55 Concentration-effect of  keratinocytes exposed to 4-HC alone for 48 hours or 
following pre-treatment with MSA prior to 4-HC exposure. Results expressed relative to 
control. 
 
Doxorubicin nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
10 98.2 109.8 108.2 105.4 6.3 
50 82.8 96.3 88.6 89.2 6.8 
100 71.1 84.6 76.9 77.6 6.8 
250 52.4 70.5 51.6 58.2 10.7 
500 31.9 41.4 34.8 36.1 4.8 
7 days pre-treatment with 0.5µmol/L MSA   
MSA alone 94.1 100.9 105.1 100.0 5.6 
10 91.9 105.8 103.8 100.5 7.5 
50 78.0 96.6 93.3 89.3 9.9 
100 69.4 87.1 84.1 80.2 9.5 
250 54.4 70.2 61.3 62.0 7.9 
500 31.5 44.7 34.1 36.8 7.0 
Table 56 Concentration-effect of keratinocytes exposed to doxorubicin alone for 48 
hours or following pre-treatment with MSA prior to doxorubicin exposure. Results are 
expressed relative to control. 
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MSA 
µmol/L 
Time 
(hours) 
1 2 3 4 5 6 7 8 9 10 Mean +/-SD 
20 0 1 1 1 1 1 1 1 1 1 1 1 0 
20 4 8.8  4.2 1.2 5.7 4.7 2.7 3.8 2.5 3.5 4.4 2.1 
20 6 4.2  3.9 1.7 2.6 5.7 1.9 2.7 2.5 2.7 3.2 1.2 
20 24 12.9 16.1 8.9  11.8  4.7 10.9 5.9 13.2 10.9 3.6 
Table 57 GADD153 mRNA expression in PBMCs from 10 individuals exposed to MSA. 
Results are expressed as fold change relative to control. 
 
MSA 
µmol/L 
1 2 3 4 5 6 7 8 9 10 11 12 Mean +/-
SD 
0 100 100 100 100 100 100 100 100 100 100 100 100 100 0 
5        90.0  92.0   91.0 1.4 
10 110.1 125.0    110.0   81.0  104.0  106.0 16.0 
20 108.2 123.7 119.5    106.0     95.0 110.5 11.4 
40    91.0 61.1        76.1 21.2 
Table 58 NK-κB binding activity in whole cell lyastes of PBMCs exposed to MSA. 
Results expressed relative to control.  
 
 Experiment 1 Mean +/-SD 
Control 100.0 100.0 100.0 0.0 
TNF alone 157.7 191.3 174.5 23.7 
TNF+MSA 5µmol/L 206.8 250.1 228.4 30.6 
TNF+MSA 10µmol/L 339.0 308.0 323.5 21.9 
TNF+MSA 20µmol/L 351.5 354.6 353.1 2.2 
 Experiment 2   
Control 100 100 100 0 
TNF alone 167.8 173.1 170.5 3.7 
TNF+MSA 5µmol/L 121.4 133.1 127.2 8.3 
TNF+MSA 10µmol/L 187.9 166.3 177.1 15.3 
TNF+MSA 20µmol/L 167.2 183.5 175.3 11.5 
 Experiment 3   
Control 100.0 100.0 100.0 0.0 
TNF alone 167.2 163.9 165.6 2.4 
TNF+MSA 5µmol/L 391.2 423.4 407.3 22.8 
TNF+MSA 10µmol/L 336.8 423.5 380.1 61.3 
TNF+MSA 20µmol/L 457.0 385.3 421.2 50.7 
Table 59 NK-κB binding activity in nuclear extracts of PBMCs from 3 different 
individuals exposed to MSA. Results are expressed relative to control.  
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MSA µmol/L 1 2 3 4 5 6 7 8 Mean +/-SD 
Control 1 1 1 1 1 1 1 1 1 0 
20 2.5 2.1 4.5 0.7 4.8 2.5 2 1 2.5 1.5 
Table 60 Densitometry values of western blots of NF-κB expression in nuclear extracts 
of PBMCs from 8 different individuals exposed to MSA. Results are expressed as fold 
change relative to control. 
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MSA μmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 95.4 98.7 92.4 95.5 3.2 
10 91 95.1 89.2 91.8 3.0 
20 64.5 79.6 69 71.0 7.8 
50 30.9 50.5 30.7 37.4 11.4 
100 25 28.9 19.7 24.5 4.6 
Table 61 Cell viability of the JeKo-1 cell line exposed to MSA. Results expressed 
relative to control.  
 
 
MSA μmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 99.1 96.8 98.9 98.3 1.3 
10 97.8 94.7 95.4 96.0 1.6 
20 69.2 70.4 82.4 74.0 7.3 
50 56.8 38.5 43.1 46.1 9.5 
100 38.4 32.4 34.6 35.1 3.0 
Table 62 Cell viability of the Granta-519 cell line exposed to MSA. Results expressed 
relative to control.  
 
MSA μmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100.0 100.0 100.0 100.0 0.0 
5 53.6 49.3 46.8 49.9 3.4 
10 43.1 39.9 34.0 39.0 4.6 
20 37.0 33.1 27.5 32.5 4.8 
50 30.4 28.9 27.7 29.0 1.4 
100 30.1 28.1 27.5 28.6 1.3 
Table 63 Cell number of JeKo-1 cells exposed to MSA. Results expressed relative to 
control.  
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MSA μmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100.0 100.0 100.0 100.0 0.0 
5 47.2 49.1 56.4 50.9 4.8 
10 35.8 36.1 36.5 36.1 0.3 
20 29.1 29.5 35.7 31.4 3.7 
50 23.6 27.2 43.6 31.5 10.6 
100 23.0 27.9 34.0 28.3 5.5 
Table 64 Cell number of Granta-519 cells exposed to MSA. Results expressed relative to 
control.  
 
Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 99.4 100.1 100.3 99.9 0.5 
10 98.6 99.6 100 99.4 0.7 
20 94.9 97.3 96.5 96.2 1.2 
50 52.1 60.3 65.2 59.2 6.6 
100 37.3 30.8 51.4 39.8 10.5 
Table 65 Cell viability of the JeKo-1 cell line exposed to bortezomib. Results expressed 
relative to control.  
 
 
Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 100.3 99.8 99.5 99.9 0.4 
10 100.1 99.4 99.3 99.6 0.4 
20 99.2 96.8 96.6 97.5 1.4 
50 72.6 58.2 64.8 65.2 7.2 
100 64.2 26.4 43.2 44.6 18.9 
Table 66 Cell viability of the Granta-519 cell line exposed to bortezomib. Results 
expressed relative to control.  
 
 
Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100.0 100.0 100.0 100.0 0.0 
5 102.2 93.5 91.3 95.6 5.8 
10 89.1 96.6 82.4 89.4 7.1 
20 54.9 58.9 51.9 55.2 3.5 
50 30.6 29.0 24.8 28.1 3.0 
100 28.5 23.3 24.4 25.4 2.8 
Table 67 Cell number of JeKo-1 cells exposed to bortezomib. Results expressed relative 
to control.  
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Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
control 100.0 100.0 100.0 100.0 0.0 
5 98.0 92.9 97.2 96.0 2.8 
10 90.0 81.7 93.5 88.4 6.0 
20 54.2 65.7 76.0 65.3 10.9 
50 27.4 34.5 21.2 27.7 6.6 
100 26.1 23.5 38.5 29.3 8.0 
Table 68 Cell number of Granta-519 cells exposed to bortezomib. Results expressed 
relative to control.  
 
Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 99.7 99.7 100.1 99.8 0.2 
10 99.6 99.6 99.5 99.6 0.1 
20 98.0 96.4 82.0 92.1 8.8 
50 60.1 51.0 43.5 51.5 8.3 
Bortezomib+MSA 10μmol/L    
MSA alone 95.4 92.6 97.6 95.2 2.5 
5 93.5 90.8 96.9 93.7 3.1 
10 91.8 90.6 95.5 92.6 2.6 
20 86.2 85.6 90.0 87.3 2.3 
50 73.4 67.2 63.4 68.0 5.1 
Bortezomib+MSA 10μmol/L Expected cell viability   
MSA alone 95.4 92.6 97.6 95.2 2.5 
5 95.1 92.3 97.7 95.0 2.7 
10 95.0 92.2 97.1 94.8 2.4 
20 93.4 89.0 79.6 87.3 7.1 
50 55.5 43.6 41.1 46.7 7.7 
Table 69 The effect on JeKo-1 cell viability of combining MSA and bortezomib for 48 
hours. Results expressed relative to control 
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Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 100 100.7 98.3 99.6 1.3 
10 99.9 100.2 96.6 98.9 2.0 
20 98.1 98.4 95.4 97.3 1.7 
50 63.3 58.1 66.6 62.7 4.3 
Bortezomib+MSA 10μM    
MSA alone 96.7 93.1 85.0 91.6 6.0 
5 95.7 91.5 84.8 90.7 5.5 
10 94.9 91.9 78.8 88.5 8.5 
20 89.6 88.3 83.2 87.0 3.4 
50 73.5 69.0 71.5 71.3 2.2 
Bortezomib+MSA 10μM Expected cell viability   
MSA alone 96.7 93.1 85.0 91.6 6.0 
5 96.7 93.8 83.3 91.2 7.1 
10 96.6 93.3 81.6 90.5 7.9 
20 94.8 91.5 80.4 88.9 7.6 
50 60.0 51.2 51.6 54.3 5.0 
Table 70 The effect on Granta-519 cell viability of combining MSA and bortezomib for 
48 hour. Results expressed relative to control. 
 
Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 99.7 99.6 100.2 99.8 0.4 
10 99.4 99.9 99.2 99.5 0.3 
20 88.0 84.6 82.3 85.0 2.9 
50 38.4 53.8 44.4 45.5 7.8 
Bortezomib+MSA 10μmol/L    
MSA alone 96.3 100.0 99.4 98.6 2.0 
5 97.9 100.3 99.4 99.2 1.2 
10 97.7 100.1 97.7 98.5 1.4 
20 96.3 95.4 97.3 96.3 1.0 
50 91.6 80.5 84.0 85.3 5.7 
Bortezomib+MSA 10μmol/L Expected cell viability    
0 96.3 100.0 99.4 100.0 0 
5 96.0 99.6 99.6 98.4 2.1 
10 95.7 99.9 98.6 98.1 2.2 
20 84.3 84.6 81.7 83.6 1.6 
50 34.7 53.8 43.8 44.1 9.6 
Table 71 The effect on JeKo-1 cell viability of pre-treatment with MSA for 48 hours 
followed by treatment with bortezomib for a further 48 hours. Results expressed relative 
to control. 
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Bortezomib nmol/L Set 1 Set 2 Set 3 Mean +/-SD 
0 100 100 100 100 0 
5 100.2 98.8 100.5 99.8 0.9 
10 99.5 99.1 100.4 99.7 0.7 
20 85.8 79.8 82.0 82.5 3.0 
50 30.2 32.9 30.5 31.2 1.5 
Bortezomib+MSA 10μmol/L    
MSA alone 98.4 100 99.7 99.4 0.9 
5 98.4 99.5 99.8 99.2 0.8 
10 98.3 99.5 100.1 99.3 0.9 
20 97.3 97.4 96.2 96.9 0.6 
50 91.2 86.7 84.4 87.4 3.4 
Bortezomib+MSA 10μmol/L Expected cell viability    
MSA alone 98.4 100 99.7 99.4 0.9 
5 98.6 98.8 100.2 99.2 0.9 
10 97.9 99.1 100.1 99.0 1.1 
20 84.2 79.8 81.7 81.9 2.2 
50 28.6 32.9 30.2 30.6 2.2 
Table 72 The effect on Granta-519 cell viability of pre-treatment with MSA for 48 hours 
followed by treatment with bortezomib for a further 48 hours. Results expressed relative 
to control. 
 
 
JeKo-1 Set 1 Set 2 Set 3 Mean SD 
Control 311.0 243.7 290.1 281.6 34.4 
MSA 10µmol/L 281.6 205.4 243.6 243.6 38.1 
Bortezomib 20nmol/L 19.2 9.1 19.8 16.0 6.0 
MSA and bortezomib 20nmol/L 24.5 7.8 16.4 16.2 8.4 
Bortezomib 50nmol/L 5.9 4.5  5.2 1.0 
MSA and bortezomib 50nmol/L 7.5 4.2  5.8 2.3 
Granta-519      
Control 247.3 275.8 259.4 260.8 14.3 
MSA 10µmol/L 225.9 218.1 225.6 223.2 4.4 
Bortezomib 20nmol/L 22.0 10.7 35.4 22.7 12.4 
MSA and bortezomib 31.3 11.9 19.0 20.8 9.8 
Bortezomib 50nmol/L 4.2 6.3  5.2 1.5 
MSA and bortezomib 50nmol/L 3.7 6.0  4.8 1.6 
Table 73 Proteasome activity in JeKo-1 and Granta-519 cell lines treated with MSA 
10µmol/L and bortezomib alone and in combination. Results expressed as  
µM AMC/mg/hr. 
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RL cells Set 1 Set 2 Mean +/-SD 
Control 0.5 1.3 0.9 0.6 
10 minutes 379.5 148.0 263.8 163.7 
30 minutes 230.2 120.0 175.1 77.9 
1 hour 261.9 116.0 189.0 103.2 
2 hours 246.7 124.0 185.3 86.8 
4 hours 276.8 93.0 184.9 130.0 
6 hours 136.7 100.0 118.4 26.0 
24 hours 213.9 65.0 139.5 105.3 
DHL4 cells     
Control -0.3 2.1 0.9 1.7 
10 minutes 337.2 130.0 233.6 146.5 
30 minutes 374.8 106.0 240.4 190.0 
1 hour 329.3 145.0 237.1 130.3 
2 hours 192.5 132.0 162.2 42.8 
4 hours 280.3 160.0 220.2 85.1 
6 hours 197.7 96.0 146.8 71.9 
24 hours 66.3 70.0 68.2 2.6 
Table 74 Intracellular Se concentration (µg/kg) in RL and DHL4 cell lines exposed to 
20µmol/L MSA. 
 
PBMCs Set 1 Set 2 Set 3 Set 4 Set 5 Mean +/-SD 
Control 2.8 1.3 -0.9 0.7 1.6 1.1 1.4 
10 minutes 17.7 30.9 27.5 54.0 96.5 45.3 31.6 
30 minutes 21.3 41.5 41.3 74.0 118.4 59.3 38.1 
1 hour 31.1 51.1 39.9 115.0 150.2 77.5 52.3 
2 hours 42.1 66.5 52.7 164.0 96.8 84.4 49.0 
4 hours 58.9 67.1 60.9 200.0 156.1 108.6 65.3 
6 hours 64.6 72.0 74.4 218.0 131.7 112.1 65.0 
24 hours 29.2 33.5 33.0 153.0 127.0 75.2 59.9 
Table 75 Intracellular Se concentration (µg/kg) in PBMCs exposed to 20µmol/L MSA. 
 
 
 
 
 
 
 
 
 
 
490 
 
 Set 1 Set 2 Set 3 Set 4 Set 5 Mean +/-SD 
DHL4 control 100.0 100.0 100.0 100.0 100.0 100.0 0.0 
DHL4 + 'RM' 94.6 99.0 103.5 102.7 115.7 103.1 7.9 
RL control 100.0 100.0 100.0 100.0  100.0 0.0 
RL + 'RM' 169.0 137.9 143.9 152.4  150.8 13.5 
JVM2 control 100.0 100.0  100.0 100.0 100.0 0.0 
JVM2 + 'RM' 111.2 116.0  98.5 142.9 117.2 18.7 
ACHN control 100.0 100.0   100.0 100.0 0.0 
ACHN + 'RM' 293.7 511.6   342.3 382.5 114.4 
Table 76 Pyruvate generation as a measure of β-lyase activity in 3 lymphoma cell lines 
and the renal adenocarcinoma cell line, ACHN. Results expressed relative to the relevant 
control. ‘RM’=reaction mix 
 
MSC µmol/L Set 1 Set 2 Set 3 Set 4 Mean +/-SD 
0 100 100 100 100 100 0 
1 90.6 84.9 90.2 94.8 90.1 4.0 
3 85.1 81.0 84.0 90.2 85.1 3.8 
5 79.3 82.7 68.7 79.3 77.5 6.1 
10 70.7 73.0 62.2 73.9 69.9 5.3 
20 45.2 54.0 37.5 44.1 45.2 6.8 
30   33.8 22.7 28.2 7.9 
40   26.7 20.4 23.6 4.5 
50   21.9 21.0 21.4 0.7 
Table 77 Concentration-response of ACHN cells exposed to MSC. Results are expressed 
relative to control.  
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Method for phospho-proteomics experiments described in full 
Sample preparation 
The RL and DHL4 cell lines were exposed to MSA 1μmol/L and 10μmol/L respectively 
for 24 hours. Following this, 10 million cells were centrifuged at 110g for 5 minutes at 
5°C and the supernatant discarded. Cells were resuspended in ice-cold PBS containing 
Na3VO4 (Sigma-Aldrich), final concentration 100mM, and NaF (Sigma-Aldrich), final 
concentration 0.5M. Cells were centrifuged at 110g for 5 minutes at 5°C and the 
supernatant discarded. This step was repeated twice more after which the cell pellets were 
snap-frozen on dry ice and stored at -20°C until further use.  These experiments were 
performed on 3 separate occasions to obtain independent triplicate samples. The stored 
samples were then all processed together as described below.  
 
Cell lysis 
The frozen cells pellets were thawed on ice and resuspended in 1 ml of lysis buffer 
(20mM HEPES, pH 8.0, 8M urea, 100mM Na3VO4, 0.5M NaF, 0.25M sodium 
pyrophosphate and 1M β-glycerol phosphate; all from Sigma-Aldrich). The cell 
suspension was then sonicated 3 times for 15 seconds to further solubilise the proteins. 
Samples were centrifuged at 20000g for 10 minutes at 5°C to remove any cellular debris 
and the supernatant was recovered into protein Lobind
®
 tubes (Eppendorf UK Limited). 
Where possible, samples were kept in protein LoBind
®
 tubes from this stage onwards. 
Cellular proteins were reduced with DTT, final concentration 4.1mM, in the dark for 15 
minutes at room temperature followed by alkylation with iodoacetamide, final 
concentration 8.3mM in the dark for 15 minutes at room temperature. Protein extracts 
were then diluted in 20mM HEPES pH 8.0 (1:4 dilution).  
 
Protein digestion 
Protein digestion was achieved with the use of immobilised L-1-tosylamido-2-
phenylethyl chloromethyl ketone (TPCK)-trypsin beads (Thermo Fisher Scientific, 
Cramlington, UK). The beads were conditioned prior to use according to the 
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manufacturers’ instruction. 80μl of trypsin beads [≥200 TAME units per ml; (TAME 
Unit: One Unit hydrolyzes 1μmole of p-toluene-sulfonyl-L-arginine methyl ester 
(TAME) per minute at 25°C, pH 8.2, in the presence of 10mM calcium)] were used for 
protein extracted from 10 million cells. The appropriate amount of trypsin beads were 
transferred to a fresh tube and centrifuged at 2000g for 5 minutes at 5°C. The supernatant 
was discarded and the beads were re-suspended in 20mM HEPES (double the volume of 
beads) followed by thorough mixing. The beads were centrifuged again at 2000g for 5 
minutes at 5°C and the supernatant discarded. This step was repeated twice more. The 
beads were then resuspended in 20mM HEPES at a volume equal to the original volume 
of beads. 80μl was added to each sample and incubated for 16 hours at 37°C with 
shaking. Following this, digestion was stopped by adding TFA (LGC Standards) at a final 
concentration of 1%. Samples were centrifuged at 2000g for 5 minutes at 5°C to remove 
the trypsin beads and the supernatant was recovered into fresh tubes. 
 
Peptide desalting 
Sep-Pak
® 
C18 cartridges (Waters UK Ltd., Manchester, UK) were used to desalt the 
peptide samples. The cartridges were initially washed with 10mls of 100% ACN and then 
with 10mls of 98% H2O/2% ACN/0.1% TFA.  Following this, samples were loaded into 
the cartridges.  Cartridges were washed again with 10mls of 98% H2O/2% ACN/0.1% 
TFA. Bound peptides were then eluted with 5mls of 50% ACN/0.1% TFA and ready to 
use for further work. 
 
Phospho-peptide enrichment by immobilized metal ion affinity chromatography 
(IMAC) 
IMAC sepharose
TM
 high performance beads (GE healthcare) were used to separate the 
phospho-peptide component of the peptide elution. Firstly, the beads were conditioned 
and charged with Fe
3+
. 
 300μl of highly cross-linked agarose beads (particle size 34μm) 
were used for 10 million cells. All centrifugation/wash steps were at 110g for 1 minute at 
5°C. The beads were pre-swollen in 20% ethanol and therefore the required volume was 
centrifuged, the supernatant discarded and the beads re-suspended in LC-MS grade H2O 
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(same volume as the compacted beads). The beads were centrifuged again, the 
supernatant discarded and washed twice with 200mM EDTA. The beads were then 
washed three times with 50% ACN/0.1% TFA and the supernatant discarded. Iron 
chloride (FeCl3; Sigma-Aldrich), 100mM, was added to the beads and incubated for 5 
minutes at room temperature. The beads were centrifuged, the supernatant discarded and 
the same FeCl3 incubation step repeated. The beads were then washed six times with 50% 
ACN/0.1% TFA and finally re-suspended in 50% ACN/0.1% TFA and ready for use. 
 
300μl of the Fe3+ charged beads were added to each sample and placed on a rotatory 
mixer for 1 hour at room temperature. The samples were then centrifuged at 420g for 1 
minute and the supernatant recovered (i.e. non-phosphorylated peptides). The beads were 
washed with 50% ACN/0.1% TFA and the supernatant recovered again and added to the 
previous supernatant sample. The phospho-peptides were eluted with ammonia water 
[60μl of 25% ammonia solution (LGC standards) was diluted in 940μl of ultrapure 
water]. 300μl was added to each sample and incubated for 5 minutes at room 
temperature. The samples were centrifuged at 420g for 1 minute and the supernatant 
recovered into protein LoBind
®
 tubes. The addition of ammonia water was repeated and 
the supernatant recovered once again. Finally, the beads were washed twice with 100μl 
50% ACN/0.1% TFA and the supernatant recovered.  
 
Both the fractions containing the non-phosphorylated and phospho-enriched peptides 
were dried down in a vacuum centrifuge (Christ rotational vacuum concentrator, 
Osterode, Germany). 
 
Reconstitution of samples for mass spectrometry 
11μl of 0.1% FA in LC-MS grade H2O was added to the dried samples and the sample re-
suspended. The samples were incubated for 10 minutes at room temperature and then 
centrifuged at 2700g for 5 minutes at 5°C to remove any debris. 10μl of the supernatant 
was drawn up and placed in lubricated hydrophobic tubes (Bioquote Limited, York, UK) 
ready for analysis by MS  
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Nanoflow-UPLC
®
 coupled to tandem MS (LC-MS/MS) 
A nanoflow UPLC
®
 system (nanoAquity, Waters/Micromass UK Ltd. Manchester) was 
coupled to a LTQ-Orbitrap XL MS (Thermo Fisher Scientific, Hemel Hempstead, UK). 
3µl of each sample was injected into a trap column (nanoAcquity UPLC
® 
Symmetry
®
 C18 
Trap; 20mm length, 180µm id, 5µm particle size; Waters/Micromass) and then into a 
nanoflow column (nanoAquity UPLC
® 
BEH C18 column; 100mm length, 100µm id, 
1.7µm particle size; Waters/Micromass). The mobile phases consisted of solution A 
(0.1% FA in LC-MS grade water) and solution B (0.1% FA in LC-MS grade ACN). 
Gradient runs were from 1% B to 35% B in 100 minutes and the flow rate was 5µl/min 
for loading and 0.4µl/min for elution. The spray voltage was set to 2kV, the temperature 
of the heated capillary to 150°C and a positive ionisation mode was used. The MS was 
operated in data-dependent mode to automatically acquire MS and MS/MS spectra. Full 
scan survey spectra (m/z 375-1800) were acquired in the LTQ-Orbitrap XL. The five 
most intense ions in each full scan (every 0.6 of a second) were sequentially isolated and 
fragmented by collision-induced dissociation. The collision gas was helium. Data were 
acquired using the Xcalibur software version 2.0.7 (Thermo Fisher Scientific).  
 
Data analysis 
LTQ-Orbitrap MS/MS data were smoothed and centroided using Mascot Distiller 
(v2.1.10, Matrix Science, London, UK). For protein identification, the processed files 
were searched against the Swiss-Prot database of protein sequences using the Mascot 
search engine (Mascot Daemon, v2.3.0; Matrix Science). The searches were performed 
choosing trypsin as digestion enzyme with two missed cleavages allowed. 
Carbomidomethyl (C) was set as a fixed modification and oxidation (M), phospho (ST), 
phospho (Y) and pyro-glu (N-term) as variable modifications. Data sets were searched 
with a mass tolerance of ±5ppm and a fragment mass tolerance of ±600mmu. Protein 
identifications were accepted when Mascot scores were above the statistically significant 
threshold (p<0.05).  
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For quantitative analysis of the MS data, a program written by the Analytical Signalling 
Group (Institute of Cancer, Barts Cancer Centre, London, UK) was used (Cutillas & 
Vanhaesebroeck, 2007). It is a program written in Visual Basic termed Pescal (Peak 
Statistic Calculator). The program uses the m/z and retention time values for each 
identified peptide ion to generate extracted ion chromatograms. Algorithms in Pescal 
calculate intensity at maximum peak height and area under the curve and generate peak 
intensity values for each of the peptide sequences identified by Mascot. These peak 
intensities were then normalised by dividing each peak intensity by the sum of all the 
peak intensities. Each experiment was performed in triplicate and therefore for each 
peptide the mean peak intensities for control and MSA-treated samples were calculated. 
If more than one peptide belonging to the same protein was present, then the peak 
intensity values for all peptides were combined and the mean calculated. A paired t-test 
was used to determine significant differences in peptide intensities between control and 
MSA-treated samples. p<0.05 was considered statistically significant. Peptides that did 
not change in intensity between control and MSA-treated samples were excluded from 
further analysis. These quantitative data were then analysed using the MetaboAnalyst 
software (www.metaboanalyst.ca) which performs both univariate (t-test and fold 
change) and multivariate analysis (principle component analysis and hierarchical cluster 
analysis). The data entered into this software was the m/z, the retention time and the peak 
intensity. 
 
Network and pathway analysis was performed using Ingenuity Pathway Analysis (IPA) 
software™ v8.6 (Ingenuity Systems, www.ingenuity.com). The fold-change was 
calculated for the peptides that changed significantly between control and MSA-treated 
samples and peptides with a ≥2 fold change in intensity were used in pathway analysis. 
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Table 78 The complete list of differentially expressed proteins in DHL4 cells exposed to 
MSA 10µmol/L 
Gene Symbol Protein Phospho FC p value 
C1QBP Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
 ↓229 0.001 
MCM7 Isoform 1 of DNA replication licensing 
factor MCM7 
 ↓98.4 0.03 
VEPH1 Isoform 1 of Ventricular zone-expressed 
PH domain-containing protein homolog 1 
ST ↓55.2 0.001 
PTPLAD1 Protein tyrosine phosphatase-like protein  ST ↑38.4 0.004 
ALDOA Fructose-bisphosphate aldolase A  ↓25.8 0.008 
HNRNPA3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 
 ↑23.7 0.02 
RRM2 Ribonucleotide reductase, subunit M2 ST ↓14.4 0.01 
TUBB3 Tubulin beta-3 chain  ↑13.5 0.002 
CCT8 Chaperonin containing T complex protein 
1, subunit 8 (theta) 
 ↑12.1 0.002 
GLO1 Glyoxalase 1  ↓11.6 0.01 
TXNRD1 Thioredoxin reductase 1  ↑9.7 0.004 
RCTPI1 Triosephosphate isomerase  ↑9 0.02 
CDC2 Cyclin-dependent kinase 1 ST, Y ↓8.7 0.02 
HMGCS1 Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic 
ST ↓7.6 0.01 
CCT4 Chaperonin containing T complex protein 
1, subunit 4  (delta) 
 ↑8.5 0.02 
SYNE2 Isoform 1 of Nesprin-2  ↑7.7 0.02 
PDCD4 Programmed cell death 4 isoform 2  ↑7.3 0.009 
SOD1 Superoxide dismutase  ↑7.1 0.03 
HSPA5 GRP78  ↑6.6 0.02 
HSPH1 Heat shock protein 105 kDa (Isoform β)  ↓6.6 0.045 
HSP90B3P GRP94  ↑6.0 0.01 
RPLP0 60S acidic ribosomal protein P0 2ST ↓5.9 0.03 
ESF1 ESF1 homolog ST ↓5.9 0.002 
HIST1H1B Histone H1.5 ST ↓5.5 0.006 
CCT7 chaperonin containing T complex protein 
1, subunit 7  (eta) 
 ↓5.3 0.0001 
HLA-A Major histocompatibility complex, class I, 
A 
 ↑5.1 0.04 
 Similar to Delta(3,5)-Delta(2,4)-dienoyl-  ↓5.0 0.04 
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CoA isomerase, mitochondrial precursor 
HSPD1 60 kDa heat shock protein, mitochondrial  ↓5.0 0.04 
NOP2 Putative uncharacterized protein NOP2 ST ↓4.9 0.007 
 Putative uncharacterized protein 
RPL14P1 
ST ↓4.9 0.02 
CFL2 Cofilin-2  ↑4.5 0.03 
RAB10 Ras-related protein Rab-10  ↑4.5 0.008 
ANKZF1 Ankyrin repeat and zinc finger domain-
containing protein 1 
ST ↓4.5 0.03 
ATP5B 13 kDa protein  ↑4.4 0.03 
TCP1 T-complex protein 1 subunit alpha  ↑4.4 0.003 
MCM7 Isoform 1 of DNA replication licensing 
factor MCM7 
 ↓4.3 0.008 
NCL Nucleolin  ↑4.3 0.008 
CAD Carbamoyl-phosphate synthetase 2 ST ↓4.1 0.004 
TUBA1C Tubulin alpha-1C chain ST ↓4.0 0.02 
HNRNPU Isoform Short of Heterogeneous nuclear 
ribonucleoprotein U 
 ↑3.9 0.03 
DDX21 Isoform 1 of Nucleolar RNA helicase 2 ST ↓3.7 0.004 
NOLC1 Isoform Beta of Nucleolar phosphoprotein 
p130 
 ↑3.7 0.02 
IGL@ Immunoglobulin lambda protein locus  ↓3.7 0.02 
PTPRCAP Protein tyrosine phosphatase receptor type 
C-associated protein 
ST ↓3.6 0.048 
 Similar to Heterogeneous nuclear 
ribonucleoprotein A1 
 ↑3.4 0.01 
RPL21 60S ribosomal protein L21  ↑3.4 0.045 
XRCC6 ATP-dependent DNA helicase 2 subunit 1  ↓3.4 0.048 
TMPO Isoform Beta of Lamina-associated 
polypeptide 2, isoforms beta/gamma 
ST ↑3.4 0.008 
ATP5B ATP synthase subunit beta, mitochondrial  ↑3.4 0.03 
DUT Isoform 2 of deoxyuridine triphosphatase  ↓3.3 0.01 
SRRM1 Isoform 1 of Serine/arginine repetitive 
matrix protein 1 
ST ↑3.3 0.007 
HIST1H4C Histone H4  ↑3.2 0.02 
MCM5 DNA replication licensing factor MCM5  ↓3.2 0.006 
SRFBP1 Serum response factor-binding protein 1 ST ↓3.2 0.006 
BCL6  B-cell lymphoma 6 protein ST ↓3.2 0.02 
RPL15 60S ribosomal protein L15  ↑3.1 0.02 
STMN2 Stathmin-2  ↑3.1 0.02 
STMN1 Stathmin ST ↓3.0 0.04 
TCOF1 Treacher Collins-Franceschetti syndrome 
1 isoform a 
ST ↓2.9 0.008 
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C17orf49 Hypothetical protein LOC124944 isoform 
1 
ST ↓2.8 0.04 
HNRNPM Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein M 
 ↑2.8 0.01 
YRDC YrdC domain-containing protein, 
mitochondrial 
ST ↓2.7 0.006 
SAMHD1 SAM domain and HD domain-containing 
protein 1 
ST ↓2.7 0.008 
RPLP1 60S acidic ribosomal protein P1 ST ↓2.7 0.04 
TERF2 Isoform 1 of Telomeric repeat-binding 
factor 2 
ST ↓2.6 0.005 
HNRNPA2B1 Isoform B1 of Heterogeneous nuclear 
ribonucleoproteins A2/B1 
ST ↓2.6 0.005 
 Hypothetical short protein ST ↓2.5 0.04 
FLJ43859 FAM75-like protein FLJ43859  ↓2.5 0.04 
FKBP1A Peptidyl-prolyl cis-trans isomerase 
FKBP1A 
 ↑2.5 0.046 
EZR Ezrin  ↑2.5 0.03 
ENO1 Enolase 1  ↑2.4 0.045 
MCM4 DNA replication licensing factor MCM4  ↓2.4 0.004 
DKC1 Dyskeratosis congenital 1 ST ↓2.4 0.006 
MCM2 DNA replication licensing factor MCM2 ST ↓2.4 0.03 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, 
member 4 
 ↑2.3 0.04 
EPRS Bifunctional aminoacyl-tRNA synthetase  ↓2.3 0.01 
AGAP3 CENTG3 protein ST ↑2.3 0.01 
WARS Tryptophanyl-tRNA synthetase, 
cytoplasmic 
 ↑2.3 0.01 
P4HB Protein disulfide-isomerase  ↑2.3 0.04 
LOC731605 Hypothetical LOC731605 ST ↑2.3 0.03 
TMPO Lamina-associated polypeptide 2, isoform 
alpha 
2ST ↓2.3 0.04 
ARHGDIB Rho GDP-dissociation inhibitor 2  ↑2.3 0.04 
ACCS 1-aminocyclopropane-1-carboxylate 
synthase-like protein 1 
 ↓2.2 0.01 
HNRNPH1 Heterogeneous nuclear ribonucleoprotein 
H 
ST ↓2.2 0.02 
ASNS  Asparagine synthetase   ↑2.2 0.007 
PTMA Putative uncharacterized protein PTMA  ↓2.2 0.004 
cDNA 
FLJ54554 
highly similar to Pyruvate kinase 
isozymes M1/M2 
 
 ↑2.2 0.02 
TMC8 Isoform 1 of Transmembrane channel-like ST ↑2.1 0.047 
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protein 8 
MDC1 Mediator of DNA damage checkpoint 
protein 1 
ST ↓2.1 0.01 
ABCF1  Isoform 2 of ATP-binding cassette sub-
family F member 1 
2ST ↓2.1 0.009 
GTF3C2 Isoform 1 of General transcription factor 
3C polypeptide 2 
ST ↓2.1 0.04 
PI4KA similar to PIK4CA variant protein ST ↓2.1 0.002 
ATP5A1 ATP synthase subunit alpha, 
mitochondrial 
 ↑2.1 0.009 
LCP1 Plastin-2  ↑2.0 0.01 
ENO3 Enolase 3  ↓2.0 0.003 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
 ↑2.0 0.02 
TUFM Tu translation elongation factor, 
mitochondrial precursor 
 ↑2.0 0.02 
DDB1 DNA damage-binding protein 1  ↓2.0 0.049 
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